id	sid	tid	token	lemma	pos
dpc-4152	1	1	dermatology	dermatology	NOUN
dpc-4152	1	2	:	:	PUNCT
dpc-4152	1	3	practical	practical	ADJ
dpc-4152	1	4	and	and	CCONJ
dpc-4152	1	5	conceptual	conceptual	ADJ
dpc-4152	1	6	review	review	NOUN
dpc-4152	1	7	|	|	ADV
dpc-4152	1	8	dermatol	dermatol	ADJ
dpc-4152	1	9	pract	pract	NOUN
dpc-4152	1	10	concept	concept	NOUN
dpc-4152	1	11	.	.	PUNCT
dpc-4152	2	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	2	2	:	:	PUNCT
dpc-4152	2	3	e2024145s	e2024145s	NOUN
dpc-4152	2	4	1	1	NUM
dpc-4152	2	5	topical	topical	ADJ
dpc-4152	2	6	pharmacological	pharmacological	ADJ
dpc-4152	2	7	treatment	treatment	NOUN
dpc-4152	2	8	of	of	ADP
dpc-4152	2	9	actinic	actinic	ADJ
dpc-4152	2	10	keratoses	keratose	NOUN
dpc-4152	2	11	:	:	PUNCT
dpc-4152	2	12	focus	focus	VERB
dpc-4152	2	13	on	on	ADP
dpc-4152	2	14	tirbanibulin	tirbanibulin	PROPN
dpc-4152	2	15	1	1	NUM
dpc-4152	2	16	%	%	NOUN
dpc-4152	2	17	ointment	ointment	NOUN
dpc-4152	2	18	mario	mario	PROPN
dpc-4152	2	19	valenti1,2	valenti1,2	PROPN
dpc-4152	2	20	,	,	PUNCT
dpc-4152	2	21	matteo	matteo	PROPN
dpc-4152	2	22	bianco1,2	bianco1,2	PROPN
dpc-4152	2	23	,	,	PUNCT
dpc-4152	2	24	alessandra	alessandra	PROPN
dpc-4152	2	25	narcisi1,2	narcisi1,2	PROPN
dpc-4152	2	26	,	,	PUNCT
dpc-4152	2	27	antonio	antonio	PROPN
dpc-4152	2	28	costanzo1,2	costanzo1,2	PROPN
dpc-4152	2	29	,	,	PUNCT
dpc-4152	2	30	riccardo	riccardo	PROPN
dpc-4152	2	31	borroni1,2	borroni1,2	PROPN
dpc-4152	2	32	,	,	PUNCT
dpc-4152	2	33	marco	marco	PROPN
dpc-4152	2	34	ardigò1,2	ardigò1,2	PROPN
dpc-4152	2	35	1	1	NUM
dpc-4152	2	36	department	department	NOUN
dpc-4152	2	37	of	of	ADP
dpc-4152	2	38	biomedical	biomedical	ADJ
dpc-4152	2	39	sciences	sciences	PROPN
dpc-4152	2	40	,	,	PUNCT
dpc-4152	2	41	humanitas	humanita	NOUN
dpc-4152	2	42	university	university	NOUN
dpc-4152	2	43	,	,	PUNCT
dpc-4152	2	44	pieve	pieve	PROPN
dpc-4152	2	45	emanuele	emanuele	PROPN
dpc-4152	2	46	,	,	PUNCT
dpc-4152	2	47	italy	italy	PROPN
dpc-4152	2	48	2	2	NUM
dpc-4152	2	49	dermatology	dermatology	NOUN
dpc-4152	2	50	unit	unit	NOUN
dpc-4152	2	51	,	,	PUNCT
dpc-4152	2	52	irccs	ircc	VERB
dpc-4152	2	53	humanitas	humanitas	NOUN
dpc-4152	2	54	research	research	NOUN
dpc-4152	2	55	hospital	hospital	NOUN
dpc-4152	2	56	,	,	PUNCT
dpc-4152	2	57	rozzano	rozzano	PROPN
dpc-4152	2	58	,	,	PUNCT
dpc-4152	2	59	italy	italy	PROPN
dpc-4152	2	60	key	key	ADJ
dpc-4152	2	61	words	word	NOUN
dpc-4152	2	62	:	:	PUNCT
dpc-4152	2	63	tirbanibulin	tirbanibulin	ADV
dpc-4152	2	64	,	,	PUNCT
dpc-4152	2	65	actinic	actinic	ADJ
dpc-4152	2	66	keratoses	keratose	NOUN
dpc-4152	2	67	,	,	PUNCT
dpc-4152	2	68	field	field	NOUN
dpc-4152	2	69	of	of	ADP
dpc-4152	2	70	cancerization	cancerization	NOUN
dpc-4152	2	71	,	,	PUNCT
dpc-4152	2	72	local	local	ADJ
dpc-4152	2	73	adverse	adverse	ADJ
dpc-4152	2	74	events	event	NOUN
dpc-4152	2	75	citation	citation	NOUN
dpc-4152	2	76	:	:	PUNCT
dpc-4152	3	1	valenti	valenti	PROPN
dpc-4152	3	2	m	m	PROPN
dpc-4152	3	3	,	,	PUNCT
dpc-4152	3	4	bianco	bianco	PROPN
dpc-4152	3	5	m	m	PROPN
dpc-4152	3	6	,	,	PUNCT
dpc-4152	3	7	narcisi	narcisi	ADV
dpc-4152	3	8	a	a	PRON
dpc-4152	3	9	,	,	PUNCT
dpc-4152	3	10	costanzo	costanzo	PROPN
dpc-4152	3	11	a	a	PRON
dpc-4152	3	12	,	,	PUNCT
dpc-4152	3	13	borroni	borroni	PROPN
dpc-4152	3	14	rg	rg	NOUN
dpc-4152	3	15	,	,	PUNCT
dpc-4152	3	16	ardigò	ardigò	NOUN
dpc-4152	3	17	m.	m.	NOUN
dpc-4152	3	18	topical	topical	ADJ
dpc-4152	3	19	pharmacological	pharmacological	ADJ
dpc-4152	3	20	treatment	treatment	NOUN
dpc-4152	3	21	of	of	ADP
dpc-4152	3	22	actinic	actinic	ADJ
dpc-4152	3	23	keratoses	keratose	NOUN
dpc-4152	3	24	:	:	PUNCT
dpc-4152	3	25	focus	focus	VERB
dpc-4152	3	26	on	on	ADP
dpc-4152	3	27	tirbanibulin	tirbanibulin	PROPN
dpc-4152	3	28	1	1	NUM
dpc-4152	3	29	%	%	NOUN
dpc-4152	3	30	ointment	ointment	NOUN
dpc-4152	3	31	.	.	PUNCT
dpc-4152	4	1	dermatol	dermatol	NOUN
dpc-4152	4	2	pract	pract	PROPN
dpc-4152	4	3	concept	concept	NOUN
dpc-4152	4	4	.	.	PUNCT
dpc-4152	5	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	5	2	:	:	PUNCT
dpc-4152	6	1	e2024145s	e2024145s	NOUN
dpc-4152	6	2	.	.	PUNCT
dpc-4152	6	3	doi	doi	NOUN
dpc-4152	6	4	:	:	PUNCT
dpc-4152	6	5	https://doi.org/10.5826/dpc.1403s1a145s	https://doi.org/10.5826/dpc.1403s1a145s	NOUN
dpc-4152	6	6	accepted	accept	VERB
dpc-4152	6	7	:	:	PUNCT
dpc-4152	6	8	april	april	PROPN
dpc-4152	6	9	22	22	NUM
dpc-4152	6	10	,	,	PUNCT
dpc-4152	6	11	2024	2024	NUM
dpc-4152	6	12	;	;	PUNCT
dpc-4152	6	13	published	publish	VERB
dpc-4152	6	14	:	:	PUNCT
dpc-4152	7	1	july	july	PROPN
dpc-4152	7	2	2024	2024	NUM
dpc-4152	7	3	copyright	copyright	NOUN
dpc-4152	7	4	:	:	PUNCT
dpc-4152	7	5	©	©	PROPN
dpc-4152	7	6	2024	2024	NUM
dpc-4152	7	7	valenti	valenti	PROPN
dpc-4152	7	8	et	et	PROPN
dpc-4152	7	9	al	al	PROPN
dpc-4152	7	10	.	.	PUNCT
dpc-4152	8	1	this	this	PRON
dpc-4152	8	2	is	be	AUX
dpc-4152	8	3	an	an	DET
dpc-4152	8	4	open	open	ADJ
dpc-4152	8	5	-	-	PUNCT
dpc-4152	8	6	access	access	NOUN
dpc-4152	8	7	article	article	NOUN
dpc-4152	8	8	distributed	distribute	VERB
dpc-4152	8	9	under	under	ADP
dpc-4152	8	10	the	the	DET
dpc-4152	8	11	terms	term	NOUN
dpc-4152	8	12	of	of	ADP
dpc-4152	8	13	the	the	DET
dpc-4152	8	14	creative	creative	ADJ
dpc-4152	8	15	commons	common	NOUN
dpc-4152	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4152	8	17	license	license	NOUN
dpc-4152	8	18	(	(	PUNCT
dpc-4152	8	19	by	by	ADP
dpc-4152	8	20	-	-	PUNCT
dpc-4152	8	21	nc-4.0	nc-4.0	NOUN
dpc-4152	8	22	)	)	PUNCT
dpc-4152	8	23	,	,	PUNCT
dpc-4152	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4152	8	25	,	,	PUNCT
dpc-4152	8	26	which	which	PRON
dpc-4152	8	27	permits	permit	VERB
dpc-4152	8	28	unrestricted	unrestricted	ADJ
dpc-4152	8	29	noncommercial	noncommercial	ADJ
dpc-4152	8	30	use	use	NOUN
dpc-4152	8	31	,	,	PUNCT
dpc-4152	8	32	distribution	distribution	NOUN
dpc-4152	8	33	,	,	PUNCT
dpc-4152	8	34	and	and	CCONJ
dpc-4152	8	35	reproduction	reproduction	NOUN
dpc-4152	8	36	in	in	ADP
dpc-4152	8	37	any	any	DET
dpc-4152	8	38	medium	medium	NOUN
dpc-4152	8	39	,	,	PUNCT
dpc-4152	8	40	provided	provide	VERB
dpc-4152	8	41	the	the	DET
dpc-4152	8	42	original	original	ADJ
dpc-4152	8	43	authors	author	NOUN
dpc-4152	8	44	and	and	CCONJ
dpc-4152	8	45	source	source	NOUN
dpc-4152	8	46	are	be	AUX
dpc-4152	8	47	credited	credit	VERB
dpc-4152	8	48	.	.	PUNCT
dpc-4152	9	1	funding	funding	NOUN
dpc-4152	9	2	:	:	PUNCT
dpc-4152	9	3	none	none	NOUN
dpc-4152	9	4	.	.	PUNCT
dpc-4152	10	1	competing	compete	VERB
dpc-4152	10	2	interests	interest	NOUN
dpc-4152	10	3	:	:	PUNCT
dpc-4152	10	4	none	none	NOUN
dpc-4152	10	5	.	.	PUNCT
dpc-4152	11	1	authorship	authorship	NOUN
dpc-4152	11	2	:	:	PUNCT
dpc-4152	11	3	all	all	DET
dpc-4152	11	4	authors	author	NOUN
dpc-4152	11	5	have	have	AUX
dpc-4152	11	6	contributed	contribute	VERB
dpc-4152	11	7	significantly	significantly	ADV
dpc-4152	11	8	to	to	ADP
dpc-4152	11	9	this	this	DET
dpc-4152	11	10	publication	publication	NOUN
dpc-4152	11	11	.	.	PUNCT
dpc-4152	12	1	corresponding	correspond	VERB
dpc-4152	12	2	author	author	NOUN
dpc-4152	12	3	:	:	PUNCT
dpc-4152	12	4	mario	mario	PROPN
dpc-4152	12	5	valenti	valenti	PROPN
dpc-4152	12	6	,	,	PUNCT
dpc-4152	12	7	md	md	PROPN
dpc-4152	12	8	,	,	PUNCT
dpc-4152	12	9	department	department	PROPN
dpc-4152	12	10	of	of	ADP
dpc-4152	12	11	biomedical	biomedical	ADJ
dpc-4152	12	12	sciences	sciences	PROPN
dpc-4152	12	13	,	,	PUNCT
dpc-4152	12	14	humanitas	humanita	NOUN
dpc-4152	12	15	university	university	NOUN
dpc-4152	12	16	,	,	PUNCT
dpc-4152	12	17	pieve	pieve	PROPN
dpc-4152	12	18	emanuele	emanuele	PROPN
dpc-4152	12	19	;	;	PUNCT
dpc-4152	12	20	dermatology	dermatology	NOUN
dpc-4152	12	21	unit	unit	NOUN
dpc-4152	12	22	,	,	PUNCT
dpc-4152	12	23	irccs	ircc	VERB
dpc-4152	12	24	humanitas	humanitas	NOUN
dpc-4152	12	25	research	research	NOUN
dpc-4152	12	26	hospital	hospital	NOUN
dpc-4152	12	27	,	,	PUNCT
dpc-4152	12	28	rozzano	rozzano	PROPN
dpc-4152	12	29	,	,	PUNCT
dpc-4152	12	30	italy	italy	PROPN
dpc-4152	12	31	.	.	PUNCT
dpc-4152	13	1	email	email	NOUN
dpc-4152	13	2	:	:	PUNCT
dpc-4152	13	3	mario.valenti@hunimed.eu	mario.valenti@hunimed.eu	PROPN
dpc-4152	13	4	actinic	actinic	ADJ
dpc-4152	13	5	keratosis	keratosis	NOUN
dpc-4152	13	6	(	(	PUNCT
dpc-4152	13	7	ak	ak	PROPN
dpc-4152	13	8	)	)	PUNCT
dpc-4152	13	9	is	be	AUX
dpc-4152	13	10	a	a	DET
dpc-4152	13	11	frequent	frequent	ADJ
dpc-4152	13	12	precancerous	precancerous	ADJ
dpc-4152	13	13	skin	skin	NOUN
dpc-4152	13	14	lesion	lesion	NOUN
dpc-4152	13	15	that	that	PRON
dpc-4152	13	16	mostly	mostly	ADV
dpc-4152	13	17	affects	affect	VERB
dpc-4152	13	18	chronically	chronically	ADV
dpc-4152	13	19	sun	sun	NOUN
dpc-4152	13	20	exposed	expose	VERB
dpc-4152	13	21	areas	area	NOUN
dpc-4152	13	22	.	.	PUNCT
dpc-4152	14	1	chronic	chronic	ADJ
dpc-4152	14	2	sun	sun	NOUN
dpc-4152	14	3	damage	damage	NOUN
dpc-4152	14	4	leads	lead	VERB
dpc-4152	14	5	to	to	ADP
dpc-4152	14	6	various	various	ADJ
dpc-4152	14	7	mutations	mutation	NOUN
dpc-4152	14	8	in	in	ADP
dpc-4152	14	9	onco	onco	NOUN
dpc-4152	14	10	-	-	PUNCT
dpc-4152	14	11	suppressor	suppressor	NOUN
dpc-4152	14	12	and	and	CCONJ
dpc-4152	14	13	oncogenic	oncogenic	ADJ
dpc-4152	14	14	genes	gene	NOUN
dpc-4152	14	15	which	which	PRON
dpc-4152	14	16	cause	cause	VERB
dpc-4152	14	17	an	an	DET
dpc-4152	14	18	uncontrolled	uncontrolled	ADJ
dpc-4152	14	19	proliferation	proliferation	NOUN
dpc-4152	14	20	of	of	ADP
dpc-4152	14	21	atypical	atypical	ADJ
dpc-4152	14	22	keratinocytes	keratinocyte	NOUN
dpc-4152	14	23	.	.	PUNCT
dpc-4152	15	1	untreated	untreated	ADJ
dpc-4152	15	2	aks	ak	NOUN
dpc-4152	15	3	may	may	AUX
dpc-4152	15	4	evolve	evolve	VERB
dpc-4152	15	5	in	in	ADP
dpc-4152	15	6	cutaneous	cutaneous	ADJ
dpc-4152	15	7	squamous	squamous	ADJ
dpc-4152	15	8	cell	cell	NOUN
dpc-4152	15	9	carcinoma	carcinoma	NOUN
dpc-4152	15	10	(	(	PUNCT
dpc-4152	15	11	cscc	cscc	ADJ
dpc-4152	15	12	)	)	PUNCT
dpc-4152	15	13	,	,	PUNCT
dpc-4152	15	14	with	with	ADP
dpc-4152	15	15	the	the	DET
dpc-4152	15	16	consequent	consequent	ADJ
dpc-4152	15	17	need	need	NOUN
dpc-4152	15	18	for	for	ADP
dpc-4152	15	19	dermato	dermato	NOUN
dpc-4152	15	20	-	-	PUNCT
dpc-4152	15	21	surgical	surgical	ADJ
dpc-4152	15	22	excision	excision	NOUN
dpc-4152	15	23	or	or	CCONJ
dpc-4152	15	24	even	even	ADV
dpc-4152	15	25	for	for	ADP
dpc-4152	15	26	systemic	systemic	ADJ
dpc-4152	15	27	immunotherapy	immunotherapy	NOUN
dpc-4152	15	28	in	in	ADP
dpc-4152	15	29	case	case	NOUN
dpc-4152	15	30	of	of	ADP
dpc-4152	15	31	invasive	invasive	ADJ
dpc-4152	15	32	/	/	SYM
dpc-4152	15	33	metastatic	metastatic	ADJ
dpc-4152	15	34	csccs	csccs	NOUN
dpc-4152	15	35	.	.	PUNCT
dpc-4152	16	1	epidemiology	epidemiology	NOUN
dpc-4152	16	2	data	datum	NOUN
dpc-4152	16	3	on	on	ADP
dpc-4152	16	4	ak	ak	PROPN
dpc-4152	16	5	prevalence	prevalence	NOUN
dpc-4152	16	6	are	be	AUX
dpc-4152	16	7	various	various	ADJ
dpc-4152	16	8	,	,	PUNCT
dpc-4152	16	9	however	however	ADV
dpc-4152	16	10	,	,	PUNCT
dpc-4152	16	11	the	the	DET
dpc-4152	16	12	literature	literature	NOUN
dpc-4152	16	13	unanimously	unanimously	ADV
dpc-4152	16	14	reports	report	VERB
dpc-4152	16	15	an	an	DET
dpc-4152	16	16	increasing	increase	VERB
dpc-4152	16	17	prevalence	prevalence	NOUN
dpc-4152	16	18	due	due	ADP
dpc-4152	16	19	to	to	ADP
dpc-4152	16	20	the	the	DET
dpc-4152	16	21	aging	aging	NOUN
dpc-4152	16	22	of	of	ADP
dpc-4152	16	23	the	the	DET
dpc-4152	16	24	population	population	NOUN
dpc-4152	16	25	.	.	PUNCT
dpc-4152	17	1	clinically	clinically	ADV
dpc-4152	17	2	aks	ak	NOUN
dpc-4152	17	3	appear	appear	VERB
dpc-4152	17	4	as	as	ADP
dpc-4152	17	5	a	a	DET
dpc-4152	17	6	scaly	scaly	NOUN
dpc-4152	17	7	,	,	PUNCT
dpc-4152	17	8	erythematous	erythematous	ADJ
dpc-4152	17	9	macule	macule	NOUN
dpc-4152	17	10	or	or	CCONJ
dpc-4152	17	11	papule	papule	NOUN
dpc-4152	17	12	or	or	CCONJ
dpc-4152	17	13	hyperkeratotic	hyperkeratotic	ADJ
dpc-4152	17	14	plaque	plaque	NOUN
dpc-4152	17	15	.	.	PUNCT
dpc-4152	18	1	management	management	NOUN
dpc-4152	18	2	of	of	ADP
dpc-4152	18	3	aks	ak	NOUN
dpc-4152	18	4	and	and	CCONJ
dpc-4152	18	5	the	the	DET
dpc-4152	18	6	field	field	NOUN
dpc-4152	18	7	of	of	ADP
dpc-4152	18	8	cancerization	cancerization	NOUN
dpc-4152	18	9	is	be	AUX
dpc-4152	18	10	important	important	ADJ
dpc-4152	18	11	to	to	PART
dpc-4152	18	12	avoid	avoid	VERB
dpc-4152	18	13	the	the	DET
dpc-4152	18	14	natural	natural	ADJ
dpc-4152	18	15	evolution	evolution	NOUN
dpc-4152	18	16	into	into	ADP
dpc-4152	18	17	squamous	squamous	ADJ
dpc-4152	18	18	cell	cell	NOUN
dpc-4152	18	19	carcinomas	carcinoma	NOUN
dpc-4152	18	20	(	(	PUNCT
dpc-4152	18	21	sccs	sccs	PROPN
dpc-4152	18	22	)	)	PUNCT
dpc-4152	18	23	.	.	PUNCT
dpc-4152	19	1	both	both	DET
dpc-4152	19	2	physical	physical	ADJ
dpc-4152	19	3	and	and	CCONJ
dpc-4152	19	4	topical	topical	ADJ
dpc-4152	19	5	treatments	treatment	NOUN
dpc-4152	19	6	are	be	AUX
dpc-4152	19	7	approved	approve	VERB
dpc-4152	19	8	for	for	ADP
dpc-4152	19	9	managing	manage	VERB
dpc-4152	19	10	aks	ak	NOUN
dpc-4152	19	11	.	.	PUNCT
dpc-4152	20	1	patient	patient	ADJ
dpc-4152	20	2	compliance	compliance	NOUN
dpc-4152	20	3	with	with	ADP
dpc-4152	20	4	topical	topical	ADJ
dpc-4152	20	5	regimens	regimen	NOUN
dpc-4152	20	6	is	be	AUX
dpc-4152	20	7	usually	usually	ADV
dpc-4152	20	8	low	low	ADJ
dpc-4152	20	9	due	due	ADP
dpc-4152	20	10	to	to	ADP
dpc-4152	20	11	the	the	DET
dpc-4152	20	12	length	length	NOUN
dpc-4152	20	13	of	of	ADP
dpc-4152	20	14	the	the	DET
dpc-4152	20	15	posology	posology	NOUN
dpc-4152	20	16	and	and	CCONJ
dpc-4152	20	17	frequent	frequent	ADJ
dpc-4152	20	18	skin	skin	NOUN
dpc-4152	20	19	adverse	adverse	ADJ
dpc-4152	20	20	events	event	NOUN
dpc-4152	20	21	.	.	PUNCT
dpc-4152	21	1	a	a	DET
dpc-4152	21	2	recently	recently	ADV
dpc-4152	21	3	approved	approve	VERB
dpc-4152	21	4	tirbanibulin	tirbanibulin	ADV
dpc-4152	21	5	-	-	PUNCT
dpc-4152	21	6	based	base	VERB
dpc-4152	21	7	ointment	ointment	NOUN
dpc-4152	21	8	,	,	PUNCT
dpc-4152	21	9	showed	show	VERB
dpc-4152	21	10	potential	potential	NOUN
dpc-4152	21	11	for	for	ADP
dpc-4152	21	12	inhibiting	inhibit	VERB
dpc-4152	21	13	cell	cell	NOUN
dpc-4152	21	14	proliferation	proliferation	NOUN
dpc-4152	21	15	and	and	CCONJ
dpc-4152	21	16	blocking	block	VERB
dpc-4152	21	17	src	src	NOUN
dpc-4152	21	18	-	-	PUNCT
dpc-4152	21	19	kinases	kinase	NOUN
dpc-4152	21	20	,	,	PUNCT
dpc-4152	21	21	implicated	implicate	VERB
dpc-4152	21	22	in	in	ADP
dpc-4152	21	23	the	the	DET
dpc-4152	21	24	progression	progression	NOUN
dpc-4152	21	25	of	of	ADP
dpc-4152	21	26	aks	ak	NOUN
dpc-4152	21	27	in	in	ADP
dpc-4152	21	28	sccs	sccs	PROPN
dpc-4152	21	29	.	.	PUNCT
dpc-4152	22	1	the	the	DET
dpc-4152	22	2	advantage	advantage	NOUN
dpc-4152	22	3	of	of	ADP
dpc-4152	22	4	this	this	DET
dpc-4152	22	5	new	new	ADJ
dpc-4152	22	6	treatment	treatment	NOUN
dpc-4152	22	7	is	be	AUX
dpc-4152	22	8	the	the	DET
dpc-4152	22	9	practical	practical	ADJ
dpc-4152	22	10	posology	posology	NOUN
dpc-4152	22	11	,	,	PUNCT
dpc-4152	22	12	with	with	ADP
dpc-4152	22	13	a	a	DET
dpc-4152	22	14	daily	daily	ADJ
dpc-4152	22	15	application	application	NOUN
dpc-4152	22	16	for	for	ADP
dpc-4152	22	17	5	5	NUM
dpc-4152	22	18	consecutive	consecutive	ADJ
dpc-4152	22	19	days	day	NOUN
dpc-4152	22	20	on	on	ADP
dpc-4152	22	21	aks	ak	NOUN
dpc-4152	22	22	of	of	ADP
dpc-4152	22	23	the	the	DET
dpc-4152	22	24	face	face	NOUN
dpc-4152	22	25	-	-	PUNCT
dpc-4152	22	26	scalp	scalp	NOUN
dpc-4152	22	27	area	area	NOUN
dpc-4152	22	28	.	.	PUNCT
dpc-4152	23	1	local	local	ADJ
dpc-4152	23	2	skin	skin	NOUN
dpc-4152	23	3	reactions	reaction	NOUN
dpc-4152	23	4	are	be	AUX
dpc-4152	23	5	usually	usually	ADV
dpc-4152	23	6	mild	mild	ADJ
dpc-4152	23	7	and	and	CCONJ
dpc-4152	23	8	do	do	AUX
dpc-4152	23	9	not	not	PART
dpc-4152	23	10	require	require	VERB
dpc-4152	23	11	treatment	treatment	NOUN
dpc-4152	23	12	discontinuation	discontinuation	NOUN
dpc-4152	23	13	.	.	PUNCT
dpc-4152	24	1	the	the	DET
dpc-4152	24	2	short	short	ADJ
dpc-4152	24	3	course	course	NOUN
dpc-4152	24	4	of	of	ADP
dpc-4152	24	5	this	this	DET
dpc-4152	24	6	new	new	ADJ
dpc-4152	24	7	therapy	therapy	NOUN
dpc-4152	24	8	and	and	CCONJ
dpc-4152	24	9	its	its	PRON
dpc-4152	24	10	excellent	excellent	ADJ
dpc-4152	24	11	tolerance	tolerance	NOUN
dpc-4152	24	12	massively	massively	ADV
dpc-4152	24	13	increased	increase	VERB
dpc-4152	24	14	patient	patient	ADJ
dpc-4152	24	15	compliance	compliance	NOUN
dpc-4152	24	16	.	.	PUNCT
dpc-4152	25	1	this	this	DET
dpc-4152	25	2	article	article	NOUN
dpc-4152	25	3	reviews	review	VERB
dpc-4152	25	4	what	what	PRON
dpc-4152	25	5	is	be	AUX
dpc-4152	25	6	currently	currently	ADV
dpc-4152	25	7	known	know	VERB
dpc-4152	25	8	about	about	ADP
dpc-4152	25	9	this	this	DET
dpc-4152	25	10	new	new	ADJ
dpc-4152	25	11	therapy	therapy	NOUN
dpc-4152	25	12	from	from	ADP
dpc-4152	25	13	its	its	PRON
dpc-4152	25	14	mechanism	mechanism	NOUN
dpc-4152	25	15	of	of	ADP
dpc-4152	25	16	action	action	NOUN
dpc-4152	25	17	to	to	ADP
dpc-4152	25	18	clinical	clinical	ADJ
dpc-4152	25	19	trial	trial	NOUN
dpc-4152	25	20	outcomes	outcome	NOUN
dpc-4152	25	21	regarding	regard	VERB
dpc-4152	25	22	safety	safety	NOUN
dpc-4152	25	23	,	,	PUNCT
dpc-4152	25	24	effectiveness	effectiveness	NOUN
dpc-4152	25	25	,	,	PUNCT
dpc-4152	25	26	and	and	CCONJ
dpc-4152	25	27	patient	patient	ADJ
dpc-4152	25	28	adherence	adherence	NOUN
dpc-4152	25	29	to	to	ADP
dpc-4152	25	30	the	the	DET
dpc-4152	25	31	treatment	treatment	NOUN
dpc-4152	25	32	.	.	PUNCT
dpc-4152	26	1	abstract	abstract	ADJ
dpc-4152	26	2	2	2	NUM
dpc-4152	26	3	review	review	NOUN
dpc-4152	26	4	|	|	ADV
dpc-4152	26	5	dermatol	dermatol	ADJ
dpc-4152	26	6	pract	pract	NOUN
dpc-4152	26	7	concept	concept	NOUN
dpc-4152	26	8	.	.	PUNCT
dpc-4152	27	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	27	2	:	:	PUNCT
dpc-4152	27	3	e2024145s	e2024145s	NOUN
dpc-4152	27	4	introduction	introduction	NOUN
dpc-4152	27	5	actinic	actinic	ADJ
dpc-4152	27	6	keratoses	keratose	NOUN
dpc-4152	27	7	(	(	PUNCT
dpc-4152	27	8	or	or	CCONJ
dpc-4152	27	9	solar	solar	ADJ
dpc-4152	27	10	keratoses	keratose	NOUN
dpc-4152	27	11	)	)	PUNCT
dpc-4152	27	12	are	be	AUX
dpc-4152	27	13	the	the	DET
dpc-4152	27	14	clinical	clinical	ADJ
dpc-4152	27	15	manifestation	manifestation	NOUN
dpc-4152	27	16	of	of	ADP
dpc-4152	27	17	a	a	DET
dpc-4152	27	18	common	common	ADJ
dpc-4152	27	19	,	,	PUNCT
dpc-4152	27	20	chronic	chronic	ADJ
dpc-4152	27	21	disease	disease	NOUN
dpc-4152	27	22	of	of	ADP
dpc-4152	27	23	the	the	DET
dpc-4152	27	24	skin	skin	NOUN
dpc-4152	27	25	of	of	ADP
dpc-4152	27	26	adults	adult	NOUN
dpc-4152	27	27	[	[	X
dpc-4152	27	28	1	1	NUM
dpc-4152	27	29	]	]	PUNCT
dpc-4152	27	30	,	,	PUNCT
dpc-4152	27	31	which	which	PRON
dpc-4152	27	32	develops	develop	VERB
dpc-4152	27	33	in	in	ADP
dpc-4152	27	34	areas	area	NOUN
dpc-4152	27	35	exposed	expose	VERB
dpc-4152	27	36	to	to	ADP
dpc-4152	27	37	sunlight	sunlight	NOUN
dpc-4152	27	38	[	[	X
dpc-4152	27	39	2	2	NUM
dpc-4152	27	40	]	]	PUNCT
dpc-4152	27	41	.	.	PUNCT
dpc-4152	28	1	risk	risk	NOUN
dpc-4152	28	2	factors	factor	NOUN
dpc-4152	28	3	for	for	ADP
dpc-4152	28	4	the	the	DET
dpc-4152	28	5	development	development	NOUN
dpc-4152	28	6	of	of	ADP
dpc-4152	28	7	actinic	actinic	ADJ
dpc-4152	28	8	keratoses	keratose	NOUN
dpc-4152	28	9	and	and	CCONJ
dpc-4152	28	10	scc	scc	NOUN
dpc-4152	28	11	are	be	AUX
dpc-4152	28	12	i	i	PROPN
dpc-4152	28	13	-	-	PUNCT
dpc-4152	28	14	ii	ii	PROPN
dpc-4152	28	15	phototypes	phototype	NOUN
dpc-4152	28	16	according	accord	VERB
dpc-4152	28	17	to	to	ADP
dpc-4152	28	18	fitzpatrick	fitzpatrick	PROPN
dpc-4152	28	19	’s	’s	PART
dpc-4152	28	20	scale	scale	NOUN
dpc-4152	28	21	,	,	PUNCT
dpc-4152	28	22	male	male	ADJ
dpc-4152	28	23	sex	sex	NOUN
dpc-4152	28	24	,	,	PUNCT
dpc-4152	28	25	age	age	NOUN
dpc-4152	28	26	,	,	PUNCT
dpc-4152	28	27	and	and	CCONJ
dpc-4152	28	28	immunodepression	immunodepression	NOUN
dpc-4152	28	29	[	[	X
dpc-4152	28	30	3	3	NUM
dpc-4152	28	31	-	-	SYM
dpc-4152	28	32	5	5	NUM
dpc-4152	28	33	]	]	PUNCT
dpc-4152	28	34	.	.	PUNCT
dpc-4152	29	1	the	the	DET
dpc-4152	29	2	incidence	incidence	NOUN
dpc-4152	29	3	of	of	ADP
dpc-4152	29	4	aks	ak	NOUN
dpc-4152	29	5	is	be	AUX
dpc-4152	29	6	likely	likely	ADV
dpc-4152	29	7	underestimated	underestimate	VERB
dpc-4152	29	8	,	,	PUNCT
dpc-4152	29	9	as	as	SCONJ
dpc-4152	29	10	they	they	PRON
dpc-4152	29	11	are	be	AUX
dpc-4152	29	12	not	not	PART
dpc-4152	29	13	recorded	record	VERB
dpc-4152	29	14	routinely	routinely	ADV
dpc-4152	29	15	in	in	ADP
dpc-4152	29	16	cancer	cancer	NOUN
dpc-4152	29	17	registries	registry	NOUN
dpc-4152	29	18	.	.	PUNCT
dpc-4152	30	1	unsurprisingly	unsurprisingly	ADV
dpc-4152	30	2	,	,	PUNCT
dpc-4152	30	3	the	the	DET
dpc-4152	30	4	prevalence	prevalence	NOUN
dpc-4152	30	5	of	of	ADP
dpc-4152	30	6	aks	aks	PROPN
dpc-4152	30	7	shows	show	VERB
dpc-4152	30	8	an	an	DET
dpc-4152	30	9	increase	increase	NOUN
dpc-4152	30	10	in	in	ADP
dpc-4152	30	11	its	its	PRON
dpc-4152	30	12	trend	trend	NOUN
dpc-4152	30	13	[	[	X
dpc-4152	30	14	3	3	NUM
dpc-4152	30	15	]	]	PUNCT
dpc-4152	30	16	.	.	PUNCT
dpc-4152	31	1	aks	ak	NOUN
dpc-4152	31	2	represent	represent	VERB
dpc-4152	31	3	one	one	NUM
dpc-4152	31	4	of	of	ADP
dpc-4152	31	5	the	the	DET
dpc-4152	31	6	most	most	ADV
dpc-4152	31	7	common	common	ADJ
dpc-4152	31	8	conditions	condition	NOUN
dpc-4152	31	9	diagnosed	diagnose	VERB
dpc-4152	31	10	and	and	CCONJ
dpc-4152	31	11	treated	treat	VERB
dpc-4152	31	12	by	by	ADP
dpc-4152	31	13	dermatologists	dermatologist	NOUN
dpc-4152	31	14	in	in	ADP
dpc-4152	31	15	the	the	DET
dpc-4152	31	16	united	united	PROPN
dpc-4152	31	17	states	states	PROPN
dpc-4152	31	18	(	(	PUNCT
dpc-4152	31	19	us	us	PROPN
dpc-4152	31	20	)	)	PUNCT
dpc-4152	31	21	,	,	PUNCT
dpc-4152	31	22	where	where	SCONJ
dpc-4152	31	23	currently	currently	ADV
dpc-4152	31	24	up	up	ADP
dpc-4152	31	25	to	to	PART
dpc-4152	31	26	12	12	NUM
dpc-4152	31	27	%	%	NOUN
dpc-4152	31	28	of	of	ADP
dpc-4152	31	29	individuals	individual	NOUN
dpc-4152	31	30	have	have	VERB
dpc-4152	31	31	aks	ak	NOUN
dpc-4152	31	32	[	[	X
dpc-4152	31	33	6	6	NUM
dpc-4152	31	34	]	]	PUNCT
dpc-4152	31	35	.	.	PUNCT
dpc-4152	32	1	a	a	DET
dpc-4152	32	2	rotterdam	rotterdam	PROPN
dpc-4152	32	3	prevalence	prevalence	NOUN
dpc-4152	32	4	study	study	NOUN
dpc-4152	32	5	of	of	ADP
dpc-4152	32	6	>	>	SYM
dpc-4152	32	7	2,000	2,000	NUM
dpc-4152	32	8	dutch	dutch	ADJ
dpc-4152	32	9	men	man	NOUN
dpc-4152	32	10	and	and	CCONJ
dpc-4152	32	11	women	woman	NOUN
dpc-4152	32	12	,	,	PUNCT
dpc-4152	32	13	with	with	ADP
dpc-4152	32	14	a	a	DET
dpc-4152	32	15	mean	mean	ADJ
dpc-4152	32	16	age	age	NOUN
dpc-4152	32	17	of	of	ADP
dpc-4152	32	18	72	72	NUM
dpc-4152	32	19	years	year	NOUN
dpc-4152	32	20	,	,	PUNCT
dpc-4152	32	21	found	find	VERB
dpc-4152	32	22	ak	ak	PROPN
dpc-4152	32	23	in	in	ADP
dpc-4152	32	24	49	49	NUM
dpc-4152	32	25	%	%	NOUN
dpc-4152	32	26	of	of	ADP
dpc-4152	32	27	men	man	NOUN
dpc-4152	32	28	and	and	CCONJ
dpc-4152	32	29	28	28	NUM
dpc-4152	32	30	%	%	NOUN
dpc-4152	32	31	of	of	ADP
dpc-4152	32	32	women	woman	NOUN
dpc-4152	32	33	[	[	X
dpc-4152	32	34	7	7	NUM
dpc-4152	32	35	]	]	PUNCT
dpc-4152	32	36	.	.	PUNCT
dpc-4152	33	1	in	in	ADP
dpc-4152	33	2	galway	galway	PROPN
dpc-4152	33	3	,	,	PUNCT
dpc-4152	33	4	south	south	PROPN
dpc-4152	33	5	wales	wales	PROPN
dpc-4152	33	6	and	and	CCONJ
dpc-4152	33	7	merseyside	merseyside	NOUN
dpc-4152	33	8	(	(	PUNCT
dpc-4152	33	9	uk	uk	PROPN
dpc-4152	33	10	)	)	PUNCT
dpc-4152	33	11	,	,	PUNCT
dpc-4152	33	12	19	19	NUM
dpc-4152	33	13	-	-	SYM
dpc-4152	33	14	24	24	NUM
dpc-4152	33	15	%	%	NOUN
dpc-4152	33	16	of	of	ADP
dpc-4152	33	17	individuals	individual	NOUN
dpc-4152	33	18	aged	age	VERB
dpc-4152	33	19	>	>	SYM
dpc-4152	33	20	60	60	NUM
dpc-4152	33	21	had	have	VERB
dpc-4152	33	22	at	at	ADV
dpc-4152	33	23	least	least	ADV
dpc-4152	33	24	one	one	NUM
dpc-4152	33	25	ak	ak	PROPN
dpc-4152	33	26	.	.	PROPN
dpc-4152	34	1	over	over	ADP
dpc-4152	34	2	30	30	NUM
dpc-4152	34	3	%	%	NOUN
dpc-4152	34	4	of	of	ADP
dpc-4152	34	5	those	those	PRON
dpc-4152	34	6	attending	attend	VERB
dpc-4152	34	7	a	a	DET
dpc-4152	34	8	dermatology	dermatology	NOUN
dpc-4152	34	9	clinic	clinic	NOUN
dpc-4152	34	10	(	(	PUNCT
dpc-4152	34	11	mean	mean	INTJ
dpc-4152	34	12	age	age	NOUN
dpc-4152	34	13	of	of	ADP
dpc-4152	34	14	attendance	attendance	NOUN
dpc-4152	34	15	61	61	NUM
dpc-4152	34	16	years	year	NOUN
dpc-4152	34	17	)	)	PUNCT
dpc-4152	34	18	in	in	ADP
dpc-4152	34	19	austria	austria	PROPN
dpc-4152	34	20	had	have	VERB
dpc-4152	34	21	ak	ak	PROPN
dpc-4152	34	22	.	.	PROPN
dpc-4152	34	23	up	up	ADP
dpc-4152	34	24	to	to	PART
dpc-4152	34	25	60	60	NUM
dpc-4152	34	26	%	%	NOUN
dpc-4152	34	27	of	of	ADP
dpc-4152	34	28	australians	australian	NOUN
dpc-4152	34	29	over	over	ADP
dpc-4152	34	30	the	the	DET
dpc-4152	34	31	age	age	NOUN
dpc-4152	34	32	of	of	ADP
dpc-4152	34	33	40	40	NUM
dpc-4152	34	34	have	have	VERB
dpc-4152	34	35	aks	ak	NOUN
dpc-4152	34	36	[	[	X
dpc-4152	34	37	8,9	8,9	NUM
dpc-4152	34	38	]	]	PUNCT
dpc-4152	34	39	.	.	PUNCT
dpc-4152	35	1	histologically	histologically	PROPN
dpc-4152	35	2	,	,	PUNCT
dpc-4152	35	3	aks	ak	NOUN
dpc-4152	35	4	are	be	AUX
dpc-4152	35	5	characterized	characterize	VERB
dpc-4152	35	6	by	by	ADP
dpc-4152	35	7	epidermal	epidermal	ADJ
dpc-4152	35	8	hyperplasia	hyperplasia	NOUN
dpc-4152	35	9	and	and	CCONJ
dpc-4152	35	10	by	by	ADP
dpc-4152	35	11	variable	variable	ADJ
dpc-4152	35	12	degrees	degree	NOUN
dpc-4152	35	13	of	of	ADP
dpc-4152	35	14	keratinocyte	keratinocyte	NOUN
dpc-4152	35	15	atypia	atypia	PROPN
dpc-4152	35	16	,	,	PUNCT
dpc-4152	35	17	which	which	PRON
dpc-4152	35	18	can	can	AUX
dpc-4152	35	19	involve	involve	VERB
dpc-4152	35	20	all	all	DET
dpc-4152	35	21	layers	layer	NOUN
dpc-4152	35	22	of	of	ADP
dpc-4152	35	23	the	the	DET
dpc-4152	35	24	epidermis	epidermis	NOUN
dpc-4152	35	25	,	,	PUNCT
dpc-4152	35	26	as	as	ADP
dpc-4152	35	27	in	in	ADP
dpc-4152	35	28	the	the	DET
dpc-4152	35	29	in	in	ADP
dpc-4152	35	30	-	-	PUNCT
dpc-4152	35	31	situ	situ	NOUN
dpc-4152	35	32	forms	form	NOUN
dpc-4152	35	33	of	of	ADP
dpc-4152	35	34	squamous	squamous	ADJ
dpc-4152	35	35	cell	cell	NOUN
dpc-4152	35	36	carcinoma	carcinoma	NOUN
dpc-4152	36	1	[	[	X
dpc-4152	36	2	10	10	NUM
dpc-4152	36	3	]	]	PUNCT
dpc-4152	36	4	.	.	PUNCT
dpc-4152	37	1	indeed	indeed	ADV
dpc-4152	37	2	,	,	PUNCT
dpc-4152	37	3	aks	ak	NOUN
dpc-4152	37	4	are	be	AUX
dpc-4152	37	5	considered	consider	VERB
dpc-4152	37	6	by	by	ADP
dpc-4152	37	7	some	some	PRON
dpc-4152	37	8	to	to	PART
dpc-4152	37	9	be	be	AUX
dpc-4152	37	10	a	a	DET
dpc-4152	37	11	precursor	precursor	NOUN
dpc-4152	37	12	of	of	ADP
dpc-4152	37	13	scc	scc	NOUN
dpc-4152	38	1	[	[	X
dpc-4152	38	2	11,12	11,12	NUM
dpc-4152	38	3	]	]	PUNCT
dpc-4152	38	4	by	by	ADP
dpc-4152	38	5	others	other	NOUN
dpc-4152	38	6	an	an	DET
dpc-4152	38	7	initial	initial	ADJ
dpc-4152	38	8	and	and	CCONJ
dpc-4152	38	9	superficial	superficial	ADJ
dpc-4152	38	10	form	form	NOUN
dpc-4152	38	11	[	[	X
dpc-4152	38	12	13,14	13,14	NUM
dpc-4152	38	13	]	]	PUNCT
dpc-4152	38	14	.	.	PUNCT
dpc-4152	39	1	the	the	DET
dpc-4152	39	2	histopathological	histopathological	ADJ
dpc-4152	39	3	similarities	similarity	NOUN
dpc-4152	39	4	between	between	ADP
dpc-4152	39	5	aks	ak	NOUN
dpc-4152	39	6	and	and	CCONJ
dpc-4152	39	7	squamous	squamous	ADJ
dpc-4152	39	8	cell	cell	NOUN
dpc-4152	39	9	carcinoma	carcinoma	NOUN
dpc-4152	39	10	reflect	reflect	VERB
dpc-4152	39	11	their	their	PRON
dpc-4152	39	12	same	same	ADJ
dpc-4152	39	13	pathogenesis	pathogenesis	NOUN
dpc-4152	39	14	,	,	PUNCT
dpc-4152	39	15	a	a	DET
dpc-4152	39	16	multi	multi	ADJ
dpc-4152	39	17	-	-	ADJ
dpc-4152	39	18	stage	stage	NOUN
dpc-4152	39	19	process	process	NOUN
dpc-4152	39	20	caused	cause	VERB
dpc-4152	39	21	by	by	ADP
dpc-4152	39	22	somatic	somatic	ADJ
dpc-4152	39	23	mutations	mutation	NOUN
dpc-4152	39	24	induced	induce	VERB
dpc-4152	39	25	by	by	ADP
dpc-4152	39	26	the	the	DET
dpc-4152	39	27	carcinogenic	carcinogenic	ADJ
dpc-4152	39	28	action	action	NOUN
dpc-4152	39	29	of	of	ADP
dpc-4152	39	30	ultraviolet	ultraviolet	NOUN
dpc-4152	39	31	(	(	PUNCT
dpc-4152	39	32	uv	uv	NOUN
dpc-4152	39	33	)	)	PUNCT
dpc-4152	39	34	radiation	radiation	NOUN
dpc-4152	39	35	.	.	PUNCT
dpc-4152	40	1	these	these	PRON
dpc-4152	40	2	critically	critically	ADV
dpc-4152	40	3	affect	affect	VERB
dpc-4152	40	4	the	the	DET
dpc-4152	40	5	tumor	tumor	NOUN
dpc-4152	40	6	suppressor	suppressor	NOUN
dpc-4152	40	7	tp53	tp53	PROPN
dpc-4152	40	8	gene	gene	NOUN
dpc-4152	40	9	,	,	PUNCT
dpc-4152	40	10	which	which	PRON
dpc-4152	40	11	has	have	VERB
dpc-4152	40	12	mutations	mutation	NOUN
dpc-4152	40	13	with	with	ADP
dpc-4152	40	14	uv	uv	NOUN
dpc-4152	40	15	signature	signature	NOUN
dpc-4152	40	16	(	(	PUNCT
dpc-4152	40	17	e.g.	e.g.	ADV
dpc-4152	40	18	,	,	PUNCT
dpc-4152	40	19	pyrimidine	pyrimidine	NOUN
dpc-4152	40	20	dimers	dimer	NOUN
dpc-4152	40	21	)	)	PUNCT
dpc-4152	40	22	in	in	ADP
dpc-4152	40	23	almost	almost	ADV
dpc-4152	40	24	90	90	NUM
dpc-4152	40	25	%	%	NOUN
dpc-4152	40	26	of	of	ADP
dpc-4152	40	27	ak	ak	PROPN
dpc-4152	40	28	specimens	specimen	NOUN
dpc-4152	40	29	.	.	PUNCT
dpc-4152	41	1	[	[	X
dpc-4152	41	2	7,15	7,15	NUM
dpc-4152	41	3	-	-	SYM
dpc-4152	41	4	19	19	NUM
dpc-4152	41	5	]	]	PUNCT
dpc-4152	41	6	although	although	SCONJ
dpc-4152	41	7	on	on	ADP
dpc-4152	41	8	histological	histological	ADJ
dpc-4152	41	9	examination	examination	NOUN
dpc-4152	41	10	up	up	ADP
dpc-4152	41	11	to	to	PART
dpc-4152	41	12	90	90	NUM
dpc-4152	41	13	%	%	NOUN
dpc-4152	41	14	of	of	ADP
dpc-4152	41	15	invasive	invasive	ADJ
dpc-4152	41	16	cutaneous	cutaneous	ADJ
dpc-4152	41	17	squamous	squamous	ADJ
dpc-4152	41	18	cell	cell	NOUN
dpc-4152	41	19	carcinomas	carcinoma	NOUN
dpc-4152	41	20	arise	arise	VERB
dpc-4152	41	21	contiguously	contiguously	ADV
dpc-4152	41	22	or	or	CCONJ
dpc-4152	41	23	in	in	ADP
dpc-4152	41	24	continuity	continuity	NOUN
dpc-4152	41	25	with	with	ADP
dpc-4152	41	26	aks	ak	NOUN
dpc-4152	41	27	[	[	X
dpc-4152	41	28	17,20,21	17,20,21	NUM
dpc-4152	41	29	]	]	PUNCT
dpc-4152	41	30	,	,	PUNCT
dpc-4152	41	31	prospective	prospective	ADJ
dpc-4152	41	32	evaluation	evaluation	NOUN
dpc-4152	41	33	of	of	ADP
dpc-4152	41	34	aks	ak	NOUN
dpc-4152	41	35	over	over	ADP
dpc-4152	41	36	time	time	NOUN
dpc-4152	41	37	demonstrates	demonstrate	VERB
dpc-4152	41	38	a	a	DET
dpc-4152	41	39	low	low	ADJ
dpc-4152	41	40	rate	rate	NOUN
dpc-4152	41	41	of	of	ADP
dpc-4152	41	42	transformation	transformation	NOUN
dpc-4152	41	43	to	to	ADP
dpc-4152	41	44	invasive	invasive	ADJ
dpc-4152	41	45	squamous	squamous	ADJ
dpc-4152	41	46	cell	cell	NOUN
dpc-4152	41	47	carcinoma	carcinoma	NOUN
dpc-4152	41	48	,	,	PUNCT
dpc-4152	41	49	with	with	ADP
dpc-4152	41	50	less	less	ADJ
dpc-4152	41	51	than	than	ADP
dpc-4152	41	52	one	one	NUM
dpc-4152	41	53	invasive	invasive	ADJ
dpc-4152	41	54	squamous	squamous	ADJ
dpc-4152	41	55	cell	cell	NOUN
dpc-4152	41	56	carcinoma	carcinoma	NOUN
dpc-4152	41	57	for	for	ADP
dpc-4152	41	58	every	every	DET
dpc-4152	41	59	1000	1000	NUM
dpc-4152	41	60	aks	ak	NOUN
dpc-4152	41	61	in	in	ADP
dpc-4152	41	62	a	a	DET
dpc-4152	41	63	year	year	NOUN
dpc-4152	41	64	[	[	X
dpc-4152	41	65	22	22	NUM
dpc-4152	41	66	]	]	PUNCT
dpc-4152	41	67	.	.	PUNCT
dpc-4152	42	1	in	in	ADP
dpc-4152	42	2	a	a	DET
dpc-4152	42	3	us	us	PROPN
dpc-4152	42	4	study	study	NOUN
dpc-4152	42	5	,	,	PUNCT
dpc-4152	42	6	0.6	0.6	NUM
dpc-4152	42	7	%	%	NOUN
dpc-4152	42	8	of	of	ADP
dpc-4152	42	9	patients	patient	NOUN
dpc-4152	42	10	developed	develop	VERB
dpc-4152	42	11	invasive	invasive	ADJ
dpc-4152	42	12	squamous	squamous	ADJ
dpc-4152	42	13	cell	cell	NOUN
dpc-4152	42	14	carcinoma	carcinoma	NOUN
dpc-4152	42	15	in	in	ADP
dpc-4152	42	16	the	the	DET
dpc-4152	42	17	same	same	ADJ
dpc-4152	42	18	anatomical	anatomical	ADJ
dpc-4152	42	19	site	site	NOUN
dpc-4152	42	20	as	as	ADP
dpc-4152	42	21	the	the	DET
dpc-4152	42	22	actinic	actinic	ADJ
dpc-4152	42	23	keratosis	keratosis	NOUN
dpc-4152	42	24	within	within	ADP
dpc-4152	42	25	the	the	DET
dpc-4152	42	26	first	first	ADJ
dpc-4152	42	27	year	year	NOUN
dpc-4152	42	28	,	,	PUNCT
dpc-4152	42	29	rising	rise	VERB
dpc-4152	42	30	to	to	ADP
dpc-4152	42	31	2.57	2.57	NUM
dpc-4152	42	32	%	%	NOUN
dpc-4152	42	33	at	at	ADP
dpc-4152	42	34	4	4	NUM
dpc-4152	42	35	years	year	NOUN
dpc-4152	42	36	[	[	X
dpc-4152	42	37	21	21	NUM
dpc-4152	42	38	]	]	PUNCT
dpc-4152	42	39	.	.	PUNCT
dpc-4152	43	1	rather	rather	ADV
dpc-4152	43	2	than	than	ADP
dpc-4152	43	3	referring	refer	VERB
dpc-4152	43	4	to	to	ADP
dpc-4152	43	5	the	the	DET
dpc-4152	43	6	anatomical	anatomical	ADJ
dpc-4152	43	7	regions	region	NOUN
dpc-4152	43	8	affected	affect	VERB
dpc-4152	43	9	by	by	ADP
dpc-4152	43	10	the	the	DET
dpc-4152	43	11	keratoses	keratose	NOUN
dpc-4152	43	12	actinic	actinic	ADJ
dpc-4152	43	13	keratoses	keratose	NOUN
dpc-4152	43	14	,	,	PUNCT
dpc-4152	43	15	the	the	DET
dpc-4152	43	16	risk	risk	NOUN
dpc-4152	43	17	of	of	ADP
dpc-4152	43	18	developing	develop	VERB
dpc-4152	43	19	squamous	squamous	ADJ
dpc-4152	43	20	cell	cell	NOUN
dpc-4152	43	21	carcinoma	carcinoma	NOUN
dpc-4152	43	22	can	can	AUX
dpc-4152	43	23	be	be	AUX
dpc-4152	43	24	attributed	attribute	VERB
dpc-4152	43	25	more	more	ADV
dpc-4152	43	26	correctly	correctly	ADV
dpc-4152	43	27	to	to	ADP
dpc-4152	43	28	the	the	DET
dpc-4152	43	29	subject	subject	NOUN
dpc-4152	43	30	suffering	suffer	VERB
dpc-4152	43	31	from	from	ADP
dpc-4152	43	32	actinic	actinic	ADJ
dpc-4152	43	33	keratoses	keratose	NOUN
dpc-4152	43	34	,	,	PUNCT
dpc-4152	43	35	with	with	ADP
dpc-4152	43	36	a	a	DET
dpc-4152	43	37	risk	risk	NOUN
dpc-4152	43	38	of	of	ADP
dpc-4152	43	39	invasive	invasive	ADJ
dpc-4152	43	40	squamous	squamous	ADJ
dpc-4152	43	41	cell	cell	NOUN
dpc-4152	43	42	carcinoma	carcinoma	NOUN
dpc-4152	43	43	which	which	PRON
dpc-4152	43	44	increases	increase	VERB
dpc-4152	43	45	proportionally	proportionally	ADV
dpc-4152	43	46	to	to	ADP
dpc-4152	43	47	the	the	DET
dpc-4152	43	48	number	number	NOUN
dpc-4152	43	49	of	of	ADP
dpc-4152	43	50	actinic	actinic	ADJ
dpc-4152	43	51	keratoses	keratose	NOUN
dpc-4152	43	52	[	[	X
dpc-4152	43	53	23	23	NUM
dpc-4152	43	54	]	]	PUNCT
dpc-4152	43	55	and	and	CCONJ
dpc-4152	43	56	which	which	PRON
dpc-4152	43	57	is	be	AUX
dpc-4152	43	58	estimated	estimate	VERB
dpc-4152	43	59	at	at	ADP
dpc-4152	43	60	10	10	NUM
dpc-4152	43	61	%	%	NOUN
dpc-4152	43	62	in	in	ADP
dpc-4152	43	63	10	10	NUM
dpc-4152	43	64	years	year	NOUN
dpc-4152	43	65	for	for	ADP
dpc-4152	43	66	an	an	DET
dpc-4152	43	67	average	average	ADJ
dpc-4152	43	68	patient	patient	NOUN
dpc-4152	43	69	with	with	ADP
dpc-4152	43	70	7	7	NUM
dpc-4152	43	71	-	-	SYM
dpc-4152	43	72	8	8	NUM
dpc-4152	43	73	actinic	actinic	ADJ
dpc-4152	43	74	keratoses	keratose	NOUN
dpc-4152	43	75	[	[	X
dpc-4152	43	76	1,21,24	1,21,24	NUM
dpc-4152	43	77	]	]	X
dpc-4152	43	78	.	.	PUNCT
dpc-4152	44	1	a	a	DET
dpc-4152	44	2	clinical	clinical	ADJ
dpc-4152	44	3	categorization	categorization	NOUN
dpc-4152	44	4	method	method	NOUN
dpc-4152	44	5	for	for	ADP
dpc-4152	44	6	ak	ak	PROPN
dpc-4152	44	7	grading	grade	VERB
dpc-4152	44	8	based	base	VERB
dpc-4152	44	9	on	on	ADP
dpc-4152	44	10	the	the	DET
dpc-4152	44	11	total	total	ADJ
dpc-4152	44	12	thickness	thickness	NOUN
dpc-4152	44	13	of	of	ADP
dpc-4152	44	14	different	different	ADJ
dpc-4152	44	15	lesions	lesion	NOUN
dpc-4152	44	16	was	be	AUX
dpc-4152	44	17	proposed	propose	VERB
dpc-4152	44	18	by	by	ADP
dpc-4152	44	19	olsen	olsen	PROPN
dpc-4152	44	20	et	et	PROPN
dpc-4152	44	21	al	al	PROPN
dpc-4152	45	1	[	[	X
dpc-4152	45	2	25	25	NUM
dpc-4152	45	3	]	]	PUNCT
dpc-4152	45	4	.	.	PUNCT
dpc-4152	46	1	grade	grade	NOUN
dpc-4152	46	2	1	1	NUM
dpc-4152	46	3	lesions	lesion	NOUN
dpc-4152	46	4	are	be	AUX
dpc-4152	46	5	hardly	hardly	ADV
dpc-4152	46	6	tangible	tangible	ADJ
dpc-4152	46	7	,	,	PUNCT
dpc-4152	46	8	grade	grade	NOUN
dpc-4152	46	9	2	2	NUM
dpc-4152	46	10	lesions	lesion	NOUN
dpc-4152	46	11	are	be	AUX
dpc-4152	46	12	rather	rather	ADV
dpc-4152	46	13	thick	thick	ADJ
dpc-4152	46	14	,	,	PUNCT
dpc-4152	46	15	and	and	CCONJ
dpc-4152	46	16	grade	grade	NOUN
dpc-4152	46	17	3	3	NUM
dpc-4152	46	18	lesions	lesion	NOUN
dpc-4152	46	19	are	be	AUX
dpc-4152	46	20	very	very	ADV
dpc-4152	46	21	thick	thick	ADJ
dpc-4152	46	22	and	and	CCONJ
dpc-4152	46	23	hyperkeratotic	hyperkeratotic	ADJ
dpc-4152	46	24	according	accord	VERB
dpc-4152	46	25	to	to	ADP
dpc-4152	46	26	this	this	DET
dpc-4152	46	27	system	system	NOUN
dpc-4152	46	28	.	.	PUNCT
dpc-4152	47	1	this	this	DET
dpc-4152	47	2	clinical	clinical	ADJ
dpc-4152	47	3	classifying	classify	VERB
dpc-4152	47	4	system	system	NOUN
dpc-4152	47	5	is	be	AUX
dpc-4152	47	6	often	often	ADV
dpc-4152	47	7	used	use	VERB
dpc-4152	47	8	to	to	PART
dpc-4152	47	9	set	set	VERB
dpc-4152	47	10	patient	patient	ADJ
dpc-4152	47	11	inclusion	inclusion	NOUN
dpc-4152	47	12	criteria	criterion	NOUN
dpc-4152	47	13	in	in	ADP
dpc-4152	47	14	randomized	randomized	ADJ
dpc-4152	47	15	clinical	clinical	ADJ
dpc-4152	47	16	trials	trial	NOUN
dpc-4152	47	17	of	of	ADP
dpc-4152	47	18	ak	ak	PROPN
dpc-4152	47	19	treatments	treatment	NOUN
dpc-4152	47	20	.	.	PUNCT
dpc-4152	48	1	the	the	DET
dpc-4152	48	2	concept	concept	NOUN
dpc-4152	48	3	of	of	ADP
dpc-4152	48	4	the	the	DET
dpc-4152	48	5	field	field	NOUN
dpc-4152	48	6	of	of	ADP
dpc-4152	48	7	cancerization	cancerization	NOUN
dpc-4152	48	8	was	be	AUX
dpc-4152	48	9	proposed	propose	VERB
dpc-4152	48	10	by	by	ADP
dpc-4152	48	11	slaugther	slaugther	NOUN
dpc-4152	48	12	in	in	ADP
dpc-4152	48	13	1953	1953	NUM
dpc-4152	49	1	[	[	X
dpc-4152	49	2	28	28	NUM
dpc-4152	49	3	]	]	PUNCT
dpc-4152	49	4	and	and	CCONJ
dpc-4152	49	5	was	be	AUX
dpc-4152	49	6	applied	apply	VERB
dpc-4152	49	7	to	to	ADP
dpc-4152	49	8	squamous	squamous	ADJ
dpc-4152	49	9	cell	cell	NOUN
dpc-4152	49	10	carcinomas	carcinoma	NOUN
dpc-4152	49	11	of	of	ADP
dpc-4152	49	12	the	the	DET
dpc-4152	49	13	oral	oral	ADJ
dpc-4152	49	14	cavity	cavity	NOUN
dpc-4152	49	15	,	,	PUNCT
dpc-4152	49	16	although	although	SCONJ
dpc-4152	49	17	willis	willis	PROPN
dpc-4152	49	18	in	in	ADP
dpc-4152	49	19	his	his	PRON
dpc-4152	49	20	seminal	seminal	ADJ
dpc-4152	49	21	article	article	NOUN
dpc-4152	49	22	in	in	ADP
dpc-4152	49	23	1944	1944	NUM
dpc-4152	49	24	first	first	ADV
dpc-4152	49	25	hypothesized	hypothesize	VERB
dpc-4152	49	26	that	that	SCONJ
dpc-4152	49	27	the	the	DET
dpc-4152	49	28	proliferation	proliferation	NOUN
dpc-4152	49	29	of	of	ADP
dpc-4152	49	30	keratinocytes	keratinocyte	NOUN
dpc-4152	49	31	can	can	AUX
dpc-4152	49	32	occur	occur	VERB
dpc-4152	49	33	multifocally	multifocally	ADV
dpc-4152	49	34	in	in	ADP
dpc-4152	49	35	the	the	DET
dpc-4152	49	36	epidermis	epidermis	NOUN
dpc-4152	50	1	[	[	X
dpc-4152	50	2	28	28	NUM
dpc-4152	50	3	]	]	PUNCT
dpc-4152	50	4	.	.	PUNCT
dpc-4152	51	1	from	from	ADP
dpc-4152	51	2	a	a	DET
dpc-4152	51	3	pathological	pathological	ADJ
dpc-4152	51	4	point	point	NOUN
dpc-4152	51	5	of	of	ADP
dpc-4152	51	6	view	view	NOUN
dpc-4152	51	7	,	,	PUNCT
dpc-4152	51	8	field	field	NOUN
dpc-4152	51	9	of	of	ADP
dpc-4152	51	10	cancerization	cancerization	NOUN
dpc-4152	51	11	could	could	AUX
dpc-4152	51	12	currently	currently	ADV
dpc-4152	51	13	be	be	AUX
dpc-4152	51	14	defined	define	VERB
dpc-4152	51	15	as	as	ADP
dpc-4152	51	16	one	one	NUM
dpc-4152	51	17	or	or	CCONJ
dpc-4152	51	18	more	more	ADJ
dpc-4152	51	19	areas	area	NOUN
dpc-4152	51	20	of	of	ADP
dpc-4152	51	21	epithelial	epithelial	ADJ
dpc-4152	51	22	and	and	CCONJ
dpc-4152	51	23	stromal	stromal	ADJ
dpc-4152	51	24	tissue	tissue	NOUN
dpc-4152	51	25	characterized	characterize	VERB
dpc-4152	51	26	by	by	ADP
dpc-4152	51	27	genetic	genetic	ADJ
dpc-4152	51	28	and	and	CCONJ
dpc-4152	51	29	epigenetic	epigenetic	ADJ
dpc-4152	51	30	abnormalities	abnormality	NOUN
dpc-4152	51	31	,	,	PUNCT
dpc-4152	51	32	some	some	PRON
dpc-4152	51	33	of	of	ADP
dpc-4152	51	34	which	which	PRON
dpc-4152	51	35	are	be	AUX
dpc-4152	51	36	also	also	ADV
dpc-4152	51	37	present	present	ADJ
dpc-4152	51	38	in	in	ADP
dpc-4152	51	39	cancer	cancer	NOUN
dpc-4152	51	40	,	,	PUNCT
dpc-4152	51	41	even	even	ADV
dpc-4152	51	42	in	in	ADP
dpc-4152	51	43	the	the	DET
dpc-4152	51	44	absence	absence	NOUN
dpc-4152	51	45	of	of	ADP
dpc-4152	51	46	histopathological	histopathological	ADJ
dpc-4152	51	47	alterations	alteration	NOUN
dpc-4152	51	48	.	.	PUNCT
dpc-4152	52	1	in	in	ADP
dpc-4152	52	2	this	this	DET
dpc-4152	52	3	perspective	perspective	NOUN
dpc-4152	52	4	,	,	PUNCT
dpc-4152	52	5	the	the	DET
dpc-4152	52	6	concept	concept	NOUN
dpc-4152	52	7	of	of	ADP
dpc-4152	52	8	field	field	NOUN
dpc-4152	52	9	cancerization	cancerization	NOUN
dpc-4152	52	10	has	have	VERB
dpc-4152	52	11	diagnostic	diagnostic	ADJ
dpc-4152	52	12	and	and	CCONJ
dpc-4152	52	13	prognostic	prognostic	ADJ
dpc-4152	52	14	implications	implication	NOUN
dpc-4152	52	15	,	,	PUNCT
dpc-4152	52	16	especially	especially	ADV
dpc-4152	52	17	when	when	SCONJ
dpc-4152	52	18	considering	consider	VERB
dpc-4152	52	19	that	that	SCONJ
dpc-4152	52	20	“	"	PUNCT
dpc-4152	52	21	healthy	healthy	ADJ
dpc-4152	52	22	”	"	PUNCT
dpc-4152	52	23	perilesional	perilesional	ADJ
dpc-4152	52	24	skin	skin	NOUN
dpc-4152	52	25	surrounding	surround	VERB
dpc-4152	52	26	clinically	clinically	ADV
dpc-4152	52	27	evident	evident	ADJ
dpc-4152	52	28	,	,	PUNCT
dpc-4152	52	29	multiple	multiple	ADJ
dpc-4152	52	30	aks	ak	NOUN
dpc-4152	52	31	could	could	AUX
dpc-4152	52	32	indeed	indeed	ADV
dpc-4152	52	33	be	be	AUX
dpc-4152	52	34	treated	treat	VERB
dpc-4152	52	35	treatment	treatment	NOUN
dpc-4152	52	36	of	of	ADP
dpc-4152	52	37	aks	ak	NOUN
dpc-4152	52	38	,	,	PUNCT
dpc-4152	52	39	since	since	SCONJ
dpc-4152	52	40	therapy	therapy	NOUN
dpc-4152	52	41	of	of	ADP
dpc-4152	52	42	aks	ak	NOUN
dpc-4152	52	43	should	should	AUX
dpc-4152	52	44	be	be	AUX
dpc-4152	52	45	directed	direct	VERB
dpc-4152	52	46	not	not	PART
dpc-4152	52	47	only	only	ADV
dpc-4152	52	48	to	to	PART
dpc-4152	52	49	visible	visible	ADJ
dpc-4152	52	50	lesions	lesion	NOUN
dpc-4152	52	51	but	but	CCONJ
dpc-4152	52	52	also	also	ADV
dpc-4152	52	53	to	to	ADP
dpc-4152	52	54	the	the	DET
dpc-4152	52	55	field	field	NOUN
dpc-4152	52	56	of	of	ADP
dpc-4152	52	57	cancerization	cancerization	NOUN
dpc-4152	52	58	from	from	ADP
dpc-4152	52	59	which	which	PRON
dpc-4152	52	60	they	they	PRON
dpc-4152	52	61	originate	originate	VERB
dpc-4152	52	62	.	.	PUNCT
dpc-4152	53	1	for	for	ADP
dpc-4152	53	2	practical	practical	ADJ
dpc-4152	53	3	purposes	purpose	NOUN
dpc-4152	53	4	,	,	PUNCT
dpc-4152	53	5	however	however	ADV
dpc-4152	53	6	,	,	PUNCT
dpc-4152	53	7	a	a	DET
dpc-4152	53	8	univocal	univocal	ADJ
dpc-4152	53	9	consensus	consensus	NOUN
dpc-4152	53	10	on	on	ADP
dpc-4152	53	11	the	the	DET
dpc-4152	53	12	criteria	criterion	NOUN
dpc-4152	53	13	required	require	VERB
dpc-4152	53	14	to	to	PART
dpc-4152	53	15	clinically	clinically	ADV
dpc-4152	53	16	identify	identify	VERB
dpc-4152	53	17	and	and	CCONJ
dpc-4152	53	18	treat	treat	VERB
dpc-4152	53	19	the	the	DET
dpc-4152	53	20	cutaneous	cutaneous	ADJ
dpc-4152	53	21	field	field	NOUN
dpc-4152	53	22	of	of	ADP
dpc-4152	53	23	cancerization	cancerization	NOUN
dpc-4152	53	24	is	be	AUX
dpc-4152	53	25	still	still	ADV
dpc-4152	53	26	lacking	lack	VERB
dpc-4152	53	27	and	and	CCONJ
dpc-4152	53	28	it	it	PRON
dpc-4152	53	29	was	be	AUX
dpc-4152	53	30	defined	define	VERB
dpc-4152	53	31	in	in	ADP
dpc-4152	53	32	a	a	DET
dpc-4152	53	33	recent	recent	ADJ
dpc-4152	53	34	review	review	NOUN
dpc-4152	54	1	[	[	X
dpc-4152	54	2	26	26	NUM
dpc-4152	54	3	-	-	SYM
dpc-4152	54	4	29	29	NUM
dpc-4152	54	5	]	]	PUNCT
dpc-4152	54	6	as	as	ADP
dpc-4152	54	7	multifocal	multifocal	ADJ
dpc-4152	54	8	clinical	clinical	ADJ
dpc-4152	54	9	atypia	atypia	NOUN
dpc-4152	54	10	,	,	PUNCT
dpc-4152	54	11	characterized	characterize	VERB
dpc-4152	54	12	by	by	ADP
dpc-4152	54	13	aks	ak	NOUN
dpc-4152	54	14	and/or	and/or	CCONJ
dpc-4152	54	15	squamous	squamous	ADJ
dpc-4152	54	16	cell	cell	NOUN
dpc-4152	54	17	carcinoma	carcinoma	NOUN
dpc-4152	54	18	in	in	ADP
dpc-4152	54	19	situ	situ	PROPN
dpc-4152	54	20	(	(	PUNCT
dpc-4152	54	21	sccis	sccis	NOUN
dpc-4152	54	22	)	)	PUNCT
dpc-4152	54	23	with	with	ADP
dpc-4152	54	24	or	or	CCONJ
dpc-4152	54	25	without	without	ADP
dpc-4152	54	26	invasive	invasive	ADJ
dpc-4152	54	27	cscc	cscc	NOUN
dpc-4152	54	28	,	,	PUNCT
dpc-4152	54	29	occurring	occur	VERB
dpc-4152	54	30	in	in	ADP
dpc-4152	54	31	a	a	DET
dpc-4152	54	32	field	field	NOUN
dpc-4152	54	33	exposed	expose	VERB
dpc-4152	54	34	to	to	ADP
dpc-4152	54	35	chronic	chronic	ADJ
dpc-4152	54	36	uvr	uvr	NOUN
dpc-4152	54	37	.	.	PUNCT
dpc-4152	55	1	sunscreens	sunscreen	NOUN
dpc-4152	55	2	and	and	CCONJ
dpc-4152	55	3	protective	protective	ADJ
dpc-4152	55	4	clothing	clothing	NOUN
dpc-4152	55	5	,	,	PUNCT
dpc-4152	55	6	together	together	ADV
dpc-4152	55	7	with	with	ADP
dpc-4152	55	8	adequate	adequate	ADJ
dpc-4152	55	9	sun	sun	NOUN
dpc-4152	55	10	-	-	PUNCT
dpc-4152	55	11	exposure	exposure	NOUN
dpc-4152	55	12	education	education	NOUN
dpc-4152	55	13	,	,	PUNCT
dpc-4152	55	14	are	be	AUX
dpc-4152	55	15	crucial	crucial	ADJ
dpc-4152	55	16	in	in	ADP
dpc-4152	55	17	managing	manage	VERB
dpc-4152	55	18	patients	patient	NOUN
dpc-4152	55	19	with	with	ADP
dpc-4152	55	20	aks	ak	NOUN
dpc-4152	55	21	;	;	PUNCT
dpc-4152	55	22	however	however	ADV
dpc-4152	55	23	,	,	PUNCT
dpc-4152	55	24	they	they	PRON
dpc-4152	55	25	are	be	AUX
dpc-4152	55	26	often	often	ADV
dpc-4152	55	27	insufficient	insufficient	ADJ
dpc-4152	55	28	to	to	PART
dpc-4152	55	29	treat	treat	VERB
dpc-4152	55	30	existing	exist	VERB
dpc-4152	55	31	lesions	lesion	NOUN
dpc-4152	56	1	[	[	X
dpc-4152	56	2	30,31	30,31	NOUN
dpc-4152	56	3	]	]	PUNCT
dpc-4152	56	4	.	.	PUNCT
dpc-4152	57	1	currently	currently	ADV
dpc-4152	57	2	,	,	PUNCT
dpc-4152	57	3	available	available	ADJ
dpc-4152	57	4	therapies	therapy	NOUN
dpc-4152	57	5	for	for	ADP
dpc-4152	57	6	aks	ak	NOUN
dpc-4152	57	7	are	be	AUX
dpc-4152	57	8	divided	divide	VERB
dpc-4152	57	9	into	into	ADP
dpc-4152	57	10	field	field	NOUN
dpc-4152	57	11	-	-	PUNCT
dpc-4152	57	12	directed	direct	VERB
dpc-4152	57	13	treatments	treatment	NOUN
dpc-4152	57	14	and	and	CCONJ
dpc-4152	57	15	lesion	lesion	NOUN
dpc-4152	57	16	-	-	PUNCT
dpc-4152	57	17	directed	direct	VERB
dpc-4152	57	18	treatments	treatment	NOUN
dpc-4152	57	19	[	[	X
dpc-4152	57	20	31,32	31,32	NUM
dpc-4152	57	21	]	]	PUNCT
dpc-4152	57	22	.	.	PUNCT
dpc-4152	58	1	the	the	DET
dpc-4152	58	2	latter	latter	ADJ
dpc-4152	58	3	mostly	mostly	ADV
dpc-4152	58	4	include	include	VERB
dpc-4152	58	5	physical	physical	ADJ
dpc-4152	58	6	treatments	treatment	NOUN
dpc-4152	58	7	,	,	PUNCT
dpc-4152	58	8	of	of	ADP
dpc-4152	58	9	which	which	PRON
dpc-4152	58	10	cryotherapy	cryotherapy	NOUN
dpc-4152	58	11	is	be	AUX
dpc-4152	58	12	probably	probably	ADV
dpc-4152	58	13	the	the	DET
dpc-4152	58	14	most	most	ADV
dpc-4152	58	15	widely	widely	ADV
dpc-4152	58	16	used	use	VERB
dpc-4152	58	17	technique	technique	NOUN
dpc-4152	58	18	[	[	X
dpc-4152	58	19	33	33	NUM
dpc-4152	58	20	]	]	PUNCT
dpc-4152	58	21	.	.	PUNCT
dpc-4152	59	1	lesion	lesion	NOUN
dpc-4152	59	2	-	-	PUNCT
dpc-4152	59	3	directed	direct	VERB
dpc-4152	59	4	therapies	therapy	NOUN
dpc-4152	59	5	,	,	PUNCT
dpc-4152	59	6	however	however	ADV
dpc-4152	59	7	,	,	PUNCT
dpc-4152	59	8	do	do	AUX
dpc-4152	59	9	not	not	PART
dpc-4152	59	10	impact	impact	VERB
dpc-4152	59	11	the	the	DET
dpc-4152	59	12	field	field	NOUN
dpc-4152	59	13	of	of	ADP
dpc-4152	59	14	cancerization	cancerization	NOUN
dpc-4152	59	15	,	,	PUNCT
dpc-4152	59	16	leaving	leave	VERB
dpc-4152	59	17	invisible	invisible	ADJ
dpc-4152	59	18	aks	ak	NOUN
dpc-4152	59	19	that	that	PRON
dpc-4152	59	20	might	might	AUX
dpc-4152	59	21	arise	arise	VERB
dpc-4152	59	22	in	in	ADP
dpc-4152	59	23	the	the	DET
dpc-4152	59	24	future	future	NOUN
dpc-4152	59	25	.	.	PUNCT
dpc-4152	60	1	moreover	moreover	ADV
dpc-4152	60	2	,	,	PUNCT
dpc-4152	60	3	they	they	PRON
dpc-4152	60	4	are	be	AUX
dpc-4152	60	5	usually	usually	ADV
dpc-4152	60	6	painful	painful	ADJ
dpc-4152	60	7	and	and	CCONJ
dpc-4152	60	8	can	can	AUX
dpc-4152	60	9	lead	lead	VERB
dpc-4152	60	10	to	to	ADP
dpc-4152	60	11	melanocyte	melanocyte	NOUN
dpc-4152	60	12	necrosis	necrosis	NOUN
dpc-4152	60	13	with	with	ADP
dpc-4152	60	14	consequent	consequent	ADJ
dpc-4152	60	15	hypoor	hypoor	ADJ
dpc-4152	60	16	hyperpigmentation	hyperpigmentation	NOUN
dpc-4152	60	17	and	and	CCONJ
dpc-4152	60	18	cosmetic	cosmetic	ADJ
dpc-4152	60	19	concerns	concern	NOUN
dpc-4152	60	20	[	[	X
dpc-4152	60	21	34	34	NUM
dpc-4152	60	22	]	]	PUNCT
dpc-4152	60	23	.	.	PUNCT
dpc-4152	61	1	a	a	DET
dpc-4152	61	2	summary	summary	NOUN
dpc-4152	61	3	of	of	ADP
dpc-4152	61	4	the	the	DET
dpc-4152	61	5	characteristics	characteristic	NOUN
dpc-4152	61	6	,	,	PUNCT
dpc-4152	61	7	efficacy	efficacy	NOUN
dpc-4152	61	8	,	,	PUNCT
dpc-4152	61	9	and	and	CCONJ
dpc-4152	61	10	mechanism	mechanism	NOUN
dpc-4152	61	11	of	of	ADP
dpc-4152	61	12	action	action	NOUN
dpc-4152	61	13	of	of	ADP
dpc-4152	61	14	topical	topical	ADJ
dpc-4152	61	15	treatments	treatment	NOUN
dpc-4152	61	16	are	be	AUX
dpc-4152	61	17	shown	show	VERB
dpc-4152	61	18	in	in	ADP
dpc-4152	61	19	table	table	NOUN
dpc-4152	61	20	1	1	NUM
dpc-4152	61	21	.	.	PUNCT
dpc-4152	61	22	tirbanibulin	tirbanibulin	PROPN
dpc-4152	61	23	in	in	ADP
dpc-4152	61	24	2020	2020	NUM
dpc-4152	61	25	and	and	CCONJ
dpc-4152	61	26	2021	2021	NUM
dpc-4152	61	27	respectively	respectively	ADV
dpc-4152	61	28	,	,	PUNCT
dpc-4152	61	29	tirbanibulin	tirbanibulin	PROPN
dpc-4152	61	30	1	1	NUM
dpc-4152	61	31	%	%	NOUN
dpc-4152	61	32	ointment	ointment	NOUN
dpc-4152	61	33	has	have	AUX
dpc-4152	61	34	been	be	AUX
dpc-4152	61	35	approved	approve	VERB
dpc-4152	61	36	by	by	ADP
dpc-4152	61	37	food	food	NOUN
dpc-4152	61	38	and	and	CCONJ
dpc-4152	61	39	drug	drug	PROPN
dpc-4152	61	40	administration	administration	PROPN
dpc-4152	61	41	(	(	PUNCT
dpc-4152	61	42	fda	fda	PROPN
dpc-4152	61	43	)	)	PUNCT
dpc-4152	61	44	and	and	CCONJ
dpc-4152	61	45	european	european	ADJ
dpc-4152	61	46	medicines	medicine	NOUN
dpc-4152	61	47	agency	agency	NOUN
dpc-4152	61	48	(	(	PUNCT
dpc-4152	61	49	ema	ema	PROPN
dpc-4152	61	50	)	)	PUNCT
dpc-4152	61	51	for	for	ADP
dpc-4152	61	52	the	the	DET
dpc-4152	61	53	treatment	treatment	NOUN
dpc-4152	61	54	of	of	ADP
dpc-4152	61	55	olsen	olsen	NOUN
dpc-4152	61	56	grade	grade	NOUN
dpc-4152	61	57	1	1	NUM
dpc-4152	61	58	aks	ak	NOUN
dpc-4152	61	59	of	of	ADP
dpc-4152	61	60	the	the	DET
dpc-4152	61	61	scalp	scalp	NOUN
dpc-4152	61	62	and	and	CCONJ
dpc-4152	61	63	the	the	DET
dpc-4152	61	64	face	face	NOUN
dpc-4152	61	65	[	[	X
dpc-4152	61	66	35	35	NUM
dpc-4152	61	67	]	]	PUNCT
dpc-4152	61	68	.	.	PUNCT
dpc-4152	62	1	tirbanibulin	tirbanibulin	PROPN
dpc-4152	62	2	has	have	VERB
dpc-4152	62	3	a	a	DET
dpc-4152	62	4	short	short	ADJ
dpc-4152	62	5	course	course	NOUN
dpc-4152	62	6	of	of	ADP
dpc-4152	62	7	application	application	NOUN
dpc-4152	62	8	,	,	PUNCT
dpc-4152	62	9	just	just	ADV
dpc-4152	62	10	5	5	NUM
dpc-4152	62	11	consecutive	consecutive	ADJ
dpc-4152	62	12	days	day	NOUN
dpc-4152	62	13	on	on	ADP
dpc-4152	62	14	an	an	DET
dpc-4152	62	15	area	area	NOUN
dpc-4152	62	16	of	of	ADP
dpc-4152	62	17	a	a	DET
dpc-4152	62	18	maximum	maximum	NOUN
dpc-4152	62	19	of	of	ADP
dpc-4152	62	20	25	25	NUM
dpc-4152	62	21	cm2	cm2	NOUN
dpc-4152	62	22	.	.	PROPN
dpc-4152	63	1	furthermore	furthermore	ADV
dpc-4152	63	2	,	,	PUNCT
dpc-4152	63	3	the	the	DET
dpc-4152	63	4	rate	rate	NOUN
dpc-4152	63	5	of	of	ADP
dpc-4152	63	6	skin	skin	NOUN
dpc-4152	63	7	adverse	adverse	ADJ
dpc-4152	63	8	events	event	NOUN
dpc-4152	63	9	is	be	AUX
dpc-4152	63	10	very	very	ADV
dpc-4152	63	11	low	low	ADJ
dpc-4152	63	12	,	,	PUNCT
dpc-4152	63	13	with	with	ADP
dpc-4152	63	14	a	a	DET
dpc-4152	63	15	vast	vast	ADJ
dpc-4152	63	16	majority	majority	NOUN
dpc-4152	63	17	of	of	ADP
dpc-4152	63	18	just	just	ADV
dpc-4152	63	19	review	review	VERB
dpc-4152	63	20	|	|	ADV
dpc-4152	63	21	dermatol	dermatol	ADJ
dpc-4152	63	22	pract	pract	NOUN
dpc-4152	63	23	concept	concept	NOUN
dpc-4152	63	24	.	.	PUNCT
dpc-4152	64	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	64	2	:	:	PUNCT
dpc-4152	64	3	e2024145s	e2024145s	NOUN
dpc-4152	64	4	3	3	NUM
dpc-4152	64	5	mild	mild	ADJ
dpc-4152	64	6	irritative	irritative	ADJ
dpc-4152	64	7	reactions	reaction	NOUN
dpc-4152	64	8	.	.	PUNCT
dpc-4152	65	1	for	for	ADP
dpc-4152	65	2	these	these	DET
dpc-4152	65	3	characteristics	characteristic	NOUN
dpc-4152	65	4	,	,	PUNCT
dpc-4152	65	5	tirbanibulin	tirbanibulin	PROPN
dpc-4152	65	6	represents	represent	VERB
dpc-4152	65	7	a	a	DET
dpc-4152	65	8	new	new	ADJ
dpc-4152	65	9	effective	effective	ADJ
dpc-4152	65	10	,	,	PUNCT
dpc-4152	65	11	safe	safe	ADJ
dpc-4152	65	12	,	,	PUNCT
dpc-4152	65	13	and	and	CCONJ
dpc-4152	65	14	practical	practical	ADJ
dpc-4152	65	15	option	option	NOUN
dpc-4152	65	16	for	for	ADP
dpc-4152	65	17	addressing	address	VERB
dpc-4152	65	18	the	the	DET
dpc-4152	65	19	problem	problem	NOUN
dpc-4152	65	20	of	of	ADP
dpc-4152	65	21	patient	patient	ADJ
dpc-4152	65	22	compliance	compliance	NOUN
dpc-4152	65	23	in	in	ADP
dpc-4152	65	24	aks	ak	NOUN
dpc-4152	65	25	management	management	NOUN
dpc-4152	65	26	.	.	PUNCT
dpc-4152	66	1	this	this	DET
dpc-4152	66	2	article	article	NOUN
dpc-4152	66	3	reviews	review	VERB
dpc-4152	66	4	what	what	PRON
dpc-4152	66	5	is	be	AUX
dpc-4152	66	6	currently	currently	ADV
dpc-4152	66	7	known	know	VERB
dpc-4152	66	8	about	about	ADP
dpc-4152	66	9	tirbanibulin	tirbanibulin	PROPN
dpc-4152	66	10	,	,	PUNCT
dpc-4152	66	11	from	from	ADP
dpc-4152	66	12	its	its	PRON
dpc-4152	66	13	mechanism	mechanism	NOUN
dpc-4152	66	14	of	of	ADP
dpc-4152	66	15	action	action	NOUN
dpc-4152	66	16	to	to	ADP
dpc-4152	66	17	clinical	clinical	ADJ
dpc-4152	66	18	trial	trial	NOUN
dpc-4152	66	19	outcomes	outcome	NOUN
dpc-4152	66	20	and	and	CCONJ
dpc-4152	66	21	preliminary	preliminary	ADJ
dpc-4152	66	22	real	real	ADJ
dpc-4152	66	23	-	-	PUNCT
dpc-4152	66	24	life	life	NOUN
dpc-4152	66	25	reports	report	NOUN
dpc-4152	66	26	regarding	regard	VERB
dpc-4152	66	27	safety	safety	NOUN
dpc-4152	66	28	,	,	PUNCT
dpc-4152	66	29	effectiveness	effectiveness	NOUN
dpc-4152	66	30	,	,	PUNCT
dpc-4152	66	31	and	and	CCONJ
dpc-4152	66	32	patient	patient	ADJ
dpc-4152	66	33	adherence	adherence	NOUN
dpc-4152	66	34	to	to	ADP
dpc-4152	66	35	the	the	DET
dpc-4152	66	36	treatment	treatment	NOUN
dpc-4152	66	37	.	.	PUNCT
dpc-4152	67	1	mechanism	mechanism	NOUN
dpc-4152	67	2	of	of	ADP
dpc-4152	67	3	action	action	NOUN
dpc-4152	67	4	tirbanibulin	tirbanibulin	PROPN
dpc-4152	67	5	is	be	AUX
dpc-4152	67	6	a	a	DET
dpc-4152	67	7	new	new	ADJ
dpc-4152	67	8	synthetic	synthetic	ADJ
dpc-4152	67	9	drug	drug	NOUN
dpc-4152	67	10	that	that	PRON
dpc-4152	67	11	targets	target	VERB
dpc-4152	67	12	α	α	NOUN
dpc-4152	67	13	and	and	CCONJ
dpc-4152	67	14	β	β	X
dpc-4152	67	15	tubulin	tubulin	NOUN
dpc-4152	67	16	,	,	PUNCT
dpc-4152	67	17	like	like	ADP
dpc-4152	67	18	other	other	ADJ
dpc-4152	67	19	antitumoral	antitumoral	ADJ
dpc-4152	67	20	drugs	drug	NOUN
dpc-4152	67	21	including	include	VERB
dpc-4152	67	22	vinca	vinca	NOUN
dpc-4152	67	23	alkaloids	alkaloid	NOUN
dpc-4152	67	24	,	,	PUNCT
dpc-4152	67	25	taxanes	taxane	NOUN
dpc-4152	67	26	,	,	PUNCT
dpc-4152	67	27	colchicine	colchicine	NOUN
dpc-4152	67	28	,	,	PUNCT
dpc-4152	67	29	and	and	CCONJ
dpc-4152	67	30	docetaxel	docetaxel	PROPN
dpc-4152	67	31	.	.	PUNCT
dpc-4152	68	1	in	in	ADP
dpc-4152	68	2	immunofluorescence	immunofluorescence	NOUN
dpc-4152	68	3	,	,	PUNCT
dpc-4152	68	4	studies	study	NOUN
dpc-4152	68	5	mechanism	mechanism	NOUN
dpc-4152	68	6	is	be	AUX
dpc-4152	68	7	concentration	concentration	NOUN
dpc-4152	68	8	dependent	dependent	ADJ
dpc-4152	68	9	on	on	ADP
dpc-4152	68	10	both	both	CCONJ
dpc-4152	68	11	in	in	ADP
dpc-4152	68	12	in	in	ADP
dpc-4152	68	13	-	-	PUNCT
dpc-4152	68	14	vitro	vitro	X
dpc-4152	68	15	tumoral	tumoral	ADJ
dpc-4152	68	16	lines	line	NOUN
dpc-4152	68	17	and	and	CCONJ
dpc-4152	68	18	murine	murine	ADJ
dpc-4152	68	19	tumor	tumor	NOUN
dpc-4152	68	20	tissues	tissue	NOUN
dpc-4152	68	21	[	[	X
dpc-4152	68	22	36	36	NUM
dpc-4152	68	23	-	-	SYM
dpc-4152	68	24	38	38	NUM
dpc-4152	68	25	]	]	PUNCT
dpc-4152	68	26	.	.	PUNCT
dpc-4152	69	1	immortalized	immortalize	VERB
dpc-4152	69	2	keratinocytes	keratinocyte	VERB
dpc-4152	69	3	incubation	incubation	NOUN
dpc-4152	69	4	with	with	ADP
dpc-4152	69	5	tirbanibulin	tirbanibulin	PROPN
dpc-4152	69	6	has	have	AUX
dpc-4152	69	7	proven	prove	VERB
dpc-4152	69	8	to	to	PART
dpc-4152	69	9	cause	cause	VERB
dpc-4152	69	10	the	the	DET
dpc-4152	69	11	arrest	arrest	NOUN
dpc-4152	69	12	of	of	ADP
dpc-4152	69	13	the	the	DET
dpc-4152	69	14	end	end	NOUN
dpc-4152	69	15	of	of	ADP
dpc-4152	69	16	the	the	DET
dpc-4152	69	17	interphase	interphase	NOUN
dpc-4152	69	18	of	of	ADP
dpc-4152	69	19	phase	phase	NOUN
dpc-4152	69	20	growth	growth	NOUN
dpc-4152	69	21	2	2	NUM
dpc-4152	69	22	and	and	CCONJ
dpc-4152	69	23	mitosis	mitosis	NOUN
dpc-4152	69	24	when	when	SCONJ
dpc-4152	69	25	the	the	DET
dpc-4152	69	26	assembly	assembly	NOUN
dpc-4152	69	27	of	of	ADP
dpc-4152	69	28	microtubules	microtubule	NOUN
dpc-4152	69	29	allows	allow	VERB
dpc-4152	69	30	for	for	ADP
dpc-4152	69	31	the	the	DET
dpc-4152	69	32	migration	migration	NOUN
dpc-4152	69	33	of	of	ADP
dpc-4152	69	34	genetic	genetic	ADJ
dpc-4152	69	35	material	material	NOUN
dpc-4152	69	36	to	to	ADP
dpc-4152	69	37	opposite	opposite	ADJ
dpc-4152	69	38	poles	pole	NOUN
dpc-4152	69	39	of	of	ADP
dpc-4152	69	40	the	the	DET
dpc-4152	69	41	cell	cell	NOUN
dpc-4152	70	1	[	[	X
dpc-4152	70	2	36	36	NUM
dpc-4152	70	3	-	-	SYM
dpc-4152	70	4	38	38	NUM
dpc-4152	70	5	]	]	PUNCT
dpc-4152	70	6	.	.	PUNCT
dpc-4152	71	1	of	of	ADP
dpc-4152	71	2	note	note	NOUN
dpc-4152	71	3	,	,	PUNCT
dpc-4152	71	4	the	the	DET
dpc-4152	71	5	good	good	ADJ
dpc-4152	71	6	tolerability	tolerability	NOUN
dpc-4152	71	7	of	of	ADP
dpc-4152	71	8	this	this	DET
dpc-4152	71	9	drug	drug	NOUN
dpc-4152	71	10	could	could	AUX
dpc-4152	71	11	be	be	AUX
dpc-4152	71	12	attributable	attributable	ADJ
dpc-4152	71	13	to	to	ADP
dpc-4152	71	14	the	the	DET
dpc-4152	71	15	reversibility	reversibility	NOUN
dpc-4152	71	16	of	of	ADP
dpc-4152	71	17	its	its	PRON
dpc-4152	71	18	effect	effect	NOUN
dpc-4152	71	19	[	[	X
dpc-4152	71	20	38	38	NUM
dpc-4152	71	21	]	]	PUNCT
dpc-4152	71	22	.	.	PUNCT
dpc-4152	72	1	alongside	alongside	ADP
dpc-4152	72	2	the	the	DET
dpc-4152	72	3	above	above	ADJ
dpc-4152	72	4	,	,	PUNCT
dpc-4152	72	5	preclinical	preclinical	ADJ
dpc-4152	72	6	studies	study	NOUN
dpc-4152	72	7	have	have	AUX
dpc-4152	72	8	proven	prove	VERB
dpc-4152	72	9	tirbanibulin	tirbanibulin	PROPN
dpc-4152	72	10	to	to	PART
dpc-4152	72	11	have	have	VERB
dpc-4152	72	12	a	a	DET
dpc-4152	72	13	pro	pro	ADJ
dpc-4152	72	14	-	-	ADJ
dpc-4152	72	15	apoptotic	apoptotic	ADJ
dpc-4152	72	16	effect	effect	NOUN
dpc-4152	72	17	in	in	ADP
dpc-4152	72	18	both	both	CCONJ
dpc-4152	72	19	in	in	ADP
dpc-4152	72	20	-	-	PUNCT
dpc-4152	72	21	vitro	vitro	X
dpc-4152	72	22	and	and	CCONJ
dpc-4152	72	23	murine	murine	ADJ
dpc-4152	72	24	models	model	NOUN
dpc-4152	72	25	by	by	ADP
dpc-4152	72	26	activating	activate	VERB
dpc-4152	72	27	both	both	CCONJ
dpc-4152	72	28	intrinsic	intrinsic	ADJ
dpc-4152	72	29	and	and	CCONJ
dpc-4152	72	30	extrinsic	extrinsic	ADJ
dpc-4152	72	31	pathways	pathway	NOUN
dpc-4152	72	32	such	such	ADJ
dpc-4152	72	33	as	as	ADP
dpc-4152	72	34	bcl-2	bcl-2	NOUN
dpc-4152	72	35	hyperphosphorylation	hyperphosphorylation	NOUN
dpc-4152	72	36	,	,	PUNCT
dpc-4152	72	37	and	and	CCONJ
dpc-4152	72	38	caspase	caspase	NOUN
dpc-4152	72	39	-	-	PUNCT
dpc-4152	72	40	mediated	mediate	VERB
dpc-4152	72	41	mechanisms	mechanism	NOUN
dpc-4152	72	42	[	[	X
dpc-4152	72	43	36,37,39	36,37,39	NOUN
dpc-4152	72	44	]	]	PUNCT
dpc-4152	72	45	.	.	PUNCT
dpc-4152	73	1	not	not	PART
dpc-4152	73	2	only	only	ADV
dpc-4152	73	3	does	do	AUX
dpc-4152	73	4	tirbanibulin	tirbanibulin	PROPN
dpc-4152	73	5	show	show	VERB
dpc-4152	73	6	an	an	DET
dpc-4152	73	7	antiproliferative	antiproliferative	NOUN
dpc-4152	73	8	and	and	CCONJ
dpc-4152	73	9	pro	pro	ADJ
dpc-4152	73	10	-	-	ADJ
dpc-4152	73	11	apoptotic	apoptotic	ADJ
dpc-4152	73	12	effect	effect	NOUN
dpc-4152	73	13	[	[	X
dpc-4152	73	14	38	38	NUM
dpc-4152	73	15	]	]	PUNCT
dpc-4152	73	16	,	,	PUNCT
dpc-4152	73	17	but	but	CCONJ
dpc-4152	73	18	some	some	DET
dpc-4152	73	19	evidence	evidence	NOUN
dpc-4152	73	20	also	also	ADV
dpc-4152	73	21	[	[	X
dpc-4152	73	22	39,40	39,40	NUM
dpc-4152	73	23	]	]	PUNCT
dpc-4152	73	24	suggests	suggest	VERB
dpc-4152	73	25	that	that	SCONJ
dpc-4152	73	26	it	it	PRON
dpc-4152	73	27	plays	play	VERB
dpc-4152	73	28	a	a	DET
dpc-4152	73	29	role	role	NOUN
dpc-4152	73	30	in	in	ADP
dpc-4152	73	31	the	the	DET
dpc-4152	73	32	rapid	rapid	ADJ
dpc-4152	73	33	decrease	decrease	NOUN
dpc-4152	73	34	of	of	ADP
dpc-4152	73	35	phosphorated	phosphorate	VERB
dpc-4152	73	36	scr	scr	NOUN
dpc-4152	73	37	tyrosine	tyrosine	NOUN
dpc-4152	73	38	kinase	kinase	PROPN
dpc-4152	73	39	,	,	PUNCT
dpc-4152	73	40	which	which	PRON
dpc-4152	73	41	plays	play	VERB
dpc-4152	73	42	a	a	DET
dpc-4152	73	43	role	role	NOUN
dpc-4152	73	44	in	in	ADP
dpc-4152	73	45	the	the	DET
dpc-4152	73	46	alterations	alteration	NOUN
dpc-4152	73	47	of	of	ADP
dpc-4152	73	48	table	table	NOUN
dpc-4152	73	49	1	1	NUM
dpc-4152	73	50	.	.	PUNCT
dpc-4152	73	51	comparative	comparative	ADJ
dpc-4152	73	52	treatment	treatment	NOUN
dpc-4152	73	53	efficacy	efficacy	NOUN
dpc-4152	73	54	and	and	CCONJ
dpc-4152	73	55	safety	safety	NOUN
dpc-4152	73	56	of	of	ADP
dpc-4152	73	57	face	face	NOUN
dpc-4152	73	58	-	-	PUNCT
dpc-4152	73	59	scalp	scalp	NOUN
dpc-4152	73	60	typical	typical	ADJ
dpc-4152	73	61	actinic	actinic	ADJ
dpc-4152	73	62	keratosis	keratosis	NOUN
dpc-4152	73	63	approved	approve	VERB
dpc-4152	73	64	in	in	ADP
dpc-4152	73	65	europe	europe	PROPN
dpc-4152	73	66	[	[	X
dpc-4152	73	67	24	24	NUM
dpc-4152	73	68	]	]	PUNCT
dpc-4152	73	69	medication	medication	NOUN
dpc-4152	73	70	mechanism	mechanism	NOUN
dpc-4152	73	71	of	of	ADP
dpc-4152	73	72	action	action	NOUN
dpc-4152	73	73	duration	duration	NOUN
dpc-4152	73	74	of	of	ADP
dpc-4152	73	75	treatment	treatment	NOUN
dpc-4152	73	76	complete	complete	ADJ
dpc-4152	73	77	clearance	clearance	NOUN
dpc-4152	73	78	rates	rate	NOUN
dpc-4152	73	79	at	at	ADP
dpc-4152	73	80	the	the	DET
dpc-4152	73	81	end	end	NOUN
dpc-4152	73	82	of	of	ADP
dpc-4152	73	83	the	the	DET
dpc-4152	73	84	standard	standard	ADJ
dpc-4152	73	85	duration	duration	NOUN
dpc-4152	73	86	treatment	treatment	NOUN
dpc-4152	73	87	or	or	CCONJ
dpc-4152	73	88	(	(	PUNCT
dpc-4152	73	89	95	95	NUM
dpc-4152	73	90	%	%	NOUN
dpc-4152	73	91	ci	ci	NOUN
dpc-4152	73	92	)	)	PUNCT
dpc-4152	73	93	rate	rate	NOUN
dpc-4152	73	94	of	of	ADP
dpc-4152	73	95	discontinuation	discontinuation	NOUN
dpc-4152	73	96	due	due	ADP
dpc-4152	73	97	to	to	ADP
dpc-4152	73	98	adverse	adverse	ADJ
dpc-4152	73	99	events	event	NOUN
dpc-4152	73	100	cryosurgery	cryosurgery	PROPN
dpc-4152	73	101	physical	physical	ADJ
dpc-4152	73	102	destruction	destruction	NOUN
dpc-4152	73	103	of	of	ADP
dpc-4152	73	104	the	the	DET
dpc-4152	73	105	affected	affected	ADJ
dpc-4152	73	106	tissue	tissue	NOUN
dpc-4152	73	107	once	once	ADV
dpc-4152	73	108	13.4	13.4	NUM
dpc-4152	73	109	(	(	PUNCT
dpc-4152	73	110	6.2	6.2	NUM
dpc-4152	73	111	-	-	SYM
dpc-4152	73	112	30.3	30.3	NUM
dpc-4152	73	113	)	)	PUNCT
dpc-4152	73	114	not	not	PART
dpc-4152	73	115	applicable	applicable	ADJ
dpc-4152	73	116	tirbanibulin	tirbanibulin	DET
dpc-4152	73	117	1	1	NUM
dpc-4152	73	118	%	%	NOUN
dpc-4152	73	119	ointment	ointment	NOUN
dpc-4152	73	120	inhibits	inhibit	VERB
dpc-4152	73	121	microtubule	microtubule	NOUN
dpc-4152	73	122	assembly	assembly	NOUN
dpc-4152	73	123	and	and	CCONJ
dpc-4152	73	124	inhibits	inhibit	VERB
dpc-4152	73	125	scr	scr	PROPN
dpc-4152	73	126	kinase	kinase	PROPN
dpc-4152	73	127	5	5	NUM
dpc-4152	73	128	consecutive	consecutive	ADJ
dpc-4152	73	129	days	day	NOUN
dpc-4152	73	130	11.1	11.1	NUM
dpc-4152	73	131	(	(	PUNCT
dpc-4152	73	132	6.2	6.2	NUM
dpc-4152	73	133	-	-	SYM
dpc-4152	73	134	20.9	20.9	NUM
dpc-4152	73	135	)	)	PUNCT
dpc-4152	73	136	0	0	NUM
dpc-4152	73	137	%	%	NOUN
dpc-4152	73	138	5	5	NUM
dpc-4152	73	139	-	-	PUNCT
dpc-4152	73	140	fluorouracil	fluorouracil	NOUN
dpc-4152	73	141	(	(	PUNCT
dpc-4152	73	142	fu	fu	NOUN
dpc-4152	73	143	)	)	PUNCT
dpc-4152	73	144	0.5	0.5	NUM
dpc-4152	73	145	%	%	NOUN
dpc-4152	73	146	+	+	CCONJ
dpc-4152	73	147	salicylate	salicylate	NOUN
dpc-4152	73	148	10	10	NUM
dpc-4152	73	149	%	%	NOUN
dpc-4152	73	150	5	5	NUM
dpc-4152	73	151	-	-	PUNCT
dpc-4152	73	152	fu	fu	NOUN
dpc-4152	73	153	acts	act	VERB
dpc-4152	73	154	as	as	ADP
dpc-4152	73	155	a	a	DET
dpc-4152	73	156	pyrimidine	pyrimidine	NOUN
dpc-4152	73	157	analogue	analogue	NOUN
dpc-4152	73	158	,	,	PUNCT
dpc-4152	73	159	while	while	SCONJ
dpc-4152	73	160	salicylate	salicylate	NOUN
dpc-4152	73	161	has	have	VERB
dpc-4152	73	162	a	a	DET
dpc-4152	73	163	keratolytic	keratolytic	ADJ
dpc-4152	73	164	effect	effect	NOUN
dpc-4152	73	165	up	up	ADP
dpc-4152	73	166	to	to	PART
dpc-4152	73	167	12	12	NUM
dpc-4152	73	168	consecutive	consecutive	ADJ
dpc-4152	73	169	weeks	week	NOUN
dpc-4152	73	170	7.6	7.6	NUM
dpc-4152	73	171	(	(	PUNCT
dpc-4152	73	172	4.6	4.6	NUM
dpc-4152	73	173	-	-	SYM
dpc-4152	73	174	13.5	13.5	NUM
dpc-4152	73	175	)	)	PUNCT
dpc-4152	73	176	1.9%-9.1	1.9%-9.1	NUM
dpc-4152	73	177	%	%	NOUN
dpc-4152	73	178	diclofenac	diclofenac	NOUN
dpc-4152	73	179	3	3	NUM
dpc-4152	73	180	%	%	NOUN
dpc-4152	73	181	gel	gel	NOUN
dpc-4152	73	182	inhibits	inhibit	VERB
dpc-4152	73	183	cyclooxygenases	cyclooxygenase	NOUN
dpc-4152	73	184	,	,	PUNCT
dpc-4152	73	185	and	and	CCONJ
dpc-4152	73	186	thus	thus	ADV
dpc-4152	73	187	prostaglandin	prostaglandin	NOUN
dpc-4152	73	188	e2	e2	PROPN
dpc-4152	73	189	production	production	NOUN
dpc-4152	73	190	up	up	ADP
dpc-4152	73	191	to	to	PART
dpc-4152	73	192	12	12	NUM
dpc-4152	73	193	consecutive	consecutive	ADJ
dpc-4152	73	194	weeks	week	NOUN
dpc-4152	73	195	2.9	2.9	NUM
dpc-4152	73	196	(	(	PUNCT
dpc-4152	73	197	1.9	1.9	NUM
dpc-4152	73	198	-	-	SYM
dpc-4152	73	199	4.3	4.3	NUM
dpc-4152	73	200	)	)	PUNCT
dpc-4152	73	201	2.1%-12.3	2.1%-12.3	NUM
dpc-4152	73	202	%	%	NOUN
dpc-4152	73	203	imiquimod	imiquimod	ADJ
dpc-4152	73	204	3.75	3.75	NUM
dpc-4152	73	205	%	%	NOUN
dpc-4152	73	206	cream	cream	NOUN
dpc-4152	73	207	activates	activate	VERB
dpc-4152	73	208	innate	innate	ADJ
dpc-4152	73	209	immune	immune	ADJ
dpc-4152	73	210	system	system	NOUN
dpc-4152	73	211	2	2	NUM
dpc-4152	73	212	weeks	week	NOUN
dpc-4152	73	213	,	,	PUNCT
dpc-4152	73	214	followed	follow	VERB
dpc-4152	73	215	by	by	ADP
dpc-4152	73	216	a	a	DET
dpc-4152	73	217	2	2	NUM
dpc-4152	73	218	-	-	PUNCT
dpc-4152	73	219	week	week	NOUN
dpc-4152	73	220	stop	stop	NOUN
dpc-4152	73	221	,	,	PUNCT
dpc-4152	73	222	followed	follow	VERB
dpc-4152	73	223	by	by	ADP
dpc-4152	73	224	another	another	DET
dpc-4152	73	225	2	2	NUM
dpc-4152	73	226	weeks	week	NOUN
dpc-4152	73	227	cycle	cycle	NOUN
dpc-4152	73	228	8.5	8.5	NUM
dpc-4152	73	229	(	(	PUNCT
dpc-4152	73	230	3.5	3.5	NUM
dpc-4152	73	231	-	-	SYM
dpc-4152	73	232	22.4	22.4	NUM
dpc-4152	73	233	)	)	PUNCT
dpc-4152	73	234	0	0	NUM
dpc-4152	73	235	-	-	SYM
dpc-4152	73	236	1.6	1.6	NUM
dpc-4152	73	237	%	%	NOUN
dpc-4152	73	238	pdt	pdt	NOUN
dpc-4152	73	239	with	with	ADP
dpc-4152	73	240	aminolevulinate	aminolevulinate	PROPN
dpc-4152	73	241	(	(	PUNCT
dpc-4152	73	242	ala	ala	PROPN
dpc-4152	73	243	)	)	PUNCT
dpc-4152	73	244	the	the	DET
dpc-4152	73	245	combined	combined	ADJ
dpc-4152	73	246	activity	activity	NOUN
dpc-4152	73	247	of	of	ADP
dpc-4152	73	248	a	a	DET
dpc-4152	73	249	photosensitizer	photosensitizer	NOUN
dpc-4152	73	250	(	(	PUNCT
dpc-4152	73	251	ala	ala	PROPN
dpc-4152	73	252	)	)	PUNCT
dpc-4152	73	253	and	and	CCONJ
dpc-4152	73	254	a	a	DET
dpc-4152	73	255	specific	specific	ADJ
dpc-4152	73	256	wavelength	wavelength	NOUN
dpc-4152	73	257	cause	cause	VERB
dpc-4152	73	258	the	the	DET
dpc-4152	73	259	formation	formation	NOUN
dpc-4152	73	260	of	of	ADP
dpc-4152	73	261	free	free	ADJ
dpc-4152	73	262	radicals	radical	NOUN
dpc-4152	73	263	2	2	NUM
dpc-4152	73	264	outpatient	outpatient	NOUN
dpc-4152	73	265	accesses	access	VERB
dpc-4152	73	266	24.1	24.1	NUM
dpc-4152	73	267	(	(	PUNCT
dpc-4152	73	268	10.9	10.9	NUM
dpc-4152	73	269	-	-	SYM
dpc-4152	73	270	52.8	52.8	NUM
dpc-4152	73	271	)	)	PUNCT
dpc-4152	73	272	0.6	0.6	NUM
dpc-4152	73	273	%	%	NOUN
dpc-4152	73	274	pdt	pdt	NOUN
dpc-4152	73	275	with	with	ADP
dpc-4152	73	276	methyl	methyl	NOUN
dpc-4152	73	277	aminolevulinate	aminolevulinate	NOUN
dpc-4152	73	278	(	(	PUNCT
dpc-4152	73	279	mal	mal	ADJ
dpc-4152	73	280	)	)	PUNCT
dpc-4152	73	281	the	the	DET
dpc-4152	73	282	combined	combined	ADJ
dpc-4152	73	283	activity	activity	NOUN
dpc-4152	73	284	of	of	ADP
dpc-4152	73	285	a	a	DET
dpc-4152	73	286	photosensitizer	photosensitizer	NOUN
dpc-4152	73	287	(	(	PUNCT
dpc-4152	73	288	mla	mla	NOUN
dpc-4152	73	289	)	)	PUNCT
dpc-4152	73	290	and	and	CCONJ
dpc-4152	73	291	a	a	DET
dpc-4152	73	292	specific	specific	ADJ
dpc-4152	73	293	wavelength	wavelength	NOUN
dpc-4152	73	294	cause	cause	VERB
dpc-4152	73	295	the	the	DET
dpc-4152	73	296	formation	formation	NOUN
dpc-4152	73	297	of	of	ADP
dpc-4152	73	298	free	free	ADJ
dpc-4152	73	299	radicals	radical	NOUN
dpc-4152	73	300	2	2	NUM
dpc-4152	73	301	outpatient	outpatient	NOUN
dpc-4152	73	302	accesses	access	VERB
dpc-4152	73	303	11.7	11.7	NUM
dpc-4152	73	304	(	(	PUNCT
dpc-4152	73	305	6.0	6.0	NUM
dpc-4152	73	306	-	-	SYM
dpc-4152	73	307	21.9	21.9	NUM
dpc-4152	73	308	)	)	PUNCT
dpc-4152	73	309	1.1	1.1	NUM
dpc-4152	73	310	%	%	NOUN
dpc-4152	73	311	5	5	NUM
dpc-4152	73	312	-	-	PUNCT
dpc-4152	73	313	fluorouracil	fluorouracil	NOUN
dpc-4152	73	314	(	(	PUNCT
dpc-4152	73	315	fu	fu	NOUN
dpc-4152	73	316	)	)	PUNCT
dpc-4152	73	317	4	4	NUM
dpc-4152	73	318	%	%	NOUN
dpc-4152	73	319	5	5	NUM
dpc-4152	73	320	-	-	PUNCT
dpc-4152	73	321	fu	fu	NOUN
dpc-4152	73	322	acts	act	VERB
dpc-4152	73	323	as	as	ADP
dpc-4152	73	324	a	a	DET
dpc-4152	73	325	pyrimidine	pyrimidine	NOUN
dpc-4152	73	326	analogue	analogue	NOUN
dpc-4152	73	327	up	up	ADP
dpc-4152	73	328	to	to	PART
dpc-4152	73	329	4	4	NUM
dpc-4152	73	330	weeks	week	NOUN
dpc-4152	73	331	30.3	30.3	NUM
dpc-4152	73	332	(	(	PUNCT
dpc-4152	73	333	9.1	9.1	NUM
dpc-4152	73	334	-	-	SYM
dpc-4152	73	335	144.7	144.7	NUM
dpc-4152	73	336	)	)	PUNCT
dpc-4152	73	337	not	not	PART
dpc-4152	73	338	applicable	applicable	ADJ
dpc-4152	73	339	5	5	NUM
dpc-4152	73	340	-	-	PUNCT
dpc-4152	73	341	fluorouracil	fluorouracil	NOUN
dpc-4152	73	342	(	(	PUNCT
dpc-4152	73	343	fu	fu	NOUN
dpc-4152	73	344	)	)	PUNCT
dpc-4152	73	345	5	5	NUM
dpc-4152	73	346	%	%	NOUN
dpc-4152	73	347	5	5	NUM
dpc-4152	73	348	-	-	PUNCT
dpc-4152	73	349	fu	fu	NOUN
dpc-4152	73	350	acts	act	VERB
dpc-4152	73	351	as	as	ADP
dpc-4152	73	352	a	a	DET
dpc-4152	73	353	pyrimidine	pyrimidine	NOUN
dpc-4152	73	354	analogue	analogue	NOUN
dpc-4152	73	355	up	up	ADP
dpc-4152	73	356	to	to	PART
dpc-4152	73	357	4	4	NUM
dpc-4152	73	358	weeks	week	NOUN
dpc-4152	73	359	35.0	35.0	NUM
dpc-4152	73	360	(	(	PUNCT
dpc-4152	73	361	10.2	10.2	NUM
dpc-4152	73	362	-	-	SYM
dpc-4152	73	363	164.4	164.4	NUM
dpc-4152	73	364	)	)	PUNCT
dpc-4152	73	365	0	0	NUM
dpc-4152	73	366	%	%	NOUN
dpc-4152	73	367	4	4	NUM
dpc-4152	73	368	review	review	NOUN
dpc-4152	73	369	|	|	ADV
dpc-4152	73	370	dermatol	dermatol	ADJ
dpc-4152	73	371	pract	pract	NOUN
dpc-4152	73	372	concept	concept	NOUN
dpc-4152	73	373	.	.	PUNCT
dpc-4152	74	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	74	2	:	:	PUNCT
dpc-4152	74	3	e2024145s	e2024145s	NOUN
dpc-4152	74	4	consent	consent	NOUN
dpc-4152	74	5	,	,	PUNCT
dpc-4152	74	6	while	while	SCONJ
dpc-4152	74	7	the	the	DET
dpc-4152	74	8	rest	rest	NOUN
dpc-4152	74	9	(	(	PUNCT
dpc-4152	74	10	n=29	n=29	NOUN
dpc-4152	74	11	)	)	PUNCT
dpc-4152	74	12	completed	complete	VERB
dpc-4152	74	13	the	the	DET
dpc-4152	74	14	treatment	treatment	NOUN
dpc-4152	74	15	and	and	CCONJ
dpc-4152	74	16	the	the	DET
dpc-4152	74	17	follow	follow	NOUN
dpc-4152	74	18	-	-	PUNCT
dpc-4152	74	19	up	up	NOUN
dpc-4152	74	20	.	.	PUNCT
dpc-4152	75	1	complete	complete	ADJ
dpc-4152	75	2	clearance	clearance	NOUN
dpc-4152	75	3	was	be	AUX
dpc-4152	75	4	achieved	achieve	VERB
dpc-4152	75	5	in	in	ADP
dpc-4152	75	6	participants	participant	NOUN
dpc-4152	75	7	by	by	ADP
dpc-4152	75	8	rates	rate	NOUN
dpc-4152	75	9	of	of	ADP
dpc-4152	75	10	25	25	NUM
dpc-4152	75	11	%	%	NOUN
dpc-4152	75	12	in	in	ADP
dpc-4152	75	13	cohort	cohort	NOUN
dpc-4152	75	14	1	1	NUM
dpc-4152	75	15	,	,	PUNCT
dpc-4152	75	16	0	0	NUM
dpc-4152	75	17	%	%	NOUN
dpc-4152	75	18	in	in	ADP
dpc-4152	75	19	cohort	cohort	NOUN
dpc-4152	75	20	2	2	NUM
dpc-4152	75	21	,	,	PUNCT
dpc-4152	75	22	50	50	NUM
dpc-4152	75	23	%	%	NOUN
dpc-4152	75	24	in	in	ADP
dpc-4152	75	25	cohort	cohort	NOUN
dpc-4152	75	26	3	3	NUM
dpc-4152	75	27	,	,	PUNCT
dpc-4152	75	28	and	and	CCONJ
dpc-4152	75	29	12.5	12.5	NUM
dpc-4152	75	30	%	%	NOUN
dpc-4152	75	31	in	in	ADP
dpc-4152	75	32	cohort	cohort	NOUN
dpc-4152	75	33	4	4	NUM
dpc-4152	75	34	,	,	PUNCT
dpc-4152	75	35	while	while	SCONJ
dpc-4152	75	36	partial	partial	ADJ
dpc-4152	75	37	clearance	clearance	NOUN
dpc-4152	75	38	was	be	AUX
dpc-4152	75	39	respectively	respectively	ADV
dpc-4152	75	40	50	50	NUM
dpc-4152	75	41	%	%	NOUN
dpc-4152	75	42	,	,	PUNCT
dpc-4152	75	43	30	30	NUM
dpc-4152	75	44	%	%	NOUN
dpc-4152	75	45	,	,	PUNCT
dpc-4152	75	46	63	63	NUM
dpc-4152	75	47	%	%	NOUN
dpc-4152	75	48	,	,	PUNCT
dpc-4152	75	49	and	and	CCONJ
dpc-4152	75	50	50	50	NUM
dpc-4152	75	51	%	%	NOUN
dpc-4152	75	52	.	.	PUNCT
dpc-4152	76	1	data	datum	NOUN
dpc-4152	76	2	regarding	regard	VERB
dpc-4152	76	3	effectiveness	effectiveness	NOUN
dpc-4152	76	4	are	be	AUX
dpc-4152	76	5	summarized	summarize	VERB
dpc-4152	76	6	in	in	ADP
dpc-4152	76	7	table	table	NOUN
dpc-4152	76	8	2	2	NUM
dpc-4152	76	9	.	.	PUNCT
dpc-4152	76	10	regarding	regard	VERB
dpc-4152	76	11	safety	safety	NOUN
dpc-4152	76	12	,	,	PUNCT
dpc-4152	76	13	the	the	DET
dpc-4152	76	14	only	only	ADJ
dpc-4152	76	15	adverse	adverse	ADJ
dpc-4152	76	16	effects	effect	NOUN
dpc-4152	76	17	reported	report	VERB
dpc-4152	76	18	were	be	AUX
dpc-4152	76	19	mild	mild	ADJ
dpc-4152	76	20	local	local	ADJ
dpc-4152	76	21	skin	skin	NOUN
dpc-4152	76	22	reactions	reaction	NOUN
dpc-4152	76	23	,	,	PUNCT
dpc-4152	76	24	mostly	mostly	ADV
dpc-4152	76	25	in	in	ADP
dpc-4152	76	26	cohorts	cohort	NOUN
dpc-4152	76	27	3	3	NUM
dpc-4152	76	28	and	and	CCONJ
dpc-4152	76	29	4	4	NUM
dpc-4152	76	30	including	include	VERB
dpc-4152	76	31	itching	itching	NOUN
dpc-4152	76	32	,	,	PUNCT
dpc-4152	76	33	erythema	erythema	ADV
dpc-4152	76	34	,	,	PUNCT
dpc-4152	76	35	and	and	CCONJ
dpc-4152	76	36	stinging	sting	VERB
dpc-4152	76	37	or	or	CCONJ
dpc-4152	76	38	burning	burn	VERB
dpc-4152	76	39	sensation	sensation	NOUN
dpc-4152	76	40	,	,	PUNCT
dpc-4152	76	41	which	which	PRON
dpc-4152	76	42	did	do	AUX
dpc-4152	76	43	not	not	PART
dpc-4152	76	44	lead	lead	VERB
dpc-4152	76	45	to	to	ADP
dpc-4152	76	46	the	the	DET
dpc-4152	76	47	discontinuation	discontinuation	NOUN
dpc-4152	76	48	of	of	ADP
dpc-4152	76	49	the	the	DET
dpc-4152	76	50	treatment	treatment	NOUN
dpc-4152	76	51	and	and	CCONJ
dpc-4152	76	52	that	that	PRON
dpc-4152	76	53	self	self	NOUN
dpc-4152	76	54	-	-	PUNCT
dpc-4152	76	55	resolved	resolve	VERB
dpc-4152	76	56	.	.	PUNCT
dpc-4152	77	1	no	no	DET
dpc-4152	77	2	contact	contact	NOUN
dpc-4152	77	3	sensitization	sensitization	NOUN
dpc-4152	77	4	,	,	PUNCT
dpc-4152	77	5	phototoxic	phototoxic	NOUN
dpc-4152	77	6	,	,	PUNCT
dpc-4152	77	7	or	or	CCONJ
dpc-4152	77	8	photoallergic	photoallergic	NOUN
dpc-4152	77	9	effects	effect	NOUN
dpc-4152	77	10	were	be	AUX
dpc-4152	77	11	reported	report	VERB
dpc-4152	77	12	(	(	PUNCT
dpc-4152	77	13	table	table	NOUN
dpc-4152	77	14	3	3	NUM
dpc-4152	77	15	)	)	PUNCT
dpc-4152	77	16	.	.	PUNCT
dpc-4152	78	1	phase	phase	NOUN
dpc-4152	78	2	2	2	NUM
dpc-4152	78	3	trials	trial	NOUN
dpc-4152	78	4	the	the	DET
dpc-4152	78	5	phase	phase	NOUN
dpc-4152	78	6	2	2	NUM
dpc-4152	78	7	trial	trial	NOUN
dpc-4152	78	8	[	[	X
dpc-4152	78	9	44	44	NUM
dpc-4152	78	10	]	]	PUNCT
dpc-4152	78	11	was	be	AUX
dpc-4152	78	12	aimed	aim	VERB
dpc-4152	78	13	at	at	ADP
dpc-4152	78	14	open	open	ADJ
dpc-4152	78	15	-	-	PUNCT
dpc-4152	78	16	label	label	NOUN
dpc-4152	78	17	,	,	PUNCT
dpc-4152	78	18	uncontrolled	uncontrolled	ADJ
dpc-4152	78	19	dose	dose	NOUN
dpc-4152	78	20	regimen	regimen	NOUN
dpc-4152	78	21	-	-	PUNCT
dpc-4152	78	22	finding	find	VERB
dpc-4152	78	23	multicentric	multicentric	NOUN
dpc-4152	78	24	(	(	PUNCT
dpc-4152	78	25	16	16	NUM
dpc-4152	78	26	centers	center	NOUN
dpc-4152	78	27	)	)	PUNCT
dpc-4152	78	28	in	in	ADP
dpc-4152	78	29	which	which	PRON
dpc-4152	78	30	patients	patient	NOUN
dpc-4152	78	31	(	(	PUNCT
dpc-4152	78	32	n=168	n=168	NOUN
dpc-4152	78	33	)	)	PUNCT
dpc-4152	78	34	aged	age	VERB
dpc-4152	78	35	at	at	ADP
dpc-4152	78	36	least	least	ADV
dpc-4152	78	37	18	18	NUM
dpc-4152	78	38	years	year	NOUN
dpc-4152	78	39	were	be	AUX
dpc-4152	78	40	sequentially	sequentially	ADV
dpc-4152	78	41	enrolled	enrol	VERB
dpc-4152	78	42	in	in	ADP
dpc-4152	78	43	2	2	NUM
dpc-4152	78	44	cohorts	cohort	NOUN
dpc-4152	78	45	,	,	PUNCT
dpc-4152	78	46	each	each	PRON
dpc-4152	78	47	consisting	consist	VERB
dpc-4152	78	48	of	of	ADP
dpc-4152	78	49	84	84	NUM
dpc-4152	78	50	patients	patient	NOUN
dpc-4152	78	51	.	.	PUNCT
dpc-4152	79	1	in	in	ADP
dpc-4152	79	2	both	both	DET
dpc-4152	79	3	cohorts	cohort	NOUN
dpc-4152	79	4	,	,	PUNCT
dpc-4152	79	5	the	the	DET
dpc-4152	79	6	treated	treat	VERB
dpc-4152	79	7	area	area	NOUN
dpc-4152	79	8	was	be	AUX
dpc-4152	79	9	25	25	NUM
dpc-4152	79	10	cm2	cm2	NOUN
dpc-4152	79	11	,	,	PUNCT
dpc-4152	79	12	with	with	ADP
dpc-4152	79	13	4	4	NUM
dpc-4152	79	14	-	-	SYM
dpc-4152	79	15	8	8	NUM
dpc-4152	79	16	clinically	clinically	ADV
dpc-4152	79	17	typical	typical	ADJ
dpc-4152	79	18	aks	ak	NOUN
dpc-4152	79	19	on	on	ADP
dpc-4152	79	20	the	the	DET
dpc-4152	79	21	scalp	scalp	NOUN
dpc-4152	79	22	,	,	PUNCT
dpc-4152	79	23	face	face	NOUN
dpc-4152	79	24	,	,	PUNCT
dpc-4152	79	25	and/or	and/or	CCONJ
dpc-4152	79	26	neck	neck	NOUN
dpc-4152	79	27	area	area	NOUN
dpc-4152	79	28	.	.	PUNCT
dpc-4152	80	1	the	the	DET
dpc-4152	80	2	daily	daily	PROPN
dpc-4152	80	3	dose	dose	NOUN
dpc-4152	80	4	of	of	ADP
dpc-4152	80	5	tirbanibulin	tirbanibulin	PROPN
dpc-4152	80	6	,	,	PUNCT
dpc-4152	80	7	applied	apply	VERB
dpc-4152	80	8	as	as	ADP
dpc-4152	80	9	a	a	DET
dpc-4152	80	10	1	1	NUM
dpc-4152	80	11	%	%	NOUN
dpc-4152	80	12	ointment	ointment	NOUN
dpc-4152	80	13	once	once	ADV
dpc-4152	80	14	a	a	DET
dpc-4152	80	15	day	day	NOUN
dpc-4152	80	16	,	,	PUNCT
dpc-4152	80	17	was	be	AUX
dpc-4152	80	18	around	around	ADV
dpc-4152	80	19	50	50	NUM
dpc-4152	80	20	mg	mg	NUM
dpc-4152	80	21	/	/	SYM
dpc-4152	80	22	day	day	NOUN
dpc-4152	80	23	,	,	PUNCT
dpc-4152	80	24	however	however	ADV
dpc-4152	80	25	,	,	PUNCT
dpc-4152	80	26	group	group	NOUN
dpc-4152	80	27	1	1	NUM
dpc-4152	80	28	underwent	undergo	VERB
dpc-4152	80	29	the	the	DET
dpc-4152	80	30	treatment	treatment	NOUN
dpc-4152	80	31	for	for	ADP
dpc-4152	80	32	3	3	NUM
dpc-4152	80	33	consecutive	consecutive	ADJ
dpc-4152	80	34	days	day	NOUN
dpc-4152	80	35	,	,	PUNCT
dpc-4152	80	36	while	while	SCONJ
dpc-4152	80	37	group	group	NOUN
dpc-4152	80	38	2	2	NUM
dpc-4152	80	39	was	be	AUX
dpc-4152	80	40	for	for	ADP
dpc-4152	80	41	5	5	NUM
dpc-4152	80	42	consecutive	consecutive	ADJ
dpc-4152	80	43	days	day	NOUN
dpc-4152	80	44	.	.	PUNCT
dpc-4152	81	1	the	the	DET
dpc-4152	81	2	results	result	NOUN
dpc-4152	81	3	were	be	AUX
dpc-4152	81	4	evaluated	evaluate	VERB
dpc-4152	81	5	in	in	ADP
dpc-4152	81	6	terms	term	NOUN
dpc-4152	81	7	of	of	ADP
dpc-4152	81	8	lesion	lesion	NOUN
dpc-4152	81	9	count	count	NOUN
dpc-4152	81	10	reduction	reduction	NOUN
dpc-4152	81	11	,	,	PUNCT
dpc-4152	81	12	which	which	PRON
dpc-4152	81	13	was	be	AUX
dpc-4152	81	14	classified	classify	VERB
dpc-4152	81	15	as	as	ADP
dpc-4152	81	16	complete	complete	ADJ
dpc-4152	81	17	if	if	SCONJ
dpc-4152	81	18	100	100	NUM
dpc-4152	81	19	%	%	NOUN
dpc-4152	81	20	and	and	CCONJ
dpc-4152	81	21	partial	partial	ADJ
dpc-4152	81	22	if	if	SCONJ
dpc-4152	81	23	≥75	≥75	NOUN
dpc-4152	81	24	%	%	NOUN
dpc-4152	81	25	.	.	PUNCT
dpc-4152	82	1	each	each	DET
dpc-4152	82	2	cohort	cohort	NOUN
dpc-4152	82	3	was	be	AUX
dpc-4152	82	4	evaluated	evaluate	VERB
dpc-4152	82	5	on	on	ADP
dpc-4152	82	6	days	day	NOUN
dpc-4152	82	7	8	8	NUM
dpc-4152	82	8	,	,	PUNCT
dpc-4152	82	9	15	15	NUM
dpc-4152	82	10	,	,	PUNCT
dpc-4152	82	11	29	29	NUM
dpc-4152	82	12	,	,	PUNCT
dpc-4152	82	13	and	and	CCONJ
dpc-4152	82	14	57	57	NUM
dpc-4152	82	15	.	.	PUNCT
dpc-4152	83	1	both	both	DET
dpc-4152	83	2	cohorts	cohort	NOUN
dpc-4152	83	3	showed	show	VERB
dpc-4152	83	4	a	a	DET
dpc-4152	83	5	significant	significant	ADJ
dpc-4152	83	6	reduction	reduction	NOUN
dpc-4152	83	7	in	in	ADP
dpc-4152	83	8	the	the	DET
dpc-4152	83	9	lesion	lesion	NOUN
dpc-4152	83	10	count	count	NOUN
dpc-4152	83	11	by	by	ADP
dpc-4152	83	12	day	day	NOUN
dpc-4152	83	13	57	57	NUM
dpc-4152	83	14	,	,	PUNCT
dpc-4152	83	15	however	however	ADV
dpc-4152	83	16	,	,	PUNCT
dpc-4152	83	17	it	it	PRON
dpc-4152	83	18	was	be	AUX
dpc-4152	83	19	superior	superior	ADJ
dpc-4152	83	20	in	in	ADP
dpc-4152	83	21	those	those	DET
dpc-4152	83	22	patients	patient	NOUN
dpc-4152	83	23	who	who	PRON
dpc-4152	83	24	used	use	VERB
dpc-4152	83	25	tirbanibulin	tirbanibulin	PROPN
dpc-4152	83	26	for	for	ADP
dpc-4152	83	27	5	5	NUM
dpc-4152	83	28	days	day	NOUN
dpc-4152	83	29	.	.	PUNCT
dpc-4152	84	1	complete	complete	ADJ
dpc-4152	84	2	clearance	clearance	NOUN
dpc-4152	84	3	was	be	AUX
dpc-4152	84	4	achieved	achieve	VERB
dpc-4152	84	5	by	by	ADP
dpc-4152	84	6	43	43	NUM
dpc-4152	84	7	%	%	NOUN
dpc-4152	84	8	(	(	PUNCT
dpc-4152	84	9	95	95	NUM
dpc-4152	84	10	%	%	NOUN
dpc-4152	84	11	confidence	confidence	NOUN
dpc-4152	84	12	interval	interval	NOUN
dpc-4152	85	1	[	[	X
dpc-4152	85	2	ci	ci	X
dpc-4152	85	3	]	]	X
dpc-4152	85	4	:	:	PUNCT
dpc-4152	85	5	32	32	NUM
dpc-4152	85	6	%	%	NOUN
dpc-4152	85	7	,	,	PUNCT
dpc-4152	85	8	0,54	0,54	NUM
dpc-4152	85	9	%	%	NOUN
dpc-4152	85	10	)	)	PUNCT
dpc-4152	85	11	hemidesmosomes	hemidesmosome	NOUN
dpc-4152	85	12	necessary	necessary	ADJ
dpc-4152	85	13	to	to	ADP
dpc-4152	85	14	the	the	DET
dpc-4152	85	15	progression	progression	NOUN
dpc-4152	85	16	to	to	ADP
dpc-4152	85	17	a	a	DET
dpc-4152	85	18	cscc	cscc	NOUN
dpc-4152	86	1	[	[	X
dpc-4152	86	2	41,42	41,42	NOUN
dpc-4152	86	3	]	]	PUNCT
dpc-4152	86	4	.	.	PUNCT
dpc-4152	87	1	certain	certain	ADJ
dpc-4152	87	2	medications	medication	NOUN
dpc-4152	87	3	used	use	VERB
dpc-4152	87	4	to	to	PART
dpc-4152	87	5	treat	treat	VERB
dpc-4152	87	6	ak	ak	PROPN
dpc-4152	87	7	,	,	PUNCT
dpc-4152	87	8	such	such	ADJ
dpc-4152	87	9	as	as	ADP
dpc-4152	87	10	5	5	NUM
dpc-4152	87	11	-	-	PUNCT
dpc-4152	87	12	fluorouracil	fluorouracil	NOUN
dpc-4152	87	13	,	,	PUNCT
dpc-4152	87	14	can	can	AUX
dpc-4152	87	15	produce	produce	VERB
dpc-4152	87	16	localized	localized	ADJ
dpc-4152	87	17	skin	skin	NOUN
dpc-4152	87	18	responses	response	NOUN
dpc-4152	87	19	by	by	ADP
dpc-4152	87	20	causing	cause	VERB
dpc-4152	87	21	the	the	DET
dpc-4152	87	22	release	release	NOUN
dpc-4152	87	23	of	of	ADP
dpc-4152	87	24	proinflammatory	proinflammatory	ADJ
dpc-4152	87	25	cytokines	cytokine	NOUN
dpc-4152	87	26	such	such	ADJ
dpc-4152	87	27	as	as	ADP
dpc-4152	87	28	tumor	tumor	NOUN
dpc-4152	87	29	necrosis	necrosis	NOUN
dpc-4152	87	30	factor	factor	NOUN
dpc-4152	87	31	tnf	tnf	PROPN
dpc-4152	87	32	α	α	PROPN
dpc-4152	87	33	and	and	CCONJ
dpc-4152	87	34	interleukin	interleukin	NOUN
dpc-4152	87	35	il	il	PROPN
dpc-4152	87	36	8	8	NUM
dpc-4152	87	37	.	.	PUNCT
dpc-4152	88	1	a	a	DET
dpc-4152	88	2	preclinical	preclinical	ADJ
dpc-4152	88	3	investigation	investigation	NOUN
dpc-4152	88	4	described	describe	VERB
dpc-4152	88	5	the	the	DET
dpc-4152	88	6	potential	potential	ADJ
dpc-4152	88	7	effects	effect	NOUN
dpc-4152	88	8	of	of	ADP
dpc-4152	88	9	tirbanibulin	tirbanibulin	PRON
dpc-4152	88	10	on	on	ADP
dpc-4152	88	11	the	the	DET
dpc-4152	88	12	release	release	NOUN
dpc-4152	88	13	of	of	ADP
dpc-4152	88	14	pro	pro	ADJ
dpc-4152	88	15	-	-	ADJ
dpc-4152	88	16	inflammatory	inflammatory	ADJ
dpc-4152	88	17	cytokines	cytokine	NOUN
dpc-4152	88	18	during	during	ADP
dpc-4152	88	19	a	a	DET
dpc-4152	88	20	24	24	NUM
dpc-4152	88	21	-	-	PUNCT
dpc-4152	88	22	hour	hour	NOUN
dpc-4152	88	23	incubation	incubation	NOUN
dpc-4152	88	24	period	period	NOUN
dpc-4152	88	25	of	of	ADP
dpc-4152	88	26	ccd-1106	ccd-1106	NOUN
dpc-4152	88	27	kertr	kertr	PROPN
dpc-4152	88	28	keratinocytes	keratinocytes	PROPN
dpc-4152	88	29	.	.	PUNCT
dpc-4152	89	1	the	the	DET
dpc-4152	89	2	findings	finding	NOUN
dpc-4152	89	3	demonstrated	demonstrate	VERB
dpc-4152	89	4	that	that	SCONJ
dpc-4152	89	5	whereas	whereas	SCONJ
dpc-4152	89	6	5	5	NUM
dpc-4152	89	7	-	-	PUNCT
dpc-4152	89	8	fluorouracil	fluorouracil	NOUN
dpc-4152	89	9	generated	generate	VERB
dpc-4152	89	10	a	a	DET
dpc-4152	89	11	substantial	substantial	ADJ
dpc-4152	89	12	rise	rise	NOUN
dpc-4152	89	13	in	in	ADP
dpc-4152	89	14	tnf	tnf	PROPN
dpc-4152	89	15	α	α	PROPN
dpc-4152	89	16	and	and	CCONJ
dpc-4152	89	17	il-8	il-8	NOUN
dpc-4152	89	18	,	,	PUNCT
dpc-4152	89	19	tirbanibulin	tirbanibulin	PROPN
dpc-4152	89	20	incubation	incubation	NOUN
dpc-4152	89	21	only	only	ADV
dpc-4152	89	22	slightly	slightly	ADV
dpc-4152	89	23	increased	increase	VERB
dpc-4152	89	24	il-8	il-8	NOUN
dpc-4152	89	25	at	at	ADP
dpc-4152	89	26	the	the	DET
dpc-4152	89	27	highest	high	ADJ
dpc-4152	89	28	dosage	dosage	NOUN
dpc-4152	89	29	.	.	PUNCT
dpc-4152	90	1	furthermore	furthermore	ADV
dpc-4152	90	2	,	,	PUNCT
dpc-4152	90	3	il-1	il-1	ADP
dpc-4152	90	4	,	,	PUNCT
dpc-4152	90	5	an	an	DET
dpc-4152	90	6	indicator	indicator	NOUN
dpc-4152	90	7	of	of	ADP
dpc-4152	90	8	cell	cell	NOUN
dpc-4152	90	9	death	death	NOUN
dpc-4152	90	10	,	,	PUNCT
dpc-4152	90	11	was	be	AUX
dpc-4152	90	12	significantly	significantly	ADV
dpc-4152	90	13	higher	high	ADJ
dpc-4152	90	14	in	in	ADP
dpc-4152	90	15	tirbanibulin	tirbanibulin	ADV
dpc-4152	90	16	-	-	PUNCT
dpc-4152	90	17	treated	treat	VERB
dpc-4152	90	18	cells	cell	NOUN
dpc-4152	90	19	than	than	ADP
dpc-4152	90	20	in	in	ADP
dpc-4152	90	21	control	control	NOUN
dpc-4152	90	22	(	(	PUNCT
dpc-4152	90	23	dmso	dmso	NOUN
dpc-4152	90	24	)	)	PUNCT
dpc-4152	90	25	and	and	CCONJ
dpc-4152	90	26	5	5	NUM
dpc-4152	90	27	-	-	PUNCT
dpc-4152	90	28	fluorouracil	fluorouracil	NOUN
dpc-4152	90	29	.	.	PUNCT
dpc-4152	91	1	these	these	DET
dpc-4152	91	2	findings	finding	NOUN
dpc-4152	91	3	imply	imply	VERB
dpc-4152	91	4	that	that	SCONJ
dpc-4152	91	5	5	5	NUM
dpc-4152	91	6	-	-	PUNCT
dpc-4152	91	7	fluorouracil	fluorouracil	NOUN
dpc-4152	91	8	is	be	AUX
dpc-4152	91	9	more	more	ADV
dpc-4152	91	10	likely	likely	ADJ
dpc-4152	91	11	to	to	PART
dpc-4152	91	12	trigger	trigger	VERB
dpc-4152	91	13	a	a	DET
dpc-4152	91	14	robust	robust	ADJ
dpc-4152	91	15	proinflammatory	proinflammatory	ADJ
dpc-4152	91	16	cytokine	cytokine	NOUN
dpc-4152	91	17	response	response	NOUN
dpc-4152	91	18	than	than	ADP
dpc-4152	91	19	tirbanibulin	tirbanibulin	PROPN
dpc-4152	91	20	,	,	PUNCT
dpc-4152	91	21	which	which	PRON
dpc-4152	91	22	could	could	AUX
dpc-4152	91	23	minimize	minimize	VERB
dpc-4152	91	24	the	the	DET
dpc-4152	91	25	severity	severity	NOUN
dpc-4152	91	26	of	of	ADP
dpc-4152	91	27	local	local	ADJ
dpc-4152	91	28	skin	skin	NOUN
dpc-4152	91	29	responses	response	NOUN
dpc-4152	91	30	[	[	X
dpc-4152	91	31	41	41	NUM
dpc-4152	91	32	]	]	PUNCT
dpc-4152	91	33	.	.	PUNCT
dpc-4152	92	1	phase	phase	NOUN
dpc-4152	92	2	1	1	NUM
dpc-4152	92	3	trials	trial	NOUN
dpc-4152	92	4	the	the	DET
dpc-4152	92	5	phase	phase	NOUN
dpc-4152	92	6	1	1	NUM
dpc-4152	92	7	trial	trial	NOUN
dpc-4152	92	8	[	[	X
dpc-4152	92	9	44	44	NUM
dpc-4152	92	10	]	]	PUNCT
dpc-4152	92	11	was	be	AUX
dpc-4152	92	12	an	an	DET
dpc-4152	92	13	open	open	ADJ
dpc-4152	92	14	-	-	PUNCT
dpc-4152	92	15	label	label	NOUN
dpc-4152	92	16	single	single	ADJ
dpc-4152	92	17	-	-	PUNCT
dpc-4152	92	18	center	center	NOUN
dpc-4152	92	19	study	study	NOUN
dpc-4152	92	20	.	.	PUNCT
dpc-4152	93	1	the	the	DET
dpc-4152	93	2	enrolled	enrol	VERB
dpc-4152	93	3	patients	patient	NOUN
dpc-4152	93	4	had	have	VERB
dpc-4152	93	5	clinically	clinically	ADV
dpc-4152	93	6	typical	typical	ADJ
dpc-4152	93	7	aks	ak	NOUN
dpc-4152	93	8	,	,	PUNCT
dpc-4152	93	9	and	and	CCONJ
dpc-4152	93	10	their	their	PRON
dpc-4152	93	11	age	age	NOUN
dpc-4152	93	12	had	have	VERB
dpc-4152	93	13	to	to	PART
dpc-4152	93	14	be	be	AUX
dpc-4152	93	15	≥18	≥18	X
dpc-4152	93	16	.	.	NOUN
dpc-4152	93	17	thirty	thirty	NUM
dpc-4152	93	18	participants	participant	NOUN
dpc-4152	93	19	were	be	AUX
dpc-4152	93	20	enrolled	enrol	VERB
dpc-4152	93	21	in	in	ADP
dpc-4152	93	22	4	4	NUM
dpc-4152	93	23	successive	successive	ADJ
dpc-4152	93	24	cohorts	cohort	NOUN
dpc-4152	93	25	.	.	PUNCT
dpc-4152	94	1	cohort	cohort	NOUN
dpc-4152	94	2	1	1	NUM
dpc-4152	94	3	was	be	AUX
dpc-4152	94	4	treated	treat	VERB
dpc-4152	94	5	in	in	ADP
dpc-4152	94	6	a	a	DET
dpc-4152	94	7	25	25	NUM
dpc-4152	94	8	cm2	cm2	NOUN
dpc-4152	94	9	area	area	NOUN
dpc-4152	94	10	with	with	ADP
dpc-4152	94	11	4	4	NUM
dpc-4152	94	12	-	-	SYM
dpc-4152	94	13	8	8	NUM
dpc-4152	94	14	aks	ak	NOUN
dpc-4152	94	15	with	with	ADP
dpc-4152	94	16	tirbanibulin	tirbanibulin	PROPN
dpc-4152	94	17	ointment	ointment	NOUN
dpc-4152	94	18	1	1	NUM
dpc-4152	94	19	%	%	NOUN
dpc-4152	94	20	applied	apply	VERB
dpc-4152	94	21	once	once	ADV
dpc-4152	94	22	a	a	DET
dpc-4152	94	23	day	day	NOUN
dpc-4152	94	24	for	for	ADP
dpc-4152	94	25	3	3	NUM
dpc-4152	94	26	consecutive	consecutive	ADJ
dpc-4152	94	27	days	day	NOUN
dpc-4152	94	28	.	.	PUNCT
dpc-4152	95	1	cohort	cohort	NOUN
dpc-4152	95	2	2	2	NUM
dpc-4152	95	3	was	be	AUX
dpc-4152	95	4	1	1	NUM
dpc-4152	95	5	treated	treat	VERB
dpc-4152	95	6	in	in	ADP
dpc-4152	95	7	a	a	DET
dpc-4152	95	8	100	100	NUM
dpc-4152	95	9	cm2	cm2	NOUN
dpc-4152	95	10	area	area	NOUN
dpc-4152	95	11	with	with	ADP
dpc-4152	95	12	8	8	NUM
dpc-4152	95	13	-	-	SYM
dpc-4152	95	14	16	16	NUM
dpc-4152	95	15	aks	ak	NOUN
dpc-4152	95	16	with	with	ADP
dpc-4152	95	17	tirbanibulin	tirbanibulin	PROPN
dpc-4152	95	18	200	200	NUM
dpc-4152	95	19	mg	mg	ADV
dpc-4152	96	1	once	once	ADV
dpc-4152	96	2	a	a	DET
dpc-4152	96	3	day	day	NOUN
dpc-4152	96	4	for	for	ADP
dpc-4152	96	5	3	3	NUM
dpc-4152	96	6	consecutive	consecutive	ADJ
dpc-4152	96	7	days	day	NOUN
dpc-4152	96	8	.	.	PUNCT
dpc-4152	97	1	cohorts	cohort	NOUN
dpc-4152	97	2	3	3	NUM
dpc-4152	97	3	and	and	CCONJ
dpc-4152	97	4	4	4	NUM
dpc-4152	97	5	resembled	resemble	VERB
dpc-4152	97	6	cohorts	cohort	NOUN
dpc-4152	97	7	1	1	NUM
dpc-4152	97	8	and	and	CCONJ
dpc-4152	97	9	2	2	NUM
dpc-4152	97	10	at	at	ADP
dpc-4152	97	11	baseline	baseline	NOUN
dpc-4152	97	12	,	,	PUNCT
dpc-4152	97	13	except	except	SCONJ
dpc-4152	97	14	the	the	DET
dpc-4152	97	15	treatment	treatment	NOUN
dpc-4152	97	16	was	be	AUX
dpc-4152	97	17	carried	carry	VERB
dpc-4152	97	18	on	on	ADP
dpc-4152	97	19	for	for	ADP
dpc-4152	97	20	5	5	NUM
dpc-4152	97	21	consecutive	consecutive	ADJ
dpc-4152	97	22	days	day	NOUN
dpc-4152	97	23	.	.	PUNCT
dpc-4152	98	1	the	the	DET
dpc-4152	98	2	results	result	NOUN
dpc-4152	98	3	were	be	AUX
dpc-4152	98	4	evaluated	evaluate	VERB
dpc-4152	98	5	in	in	ADP
dpc-4152	98	6	terms	term	NOUN
dpc-4152	98	7	of	of	ADP
dpc-4152	98	8	lesion	lesion	NOUN
dpc-4152	98	9	count	count	NOUN
dpc-4152	98	10	reduction	reduction	NOUN
dpc-4152	98	11	,	,	PUNCT
dpc-4152	98	12	which	which	PRON
dpc-4152	98	13	was	be	AUX
dpc-4152	98	14	classified	classify	VERB
dpc-4152	98	15	as	as	ADP
dpc-4152	98	16	complete	complete	ADJ
dpc-4152	98	17	if	if	SCONJ
dpc-4152	98	18	100	100	NUM
dpc-4152	98	19	%	%	NOUN
dpc-4152	98	20	and	and	CCONJ
dpc-4152	98	21	partial	partial	ADJ
dpc-4152	98	22	if	if	SCONJ
dpc-4152	98	23	≥75	≥75	NOUN
dpc-4152	98	24	%	%	NOUN
dpc-4152	98	25	.	.	PUNCT
dpc-4152	99	1	each	each	DET
dpc-4152	99	2	cohort	cohort	NOUN
dpc-4152	99	3	was	be	AUX
dpc-4152	99	4	followed	follow	VERB
dpc-4152	99	5	on	on	ADP
dpc-4152	99	6	days	day	NOUN
dpc-4152	99	7	10	10	NUM
dpc-4152	99	8	,	,	PUNCT
dpc-4152	99	9	17	17	NUM
dpc-4152	99	10	,	,	PUNCT
dpc-4152	99	11	31	31	NUM
dpc-4152	99	12	,	,	PUNCT
dpc-4152	99	13	and	and	CCONJ
dpc-4152	99	14	through	through	ADP
dpc-4152	99	15	day	day	NOUN
dpc-4152	99	16	45	45	NUM
dpc-4152	99	17	.	.	PUNCT
dpc-4152	100	1	only	only	ADV
dpc-4152	100	2	1	1	NUM
dpc-4152	100	3	patient	patient	NOUN
dpc-4152	100	4	withdrew	withdraw	VERB
dpc-4152	100	5	his	his	PRON
dpc-4152	100	6	table	table	NOUN
dpc-4152	100	7	2	2	NUM
dpc-4152	100	8	.	.	PUNCT
dpc-4152	100	9	actinic	actinic	ADJ
dpc-4152	100	10	keratosis	keratosis	NOUN
dpc-4152	100	11	clearance	clearance	NOUN
dpc-4152	100	12	rates	rate	NOUN
dpc-4152	100	13	*	*	PUNCT
dpc-4152	100	14	through	through	ADP
dpc-4152	100	15	phase	phase	NOUN
dpc-4152	100	16	1,2	1,2	NUM
dpc-4152	100	17	and	and	CCONJ
dpc-4152	100	18	3	3	NUM
dpc-4152	100	19	[	[	X
dpc-4152	100	20	44,45	44,45	X
dpc-4152	100	21	]	]	SYM
dpc-4152	100	22	100	100	NUM
dpc-4152	100	23	%	%	NOUN
dpc-4152	100	24	clearance	clearance	NOUN
dpc-4152	100	25	%	%	NOUN
dpc-4152	100	26	(	(	PUNCT
dpc-4152	100	27	n	n	CCONJ
dpc-4152	100	28	)	)	PUNCT
dpc-4152	100	29	≥75	≥75	NOUN
dpc-4152	100	30	%	%	NOUN
dpc-4152	100	31	clearance	clearance	NOUN
dpc-4152	100	32	%	%	NOUN
dpc-4152	100	33	(	(	PUNCT
dpc-4152	100	34	n	n	CCONJ
dpc-4152	100	35	)	)	PUNCT
dpc-4152	100	36	phase	phase	NOUN
dpc-4152	100	37	1	1	NUM
dpc-4152	100	38	trial	trial	NOUN
dpc-4152	100	39	*	*	PUNCT
dpc-4152	100	40	cohort	cohort	NOUN
dpc-4152	100	41	1	1	NUM
dpc-4152	100	42	:	:	SYM
dpc-4152	100	43	50	50	NUM
dpc-4152	100	44	mg	mg	NOUN
dpc-4152	100	45	once	once	ADV
dpc-4152	100	46	daily	daily	ADV
dpc-4152	100	47	for	for	ADP
dpc-4152	100	48	3	3	NUM
dpc-4152	100	49	days	day	NOUN
dpc-4152	100	50	>	>	X
dpc-4152	100	51	25	25	NUM
dpc-4152	100	52	cm2	cm2	PROPN
dpc-4152	100	53	(	(	PUNCT
dpc-4152	100	54	n=4	n=4	NOUN
dpc-4152	100	55	)	)	PUNCT
dpc-4152	100	56	1	1	NUM
dpc-4152	100	57	(	(	PUNCT
dpc-4152	100	58	25	25	NUM
dpc-4152	100	59	%	%	NOUN
dpc-4152	100	60	)	)	PUNCT
dpc-4152	100	61	2	2	NUM
dpc-4152	100	62	(	(	PUNCT
dpc-4152	100	63	50	50	NUM
dpc-4152	100	64	%	%	NOUN
dpc-4152	100	65	)	)	PUNCT
dpc-4152	100	66	cohort	cohort	NOUN
dpc-4152	100	67	2	2	NUM
dpc-4152	100	68	:	:	PUNCT
dpc-4152	100	69	200	200	NUM
dpc-4152	100	70	mg	mg	NOUN
dpc-4152	100	71	once	once	ADV
dpc-4152	100	72	daily	daily	ADV
dpc-4152	100	73	for	for	ADP
dpc-4152	100	74	3	3	NUM
dpc-4152	100	75	days	day	NOUN
dpc-4152	100	76	>	>	X
dpc-4152	100	77	100	100	NUM
dpc-4152	100	78	cm2	cm2	PROPN
dpc-4152	100	79	(	(	PUNCT
dpc-4152	100	80	n=10	n=10	PROPN
dpc-4152	100	81	)	)	PUNCT
dpc-4152	100	82	0	0	NUM
dpc-4152	101	1	(	(	PUNCT
dpc-4152	101	2	0	0	NUM
dpc-4152	101	3	%	%	NOUN
dpc-4152	101	4	)	)	PUNCT
dpc-4152	101	5	3	3	NUM
dpc-4152	101	6	(	(	PUNCT
dpc-4152	101	7	30	30	NUM
dpc-4152	101	8	%	%	NOUN
dpc-4152	101	9	)	)	PUNCT
dpc-4152	101	10	cohort	cohort	NOUN
dpc-4152	101	11	3	3	NUM
dpc-4152	101	12	:	:	SYM
dpc-4152	101	13	200	200	NUM
dpc-4152	101	14	mg	mg	NOUN
dpc-4152	101	15	once	once	ADV
dpc-4152	101	16	daily	daily	ADV
dpc-4152	101	17	for	for	ADP
dpc-4152	101	18	5	5	NUM
dpc-4152	101	19	days	day	NOUN
dpc-4152	101	20	>	>	X
dpc-4152	101	21	25	25	NUM
dpc-4152	101	22	cm2	cm2	PROPN
dpc-4152	101	23	(	(	PUNCT
dpc-4152	101	24	n=8	n=8	PROPN
dpc-4152	101	25	)	)	PUNCT
dpc-4152	101	26	4	4	NUM
dpc-4152	101	27	(	(	PUNCT
dpc-4152	101	28	50	50	NUM
dpc-4152	101	29	%	%	NOUN
dpc-4152	101	30	)	)	PUNCT
dpc-4152	101	31	5	5	NUM
dpc-4152	101	32	(	(	PUNCT
dpc-4152	101	33	50	50	NUM
dpc-4152	101	34	%	%	NOUN
dpc-4152	101	35	)	)	PUNCT
dpc-4152	101	36	cohort	cohort	NOUN
dpc-4152	101	37	4	4	NUM
dpc-4152	101	38	:	:	SYM
dpc-4152	101	39	200	200	NUM
dpc-4152	101	40	mg	mg	NOUN
dpc-4152	101	41	once	once	ADV
dpc-4152	101	42	daily	daily	ADV
dpc-4152	101	43	for	for	ADP
dpc-4152	101	44	5	5	NUM
dpc-4152	101	45	days	day	NOUN
dpc-4152	101	46	>	>	X
dpc-4152	101	47	25	25	NUM
dpc-4152	101	48	cm2	cm2	PROPN
dpc-4152	101	49	(	(	PUNCT
dpc-4152	101	50	n=8	n=8	PROPN
dpc-4152	101	51	)	)	PUNCT
dpc-4152	101	52	1	1	NUM
dpc-4152	101	53	(	(	PUNCT
dpc-4152	101	54	12.5	12.5	NUM
dpc-4152	101	55	%	%	NOUN
dpc-4152	101	56	)	)	PUNCT
dpc-4152	101	57	4	4	NUM
dpc-4152	101	58	(	(	PUNCT
dpc-4152	101	59	63	63	NUM
dpc-4152	101	60	%	%	NOUN
dpc-4152	101	61	)	)	PUNCT
dpc-4152	101	62	phase	phase	NOUN
dpc-4152	101	63	2	2	NUM
dpc-4152	101	64	study	study	NOUN
dpc-4152	101	65	#	#	NOUN
dpc-4152	101	66	5	5	NUM
dpc-4152	101	67	-	-	PUNCT
dpc-4152	101	68	day	day	NOUN
dpc-4152	101	69	cohort	cohort	NOUN
dpc-4152	101	70	:	:	PUNCT
dpc-4152	101	71	50	50	NUM
dpc-4152	101	72	mg	mg	NOUN
dpc-4152	101	73	once	once	ADV
dpc-4152	101	74	-	-	PUNCT
dpc-4152	101	75	daily	daily	ADJ
dpc-4152	101	76	for	for	ADP
dpc-4152	101	77	5	5	NUM
dpc-4152	101	78	days	day	NOUN
dpc-4152	101	79	over	over	ADP
dpc-4152	101	80	25	25	NUM
dpc-4152	101	81	cm2	cm2	PROPN
dpc-4152	101	82	(	(	PUNCT
dpc-4152	101	83	n=84	n=84	PROPN
dpc-4152	101	84	)	)	PUNCT
dpc-4152	101	85	36	36	NUM
dpc-4152	101	86	(	(	PUNCT
dpc-4152	101	87	43	43	NUM
dpc-4152	101	88	%	%	NOUN
dpc-4152	101	89	)	)	PUNCT
dpc-4152	101	90	47	47	NUM
dpc-4152	101	91	(	(	PUNCT
dpc-4152	101	92	56	56	NUM
dpc-4152	101	93	%	%	NOUN
dpc-4152	101	94	)	)	PUNCT
dpc-4152	101	95	5	5	NUM
dpc-4152	101	96	-	-	PUNCT
dpc-4152	101	97	day	day	NOUN
dpc-4152	101	98	cohort	cohort	NOUN
dpc-4152	101	99	:	:	PUNCT
dpc-4152	101	100	50	50	NUM
dpc-4152	101	101	mg	mg	NOUN
dpc-4152	101	102	once	once	ADV
dpc-4152	101	103	-	-	PUNCT
dpc-4152	101	104	daily	daily	ADJ
dpc-4152	101	105	for	for	ADP
dpc-4152	101	106	3	3	NUM
dpc-4152	101	107	days	day	NOUN
dpc-4152	101	108	over	over	ADP
dpc-4152	101	109	25	25	NUM
dpc-4152	101	110	cm2	cm2	PROPN
dpc-4152	101	111	(	(	PUNCT
dpc-4152	101	112	n=84	n=84	PROPN
dpc-4152	101	113	)	)	PUNCT
dpc-4152	101	114	27	27	NUM
dpc-4152	101	115	(	(	PUNCT
dpc-4152	101	116	32	32	NUM
dpc-4152	101	117	%	%	NOUN
dpc-4152	101	118	)	)	PUNCT
dpc-4152	101	119	44	44	NUM
dpc-4152	101	120	(	(	PUNCT
dpc-4152	101	121	52	52	NUM
dpc-4152	101	122	%	%	NOUN
dpc-4152	101	123	)	)	PUNCT
dpc-4152	101	124	phase	phase	NOUN
dpc-4152	101	125	3	3	NUM
dpc-4152	101	126	study	study	NOUN
dpc-4152	101	127	°	°	PUNCT
dpc-4152	102	1	tirbanibulin	tirbanibulin	PROPN
dpc-4152	102	2	group	group	NOUN
dpc-4152	102	3	(	(	PUNCT
dpc-4152	102	4	n=353	n=353	PROPN
dpc-4152	102	5	)	)	PUNCT
dpc-4152	102	6	174	174	NUM
dpc-4152	102	7	(	(	PUNCT
dpc-4152	102	8	49	49	NUM
dpc-4152	102	9	%	%	NOUN
dpc-4152	102	10	)	)	PUNCT
dpc-4152	102	11	255	255	NUM
dpc-4152	102	12	(	(	PUNCT
dpc-4152	102	13	72	72	NUM
dpc-4152	102	14	%	%	NOUN
dpc-4152	102	15	)	)	PUNCT
dpc-4152	102	16	vehicle	vehicle	NOUN
dpc-4152	102	17	(	(	PUNCT
dpc-4152	102	18	n=349	n=349	NUM
dpc-4152	102	19	)	)	PUNCT
dpc-4152	102	20	30	30	NUM
dpc-4152	102	21	(	(	PUNCT
dpc-4152	102	22	9	9	NUM
dpc-4152	102	23	%	%	NOUN
dpc-4152	102	24	)	)	PUNCT
dpc-4152	102	25	63	63	NUM
dpc-4152	102	26	(	(	PUNCT
dpc-4152	102	27	18	18	NUM
dpc-4152	102	28	%	%	NOUN
dpc-4152	102	29	)	)	PUNCT
dpc-4152	102	30	*	*	PUNCT
dpc-4152	102	31	clearance	clearance	NOUN
dpc-4152	102	32	rates	rate	NOUN
dpc-4152	102	33	were	be	AUX
dpc-4152	102	34	either	either	CCONJ
dpc-4152	102	35	classified	classify	VERB
dpc-4152	102	36	as	as	ADP
dpc-4152	102	37	complete	complete	ADJ
dpc-4152	102	38	(	(	PUNCT
dpc-4152	102	39	100	100	NUM
dpc-4152	102	40	%	%	NOUN
dpc-4152	102	41	)	)	PUNCT
dpc-4152	102	42	or	or	CCONJ
dpc-4152	102	43	partial	partial	ADJ
dpc-4152	102	44	(	(	PUNCT
dpc-4152	102	45	≥75	≥75	NOUN
dpc-4152	102	46	%	%	NOUN
dpc-4152	102	47	)	)	PUNCT
dpc-4152	102	48	at	at	ADP
dpc-4152	102	49	day	day	NOUN
dpc-4152	102	50	45	45	NUM
dpc-4152	102	51	.	.	PUNCT
dpc-4152	103	1	data	datum	NOUN
dpc-4152	103	2	of	of	ADP
dpc-4152	103	3	cohorts	cohort	NOUN
dpc-4152	103	4	1	1	NUM
dpc-4152	103	5	-	-	SYM
dpc-4152	103	6	4	4	NUM
dpc-4152	103	7	are	be	AUX
dpc-4152	103	8	summarized	summarize	VERB
dpc-4152	103	9	above	above	ADV
dpc-4152	103	10	.	.	PUNCT
dpc-4152	104	1	#	#	NOUN
dpc-4152	104	2	clearance	clearance	NOUN
dpc-4152	104	3	rates	rate	NOUN
dpc-4152	104	4	were	be	AUX
dpc-4152	104	5	either	either	CCONJ
dpc-4152	104	6	classified	classify	VERB
dpc-4152	104	7	as	as	ADP
dpc-4152	104	8	complete	complete	ADJ
dpc-4152	104	9	(	(	PUNCT
dpc-4152	104	10	100	100	NUM
dpc-4152	104	11	%	%	NOUN
dpc-4152	104	12	)	)	PUNCT
dpc-4152	104	13	or	or	CCONJ
dpc-4152	104	14	partial	partial	ADJ
dpc-4152	104	15	(	(	PUNCT
dpc-4152	104	16	≥75	≥75	NOUN
dpc-4152	104	17	%	%	NOUN
dpc-4152	104	18	)	)	PUNCT
dpc-4152	104	19	at	at	ADP
dpc-4152	104	20	day	day	NOUN
dpc-4152	104	21	57	57	NUM
dpc-4152	104	22	.	.	PUNCT
dpc-4152	105	1	data	datum	NOUN
dpc-4152	105	2	from	from	ADP
dpc-4152	105	3	3and	3and	NUM
dpc-4152	105	4	5	5	NUM
dpc-4152	105	5	-	-	PUNCT
dpc-4152	105	6	day	day	NOUN
dpc-4152	105	7	cohorts	cohort	NOUN
dpc-4152	105	8	are	be	AUX
dpc-4152	105	9	s	s	PRON
dpc-4152	105	10	ummarized	ummarized	ADJ
dpc-4152	105	11	above	above	ADV
dpc-4152	105	12	.	.	PUNCT
dpc-4152	106	1	°	°	SCONJ
dpc-4152	106	2	clearance	clearance	NOUN
dpc-4152	106	3	rates	rate	NOUN
dpc-4152	106	4	were	be	AUX
dpc-4152	106	5	either	either	CCONJ
dpc-4152	106	6	classified	classify	VERB
dpc-4152	106	7	as	as	ADP
dpc-4152	106	8	complete	complete	ADJ
dpc-4152	106	9	(	(	PUNCT
dpc-4152	106	10	100	100	NUM
dpc-4152	106	11	%	%	NOUN
dpc-4152	106	12	)	)	PUNCT
dpc-4152	106	13	or	or	CCONJ
dpc-4152	106	14	partial	partial	ADJ
dpc-4152	106	15	(	(	PUNCT
dpc-4152	106	16	≥75	≥75	NOUN
dpc-4152	106	17	%	%	NOUN
dpc-4152	106	18	)	)	PUNCT
dpc-4152	106	19	at	at	ADP
dpc-4152	106	20	day	day	NOUN
dpc-4152	106	21	57	57	NUM
dpc-4152	106	22	.	.	PUNCT
dpc-4152	107	1	clearance	clearance	NOUN
dpc-4152	107	2	was	be	AUX
dpc-4152	107	3	assessed	assess	VERB
dpc-4152	107	4	for	for	ADP
dpc-4152	107	5	both	both	CCONJ
dpc-4152	107	6	tirbanibulin	tirbanibulin	PROPN
dpc-4152	107	7	and	and	CCONJ
dpc-4152	107	8	vehicle	vehicle	NOUN
dpc-4152	107	9	(	(	PUNCT
dpc-4152	107	10	placebo	placebo	NOUN
dpc-4152	107	11	)	)	PUNCT
dpc-4152	107	12	cohorts	cohort	NOUN
dpc-4152	107	13	.	.	PUNCT
dpc-4152	108	1	the	the	DET
dpc-4152	108	2	percentage	percentage	NOUN
dpc-4152	108	3	difference	difference	NOUN
dpc-4152	108	4	between	between	ADP
dpc-4152	108	5	the	the	DET
dpc-4152	108	6	2	2	NUM
dpc-4152	108	7	groups	group	NOUN
dpc-4152	108	8	is	be	AUX
dpc-4152	108	9	shown	show	VERB
dpc-4152	108	10	.	.	PUNCT
dpc-4152	109	1	data	datum	NOUN
dpc-4152	109	2	are	be	AUX
dpc-4152	109	3	from	from	ADP
dpc-4152	109	4	intention	intention	NOUN
dpc-4152	109	5	-	-	PUNCT
dpc-4152	109	6	to	to	ADP
dpc-4152	109	7	-	-	PUNCT
dpc-4152	109	8	treat	treat	VERB
dpc-4152	109	9	analysis	analysis	NOUN
dpc-4152	109	10	.	.	PUNCT
dpc-4152	110	1	review	review	NOUN
dpc-4152	110	2	|	|	ADV
dpc-4152	110	3	dermatol	dermatol	ADJ
dpc-4152	110	4	pract	pract	NOUN
dpc-4152	110	5	concept	concept	NOUN
dpc-4152	110	6	.	.	PUNCT
dpc-4152	111	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	111	2	:	:	PUNCT
dpc-4152	111	3	e2024145s	e2024145s	NOUN
dpc-4152	111	4	5	5	NUM
dpc-4152	111	5	complete	complete	ADJ
dpc-4152	111	6	clearance	clearance	NOUN
dpc-4152	111	7	or	or	CCONJ
dpc-4152	111	8	incomplete	incomplete	ADJ
dpc-4152	111	9	lesion	lesion	NOUN
dpc-4152	111	10	count	count	NOUN
dpc-4152	111	11	reduction	reduction	NOUN
dpc-4152	111	12	at	at	ADP
dpc-4152	111	13	day	day	NOUN
dpc-4152	111	14	57	57	NUM
dpc-4152	111	15	.	.	PUNCT
dpc-4152	112	1	these	these	DET
dpc-4152	112	2	patients	patient	NOUN
dpc-4152	112	3	were	be	AUX
dpc-4152	112	4	re	re	VERB
dpc-4152	112	5	-	-	VERB
dpc-4152	112	6	evaluated	evaluate	VERB
dpc-4152	112	7	after	after	ADP
dpc-4152	112	8	12	12	NUM
dpc-4152	112	9	months	month	NOUN
dpc-4152	112	10	to	to	PART
dpc-4152	112	11	assess	assess	VERB
dpc-4152	112	12	the	the	DET
dpc-4152	112	13	recurrence	recurrence	NOUN
dpc-4152	112	14	rate	rate	NOUN
dpc-4152	112	15	.	.	PUNCT
dpc-4152	113	1	in	in	ADP
dpc-4152	113	2	trial	trial	NOUN
dpc-4152	113	3	1	1	NUM
dpc-4152	113	4	complete	complete	ADJ
dpc-4152	113	5	clearance	clearance	NOUN
dpc-4152	113	6	occurred	occur	VERB
dpc-4152	113	7	in	in	ADP
dpc-4152	113	8	44	44	NUM
dpc-4152	113	9	%	%	NOUN
dpc-4152	113	10	of	of	ADP
dpc-4152	113	11	patients	patient	NOUN
dpc-4152	113	12	(	(	PUNCT
dpc-4152	113	13	n=77	n=77	NOUN
dpc-4152	113	14	)	)	PUNCT
dpc-4152	113	15	treated	treat	VERB
dpc-4152	113	16	with	with	ADP
dpc-4152	113	17	tirbanibulin	tirbanibulin	PROPN
dpc-4152	113	18	vs	vs	ADP
dpc-4152	113	19	the	the	DET
dpc-4152	113	20	placebo	placebo	NOUN
dpc-4152	113	21	group	group	NOUN
dpc-4152	113	22	5	5	NUM
dpc-4152	113	23	%	%	NOUN
dpc-4152	113	24	(	(	PUNCT
dpc-4152	113	25	n=8	n=8	NUM
dpc-4152	113	26	)	)	PUNCT
dpc-4152	113	27	.	.	PUNCT
dpc-4152	114	1	similar	similar	ADJ
dpc-4152	114	2	results	result	NOUN
dpc-4152	114	3	were	be	AUX
dpc-4152	114	4	reported	report	VERB
dpc-4152	114	5	in	in	ADP
dpc-4152	114	6	trial	trial	NOUN
dpc-4152	114	7	2	2	NUM
dpc-4152	114	8	with	with	ADP
dpc-4152	114	9	54	54	NUM
dpc-4152	114	10	%	%	NOUN
dpc-4152	114	11	(	(	PUNCT
dpc-4152	114	12	n=97	n=97	NOUN
dpc-4152	114	13	)	)	PUNCT
dpc-4152	114	14	vs	vs	ADP
dpc-4152	114	15	13	13	NUM
dpc-4152	114	16	%	%	NOUN
dpc-4152	114	17	(	(	PUNCT
dpc-4152	114	18	n=22	n=22	PROPN
dpc-4152	114	19	)	)	PUNCT
dpc-4152	114	20	.	.	PUNCT
dpc-4152	115	1	overall	overall	ADV
dpc-4152	115	2	,	,	PUNCT
dpc-4152	115	3	a	a	DET
dpc-4152	115	4	complete	complete	ADJ
dpc-4152	115	5	clearance	clearance	NOUN
dpc-4152	115	6	was	be	AUX
dpc-4152	115	7	achieved	achieve	VERB
dpc-4152	115	8	by	by	ADP
dpc-4152	115	9	49	49	NUM
dpc-4152	115	10	%	%	NOUN
dpc-4152	115	11	(	(	PUNCT
dpc-4152	115	12	n=174	n=174	PROPN
dpc-4152	115	13	)	)	PUNCT
dpc-4152	115	14	of	of	ADP
dpc-4152	115	15	the	the	DET
dpc-4152	115	16	tirbanibulin	tirbanibulin	PROPN
dpc-4152	115	17	group	group	NOUN
dpc-4152	115	18	vs	vs	ADP
dpc-4152	115	19	9	9	NUM
dpc-4152	115	20	%	%	NOUN
dpc-4152	115	21	(	(	PUNCT
dpc-4152	115	22	n=30	n=30	NOUN
dpc-4152	115	23	)	)	PUNCT
dpc-4152	115	24	of	of	ADP
dpc-4152	115	25	the	the	DET
dpc-4152	115	26	controls	control	NOUN
dpc-4152	115	27	,	,	PUNCT
dpc-4152	115	28	with	with	ADP
dpc-4152	115	29	a	a	DET
dpc-4152	115	30	difference	difference	NOUN
dpc-4152	115	31	of	of	ADP
dpc-4152	115	32	41	41	NUM
dpc-4152	115	33	%	%	NOUN
dpc-4152	115	34	(	(	PUNCT
dpc-4152	115	35	95	95	NUM
dpc-4152	115	36	%	%	NOUN
dpc-4152	115	37	ci	ci	NOUN
dpc-4152	115	38	:	:	PUNCT
dpc-4152	115	39	35	35	NUM
dpc-4152	115	40	%	%	NOUN
dpc-4152	115	41	,	,	PUNCT
dpc-4152	115	42	47	47	NUM
dpc-4152	115	43	%	%	NOUN
dpc-4152	115	44	)	)	PUNCT
dpc-4152	115	45	.	.	PUNCT
dpc-4152	116	1	results	result	NOUN
dpc-4152	116	2	were	be	AUX
dpc-4152	116	3	consistent	consistent	ADJ
dpc-4152	116	4	with	with	ADP
dpc-4152	116	5	regards	regard	NOUN
dpc-4152	116	6	to	to	ADP
dpc-4152	116	7	the	the	DET
dpc-4152	116	8	partial	partial	ADJ
dpc-4152	116	9	clearance	clearance	NOUN
dpc-4152	116	10	outcome	outcome	NOUN
dpc-4152	116	11	:	:	PUNCT
dpc-4152	116	12	across	across	ADP
dpc-4152	116	13	the	the	DET
dpc-4152	116	14	2	2	NUM
dpc-4152	116	15	trials	trial	NOUN
dpc-4152	116	16	,	,	PUNCT
dpc-4152	116	17	a	a	DET
dpc-4152	116	18	≥75	≥75	NOUN
dpc-4152	116	19	%	%	NOUN
dpc-4152	116	20	clearance	clearance	NOUN
dpc-4152	116	21	was	be	AUX
dpc-4152	116	22	obtained	obtain	VERB
dpc-4152	116	23	by	by	ADP
dpc-4152	116	24	72	72	NUM
dpc-4152	116	25	%	%	NOUN
dpc-4152	116	26	(	(	PUNCT
dpc-4152	116	27	n=255	n=255	PROPN
dpc-4152	116	28	)	)	PUNCT
dpc-4152	116	29	of	of	ADP
dpc-4152	116	30	the	the	DET
dpc-4152	116	31	tirbanibulin	tirbanibulin	PROPN
dpc-4152	116	32	group	group	NOUN
dpc-4152	116	33	vs	vs	ADP
dpc-4152	116	34	18	18	NUM
dpc-4152	116	35	%	%	NOUN
dpc-4152	116	36	(	(	PUNCT
dpc-4152	116	37	n=63	n=63	NOUN
dpc-4152	116	38	)	)	PUNCT
dpc-4152	116	39	of	of	ADP
dpc-4152	116	40	the	the	DET
dpc-4152	116	41	vehicle	vehicle	NOUN
dpc-4152	116	42	,	,	PUNCT
dpc-4152	116	43	with	with	ADP
dpc-4152	116	44	a	a	DET
dpc-4152	116	45	difference	difference	NOUN
dpc-4152	116	46	of	of	ADP
dpc-4152	116	47	54	54	NUM
dpc-4152	116	48	%	%	NOUN
dpc-4152	116	49	(	(	PUNCT
dpc-4152	116	50	95	95	NUM
dpc-4152	116	51	%	%	NOUN
dpc-4152	116	52	ci	ci	NOUN
dpc-4152	116	53	:	:	PUNCT
dpc-4152	116	54	48	48	NUM
dpc-4152	116	55	%	%	NOUN
dpc-4152	116	56	,	,	PUNCT
dpc-4152	116	57	60	60	NUM
dpc-4152	116	58	%	%	NOUN
dpc-4152	116	59	)	)	PUNCT
dpc-4152	116	60	(	(	PUNCT
dpc-4152	116	61	table	table	NOUN
dpc-4152	116	62	2	2	NUM
dpc-4152	116	63	)	)	PUNCT
dpc-4152	116	64	.	.	PUNCT
dpc-4152	117	1	no	no	DET
dpc-4152	117	2	saes	sae	NOUN
dpc-4152	117	3	or	or	CCONJ
dpc-4152	117	4	discontinuation	discontinuation	NOUN
dpc-4152	117	5	due	due	ADP
dpc-4152	117	6	to	to	ADP
dpc-4152	117	7	aes	aes	PROPN
dpc-4152	117	8	occurred	occur	VERB
dpc-4152	117	9	.	.	PUNCT
dpc-4152	118	1	the	the	DET
dpc-4152	118	2	only	only	ADJ
dpc-4152	118	3	aes	aes	PROPN
dpc-4152	118	4	that	that	PRON
dpc-4152	118	5	occurred	occur	VERB
dpc-4152	118	6	at	at	ADP
dpc-4152	118	7	a	a	DET
dpc-4152	118	8	significantly	significantly	ADV
dpc-4152	118	9	higher	high	ADJ
dpc-4152	118	10	rate	rate	NOUN
dpc-4152	118	11	in	in	ADP
dpc-4152	118	12	the	the	DET
dpc-4152	118	13	tirbanibulin	tirbanibulin	PROPN
dpc-4152	118	14	group	group	NOUN
dpc-4152	118	15	vs	vs	ADP
dpc-4152	118	16	placebo	placebo	NOUN
dpc-4152	118	17	were	be	AUX
dpc-4152	118	18	lrss	lrss	ADJ
dpc-4152	118	19	,	,	PUNCT
dpc-4152	118	20	the	the	DET
dpc-4152	118	21	most	most	ADV
dpc-4152	118	22	common	common	ADJ
dpc-4152	118	23	of	of	ADP
dpc-4152	118	24	which	which	PRON
dpc-4152	118	25	were	be	AUX
dpc-4152	118	26	erythema	erythema	ADJ
dpc-4152	118	27	(	(	PUNCT
dpc-4152	118	28	91	91	NUM
dpc-4152	118	29	%	%	NOUN
dpc-4152	118	30	)	)	PUNCT
dpc-4152	118	31	and	and	CCONJ
dpc-4152	118	32	flaking	flake	VERB
dpc-4152	118	33	or	or	CCONJ
dpc-4152	118	34	scaling	scaling	NOUN
dpc-4152	118	35	(	(	PUNCT
dpc-4152	118	36	82	82	NUM
dpc-4152	118	37	%	%	NOUN
dpc-4152	118	38	)	)	PUNCT
dpc-4152	118	39	.	.	PUNCT
dpc-4152	119	1	pain	pain	NOUN
dpc-4152	119	2	in	in	ADP
dpc-4152	119	3	the	the	DET
dpc-4152	119	4	application	application	NOUN
dpc-4152	119	5	site	site	NOUN
dpc-4152	119	6	and	and	CCONJ
dpc-4152	119	7	pruritus	pruritus	NOUN
dpc-4152	119	8	were	be	AUX
dpc-4152	119	9	much	much	ADV
dpc-4152	119	10	less	less	ADV
dpc-4152	119	11	common	common	ADJ
dpc-4152	119	12	.	.	PUNCT
dpc-4152	120	1	all	all	DET
dpc-4152	120	2	the	the	DET
dpc-4152	120	3	adverse	adverse	ADJ
dpc-4152	120	4	effects	effect	NOUN
dpc-4152	120	5	were	be	AUX
dpc-4152	120	6	mild	mild	ADJ
dpc-4152	120	7	to	to	AUX
dpc-4152	120	8	moderate	moderate	ADJ
dpc-4152	120	9	and	and	CCONJ
dpc-4152	120	10	resolved	resolve	VERB
dpc-4152	120	11	without	without	ADP
dpc-4152	120	12	the	the	DET
dpc-4152	120	13	need	need	NOUN
dpc-4152	120	14	for	for	ADP
dpc-4152	120	15	further	further	ADJ
dpc-4152	120	16	treatment	treatment	NOUN
dpc-4152	120	17	.	.	PUNCT
dpc-4152	121	1	real	real	ADJ
dpc-4152	121	2	-	-	PUNCT
dpc-4152	121	3	world	world	NOUN
dpc-4152	121	4	studies	study	NOUN
dpc-4152	121	5	a	a	DET
dpc-4152	121	6	real	real	ADJ
dpc-4152	121	7	-	-	PUNCT
dpc-4152	121	8	world	world	NOUN
dpc-4152	121	9	study	study	NOUN
dpc-4152	121	10	that	that	PRON
dpc-4152	121	11	showed	show	VERB
dpc-4152	121	12	the	the	DET
dpc-4152	121	13	real	real	ADJ
dpc-4152	121	14	effectiveness	effectiveness	NOUN
dpc-4152	121	15	of	of	ADP
dpc-4152	121	16	tirbanibulin	tirbanibulin	PROPN
dpc-4152	121	17	in	in	ADP
dpc-4152	121	18	a	a	DET
dpc-4152	121	19	real	real	ADJ
dpc-4152	121	20	clinical	clinical	ADJ
dpc-4152	121	21	contest	contest	NOUN
dpc-4152	121	22	was	be	AUX
dpc-4152	121	23	published	publish	VERB
dpc-4152	121	24	by	by	ADP
dpc-4152	121	25	kirchberger	kirchberger	NOUN
dpc-4152	121	26	et	et	PROPN
dpc-4152	121	27	al	al	PROPN
dpc-4152	122	1	[	[	X
dpc-4152	122	2	46	46	NUM
dpc-4152	122	3	]	]	PUNCT
dpc-4152	122	4	.	.	PUNCT
dpc-4152	123	1	it	it	PRON
dpc-4152	123	2	was	be	AUX
dpc-4152	123	3	a	a	DET
dpc-4152	123	4	single	single	ADJ
dpc-4152	123	5	-	-	PUNCT
dpc-4152	123	6	center	center	NOUN
dpc-4152	123	7	study	study	NOUN
dpc-4152	123	8	of	of	ADP
dpc-4152	123	9	adult	adult	NOUN
dpc-4152	123	10	patients	patient	NOUN
dpc-4152	123	11	with	with	ADP
dpc-4152	123	12	ak	ak	PROPN
dpc-4152	123	13	of	of	ADP
dpc-4152	123	14	face	face	NOUN
dpc-4152	123	15	and	and	CCONJ
dpc-4152	123	16	scalp	scalp	NOUN
dpc-4152	123	17	treated	treat	VERB
dpc-4152	123	18	with	with	ADP
dpc-4152	123	19	tirbanibulin	tirbanibulin	PROPN
dpc-4152	123	20	ointment	ointment	NOUN
dpc-4152	123	21	1	1	NUM
dpc-4152	123	22	%	%	NOUN
dpc-4152	123	23	applied	apply	VERB
dpc-4152	123	24	daily	daily	ADV
dpc-4152	123	25	for	for	ADP
dpc-4152	123	26	5	5	NUM
dpc-4152	123	27	consecutive	consecutive	ADJ
dpc-4152	123	28	days	day	NOUN
dpc-4152	123	29	on	on	ADP
dpc-4152	123	30	the	the	DET
dpc-4152	123	31	same	same	ADJ
dpc-4152	123	32	lesion	lesion	NOUN
dpc-4152	123	33	or	or	CCONJ
dpc-4152	123	34	field	field	NOUN
dpc-4152	123	35	.	.	PUNCT
dpc-4152	124	1	the	the	DET
dpc-4152	124	2	results	result	NOUN
dpc-4152	124	3	of	of	ADP
dpc-4152	124	4	treatment	treatment	NOUN
dpc-4152	124	5	were	be	AUX
dpc-4152	124	6	assessed	assess	VERB
dpc-4152	124	7	4	4	NUM
dpc-4152	124	8	weeks	week	NOUN
dpc-4152	124	9	after	after	ADP
dpc-4152	124	10	the	the	DET
dpc-4152	124	11	beginning	beginning	NOUN
dpc-4152	124	12	of	of	ADP
dpc-4152	124	13	administration	administration	NOUN
dpc-4152	124	14	of	of	ADP
dpc-4152	124	15	tirbanibulin	tirbanibulin	PROPN
dpc-4152	124	16	plus	plus	CCONJ
dpc-4152	124	17	optional	optional	ADJ
dpc-4152	124	18	assessments	assessment	NOUN
dpc-4152	124	19	later	later	ADV
dpc-4152	124	20	in	in	ADP
dpc-4152	124	21	time	time	NOUN
dpc-4152	124	22	.	.	PUNCT
dpc-4152	125	1	the	the	DET
dpc-4152	125	2	effectiveness	effectiveness	NOUN
dpc-4152	125	3	of	of	ADP
dpc-4152	125	4	tirbanibulin	tirbanibulin	PROPN
dpc-4152	125	5	over	over	ADP
dpc-4152	125	6	the	the	DET
dpc-4152	125	7	aks	ak	NOUN
dpc-4152	125	8	was	be	AUX
dpc-4152	125	9	measured	measure	VERB
dpc-4152	125	10	before	before	ADP
dpc-4152	125	11	and	and	CCONJ
dpc-4152	125	12	after	after	ADP
dpc-4152	125	13	the	the	DET
dpc-4152	125	14	treatment	treatment	NOUN
dpc-4152	125	15	with	with	ADP
dpc-4152	125	16	a	a	DET
dpc-4152	125	17	specific	specific	ADJ
dpc-4152	125	18	score	score	NOUN
dpc-4152	125	19	,	,	PUNCT
dpc-4152	125	20	the	the	DET
dpc-4152	125	21	actinic	actinic	ADJ
dpc-4152	125	22	keratosis	keratosis	NOUN
dpc-4152	125	23	area	area	NOUN
dpc-4152	125	24	and	and	CCONJ
dpc-4152	125	25	severity	severity	NOUN
dpc-4152	125	26	in	in	ADP
dpc-4152	125	27	the	the	DET
dpc-4152	125	28	5	5	NUM
dpc-4152	125	29	-	-	PUNCT
dpc-4152	125	30	day	day	NOUN
dpc-4152	125	31	group	group	NOUN
dpc-4152	125	32	vs	vs	ADP
dpc-4152	125	33	32	32	NUM
dpc-4152	125	34	%	%	NOUN
dpc-4152	125	35	(	(	PUNCT
dpc-4152	125	36	95	95	NUM
dpc-4152	125	37	%	%	NOUN
dpc-4152	125	38	ci	ci	NOUN
dpc-4152	125	39	:	:	PUNCT
dpc-4152	125	40	22	22	NUM
dpc-4152	125	41	%	%	NOUN
dpc-4152	125	42	,	,	PUNCT
dpc-4152	125	43	43	43	NUM
dpc-4152	125	44	%	%	NOUN
dpc-4152	125	45	)	)	PUNCT
dpc-4152	125	46	in	in	ADP
dpc-4152	125	47	the	the	DET
dpc-4152	125	48	3	3	NUM
dpc-4152	125	49	-	-	PUNCT
dpc-4152	125	50	day	day	NOUN
dpc-4152	125	51	group	group	NOUN
dpc-4152	125	52	while	while	SCONJ
dpc-4152	125	53	a	a	DET
dpc-4152	125	54	≥75	≥75	NOUN
dpc-4152	125	55	%	%	NOUN
dpc-4152	125	56	clearance	clearance	NOUN
dpc-4152	125	57	was	be	AUX
dpc-4152	125	58	achieved	achieve	VERB
dpc-4152	125	59	by	by	ADP
dpc-4152	125	60	56	56	NUM
dpc-4152	125	61	%	%	NOUN
dpc-4152	125	62	(	(	PUNCT
dpc-4152	125	63	95	95	NUM
dpc-4152	125	64	%	%	NOUN
dpc-4152	125	65	ci	ci	NOUN
dpc-4152	125	66	:	:	PUNCT
dpc-4152	125	67	45	45	NUM
dpc-4152	125	68	%	%	NOUN
dpc-4152	125	69	,	,	PUNCT
dpc-4152	125	70	67	67	NUM
dpc-4152	125	71	%	%	NOUN
dpc-4152	125	72	)	)	PUNCT
dpc-4152	125	73	and	and	CCONJ
dpc-4152	125	74	52	52	NUM
dpc-4152	125	75	%	%	NOUN
dpc-4152	125	76	(	(	PUNCT
dpc-4152	125	77	41	41	NUM
dpc-4152	125	78	%	%	NOUN
dpc-4152	125	79	,	,	PUNCT
dpc-4152	125	80	63	63	NUM
dpc-4152	125	81	%	%	NOUN
dpc-4152	125	82	)	)	PUNCT
dpc-4152	125	83	respectively	respectively	ADV
dpc-4152	125	84	.	.	PUNCT
dpc-4152	126	1	data	datum	NOUN
dpc-4152	126	2	regarding	regard	VERB
dpc-4152	126	3	effectiveness	effectiveness	NOUN
dpc-4152	126	4	is	be	AUX
dpc-4152	126	5	summarized	summarize	VERB
dpc-4152	126	6	in	in	ADP
dpc-4152	126	7	table	table	NOUN
dpc-4152	126	8	1	1	NUM
dpc-4152	126	9	.	.	PUNCT
dpc-4152	127	1	furthermore	furthermore	ADV
dpc-4152	127	2	,	,	PUNCT
dpc-4152	127	3	all	all	DET
dpc-4152	127	4	the	the	DET
dpc-4152	127	5	patients	patient	NOUN
dpc-4152	127	6	who	who	PRON
dpc-4152	127	7	achieved	achieve	VERB
dpc-4152	127	8	complete	complete	ADJ
dpc-4152	127	9	clearance	clearance	NOUN
dpc-4152	127	10	(	(	PUNCT
dpc-4152	127	11	n=63	n=63	ADJ
dpc-4152	127	12	)	)	PUNCT
dpc-4152	127	13	were	be	AUX
dpc-4152	127	14	included	include	VERB
dpc-4152	127	15	in	in	ADP
dpc-4152	127	16	a	a	DET
dpc-4152	127	17	further	further	ADJ
dpc-4152	127	18	12	12	NUM
dpc-4152	127	19	-	-	PUNCT
dpc-4152	127	20	month	month	NOUN
dpc-4152	127	21	follow	follow	NOUN
dpc-4152	127	22	-	-	PUNCT
dpc-4152	127	23	up	up	NOUN
dpc-4152	127	24	to	to	PART
dpc-4152	127	25	evaluate	evaluate	VERB
dpc-4152	127	26	the	the	DET
dpc-4152	127	27	rate	rate	NOUN
dpc-4152	127	28	of	of	ADP
dpc-4152	127	29	recurrence	recurrence	NOUN
dpc-4152	127	30	.	.	PUNCT
dpc-4152	128	1	consistent	consistent	ADJ
dpc-4152	128	2	with	with	ADP
dpc-4152	128	3	the	the	DET
dpc-4152	128	4	data	datum	NOUN
dpc-4152	128	5	above	above	ADV
dpc-4152	128	6	,	,	PUNCT
dpc-4152	128	7	the	the	DET
dpc-4152	128	8	recurrence	recurrence	NOUN
dpc-4152	128	9	rate	rate	NOUN
dpc-4152	128	10	was	be	AUX
dpc-4152	128	11	lower	low	ADJ
dpc-4152	128	12	in	in	ADP
dpc-4152	128	13	the	the	DET
dpc-4152	128	14	5	5	NUM
dpc-4152	128	15	-	-	PUNCT
dpc-4152	128	16	day	day	NOUN
dpc-4152	128	17	cohort	cohort	NOUN
dpc-4152	128	18	(	(	PUNCT
dpc-4152	128	19	57	57	NUM
dpc-4152	128	20	%	%	NOUN
dpc-4152	128	21	[	[	X
dpc-4152	128	22	95	95	NUM
dpc-4152	128	23	%	%	NOUN
dpc-4152	128	24	ci	ci	NOUN
dpc-4152	128	25	:	:	PUNCT
dpc-4152	128	26	41	41	NUM
dpc-4152	128	27	%	%	NOUN
dpc-4152	128	28	,	,	PUNCT
dpc-4152	128	29	73	73	NUM
dpc-4152	128	30	%	%	NOUN
dpc-4152	128	31	]	]	X
dpc-4152	128	32	)	)	PUNCT
dpc-4152	128	33	when	when	SCONJ
dpc-4152	128	34	compared	compare	VERB
dpc-4152	128	35	to	to	ADP
dpc-4152	128	36	the	the	DET
dpc-4152	128	37	3	3	NUM
dpc-4152	128	38	-	-	PUNCT
dpc-4152	128	39	day	day	NOUN
dpc-4152	128	40	cohort	cohort	NOUN
dpc-4152	128	41	(	(	PUNCT
dpc-4152	128	42	70	70	NUM
dpc-4152	128	43	%	%	NOUN
dpc-4152	128	44	[	[	X
dpc-4152	128	45	95	95	NUM
dpc-4152	128	46	%	%	NOUN
dpc-4152	128	47	ci	ci	NOUN
dpc-4152	128	48	:	:	PUNCT
dpc-4152	128	49	51	51	NUM
dpc-4152	128	50	%	%	NOUN
dpc-4152	128	51	,	,	PUNCT
dpc-4152	128	52	87	87	NUM
dpc-4152	128	53	%	%	NOUN
dpc-4152	128	54	]	]	PUNCT
dpc-4152	128	55	)	)	PUNCT
dpc-4152	128	56	.	.	PUNCT
dpc-4152	129	1	one	one	NUM
dpc-4152	129	2	hundred	hundred	NUM
dpc-4152	129	3	percent	percent	NOUN
dpc-4152	129	4	of	of	ADP
dpc-4152	129	5	patients	patient	NOUN
dpc-4152	129	6	completed	complete	VERB
dpc-4152	129	7	the	the	DET
dpc-4152	129	8	treatment	treatment	NOUN
dpc-4152	129	9	and	and	CCONJ
dpc-4152	129	10	the	the	DET
dpc-4152	129	11	follow	follow	NOUN
dpc-4152	129	12	-	-	PUNCT
dpc-4152	129	13	up	up	NOUN
dpc-4152	129	14	.	.	PUNCT
dpc-4152	130	1	no	no	DET
dpc-4152	130	2	severe	severe	ADJ
dpc-4152	130	3	adverse	adverse	ADJ
dpc-4152	130	4	effects	effect	NOUN
dpc-4152	130	5	(	(	PUNCT
dpc-4152	130	6	saes	sae	NOUN
dpc-4152	130	7	)	)	PUNCT
dpc-4152	130	8	or	or	CCONJ
dpc-4152	130	9	discontinuation	discontinuation	NOUN
dpc-4152	130	10	of	of	ADP
dpc-4152	130	11	the	the	DET
dpc-4152	130	12	therapy	therapy	NOUN
dpc-4152	130	13	due	due	ADP
dpc-4152	130	14	to	to	ADP
dpc-4152	130	15	adverse	adverse	ADJ
dpc-4152	130	16	effects	effect	NOUN
dpc-4152	130	17	were	be	AUX
dpc-4152	130	18	reported	report	VERB
dpc-4152	130	19	,	,	PUNCT
dpc-4152	130	20	and	and	CCONJ
dpc-4152	130	21	7	7	NUM
dpc-4152	130	22	%	%	NOUN
dpc-4152	130	23	(	(	PUNCT
dpc-4152	130	24	n=12	n=12	NOUN
dpc-4152	130	25	)	)	PUNCT
dpc-4152	130	26	of	of	ADP
dpc-4152	130	27	the	the	DET
dpc-4152	130	28	patients	patient	NOUN
dpc-4152	130	29	reported	report	VERB
dpc-4152	130	30	adverse	adverse	ADJ
dpc-4152	130	31	effects	effect	NOUN
dpc-4152	130	32	,	,	PUNCT
dpc-4152	130	33	with	with	ADP
dpc-4152	130	34	a	a	DET
dpc-4152	130	35	slightly	slightly	ADV
dpc-4152	130	36	higher	high	ADJ
dpc-4152	130	37	occurrence	occurrence	NOUN
dpc-4152	130	38	in	in	ADP
dpc-4152	130	39	the	the	DET
dpc-4152	130	40	5	5	NUM
dpc-4152	130	41	-	-	PUNCT
dpc-4152	130	42	day	day	NOUN
dpc-4152	130	43	cohort	cohort	NOUN
dpc-4152	130	44	(	(	PUNCT
dpc-4152	130	45	11	11	NUM
dpc-4152	130	46	%	%	NOUN
dpc-4152	130	47	,	,	PUNCT
dpc-4152	130	48	n=9	n=9	PROPN
dpc-4152	130	49	)	)	PUNCT
dpc-4152	130	50	vs	vs	ADP
dpc-4152	130	51	the	the	DET
dpc-4152	130	52	3	3	NUM
dpc-4152	130	53	-	-	PUNCT
dpc-4152	130	54	day	day	NOUN
dpc-4152	130	55	cohort	cohort	NOUN
dpc-4152	130	56	(	(	PUNCT
dpc-4152	130	57	4	4	NUM
dpc-4152	130	58	%	%	NOUN
dpc-4152	130	59	,	,	PUNCT
dpc-4152	130	60	n=3	n=3	NOUN
dpc-4152	130	61	)	)	PUNCT
dpc-4152	130	62	.	.	PUNCT
dpc-4152	131	1	however	however	ADV
dpc-4152	131	2	,	,	PUNCT
dpc-4152	131	3	these	these	DET
dpc-4152	131	4	effects	effect	NOUN
dpc-4152	131	5	were	be	AUX
dpc-4152	131	6	mostly	mostly	ADV
dpc-4152	131	7	mild	mild	ADJ
dpc-4152	131	8	lysosomal	lysosomal	ADJ
dpc-4152	131	9	stress	stress	NOUN
dpc-4152	131	10	responses	response	NOUN
dpc-4152	131	11	(	(	PUNCT
dpc-4152	131	12	lsrs	lsrs	ADJ
dpc-4152	131	13	)	)	PUNCT
dpc-4152	131	14	,	,	PUNCT
dpc-4152	131	15	which	which	PRON
dpc-4152	131	16	never	never	ADV
dpc-4152	131	17	required	require	VERB
dpc-4152	131	18	discontinuation	discontinuation	NOUN
dpc-4152	131	19	of	of	ADP
dpc-4152	131	20	the	the	DET
dpc-4152	131	21	treatment	treatment	NOUN
dpc-4152	131	22	or	or	CCONJ
dpc-4152	131	23	further	further	ADJ
dpc-4152	131	24	interventions	intervention	NOUN
dpc-4152	131	25	,	,	PUNCT
dpc-4152	131	26	and	and	CCONJ
dpc-4152	131	27	that	that	PRON
dpc-4152	131	28	were	be	AUX
dpc-4152	131	29	self	self	NOUN
dpc-4152	131	30	-	-	PUNCT
dpc-4152	131	31	resolved	resolve	VERB
dpc-4152	131	32	(	(	PUNCT
dpc-4152	131	33	table	table	NOUN
dpc-4152	131	34	3	3	NUM
dpc-4152	131	35	)	)	PUNCT
dpc-4152	131	36	.	.	PUNCT
dpc-4152	132	1	phase	phase	NOUN
dpc-4152	132	2	3	3	NUM
dpc-4152	132	3	trials	trial	NOUN
dpc-4152	132	4	phase	phase	NOUN
dpc-4152	132	5	3	3	NUM
dpc-4152	132	6	trials	trial	NOUN
dpc-4152	132	7	[	[	X
dpc-4152	132	8	45	45	NUM
dpc-4152	132	9	]	]	PUNCT
dpc-4152	132	10	,	,	PUNCT
dpc-4152	132	11	conducted	conduct	VERB
dpc-4152	132	12	in	in	ADP
dpc-4152	132	13	the	the	DET
dpc-4152	132	14	united	united	PROPN
dpc-4152	132	15	states	states	PROPN
dpc-4152	132	16	,	,	PUNCT
dpc-4152	132	17	were	be	AUX
dpc-4152	132	18	multicentric	multicentric	ADJ
dpc-4152	132	19	(	(	PUNCT
dpc-4152	132	20	62	62	NUM
dpc-4152	132	21	centers	center	NOUN
dpc-4152	132	22	)	)	PUNCT
dpc-4152	132	23	,	,	PUNCT
dpc-4152	132	24	randomized	randomize	VERB
dpc-4152	132	25	,	,	PUNCT
dpc-4152	132	26	double	double	ADJ
dpc-4152	132	27	-	-	PUNCT
dpc-4152	132	28	blind	blind	ADJ
dpc-4152	132	29	,	,	PUNCT
dpc-4152	132	30	parallel	parallel	NOUN
dpc-4152	132	31	-	-	PUNCT
dpc-4152	132	32	group	group	NOUN
dpc-4152	132	33	,	,	PUNCT
dpc-4152	132	34	vehicle	vehicle	NOUN
dpc-4152	132	35	-	-	PUNCT
dpc-4152	132	36	controlled	control	VERB
dpc-4152	132	37	(	(	PUNCT
dpc-4152	132	38	placebo	placebo	NOUN
dpc-4152	132	39	trials	trial	NOUN
dpc-4152	132	40	)	)	PUNCT
dpc-4152	132	41	.	.	PUNCT
dpc-4152	133	1	patients	patient	NOUN
dpc-4152	133	2	were	be	AUX
dpc-4152	133	3	eligible	eligible	ADJ
dpc-4152	133	4	for	for	ADP
dpc-4152	133	5	enrollment	enrollment	NOUN
dpc-4152	133	6	if	if	SCONJ
dpc-4152	133	7	they	they	PRON
dpc-4152	133	8	had	have	VERB
dpc-4152	133	9	4	4	NUM
dpc-4152	133	10	-	-	SYM
dpc-4152	133	11	8	8	NUM
dpc-4152	133	12	clinically	clinically	ADV
dpc-4152	133	13	typical	typical	ADJ
dpc-4152	133	14	aks	ak	NOUN
dpc-4152	133	15	within	within	ADP
dpc-4152	133	16	a	a	DET
dpc-4152	133	17	contiguous	contiguous	ADJ
dpc-4152	133	18	area	area	NOUN
dpc-4152	133	19	of	of	ADP
dpc-4152	133	20	25	25	NUM
dpc-4152	133	21	cm2	cm2	NOUN
dpc-4152	133	22	in	in	ADP
dpc-4152	133	23	the	the	DET
dpc-4152	133	24	face	face	NOUN
dpc-4152	133	25	-	-	PUNCT
dpc-4152	133	26	scalp	scalp	NOUN
dpc-4152	133	27	area	area	NOUN
dpc-4152	133	28	and	and	CCONJ
dpc-4152	133	29	were	be	AUX
dpc-4152	133	30	aged	age	VERB
dpc-4152	133	31	≥18	≥18	NUM
dpc-4152	133	32	years	year	NOUN
dpc-4152	133	33	.	.	PUNCT
dpc-4152	134	1	the	the	DET
dpc-4152	134	2	patients	patient	NOUN
dpc-4152	134	3	(	(	PUNCT
dpc-4152	134	4	n=702	n=702	NUM
dpc-4152	134	5	)	)	PUNCT
dpc-4152	134	6	were	be	AUX
dpc-4152	134	7	divided	divide	VERB
dpc-4152	134	8	into	into	ADP
dpc-4152	134	9	2	2	NUM
dpc-4152	134	10	identical	identical	ADJ
dpc-4152	134	11	-	-	PUNCT
dpc-4152	134	12	sized	sized	ADJ
dpc-4152	134	13	groups	group	NOUN
dpc-4152	134	14	(	(	PUNCT
dpc-4152	134	15	n=301	n=301	NUM
dpc-4152	134	16	,	,	PUNCT
dpc-4152	134	17	each	each	PRON
dpc-4152	134	18	)	)	PUNCT
dpc-4152	134	19	and	and	CCONJ
dpc-4152	134	20	were	be	AUX
dpc-4152	134	21	randomly	randomly	ADV
dpc-4152	134	22	assigned	assign	VERB
dpc-4152	134	23	to	to	PART
dpc-4152	134	24	receive	receive	VERB
dpc-4152	134	25	a	a	DET
dpc-4152	134	26	vehicle	vehicle	NOUN
dpc-4152	134	27	ointment	ointment	NOUN
dpc-4152	134	28	or	or	CCONJ
dpc-4152	134	29	tirbanibulin	tirbanibulin	PRON
dpc-4152	134	30	1	1	NUM
dpc-4152	134	31	%	%	NOUN
dpc-4152	134	32	ointment	ointment	NOUN
dpc-4152	134	33	with	with	ADP
dpc-4152	134	34	a	a	DET
dpc-4152	134	35	1:1	1:1	NUM
dpc-4152	134	36	ratio	ratio	NOUN
dpc-4152	134	37	.	.	PUNCT
dpc-4152	135	1	enrollment	enrollment	NOUN
dpc-4152	135	2	,	,	PUNCT
dpc-4152	135	3	however	however	ADV
dpc-4152	135	4	,	,	PUNCT
dpc-4152	135	5	was	be	AUX
dpc-4152	135	6	controlled	control	VERB
dpc-4152	135	7	to	to	PART
dpc-4152	135	8	achieve	achieve	VERB
dpc-4152	135	9	,	,	PUNCT
dpc-4152	135	10	within	within	ADP
dpc-4152	135	11	each	each	DET
dpc-4152	135	12	trial	trial	NOUN
dpc-4152	135	13	,	,	PUNCT
dpc-4152	135	14	a	a	DET
dpc-4152	135	15	2:1	2:1	NUM
dpc-4152	135	16	facial	facial	NOUN
dpc-4152	135	17	:	:	PUNCT
dpc-4152	135	18	scalp	scalp	NOUN
dpc-4152	135	19	treated	treat	VERB
dpc-4152	135	20	area	area	NOUN
dpc-4152	135	21	ratio	ratio	NOUN
dpc-4152	135	22	.	.	PUNCT
dpc-4152	136	1	patients	patient	NOUN
dpc-4152	136	2	were	be	AUX
dpc-4152	136	3	evaluated	evaluate	VERB
dpc-4152	136	4	at	at	ADP
dpc-4152	136	5	baseline	baseline	NOUN
dpc-4152	136	6	and	and	CCONJ
dpc-4152	136	7	day	day	NOUN
dpc-4152	136	8	57	57	NUM
dpc-4152	136	9	.	.	PUNCT
dpc-4152	137	1	primary	primary	ADJ
dpc-4152	137	2	and	and	CCONJ
dpc-4152	137	3	secondary	secondary	ADJ
dpc-4152	137	4	outcomes	outcome	NOUN
dpc-4152	137	5	were	be	AUX
dpc-4152	137	6	respectively	respectively	ADV
dpc-4152	137	7	table	table	NOUN
dpc-4152	137	8	3	3	NUM
dpc-4152	137	9	.	.	PUNCT
dpc-4152	137	10	treatment	treatment	NOUN
dpc-4152	137	11	-	-	PUNCT
dpc-4152	137	12	related	relate	VERB
dpc-4152	137	13	adverse	adverse	ADJ
dpc-4152	137	14	effects	effect	NOUN
dpc-4152	137	15	*	*	PUNCT
dpc-4152	137	16	through	through	ADP
dpc-4152	137	17	phases	phase	NOUN
dpc-4152	137	18	1	1	NUM
dpc-4152	137	19	,	,	PUNCT
dpc-4152	137	20	2	2	NUM
dpc-4152	137	21	,	,	PUNCT
dpc-4152	137	22	and	and	CCONJ
dpc-4152	137	23	3	3	X
dpc-4152	137	24	.	.	PUNCT
dpc-4152	138	1	[	[	X
dpc-4152	138	2	44,45	44,45	NOUN
dpc-4152	138	3	]	]	X
dpc-4152	138	4	phase	phase	NOUN
dpc-4152	138	5	1	1	NUM
dpc-4152	138	6	study	study	NOUN
dpc-4152	138	7	mild	mild	ADJ
dpc-4152	138	8	n	n	CCONJ
dpc-4152	138	9	(	(	PUNCT
dpc-4152	138	10	%	%	INTJ
dpc-4152	138	11	)	)	PUNCT
dpc-4152	138	12	severe	severe	ADJ
dpc-4152	138	13	n	n	PROPN
dpc-4152	138	14	(	(	PUNCT
dpc-4152	138	15	%	%	INTJ
dpc-4152	138	16	)	)	PUNCT
dpc-4152	138	17	cohort	cohort	NOUN
dpc-4152	138	18	1	1	NUM
dpc-4152	138	19	:	:	SYM
dpc-4152	138	20	50	50	NUM
dpc-4152	138	21	mg	mg	NOUN
dpc-4152	138	22	once	once	ADV
dpc-4152	138	23	daily	daily	ADV
dpc-4152	138	24	for	for	ADP
dpc-4152	138	25	3	3	NUM
dpc-4152	138	26	days	day	NOUN
dpc-4152	138	27	>	>	X
dpc-4152	138	28	25	25	NUM
dpc-4152	138	29	cm2	cm2	PROPN
dpc-4152	138	30	(	(	PUNCT
dpc-4152	138	31	n=4	n=4	NOUN
dpc-4152	138	32	)	)	PUNCT
dpc-4152	138	33	0	0	NUM
dpc-4152	138	34	0	0	NUM
dpc-4152	138	35	cohort	cohort	NOUN
dpc-4152	138	36	2	2	NUM
dpc-4152	138	37	:	:	PUNCT
dpc-4152	138	38	200	200	NUM
dpc-4152	138	39	mg	mg	NOUN
dpc-4152	138	40	once	once	ADV
dpc-4152	138	41	daily	daily	ADV
dpc-4152	138	42	for	for	ADP
dpc-4152	138	43	3	3	NUM
dpc-4152	138	44	days	day	NOUN
dpc-4152	138	45	>	>	X
dpc-4152	138	46	100	100	NUM
dpc-4152	138	47	cm2	cm2	PROPN
dpc-4152	138	48	(	(	PUNCT
dpc-4152	138	49	n=4	n=4	NOUN
dpc-4152	138	50	)	)	PUNCT
dpc-4152	138	51	0	0	NUM
dpc-4152	138	52	0	0	NUM
dpc-4152	138	53	cohort	cohort	NOUN
dpc-4152	138	54	3	3	NUM
dpc-4152	138	55	:	:	SYM
dpc-4152	138	56	200	200	NUM
dpc-4152	138	57	mg	mg	NOUN
dpc-4152	138	58	once	once	ADV
dpc-4152	138	59	daily	daily	ADV
dpc-4152	138	60	for	for	ADP
dpc-4152	138	61	5	5	NUM
dpc-4152	138	62	days	day	NOUN
dpc-4152	138	63	>	>	X
dpc-4152	138	64	25	25	NUM
dpc-4152	138	65	cm2	cm2	PROPN
dpc-4152	138	66	(	(	PUNCT
dpc-4152	138	67	n=4	n=4	NOUN
dpc-4152	138	68	)	)	PUNCT
dpc-4152	138	69	0	0	NUM
dpc-4152	138	70	0	0	NUM
dpc-4152	138	71	cohort	cohort	NOUN
dpc-4152	138	72	4	4	NUM
dpc-4152	138	73	:	:	SYM
dpc-4152	138	74	200	200	NUM
dpc-4152	138	75	mg	mg	NOUN
dpc-4152	138	76	once	once	ADV
dpc-4152	138	77	daily	daily	ADV
dpc-4152	138	78	for	for	ADP
dpc-4152	138	79	5	5	NUM
dpc-4152	138	80	days	day	NOUN
dpc-4152	138	81	>	>	X
dpc-4152	138	82	25	25	NUM
dpc-4152	138	83	cm2	cm2	PROPN
dpc-4152	138	84	(	(	PUNCT
dpc-4152	138	85	n=4	n=4	NOUN
dpc-4152	138	86	)	)	PUNCT
dpc-4152	138	87	0	0	NUM
dpc-4152	138	88	0	0	NUM
dpc-4152	138	89	phase	phase	NOUN
dpc-4152	138	90	2	2	NUM
dpc-4152	138	91	study	study	NOUN
dpc-4152	138	92	5	5	NUM
dpc-4152	138	93	-	-	PUNCT
dpc-4152	138	94	day	day	NOUN
dpc-4152	138	95	cohort	cohort	NOUN
dpc-4152	138	96	:	:	PUNCT
dpc-4152	139	1	50	50	NUM
dpc-4152	139	2	mg	mg	NOUN
dpc-4152	139	3	once	once	ADV
dpc-4152	139	4	daily	daily	ADV
dpc-4152	139	5	for	for	ADP
dpc-4152	139	6	5	5	NUM
dpc-4152	139	7	days	day	NOUN
dpc-4152	139	8	>	>	X
dpc-4152	139	9	25	25	NUM
dpc-4152	139	10	cm2	cm2	PROPN
dpc-4152	139	11	(	(	PUNCT
dpc-4152	139	12	n=84	n=84	PROPN
dpc-4152	139	13	)	)	PUNCT
dpc-4152	139	14	9	9	NUM
dpc-4152	139	15	(	(	PUNCT
dpc-4152	139	16	11	11	NUM
dpc-4152	139	17	)	)	PUNCT
dpc-4152	139	18	0	0	NUM
dpc-4152	139	19	5	5	NUM
dpc-4152	139	20	-	-	PUNCT
dpc-4152	139	21	day	day	NOUN
dpc-4152	139	22	cohort	cohort	NOUN
dpc-4152	139	23	:	:	PUNCT
dpc-4152	139	24	once	once	ADV
dpc-4152	139	25	daily	daily	ADV
dpc-4152	139	26	for	for	ADP
dpc-4152	139	27	3	3	NUM
dpc-4152	139	28	days	day	NOUN
dpc-4152	139	29	>	>	X
dpc-4152	139	30	25	25	NUM
dpc-4152	139	31	cm2	cm2	PROPN
dpc-4152	139	32	(	(	PUNCT
dpc-4152	139	33	n=84	n=84	PROPN
dpc-4152	139	34	)	)	PUNCT
dpc-4152	139	35	3	3	NUM
dpc-4152	139	36	(	(	PUNCT
dpc-4152	139	37	4	4	NUM
dpc-4152	139	38	)	)	PUNCT
dpc-4152	139	39	0	0	NUM
dpc-4152	139	40	phase	phase	NOUN
dpc-4152	139	41	3	3	NUM
dpc-4152	139	42	study	study	NOUN
dpc-4152	139	43	,	,	PUNCT
dpc-4152	139	44	intention	intention	NOUN
dpc-4152	139	45	-	-	PUNCT
dpc-4152	139	46	to	to	PART
dpc-4152	139	47	-	-	PUNCT
dpc-4152	139	48	treat	treat	VERB
dpc-4152	139	49	tirbanibulin	tirbanibulin	PROPN
dpc-4152	139	50	124	124	NUM
dpc-4152	139	51	(	(	PUNCT
dpc-4152	139	52	35	35	NUM
dpc-4152	139	53	)	)	PUNCT
dpc-4152	139	54	0	0	NUM
dpc-4152	139	55	vehicle	vehicle	NOUN
dpc-4152	139	56	124	124	NUM
dpc-4152	139	57	(	(	PUNCT
dpc-4152	139	58	36	36	NUM
dpc-4152	139	59	)	)	PUNCT
dpc-4152	139	60	0	0	NUM
dpc-4152	140	1	*	*	PUNCT
dpc-4152	140	2	adverse	adverse	ADJ
dpc-4152	140	3	events	event	NOUN
dpc-4152	140	4	are	be	AUX
dpc-4152	140	5	classified	classify	VERB
dpc-4152	140	6	as	as	ADP
dpc-4152	140	7	mild	mild	ADJ
dpc-4152	140	8	(	(	PUNCT
dpc-4152	140	9	no	no	DET
dpc-4152	140	10	need	need	NOUN
dpc-4152	140	11	to	to	PART
dpc-4152	140	12	discontinue	discontinue	VERB
dpc-4152	140	13	the	the	DET
dpc-4152	140	14	treatment	treatment	NOUN
dpc-4152	140	15	)	)	PUNCT
dpc-4152	140	16	and	and	CCONJ
dpc-4152	140	17	severe	severe	ADJ
dpc-4152	140	18	(	(	PUNCT
dpc-4152	140	19	need	need	VERB
dpc-4152	140	20	to	to	PART
dpc-4152	140	21	discontinue	discontinue	VERB
dpc-4152	140	22	the	the	DET
dpc-4152	140	23	treatment	treatment	NOUN
dpc-4152	140	24	)	)	PUNCT
dpc-4152	140	25	.	.	PUNCT
dpc-4152	141	1	of	of	ADP
dpc-4152	141	2	note	note	NOUN
dpc-4152	141	3	,	,	PUNCT
dpc-4152	141	4	most	most	ADJ
dpc-4152	141	5	adverse	adverse	ADJ
dpc-4152	141	6	events	event	NOUN
dpc-4152	141	7	were	be	AUX
dpc-4152	141	8	treatment	treatment	NOUN
dpc-4152	141	9	-	-	PUNCT
dpc-4152	141	10	related	relate	VERB
dpc-4152	141	11	mild	mild	ADJ
dpc-4152	141	12	.	.	PUNCT
dpc-4152	142	1	6	6	NUM
dpc-4152	142	2	review	review	NOUN
dpc-4152	142	3	|	|	ADV
dpc-4152	142	4	dermatol	dermatol	ADJ
dpc-4152	142	5	pract	pract	NOUN
dpc-4152	142	6	concept	concept	NOUN
dpc-4152	142	7	.	.	PUNCT
dpc-4152	143	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	143	2	:	:	PUNCT
dpc-4152	143	3	e2024145s	e2024145s	ADJ
dpc-4152	143	4	cost	cost	NOUN
dpc-4152	143	5	-	-	PUNCT
dpc-4152	143	6	effectiveness	effectiveness	NOUN
dpc-4152	143	7	compared	compare	VERB
dpc-4152	143	8	to	to	ADP
dpc-4152	143	9	other	other	ADJ
dpc-4152	143	10	approved	approve	VERB
dpc-4152	143	11	treatments	treatment	NOUN
dpc-4152	143	12	are	be	AUX
dpc-4152	143	13	still	still	ADV
dpc-4152	143	14	lacking	lack	VERB
dpc-4152	143	15	.	.	PUNCT
dpc-4152	144	1	a	a	DET
dpc-4152	144	2	recent	recent	ADJ
dpc-4152	144	3	systematic	systematic	ADJ
dpc-4152	144	4	review	review	NOUN
dpc-4152	144	5	[	[	X
dpc-4152	144	6	24	24	NUM
dpc-4152	144	7	]	]	PUNCT
dpc-4152	144	8	of	of	ADP
dpc-4152	144	9	several	several	ADJ
dpc-4152	144	10	phases	phase	NOUN
dpc-4152	144	11	2	2	NUM
dpc-4152	144	12	and	and	CCONJ
dpc-4152	144	13	3	3	NUM
dpc-4152	144	14	randomized	randomize	VERB
dpc-4152	144	15	controlled	control	VERB
dpc-4152	144	16	trials	trial	NOUN
dpc-4152	144	17	(	(	PUNCT
dpc-4152	144	18	rcts	rct	NOUN
dpc-4152	144	19	)	)	PUNCT
dpc-4152	144	20	 	 	SPACE
dpc-4152	144	21	showed	show	VERB
dpc-4152	144	22	how	how	SCONJ
dpc-4152	144	23	tirbanibulin	tirbanibulin	PROPN
dpc-4152	144	24	proved	prove	VERB
dpc-4152	144	25	comparable	comparable	ADJ
dpc-4152	144	26	effectiveness	effectiveness	NOUN
dpc-4152	144	27	in	in	ADP
dpc-4152	144	28	lesion	lesion	NOUN
dpc-4152	144	29	count	count	NOUN
dpc-4152	144	30	reduction	reduction	NOUN
dpc-4152	144	31	and	and	CCONJ
dpc-4152	144	32	complete	complete	ADJ
dpc-4152	144	33	clearance	clearance	NOUN
dpc-4152	144	34	of	of	ADP
dpc-4152	144	35	the	the	DET
dpc-4152	144	36	lesions	lesion	NOUN
dpc-4152	144	37	when	when	SCONJ
dpc-4152	144	38	compared	compare	VERB
dpc-4152	144	39	to	to	ADP
dpc-4152	144	40	both	both	CCONJ
dpc-4152	144	41	physical	physical	ADJ
dpc-4152	144	42	and	and	CCONJ
dpc-4152	144	43	topical	topical	ADJ
dpc-4152	144	44	fc	fc	NOUN
dpc-4152	144	45	-	-	PUNCT
dpc-4152	144	46	directed	direct	VERB
dpc-4152	144	47	treatments	treatment	NOUN
dpc-4152	144	48	.	.	PUNCT
dpc-4152	145	1	odds	odd	NOUN
dpc-4152	145	2	ratio	ratio	NOUN
dpc-4152	145	3	(	(	PUNCT
dpc-4152	145	4	or	or	CCONJ
dpc-4152	145	5	)	)	PUNCT
dpc-4152	145	6	,	,	PUNCT
dpc-4152	145	7	for	for	ADP
dpc-4152	145	8	complete	complete	ADJ
dpc-4152	145	9	clearance	clearance	NOUN
dpc-4152	145	10	,	,	PUNCT
dpc-4152	145	11	with	with	ADP
dpc-4152	145	12	their	their	PRON
dpc-4152	145	13	respective	respective	ADJ
dpc-4152	145	14	95	95	NUM
dpc-4152	145	15	%	%	NOUN
dpc-4152	145	16	confidence	confidence	NOUN
dpc-4152	145	17	interval	interval	NOUN
dpc-4152	145	18	,	,	PUNCT
dpc-4152	145	19	assessed	assess	VERB
dpc-4152	145	20	at	at	ADP
dpc-4152	145	21	8	8	NUM
dpc-4152	145	22	weeks	week	NOUN
dpc-4152	145	23	after	after	SCONJ
dpc-4152	145	24	baseline	baseline	NOUN
dpc-4152	145	25	were	be	AUX
dpc-4152	145	26	:	:	PUNCT
dpc-4152	145	27	cryosurgery	cryosurgery	NOUN
dpc-4152	145	28	13.4	13.4	NUM
dpc-4152	145	29	(	(	PUNCT
dpc-4152	145	30	6.2	6.2	NUM
dpc-4152	145	31	-	-	SYM
dpc-4152	145	32	30.3	30.3	NUM
dpc-4152	145	33	)	)	PUNCT
dpc-4152	145	34	;	;	PUNCT
dpc-4152	145	35	diclofenac	diclofenac	VERB
dpc-4152	145	36	3	3	NUM
dpc-4152	145	37	%	%	NOUN
dpc-4152	145	38	2.9	2.9	NUM
dpc-4152	145	39	(	(	PUNCT
dpc-4152	145	40	1.9	1.9	NUM
dpc-4152	145	41	-	-	SYM
dpc-4152	145	42	4.3	4.3	NUM
dpc-4152	145	43	)	)	PUNCT
dpc-4152	145	44	;	;	PUNCT
dpc-4152	145	45	fluorouracil	fluorouracil	NOUN
dpc-4152	145	46	0.5	0.5	NUM
dpc-4152	145	47	%	%	NOUN
dpc-4152	145	48	+	+	CCONJ
dpc-4152	145	49	salicylic	salicylic	ADJ
dpc-4152	145	50	acid	acid	NOUN
dpc-4152	145	51	7.6	7.6	NUM
dpc-4152	145	52	(	(	PUNCT
dpc-4152	145	53	4.6	4.6	NUM
dpc-4152	145	54	-	-	SYM
dpc-4152	145	55	13.5	13.5	NUM
dpc-4152	145	56	)	)	PUNCT
dpc-4152	145	57	;	;	PUNCT
dpc-4152	145	58	fluorouracil	fluorouracil	NOUN
dpc-4152	145	59	4	4	NUM
dpc-4152	145	60	%	%	NOUN
dpc-4152	145	61	30.3	30.3	NUM
dpc-4152	145	62	(	(	PUNCT
dpc-4152	145	63	9.1	9.1	NUM
dpc-4152	145	64	-	-	SYM
dpc-4152	145	65	144.7	144.7	NUM
dpc-4152	145	66	)	)	PUNCT
dpc-4152	145	67	;	;	PUNCT
dpc-4152	145	68	fluorouracil	fluorouracil	NOUN
dpc-4152	145	69	5	5	NUM
dpc-4152	145	70	%	%	NOUN
dpc-4152	145	71	35.0	35.0	NUM
dpc-4152	145	72	(	(	PUNCT
dpc-4152	145	73	10.2	10.2	NUM
dpc-4152	145	74	-	-	SYM
dpc-4152	145	75	164.4	164.4	NUM
dpc-4152	145	76	)	)	PUNCT
dpc-4152	145	77	;	;	PUNCT
dpc-4152	145	78	imiquimod	imiquimod	VERB
dpc-4152	145	79	3.75	3.75	NUM
dpc-4152	145	80	%	%	NOUN
dpc-4152	145	81	8.5	8.5	NUM
dpc-4152	145	82	(	(	PUNCT
dpc-4152	145	83	3.5	3.5	NUM
dpc-4152	145	84	-	-	SYM
dpc-4152	145	85	22.4	22.4	NUM
dpc-4152	145	86	)	)	PUNCT
dpc-4152	145	87	;	;	PUNCT
dpc-4152	145	88	imiquimod	imiquimod	ADJ
dpc-4152	145	89	5	5	NUM
dpc-4152	145	90	%	%	NOUN
dpc-4152	145	91	17.9	17.9	NUM
dpc-4152	145	92	(	(	PUNCT
dpc-4152	145	93	9.136.6	9.136.6	NUM
dpc-4152	145	94	)	)	PUNCT
dpc-4152	145	95	;	;	PUNCT
dpc-4152	145	96	ingenol	ingenol	PROPN
dpc-4152	145	97	mebutate	mebutate	PROPN
dpc-4152	145	98	0.015	0.015	NUM
dpc-4152	145	99	%	%	NOUN
dpc-4152	145	100	12.5	12.5	NUM
dpc-4152	145	101	(	(	PUNCT
dpc-4152	145	102	8.1	8.1	NUM
dpc-4152	145	103	-	-	SYM
dpc-4152	145	104	19.9	19.9	NUM
dpc-4152	145	105	)	)	PUNCT
dpc-4152	145	106	;	;	PUNCT
dpc-4152	145	107	photodynamic	photodynamic	ADJ
dpc-4152	145	108	therapy	therapy	NOUN
dpc-4152	145	109	with	with	ADP
dpc-4152	145	110	aminolevulinic	aminolevulinic	ADJ
dpc-4152	145	111	acid	acid	NOUN
dpc-4152	145	112	24.1	24.1	NUM
dpc-4152	145	113	(	(	PUNCT
dpc-4152	145	114	10.9	10.9	NUM
dpc-4152	145	115	-	-	SYM
dpc-4152	145	116	52.8	52.8	NUM
dpc-4152	145	117	)	)	PUNCT
dpc-4152	145	118	;	;	PUNCT
dpc-4152	145	119	photodynamic	photodynamic	ADJ
dpc-4152	145	120	therapy	therapy	NOUN
dpc-4152	145	121	with	with	ADP
dpc-4152	145	122	methyl	methyl	PROPN
dpc-4152	145	123	aminolevulinate	aminolevulinate	NOUN
dpc-4152	145	124	11.7	11.7	NUM
dpc-4152	145	125	(	(	PUNCT
dpc-4152	145	126	6.0	6.0	NUM
dpc-4152	145	127	-	-	NUM
dpc-4152	145	128	21.9	21.9	NUM
dpc-4152	145	129	)	)	PUNCT
dpc-4152	145	130	;	;	PUNCT
dpc-4152	145	131	tirbanibulin	tirbanibulin	PROPN
dpc-4152	145	132	1	1	NUM
dpc-4152	145	133	%	%	NOUN
dpc-4152	145	134	11.1	11.1	NUM
dpc-4152	145	135	(	(	PUNCT
dpc-4152	145	136	6.2	6.2	NUM
dpc-4152	145	137	-	-	SYM
dpc-4152	145	138	20.9	20.9	NUM
dpc-4152	145	139	)	)	PUNCT
dpc-4152	145	140	.	.	PUNCT
dpc-4152	146	1	longer	long	ADJ
dpc-4152	146	2	duration	duration	NOUN
dpc-4152	146	3	of	of	ADP
dpc-4152	146	4	topical	topical	ADJ
dpc-4152	146	5	therapy	therapy	NOUN
dpc-4152	146	6	has	have	AUX
dpc-4152	146	7	repeatedly	repeatedly	ADV
dpc-4152	146	8	been	be	AUX
dpc-4152	146	9	shown	show	VERB
dpc-4152	146	10	to	to	PART
dpc-4152	146	11	lower	lower	VERB
dpc-4152	146	12	patient	patient	ADJ
dpc-4152	146	13	adherence	adherence	NOUN
dpc-4152	146	14	to	to	ADP
dpc-4152	146	15	the	the	DET
dpc-4152	146	16	therapy	therapy	NOUN
dpc-4152	146	17	,	,	PUNCT
dpc-4152	146	18	leading	lead	VERB
dpc-4152	146	19	to	to	ADP
dpc-4152	146	20	worse	bad	ADJ
dpc-4152	146	21	outcomes	outcome	NOUN
dpc-4152	146	22	in	in	ADP
dpc-4152	146	23	real	real	ADJ
dpc-4152	146	24	life	life	NOUN
dpc-4152	146	25	[	[	X
dpc-4152	146	26	2,51	2,51	X
dpc-4152	146	27	]	]	X
dpc-4152	146	28	.	.	PUNCT
dpc-4152	147	1	this	this	DET
dpc-4152	147	2	data	data	NOUN
dpc-4152	147	3	is	be	AUX
dpc-4152	147	4	coherent	coherent	ADJ
dpc-4152	147	5	with	with	ADP
dpc-4152	147	6	a	a	DET
dpc-4152	147	7	recent	recent	ADJ
dpc-4152	147	8	systematic	systematic	ADJ
dpc-4152	147	9	encompassing	encompass	VERB
dpc-4152	147	10	14	14	NUM
dpc-4152	147	11	studies	study	NOUN
dpc-4152	147	12	and	and	CCONJ
dpc-4152	147	13	over	over	ADP
dpc-4152	147	14	4,000	4,000	NUM
dpc-4152	147	15	patients	patient	NOUN
dpc-4152	147	16	of	of	ADP
dpc-4152	147	17	patient	patient	NOUN
dpc-4152	147	18	-	-	PUNCT
dpc-4152	147	19	reported	report	VERB
dpc-4152	147	20	outcomes	outcome	NOUN
dpc-4152	147	21	evaluating	evaluate	VERB
dpc-4152	147	22	topic	topic	NOUN
dpc-4152	147	23	therapies	therapy	NOUN
dpc-4152	147	24	for	for	ADP
dpc-4152	147	25	treating	treat	VERB
dpc-4152	147	26	aks	ak	NOUN
dpc-4152	147	27	,	,	PUNCT
dpc-4152	147	28	which	which	PRON
dpc-4152	147	29	improved	improve	VERB
dpc-4152	147	30	significantly	significantly	ADV
dpc-4152	147	31	in	in	ADP
dpc-4152	147	32	both	both	CCONJ
dpc-4152	147	33	shorter	short	ADJ
dpc-4152	147	34	-	-	PUNCT
dpc-4152	147	35	duration	duration	NOUN
dpc-4152	147	36	treatments	treatment	NOUN
dpc-4152	147	37	[	[	X
dpc-4152	147	38	51	51	NUM
dpc-4152	147	39	]	]	PUNCT
dpc-4152	147	40	.	.	PUNCT
dpc-4152	148	1	even	even	ADV
dpc-4152	148	2	though	though	SCONJ
dpc-4152	148	3	tirbanibulin	tirbanibulin	PROPN
dpc-4152	148	4	was	be	AUX
dpc-4152	148	5	not	not	PART
dpc-4152	148	6	directly	directly	ADV
dpc-4152	148	7	evaluated	evaluate	VERB
dpc-4152	148	8	in	in	ADP
dpc-4152	148	9	that	that	DET
dpc-4152	148	10	systematic	systematic	ADJ
dpc-4152	148	11	review	review	NOUN
dpc-4152	148	12	,	,	PUNCT
dpc-4152	148	13	it	it	PRON
dpc-4152	148	14	is	be	AUX
dpc-4152	148	15	suggested	suggest	VERB
dpc-4152	148	16	that	that	SCONJ
dpc-4152	148	17	its	its	PRON
dpc-4152	148	18	5	5	NUM
dpc-4152	148	19	-	-	PUNCT
dpc-4152	148	20	day	day	NOUN
dpc-4152	148	21	course	course	NOUN
dpc-4152	148	22	treatment	treatment	NOUN
dpc-4152	148	23	would	would	AUX
dpc-4152	148	24	lead	lead	VERB
dpc-4152	148	25	to	to	ADP
dpc-4152	148	26	high	high	ADJ
dpc-4152	148	27	compliance	compliance	NOUN
dpc-4152	148	28	and	and	CCONJ
dpc-4152	148	29	adherence	adherence	NOUN
dpc-4152	148	30	to	to	ADP
dpc-4152	148	31	the	the	DET
dpc-4152	148	32	treatment	treatment	NOUN
dpc-4152	148	33	,	,	PUNCT
dpc-4152	148	34	in	in	ADP
dpc-4152	148	35	line	line	NOUN
dpc-4152	148	36	with	with	ADP
dpc-4152	148	37	findings	finding	NOUN
dpc-4152	148	38	of	of	ADP
dpc-4152	148	39	phases	phase	NOUN
dpc-4152	148	40	1	1	NUM
dpc-4152	148	41	,	,	PUNCT
dpc-4152	148	42	2	2	NUM
dpc-4152	148	43	,	,	PUNCT
dpc-4152	148	44	and	and	CCONJ
dpc-4152	148	45	3	3	NUM
dpc-4152	148	46	of	of	ADP
dpc-4152	148	47	the	the	DET
dpc-4152	148	48	random	random	ADJ
dpc-4152	148	49	controlled	control	VERB
dpc-4152	148	50	trials	trial	NOUN
dpc-4152	148	51	.	.	PUNCT
dpc-4152	149	1	the	the	DET
dpc-4152	149	2	safety	safety	NOUN
dpc-4152	149	3	of	of	ADP
dpc-4152	149	4	the	the	DET
dpc-4152	149	5	drug	drug	NOUN
dpc-4152	149	6	is	be	AUX
dpc-4152	149	7	supported	support	VERB
dpc-4152	149	8	by	by	ADP
dpc-4152	149	9	the	the	DET
dpc-4152	149	10	lack	lack	NOUN
dpc-4152	149	11	of	of	ADP
dpc-4152	149	12	significant	significant	ADJ
dpc-4152	149	13	changes	change	NOUN
dpc-4152	149	14	in	in	ADP
dpc-4152	149	15	the	the	DET
dpc-4152	149	16	clinical	clinical	ADJ
dpc-4152	149	17	examination	examination	NOUN
dpc-4152	149	18	as	as	ADV
dpc-4152	149	19	well	well	ADV
dpc-4152	149	20	as	as	ADP
dpc-4152	149	21	in	in	ADP
dpc-4152	149	22	blood	blood	NOUN
dpc-4152	149	23	chemistry	chemistry	NOUN
dpc-4152	149	24	,	,	PUNCT
dpc-4152	149	25	urine	urine	NOUN
dpc-4152	149	26	,	,	PUNCT
dpc-4152	149	27	physical	physical	ADJ
dpc-4152	149	28	examination	examination	NOUN
dpc-4152	149	29	,	,	PUNCT
dpc-4152	149	30	and	and	CCONJ
dpc-4152	149	31	instrumental	instrumental	ADJ
dpc-4152	149	32	tests	test	NOUN
dpc-4152	149	33	(	(	PUNCT
dpc-4152	149	34	ecg	ecg	PROPN
dpc-4152	149	35	,	,	PUNCT
dpc-4152	149	36	blood	blood	NOUN
dpc-4152	149	37	pressure	pressure	NOUN
dpc-4152	149	38	)	)	PUNCT
dpc-4152	149	39	in	in	ADP
dpc-4152	149	40	phase	phase	NOUN
dpc-4152	149	41	1	1	NUM
dpc-4152	149	42	and	and	CCONJ
dpc-4152	149	43	2	2	NUM
dpc-4152	149	44	trials	trial	NOUN
dpc-4152	149	45	[	[	X
dpc-4152	149	46	44	44	NUM
dpc-4152	149	47	]	]	PUNCT
dpc-4152	149	48	and	and	CCONJ
dpc-4152	149	49	by	by	ADP
dpc-4152	149	50	phase	phase	NOUN
dpc-4152	149	51	3	3	NUM
dpc-4152	149	52	trials	trial	NOUN
dpc-4152	149	53	[	[	X
dpc-4152	149	54	45	45	NUM
dpc-4152	149	55	]	]	PUNCT
dpc-4152	149	56	.	.	PUNCT
dpc-4152	150	1	this	this	DET
dpc-4152	150	2	new	new	ADJ
dpc-4152	150	3	drug	drug	NOUN
dpc-4152	150	4	,	,	PUNCT
dpc-4152	150	5	thus	thus	ADV
dpc-4152	150	6	,	,	PUNCT
dpc-4152	150	7	not	not	PART
dpc-4152	150	8	only	only	ADV
dpc-4152	150	9	seems	seem	VERB
dpc-4152	150	10	to	to	PART
dpc-4152	150	11	bring	bring	VERB
dpc-4152	150	12	higher	high	ADJ
dpc-4152	150	13	compliance	compliance	NOUN
dpc-4152	150	14	but	but	CCONJ
dpc-4152	150	15	is	be	AUX
dpc-4152	150	16	very	very	ADV
dpc-4152	150	17	well	well	ADV
dpc-4152	150	18	tolerated	tolerate	VERB
dpc-4152	150	19	.	.	PUNCT
dpc-4152	151	1	it	it	PRON
dpc-4152	151	2	has	have	AUX
dpc-4152	151	3	been	be	AUX
dpc-4152	151	4	proposed	propose	VERB
dpc-4152	151	5	that	that	SCONJ
dpc-4152	151	6	the	the	DET
dpc-4152	151	7	safety	safety	NOUN
dpc-4152	151	8	of	of	ADP
dpc-4152	151	9	tirbanibulin	tirbanibulin	PROPN
dpc-4152	151	10	might	might	AUX
dpc-4152	151	11	be	be	AUX
dpc-4152	151	12	due	due	ADJ
dpc-4152	151	13	to	to	ADP
dpc-4152	151	14	the	the	DET
dpc-4152	151	15	reversibility	reversibility	NOUN
dpc-4152	151	16	of	of	ADP
dpc-4152	151	17	its	its	PRON
dpc-4152	151	18	mechanism	mechanism	NOUN
dpc-4152	151	19	of	of	ADP
dpc-4152	151	20	action	action	NOUN
dpc-4152	151	21	[	[	X
dpc-4152	151	22	50	50	NUM
dpc-4152	151	23	]	]	PUNCT
dpc-4152	151	24	.	.	PUNCT
dpc-4152	152	1	another	another	DET
dpc-4152	152	2	review	review	NOUN
dpc-4152	152	3	[	[	X
dpc-4152	152	4	35	35	NUM
dpc-4152	152	5	]	]	PUNCT
dpc-4152	152	6	investigated	investigate	VERB
dpc-4152	152	7	the	the	DET
dpc-4152	152	8	most	most	ADV
dpc-4152	152	9	common	common	ADJ
dpc-4152	152	10	application	application	NOUN
dpc-4152	152	11	-	-	PUNCT
dpc-4152	152	12	site	site	NOUN
dpc-4152	152	13	side	side	NOUN
dpc-4152	152	14	effects	effect	NOUN
dpc-4152	152	15	,	,	PUNCT
dpc-4152	152	16	noting	note	VERB
dpc-4152	152	17	that	that	SCONJ
dpc-4152	152	18	they	they	PRON
dpc-4152	152	19	were	be	AUX
dpc-4152	152	20	mild	mild	ADJ
dpc-4152	152	21	lsrs	lsrs	ADJ
dpc-4152	152	22	:	:	PUNCT
dpc-4152	152	23	erythema	erythema	ADJ
dpc-4152	152	24	(	(	PUNCT
dpc-4152	152	25	91	91	NUM
dpc-4152	152	26	%	%	NOUN
dpc-4152	152	27	)	)	PUNCT
dpc-4152	152	28	scaling	scale	VERB
dpc-4152	152	29	or	or	CCONJ
dpc-4152	152	30	flaking	flake	VERB
dpc-4152	152	31	(	(	PUNCT
dpc-4152	152	32	82	82	NUM
dpc-4152	152	33	%	%	NOUN
dpc-4152	152	34	)	)	PUNCT
dpc-4152	152	35	,	,	PUNCT
dpc-4152	152	36	and	and	CCONJ
dpc-4152	152	37	much	much	ADV
dpc-4152	152	38	more	more	ADV
dpc-4152	152	39	rarely	rarely	ADV
dpc-4152	152	40	pain	pain	NOUN
dpc-4152	152	41	or	or	CCONJ
dpc-4152	152	42	itching	itching	NOUN
dpc-4152	152	43	at	at	ADP
dpc-4152	152	44	the	the	DET
dpc-4152	152	45	application	application	NOUN
dpc-4152	152	46	site	site	NOUN
dpc-4152	152	47	.	.	PUNCT
dpc-4152	153	1	consistently	consistently	ADV
dpc-4152	153	2	to	to	ADP
dpc-4152	153	3	the	the	DET
dpc-4152	153	4	previous	previous	ADJ
dpc-4152	153	5	review	review	NOUN
dpc-4152	153	6	,	,	PUNCT
dpc-4152	153	7	no	no	DET
dpc-4152	153	8	severe	severe	ADJ
dpc-4152	153	9	aes	aes	NOUN
dpc-4152	153	10	were	be	AUX
dpc-4152	153	11	reported	report	VERB
dpc-4152	153	12	,	,	PUNCT
dpc-4152	153	13	all	all	DET
dpc-4152	153	14	aes	aes	NOUN
dpc-4152	153	15	were	be	AUX
dpc-4152	153	16	resolved	resolve	VERB
dpc-4152	153	17	,	,	PUNCT
dpc-4152	153	18	and	and	CCONJ
dpc-4152	153	19	did	do	AUX
dpc-4152	153	20	not	not	PART
dpc-4152	153	21	affect	affect	VERB
dpc-4152	153	22	the	the	DET
dpc-4152	153	23	adherence	adherence	NOUN
dpc-4152	153	24	to	to	ADP
dpc-4152	153	25	therapy	therapy	NOUN
dpc-4152	153	26	.	.	PUNCT
dpc-4152	154	1	all	all	PRON
dpc-4152	154	2	of	of	ADP
dpc-4152	154	3	these	these	DET
dpc-4152	154	4	data	datum	NOUN
dpc-4152	154	5	from	from	ADP
dpc-4152	154	6	different	different	ADJ
dpc-4152	154	7	trials	trial	NOUN
dpc-4152	154	8	are	be	AUX
dpc-4152	154	9	comparable	comparable	ADJ
dpc-4152	154	10	with	with	ADP
dpc-4152	154	11	the	the	DET
dpc-4152	154	12	local	local	ADJ
dpc-4152	154	13	adverse	adverse	ADJ
dpc-4152	154	14	events	event	NOUN
dpc-4152	154	15	reported	report	VERB
dpc-4152	154	16	in	in	ADP
dpc-4152	154	17	real	real	ADJ
dpc-4152	154	18	-	-	PUNCT
dpc-4152	154	19	life	life	NOUN
dpc-4152	154	20	studies	study	NOUN
dpc-4152	154	21	demonstrating	demonstrate	VERB
dpc-4152	154	22	the	the	DET
dpc-4152	154	23	real	real	ADJ
dpc-4152	154	24	safety	safety	NOUN
dpc-4152	154	25	of	of	ADP
dpc-4152	154	26	this	this	DET
dpc-4152	154	27	treatment	treatment	NOUN
dpc-4152	154	28	[	[	X
dpc-4152	154	29	59	59	NUM
dpc-4152	154	30	]	]	PUNCT
dpc-4152	154	31	.	.	PUNCT
dpc-4152	155	1	moreover	moreover	ADV
dpc-4152	155	2	,	,	PUNCT
dpc-4152	155	3	a	a	DET
dpc-4152	155	4	recent	recent	ADJ
dpc-4152	155	5	group	group	NOUN
dpc-4152	155	6	of	of	ADP
dpc-4152	155	7	phase	phase	NOUN
dpc-4152	155	8	1	1	NUM
dpc-4152	155	9	studies	study	NOUN
dpc-4152	155	10	in	in	ADP
dpc-4152	155	11	healthy	healthy	ADJ
dpc-4152	155	12	volunteers	volunteer	NOUN
dpc-4152	155	13	[	[	X
dpc-4152	155	14	54	54	NUM
dpc-4152	155	15	]	]	PUNCT
dpc-4152	155	16	demonstrated	demonstrate	VERB
dpc-4152	155	17	that	that	SCONJ
dpc-4152	155	18	tirbanibulin	tirbanibulin	PROPN
dpc-4152	155	19	ointment	ointment	NOUN
dpc-4152	155	20	1	1	NUM
dpc-4152	155	21	%	%	NOUN
dpc-4152	155	22	had	have	VERB
dpc-4152	155	23	no	no	DET
dpc-4152	155	24	sensitization	sensitization	NOUN
dpc-4152	155	25	or	or	CCONJ
dpc-4152	155	26	phototoxic	phototoxic	NOUN
dpc-4152	155	27	or	or	CCONJ
dpc-4152	155	28	photoallergic	photoallergic	ADJ
dpc-4152	155	29	potential	potential	NOUN
dpc-4152	155	30	connected	connect	VERB
dpc-4152	155	31	with	with	ADP
dpc-4152	155	32	the	the	DET
dpc-4152	155	33	treatment	treatment	NOUN
dpc-4152	155	34	and	and	CCONJ
dpc-4152	155	35	supported	support	VERB
dpc-4152	155	36	the	the	DET
dpc-4152	155	37	safety	safety	NOUN
dpc-4152	155	38	of	of	ADP
dpc-4152	155	39	this	this	DET
dpc-4152	155	40	topical	topical	ADJ
dpc-4152	155	41	medication	medication	NOUN
dpc-4152	155	42	.	.	PUNCT
dpc-4152	156	1	unsurprisingly	unsurprisingly	ADV
dpc-4152	156	2	,	,	PUNCT
dpc-4152	156	3	compliance	compliance	NOUN
dpc-4152	156	4	to	to	ADP
dpc-4152	156	5	topical	topical	ADJ
dpc-4152	156	6	treatments	treatment	NOUN
dpc-4152	156	7	seems	seem	VERB
dpc-4152	156	8	to	to	PART
dpc-4152	156	9	be	be	AUX
dpc-4152	156	10	related	relate	VERB
dpc-4152	156	11	to	to	ADP
dpc-4152	156	12	both	both	DET
dpc-4152	156	13	the	the	DET
dpc-4152	156	14	length	length	NOUN
dpc-4152	156	15	of	of	ADP
dpc-4152	156	16	the	the	DET
dpc-4152	156	17	treatments	treatment	NOUN
dpc-4152	156	18	and	and	CCONJ
dpc-4152	156	19	their	their	PRON
dpc-4152	156	20	tolerability	tolerability	NOUN
dpc-4152	156	21	profile	profile	NOUN
dpc-4152	156	22	[	[	X
dpc-4152	156	23	52,53	52,53	NOUN
dpc-4152	156	24	]	]	PUNCT
dpc-4152	156	25	.	.	PUNCT
dpc-4152	157	1	one	one	NUM
dpc-4152	157	2	crucial	crucial	ADJ
dpc-4152	157	3	point	point	NOUN
dpc-4152	157	4	was	be	AUX
dpc-4152	157	5	that	that	DET
dpc-4152	157	6	index	index	NOUN
dpc-4152	157	7	(	(	PUNCT
dpc-4152	157	8	akasi	akasi	ADJ
dpc-4152	157	9	)	)	PUNCT
dpc-4152	157	10	,	,	PUNCT
dpc-4152	157	11	and	and	CCONJ
dpc-4152	157	12	with	with	ADP
dpc-4152	157	13	digital	digital	ADJ
dpc-4152	157	14	dermoscopy	dermoscopy	NOUN
dpc-4152	157	15	.	.	PUNCT
dpc-4152	158	1	a	a	DET
dpc-4152	158	2	group	group	NOUN
dpc-4152	158	3	of	of	ADP
dpc-4152	158	4	33	33	NUM
dpc-4152	158	5	patients	patient	NOUN
dpc-4152	158	6	was	be	AUX
dpc-4152	158	7	eligible	eligible	ADJ
dpc-4152	158	8	for	for	ADP
dpc-4152	158	9	the	the	DET
dpc-4152	158	10	study	study	NOUN
dpc-4152	158	11	design	design	NOUN
dpc-4152	158	12	and	and	CCONJ
dpc-4152	158	13	treated	treat	VERB
dpc-4152	158	14	but	but	CCONJ
dpc-4152	158	15	only	only	ADV
dpc-4152	158	16	30	30	NUM
dpc-4152	158	17	were	be	AUX
dpc-4152	158	18	analyzed	analyze	VERB
dpc-4152	158	19	because	because	SCONJ
dpc-4152	158	20	3	3	NUM
dpc-4152	158	21	were	be	AUX
dpc-4152	158	22	lost	lose	VERB
dpc-4152	158	23	to	to	PART
dpc-4152	158	24	follow	follow	VERB
dpc-4152	158	25	-	-	PUNCT
dpc-4152	158	26	up	up	NOUN
dpc-4152	158	27	.	.	PUNCT
dpc-4152	159	1	the	the	DET
dpc-4152	159	2	results	result	NOUN
dpc-4152	159	3	of	of	ADP
dpc-4152	159	4	this	this	DET
dpc-4152	159	5	study	study	NOUN
dpc-4152	159	6	showed	show	VERB
dpc-4152	159	7	that	that	SCONJ
dpc-4152	159	8	before	before	ADP
dpc-4152	159	9	treatment	treatment	NOUN
dpc-4152	159	10	,	,	PUNCT
dpc-4152	159	11	the	the	DET
dpc-4152	159	12	median	median	ADJ
dpc-4152	159	13	akasi	akasi	NOUN
dpc-4152	159	14	score	score	NOUN
dpc-4152	159	15	was	be	AUX
dpc-4152	159	16	5.6	5.6	NUM
dpc-4152	159	17	(	(	PUNCT
dpc-4152	159	18	1.4–11	1.4–11	NUM
dpc-4152	159	19	)	)	PUNCT
dpc-4152	159	20	,	,	PUNCT
dpc-4152	159	21	after	after	ADP
dpc-4152	159	22	treatment	treatment	NOUN
dpc-4152	159	23	it	it	PRON
dpc-4152	159	24	was	be	AUX
dpc-4152	159	25	1.2	1.2	NUM
dpc-4152	159	26	(	(	PUNCT
dpc-4152	159	27	0–7.4	0–7.4	NUM
dpc-4152	159	28	)	)	PUNCT
dpc-4152	159	29	(	(	PUNCT
dpc-4152	159	30	p	p	X
dpc-4152	159	31	<	<	X
dpc-4152	159	32	0.0001	0.0001	NUM
dpc-4152	159	33	)	)	PUNCT
dpc-4152	159	34	,	,	PUNCT
dpc-4152	159	35	and	and	CCONJ
dpc-4152	159	36	at	at	ADP
dpc-4152	159	37	a	a	DET
dpc-4152	159	38	second	second	ADJ
dpc-4152	159	39	follow	follow	NOUN
dpc-4152	159	40	-	-	PUNCT
dpc-4152	159	41	up	up	NOUN
dpc-4152	159	42	after	after	ADP
dpc-4152	159	43	a	a	DET
dpc-4152	159	44	mean	mean	NOUN
dpc-4152	159	45	of	of	ADP
dpc-4152	159	46	3.7	3.7	NUM
dpc-4152	159	47	months	month	NOUN
dpc-4152	159	48	was	be	AUX
dpc-4152	159	49	0.6	0.6	NUM
dpc-4152	159	50	(	(	PUNCT
dpc-4152	159	51	0	0	NUM
dpc-4152	159	52	-	-	SYM
dpc-4152	159	53	1.4	1.4	NUM
dpc-4152	159	54	)	)	PUNCT
dpc-4152	159	55	.	.	PUNCT
dpc-4152	160	1	at	at	ADP
dpc-4152	160	2	the	the	DET
dpc-4152	160	3	first	first	ADJ
dpc-4152	160	4	and	and	CCONJ
dpc-4152	160	5	second	second	ADJ
dpc-4152	160	6	follow	follow	NOUN
dpc-4152	160	7	-	-	PUNCT
dpc-4152	160	8	ups	up	NOUN
dpc-4152	160	9	,	,	PUNCT
dpc-4152	160	10	47	47	NUM
dpc-4152	160	11	percent	percent	NOUN
dpc-4152	160	12	of	of	ADP
dpc-4152	160	13	patients	patient	NOUN
dpc-4152	160	14	(	(	PUNCT
dpc-4152	160	15	n	n	NOUN
dpc-4152	160	16	=	=	SYM
dpc-4152	160	17	14	14	NUM
dpc-4152	160	18	)	)	PUNCT
dpc-4152	160	19	and	and	CCONJ
dpc-4152	160	20	57	57	NUM
dpc-4152	160	21	percent	percent	NOUN
dpc-4152	160	22	of	of	ADP
dpc-4152	160	23	patients	patient	NOUN
dpc-4152	160	24	(	(	PUNCT
dpc-4152	160	25	n	n	NOUN
dpc-4152	160	26	=	=	SYM
dpc-4152	160	27	13	13	NUM
dpc-4152	160	28	)	)	PUNCT
dpc-4152	160	29	had	have	VERB
dpc-4152	160	30	complete	complete	ADJ
dpc-4152	160	31	clearance	clearance	NOUN
dpc-4152	160	32	,	,	PUNCT
dpc-4152	160	33	as	as	SCONJ
dpc-4152	160	34	indicated	indicate	VERB
dpc-4152	160	35	by	by	ADP
dpc-4152	160	36	akasi	akasi	NOUN
dpc-4152	160	37	scores	score	NOUN
dpc-4152	160	38	less	less	ADJ
dpc-4152	160	39	than	than	ADP
dpc-4152	160	40	1	1	NUM
dpc-4152	160	41	.	.	PUNCT
dpc-4152	161	1	local	local	ADJ
dpc-4152	161	2	adverse	adverse	ADJ
dpc-4152	161	3	events	event	NOUN
dpc-4152	161	4	occur	occur	VERB
dpc-4152	161	5	between	between	ADP
dpc-4152	161	6	2	2	NUM
dpc-4152	161	7	and	and	CCONJ
dpc-4152	161	8	10	10	NUM
dpc-4152	161	9	days	day	NOUN
dpc-4152	161	10	from	from	ADP
dpc-4152	161	11	the	the	DET
dpc-4152	161	12	beginning	beginning	NOUN
dpc-4152	161	13	of	of	ADP
dpc-4152	161	14	the	the	DET
dpc-4152	161	15	treatment	treatment	NOUN
dpc-4152	161	16	,	,	PUNCT
dpc-4152	161	17	with	with	ADP
dpc-4152	161	18	a	a	DET
dpc-4152	161	19	median	median	ADJ
dpc-4152	161	20	onset	onset	NOUN
dpc-4152	161	21	at	at	ADP
dpc-4152	161	22	the	the	DET
dpc-4152	161	23	seventh	seventh	ADJ
dpc-4152	161	24	day	day	NOUN
dpc-4152	161	25	and	and	CCONJ
dpc-4152	161	26	a	a	DET
dpc-4152	161	27	mean	mean	ADJ
dpc-4152	161	28	resolution	resolution	NOUN
dpc-4152	161	29	time	time	NOUN
dpc-4152	161	30	of	of	ADP
dpc-4152	161	31	5	5	NUM
dpc-4152	161	32	days	day	NOUN
dpc-4152	161	33	.	.	PUNCT
dpc-4152	162	1	the	the	DET
dpc-4152	162	2	most	most	ADV
dpc-4152	162	3	common	common	ADJ
dpc-4152	162	4	local	local	ADJ
dpc-4152	162	5	reaction	reaction	NOUN
dpc-4152	162	6	reported	report	VERB
dpc-4152	162	7	is	be	AUX
dpc-4152	162	8	erythema	erythema	ADJ
dpc-4152	162	9	(	(	PUNCT
dpc-4152	162	10	80	80	NUM
dpc-4152	162	11	%	%	NOUN
dpc-4152	162	12	,	,	PUNCT
dpc-4152	162	13	n=26	n=26	NUM
dpc-4152	162	14	)	)	PUNCT
dpc-4152	162	15	followed	follow	VERB
dpc-4152	162	16	by	by	ADP
dpc-4152	162	17	scaling	scale	VERB
dpc-4152	162	18	and	and	CCONJ
dpc-4152	162	19	flaking	flake	VERB
dpc-4152	162	20	(	(	PUNCT
dpc-4152	162	21	43	43	NUM
dpc-4152	162	22	%	%	NOUN
dpc-4152	162	23	,	,	PUNCT
dpc-4152	162	24	n=	n=	ADJ
dpc-4152	162	25	13	13	NUM
dpc-4152	162	26	%	%	NOUN
dpc-4152	162	27	)	)	PUNCT
dpc-4152	162	28	and	and	CCONJ
dpc-4152	162	29	by	by	ADP
dpc-4152	162	30	pustulation	pustulation	NOUN
dpc-4152	162	31	ad	ad	NOUN
dpc-4152	162	32	pruritus	pruritus	NOUN
dpc-4152	162	33	(	(	PUNCT
dpc-4152	162	34	7	7	NUM
dpc-4152	162	35	%	%	NOUN
dpc-4152	162	36	,	,	PUNCT
dpc-4152	162	37	n	n	NOUN
dpc-4152	162	38	=	=	SYM
dpc-4152	162	39	2	2	NUM
dpc-4152	162	40	)	)	PUNCT
dpc-4152	162	41	.	.	PUNCT
dpc-4152	163	1	six	six	NUM
dpc-4152	163	2	patients	patient	NOUN
dpc-4152	163	3	(	(	PUNCT
dpc-4152	163	4	20	20	NUM
dpc-4152	163	5	%	%	NOUN
dpc-4152	163	6	)	)	PUNCT
dpc-4152	163	7	did	do	AUX
dpc-4152	163	8	not	not	PART
dpc-4152	163	9	report	report	VERB
dpc-4152	163	10	any	any	DET
dpc-4152	163	11	local	local	ADJ
dpc-4152	163	12	adverse	adverse	ADJ
dpc-4152	163	13	event	event	NOUN
dpc-4152	163	14	.	.	PUNCT
dpc-4152	164	1	every	every	DET
dpc-4152	164	2	local	local	ADJ
dpc-4152	164	3	reaction	reaction	NOUN
dpc-4152	164	4	ended	end	VERB
dpc-4152	164	5	on	on	ADP
dpc-4152	164	6	its	its	PRON
dpc-4152	164	7	own	own	ADJ
dpc-4152	164	8	,	,	PUNCT
dpc-4152	164	9	without	without	ADP
dpc-4152	164	10	any	any	DET
dpc-4152	164	11	aftereffects	aftereffect	NOUN
dpc-4152	164	12	.	.	PUNCT
dpc-4152	165	1	another	another	DET
dpc-4152	165	2	real	real	ADJ
dpc-4152	165	3	-	-	PUNCT
dpc-4152	165	4	world	world	NOUN
dpc-4152	165	5	experience	experience	NOUN
dpc-4152	165	6	involved	involve	VERB
dpc-4152	165	7	30	30	NUM
dpc-4152	165	8	patients	patient	NOUN
dpc-4152	165	9	with	with	ADP
dpc-4152	165	10	aks	ak	NOUN
dpc-4152	165	11	on	on	ADP
dpc-4152	165	12	their	their	PRON
dpc-4152	165	13	faces	face	NOUN
dpc-4152	165	14	or	or	CCONJ
dpc-4152	165	15	scalps	scalp	NOUN
dpc-4152	165	16	in	in	ADP
dpc-4152	165	17	a	a	DET
dpc-4152	165	18	single	single	ADJ
dpc-4152	165	19	-	-	PUNCT
dpc-4152	165	20	center	center	NOUN
dpc-4152	165	21	,	,	PUNCT
dpc-4152	165	22	prospective	prospective	ADJ
dpc-4152	165	23	,	,	PUNCT
dpc-4152	165	24	observational	observational	ADJ
dpc-4152	165	25	trial	trial	NOUN
dpc-4152	165	26	in	in	ADP
dpc-4152	165	27	which	which	PRON
dpc-4152	165	28	tirbanibulin	tirbanibulin	PRON
dpc-4152	165	29	ointment	ointment	NOUN
dpc-4152	165	30	was	be	AUX
dpc-4152	165	31	applied	apply	VERB
dpc-4152	165	32	to	to	ADP
dpc-4152	165	33	a	a	DET
dpc-4152	165	34	25	25	NUM
dpc-4152	165	35	cm2	cm2	NOUN
dpc-4152	165	36	area	area	NOUN
dpc-4152	165	37	for	for	ADP
dpc-4152	165	38	five	five	NUM
dpc-4152	165	39	days	day	NOUN
dpc-4152	165	40	in	in	ADP
dpc-4152	165	41	a	a	DET
dpc-4152	165	42	row	row	NOUN
dpc-4152	165	43	.	.	PUNCT
dpc-4152	166	1	to	to	PART
dpc-4152	166	2	evaluate	evaluate	VERB
dpc-4152	166	3	the	the	DET
dpc-4152	166	4	drug	drug	NOUN
dpc-4152	166	5	’s	’s	PART
dpc-4152	166	6	safety	safety	NOUN
dpc-4152	166	7	profile	profile	NOUN
dpc-4152	166	8	,	,	PUNCT
dpc-4152	166	9	effectiveness	effectiveness	NOUN
dpc-4152	166	10	,	,	PUNCT
dpc-4152	166	11	and	and	CCONJ
dpc-4152	166	12	patient	patient	ADJ
dpc-4152	166	13	satisfaction	satisfaction	NOUN
dpc-4152	166	14	,	,	PUNCT
dpc-4152	166	15	they	they	PRON
dpc-4152	166	16	were	be	AUX
dpc-4152	166	17	monitored	monitor	VERB
dpc-4152	166	18	for	for	ADP
dpc-4152	166	19	a	a	DET
dpc-4152	166	20	minimum	minimum	NOUN
dpc-4152	166	21	of	of	ADP
dpc-4152	166	22	57	57	NUM
dpc-4152	166	23	days	day	NOUN
dpc-4152	166	24	.	.	PUNCT
dpc-4152	167	1	six	six	NUM
dpc-4152	167	2	local	local	ADJ
dpc-4152	167	3	skin	skin	NOUN
dpc-4152	167	4	response	response	NOUN
dpc-4152	167	5	(	(	PUNCT
dpc-4152	167	6	lsr	lsr	PROPN
dpc-4152	167	7	)	)	PUNCT
dpc-4152	167	8	symptoms	symptom	NOUN
dpc-4152	167	9	were	be	AUX
dpc-4152	167	10	assessed	assess	VERB
dpc-4152	167	11	and	and	CCONJ
dpc-4152	167	12	their	their	PRON
dpc-4152	167	13	intensity	intensity	NOUN
dpc-4152	167	14	was	be	AUX
dpc-4152	167	15	rated	rate	VERB
dpc-4152	167	16	as	as	ADP
dpc-4152	167	17	mild	mild	ADJ
dpc-4152	167	18	,	,	PUNCT
dpc-4152	167	19	moderate	moderate	ADJ
dpc-4152	167	20	,	,	PUNCT
dpc-4152	167	21	or	or	CCONJ
dpc-4152	167	22	severe	severe	ADJ
dpc-4152	167	23	.	.	PUNCT
dpc-4152	168	1	these	these	DET
dpc-4152	168	2	signs	sign	NOUN
dpc-4152	168	3	were	be	AUX
dpc-4152	168	4	erythema	erythema	ADJ
dpc-4152	168	5	,	,	PUNCT
dpc-4152	168	6	scaling	scaling	NOUN
dpc-4152	168	7	,	,	PUNCT
dpc-4152	168	8	crusting	crust	VERB
dpc-4152	168	9	,	,	PUNCT
dpc-4152	168	10	swelling	swelling	NOUN
dpc-4152	168	11	,	,	PUNCT
dpc-4152	168	12	blisters/	blisters/	NUM
dpc-4152	168	13	pustules	pustule	NOUN
dpc-4152	168	14	,	,	PUNCT
dpc-4152	168	15	and	and	CCONJ
dpc-4152	168	16	erosions	erosion	NOUN
dpc-4152	168	17	/	/	SYM
dpc-4152	168	18	ulcerations	ulceration	NOUN
dpc-4152	168	19	.	.	PUNCT
dpc-4152	169	1	dermatoscopically	dermatoscopically	ADV
dpc-4152	169	2	and	and	CCONJ
dpc-4152	169	3	clinically	clinically	ADV
dpc-4152	169	4	,	,	PUNCT
dpc-4152	169	5	the	the	DET
dpc-4152	169	6	efficacy	efficacy	NOUN
dpc-4152	169	7	was	be	AUX
dpc-4152	169	8	assessed	assess	VERB
dpc-4152	169	9	.	.	PUNCT
dpc-4152	170	1	the	the	DET
dpc-4152	170	2	medication	medication	NOUN
dpc-4152	170	3	treatment	treatment	NOUN
dpc-4152	170	4	satisfaction	satisfaction	NOUN
dpc-4152	170	5	questionnaire	questionnaire	NOUN
dpc-4152	170	6	(	(	PUNCT
dpc-4152	170	7	tsqm	tsqm	NOUN
dpc-4152	170	8	1.4	1.4	NUM
dpc-4152	170	9	)	)	PUNCT
dpc-4152	170	10	was	be	AUX
dpc-4152	170	11	used	use	VERB
dpc-4152	170	12	to	to	PART
dpc-4152	170	13	measure	measure	VERB
dpc-4152	170	14	treatment	treatment	NOUN
dpc-4152	170	15	satisfaction	satisfaction	NOUN
dpc-4152	170	16	.	.	PUNCT
dpc-4152	171	1	the	the	DET
dpc-4152	171	2	majority	majority	NOUN
dpc-4152	171	3	of	of	ADP
dpc-4152	171	4	lsrs	lsrs	NOUN
dpc-4152	171	5	,	,	PUNCT
dpc-4152	171	6	which	which	PRON
dpc-4152	171	7	included	include	VERB
dpc-4152	171	8	swelling	swell	VERB
dpc-4152	171	9	(	(	PUNCT
dpc-4152	171	10	3.3	3.3	NUM
dpc-4152	171	11	%	%	NOUN
dpc-4152	171	12	)	)	PUNCT
dpc-4152	171	13	,	,	PUNCT
dpc-4152	171	14	scaling	scale	VERB
dpc-4152	171	15	(	(	PUNCT
dpc-4152	171	16	30	30	NUM
dpc-4152	171	17	%	%	NOUN
dpc-4152	171	18	)	)	PUNCT
dpc-4152	171	19	,	,	PUNCT
dpc-4152	171	20	and	and	CCONJ
dpc-4152	171	21	erythema	erythema	ADJ
dpc-4152	171	22	(	(	PUNCT
dpc-4152	171	23	83.3	83.3	NUM
dpc-4152	171	24	%	%	NOUN
dpc-4152	171	25	)	)	PUNCT
dpc-4152	171	26	,	,	PUNCT
dpc-4152	171	27	appeared	appear	VERB
dpc-4152	171	28	on	on	ADP
dpc-4152	171	29	day	day	NOUN
dpc-4152	171	30	8	8	NUM
dpc-4152	171	31	but	but	CCONJ
dpc-4152	171	32	went	go	VERB
dpc-4152	171	33	away	away	ADV
dpc-4152	171	34	on	on	ADP
dpc-4152	171	35	their	their	PRON
dpc-4152	171	36	own	own	ADJ
dpc-4152	171	37	.	.	PUNCT
dpc-4152	172	1	moscopic	moscopic	ADJ
dpc-4152	172	2	response	response	NOUN
dpc-4152	172	3	was	be	AUX
dpc-4152	172	4	observed	observe	VERB
dpc-4152	172	5	in	in	ADP
dpc-4152	172	6	70	70	NUM
dpc-4152	172	7	%	%	NOUN
dpc-4152	172	8	of	of	ADP
dpc-4152	172	9	the	the	DET
dpc-4152	172	10	patients	patient	NOUN
dpc-4152	172	11	on	on	ADP
dpc-4152	172	12	day	day	NOUN
dpc-4152	172	13	57.[47	57.[47	NOUN
dpc-4152	172	14	]	]	PUNCT
dpc-4152	172	15	.	.	PUNCT
dpc-4152	173	1	to	to	PART
dpc-4152	173	2	evaluate	evaluate	VERB
dpc-4152	173	3	the	the	DET
dpc-4152	173	4	efficacy	efficacy	NOUN
dpc-4152	173	5	and	and	CCONJ
dpc-4152	173	6	safety	safety	NOUN
dpc-4152	173	7	of	of	ADP
dpc-4152	173	8	tirbanibulin	tirbanibulin	DET
dpc-4152	173	9	1	1	NUM
dpc-4152	173	10	%	%	NOUN
dpc-4152	173	11	ointment	ointment	NOUN
dpc-4152	173	12	,	,	PUNCT
dpc-4152	173	13	a	a	DET
dpc-4152	173	14	spontaneous	spontaneous	ADJ
dpc-4152	173	15	open	open	ADJ
dpc-4152	173	16	-	-	PUNCT
dpc-4152	173	17	label	label	NOUN
dpc-4152	173	18	,	,	PUNCT
dpc-4152	173	19	prospective	prospective	ADJ
dpc-4152	173	20	non	non	ADJ
dpc-4152	173	21	-	-	ADJ
dpc-4152	173	22	randomized	randomized	ADJ
dpc-4152	173	23	study	study	NOUN
dpc-4152	173	24	focused	focus	VERB
dpc-4152	173	25	on	on	ADP
dpc-4152	173	26	the	the	DET
dpc-4152	173	27	treatment	treatment	NOUN
dpc-4152	173	28	of	of	ADP
dpc-4152	173	29	228	228	NUM
dpc-4152	173	30	aks	ak	NOUN
dpc-4152	173	31	in	in	ADP
dpc-4152	173	32	38	38	NUM
dpc-4152	173	33	consecutive	consecutive	ADJ
dpc-4152	173	34	patients—28	patients—28	ADJ
dpc-4152	173	35	males	male	NOUN
dpc-4152	173	36	(	(	PUNCT
dpc-4152	173	37	73	73	NUM
dpc-4152	173	38	%	%	NOUN
dpc-4152	173	39	)	)	PUNCT
dpc-4152	173	40	and	and	CCONJ
dpc-4152	173	41	10	10	NUM
dpc-4152	173	42	females	female	NOUN
dpc-4152	173	43	(	(	PUNCT
dpc-4152	173	44	26	26	NUM
dpc-4152	173	45	%	%	NOUN
dpc-4152	173	46	)	)	PUNCT
dpc-4152	173	47	,	,	PUNCT
dpc-4152	173	48	aged	age	VERB
dpc-4152	173	49	between	between	ADP
dpc-4152	173	50	52	52	NUM
dpc-4152	173	51	and	and	CCONJ
dpc-4152	173	52	92	92	NUM
dpc-4152	173	53	years	year	NOUN
dpc-4152	173	54	(	(	PUNCT
dpc-4152	173	55	mean	mean	INTJ
dpc-4152	173	56	age	age	NOUN
dpc-4152	173	57	:	:	PUNCT
dpc-4152	173	58	72	72	NUM
dpc-4152	173	59	±	±	NUM
dpc-4152	173	60	8.92	8.92	NUM
dpc-4152	173	61	years	year	NOUN
dpc-4152	173	62	)	)	PUNCT
dpc-4152	173	63	.	.	PUNCT
dpc-4152	174	1	of	of	ADP
dpc-4152	174	2	the	the	DET
dpc-4152	174	3	lesions	lesion	NOUN
dpc-4152	174	4	that	that	PRON
dpc-4152	174	5	were	be	AUX
dpc-4152	174	6	reported	report	VERB
dpc-4152	174	7	,	,	PUNCT
dpc-4152	174	8	51	51	NUM
dpc-4152	174	9	%	%	NOUN
dpc-4152	174	10	had	have	VERB
dpc-4152	174	11	total	total	ADJ
dpc-4152	174	12	clearance	clearance	NOUN
dpc-4152	174	13	and	and	CCONJ
dpc-4152	174	14	73	73	NUM
dpc-4152	174	15	%	%	NOUN
dpc-4152	174	16	had	have	VERB
dpc-4152	174	17	partial	partial	ADJ
dpc-4152	174	18	clearance	clearance	NOUN
dpc-4152	174	19	.	.	PUNCT
dpc-4152	175	1	there	there	PRON
dpc-4152	175	2	was	be	VERB
dpc-4152	175	3	no	no	DET
dpc-4152	175	4	treatment	treatment	NOUN
dpc-4152	175	5	termination	termination	NOUN
dpc-4152	175	6	owing	owe	VERB
dpc-4152	175	7	to	to	ADP
dpc-4152	175	8	the	the	DET
dpc-4152	175	9	occurrence	occurrence	NOUN
dpc-4152	175	10	of	of	ADP
dpc-4152	175	11	adverse	adverse	ADJ
dpc-4152	175	12	events	event	NOUN
dpc-4152	175	13	,	,	PUNCT
dpc-4152	175	14	and	and	CCONJ
dpc-4152	175	15	an	an	DET
dpc-4152	175	16	outstanding	outstanding	ADJ
dpc-4152	175	17	tolerability	tolerability	NOUN
dpc-4152	175	18	profile	profile	NOUN
dpc-4152	175	19	and	and	CCONJ
dpc-4152	175	20	high	high	ADJ
dpc-4152	175	21	compliance	compliance	NOUN
dpc-4152	175	22	rate	rate	NOUN
dpc-4152	175	23	were	be	AUX
dpc-4152	175	24	noted.[48	noted.[48	NOUN
dpc-4152	175	25	]	]	PUNCT
dpc-4152	175	26	discussion	discussion	NOUN
dpc-4152	175	27	tirbanibulin	tirbanibulin	PROPN
dpc-4152	175	28	is	be	AUX
dpc-4152	175	29	approved	approve	VERB
dpc-4152	175	30	by	by	ADP
dpc-4152	175	31	the	the	DET
dpc-4152	175	32	fda	fda	PROPN
dpc-4152	175	33	and	and	CCONJ
dpc-4152	175	34	ema	ema	PROPN
dpc-4152	175	35	in	in	ADP
dpc-4152	175	36	the	the	DET
dpc-4152	175	37	formulation	formulation	NOUN
dpc-4152	175	38	of	of	ADP
dpc-4152	175	39	1	1	NUM
dpc-4152	175	40	%	%	NOUN
dpc-4152	175	41	ointment	ointment	NOUN
dpc-4152	175	42	for	for	ADP
dpc-4152	175	43	treating	treat	VERB
dpc-4152	175	44	grade	grade	NOUN
dpc-4152	175	45	i	i	PRON
dpc-4152	175	46	aks	ak	VERB
dpc-4152	175	47	(	(	PUNCT
dpc-4152	175	48	according	accord	VERB
dpc-4152	175	49	to	to	ADP
dpc-4152	175	50	olsen	olsen	PROPN
dpc-4152	175	51	’s	’s	PART
dpc-4152	175	52	grading	grading	NOUN
dpc-4152	175	53	)	)	PUNCT
dpc-4152	175	54	of	of	ADP
dpc-4152	175	55	the	the	DET
dpc-4152	175	56	head	head	NOUN
dpc-4152	175	57	and	and	CCONJ
dpc-4152	175	58	the	the	DET
dpc-4152	175	59	neck	neck	NOUN
dpc-4152	175	60	in	in	ADP
dpc-4152	175	61	a	a	DET
dpc-4152	175	62	contiguous	contiguous	ADJ
dpc-4152	175	63	area	area	NOUN
dpc-4152	175	64	of	of	ADP
dpc-4152	175	65	no	no	DET
dpc-4152	175	66	more	more	ADJ
dpc-4152	175	67	than	than	ADP
dpc-4152	175	68	25	25	NUM
dpc-4152	175	69	cm2	cm2	NOUN
dpc-4152	175	70	.	.	PUNCT
dpc-4152	176	1	the	the	DET
dpc-4152	176	2	application	application	NOUN
dpc-4152	176	3	cycle	cycle	NOUN
dpc-4152	176	4	must	must	AUX
dpc-4152	176	5	be	be	AUX
dpc-4152	176	6	of	of	ADP
dpc-4152	176	7	5	5	NUM
dpc-4152	176	8	consecutive	consecutive	ADJ
dpc-4152	176	9	days	day	NOUN
dpc-4152	177	1	[	[	X
dpc-4152	177	2	35,49	35,49	NOUN
dpc-4152	177	3	]	]	X
dpc-4152	177	4	.	.	PUNCT
dpc-4152	178	1	since	since	SCONJ
dpc-4152	178	2	this	this	DET
dpc-4152	178	3	drug	drug	NOUN
dpc-4152	178	4	has	have	AUX
dpc-4152	178	5	been	be	AUX
dpc-4152	178	6	marketed	market	VERB
dpc-4152	178	7	very	very	ADV
dpc-4152	178	8	recently	recently	ADV
dpc-4152	178	9	,	,	PUNCT
dpc-4152	178	10	studies	study	NOUN
dpc-4152	178	11	on	on	ADP
dpc-4152	178	12	compliance	compliance	NOUN
dpc-4152	178	13	,	,	PUNCT
dpc-4152	178	14	efficacy	efficacy	NOUN
dpc-4152	178	15	,	,	PUNCT
dpc-4152	178	16	and	and	CCONJ
dpc-4152	178	17	review	review	VERB
dpc-4152	178	18	|	|	ADV
dpc-4152	178	19	dermatol	dermatol	ADJ
dpc-4152	178	20	pract	pract	NOUN
dpc-4152	178	21	concept	concept	NOUN
dpc-4152	178	22	.	.	PUNCT
dpc-4152	179	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	179	2	:	:	PUNCT
dpc-4152	179	3	e2024145s	e2024145s	NOUN
dpc-4152	179	4	7	7	NUM
dpc-4152	179	5	3	3	NUM
dpc-4152	179	6	.	.	PUNCT
dpc-4152	180	1	memon	memon	PROPN
dpc-4152	180	2	aa	aa	PROPN
dpc-4152	180	3	,	,	PUNCT
dpc-4152	180	4	tomenson	tomenson	PROPN
dpc-4152	180	5	ja	ja	PROPN
dpc-4152	180	6	,	,	PUNCT
dpc-4152	180	7	bothwell	bothwell	PROPN
dpc-4152	180	8	j	j	PROPN
dpc-4152	180	9	,	,	PUNCT
dpc-4152	180	10	et	et	PROPN
dpc-4152	180	11	al	al	PROPN
dpc-4152	180	12	.	.	PUNCT
dpc-4152	181	1	prevalence	prevalence	NOUN
dpc-4152	181	2	of	of	ADP
dpc-4152	181	3	solar	solar	ADJ
dpc-4152	181	4	damage	damage	NOUN
dpc-4152	181	5	and	and	CCONJ
dpc-4152	181	6	394	394	NUM
dpc-4152	181	7	actinic	actinic	ADJ
dpc-4152	181	8	keratosis	keratosis	NOUN
dpc-4152	181	9	in	in	ADP
dpc-4152	181	10	a	a	DET
dpc-4152	181	11	merseyside	merseyside	ADJ
dpc-4152	181	12	population	population	NOUN
dpc-4152	181	13	.	.	PUNCT
dpc-4152	182	1	br	br	PROPN
dpc-4152	182	2	j	j	PROPN
dpc-4152	182	3	dermatol	dermatol	NOUN
dpc-4152	182	4	.	.	PUNCT
dpc-4152	183	1	2000;142(6):1154	2000;142(6):1154	NUM
dpc-4152	183	2	-	-	SYM
dpc-4152	183	3	1159	1159	NUM
dpc-4152	183	4	.	.	PUNCT
dpc-4152	184	1	395	395	NUM
dpc-4152	184	2	17	17	NUM
dpc-4152	184	3	4	4	NUM
dpc-4152	184	4	.	.	PUNCT
dpc-4152	185	1	hensen	hensen	PROPN
dpc-4152	185	2	p	p	PROPN
dpc-4152	185	3	,	,	PUNCT
dpc-4152	185	4	müller	müller	PROPN
dpc-4152	185	5	ml	ml	PROPN
dpc-4152	185	6	,	,	PUNCT
dpc-4152	185	7	haschemi	haschemi	ADV
dpc-4152	185	8	r	r	NOUN
dpc-4152	185	9	,	,	PUNCT
dpc-4152	185	10	et	et	PROPN
dpc-4152	185	11	al	al	PROPN
dpc-4152	185	12	.	.	PUNCT
dpc-4152	186	1	predisposing	predispose	VERB
dpc-4152	186	2	factors	factor	NOUN
dpc-4152	186	3	of	of	ADP
dpc-4152	186	4	actinic	actinic	ADJ
dpc-4152	186	5	keratosis	keratosis	NOUN
dpc-4152	186	6	in	in	ADP
dpc-4152	186	7	a	a	DET
dpc-4152	186	8	396	396	NUM
dpc-4152	186	9	north	north	NOUN
dpc-4152	186	10	-	-	PUNCT
dpc-4152	186	11	west	west	ADJ
dpc-4152	186	12	german	german	ADJ
dpc-4152	186	13	population	population	NOUN
dpc-4152	186	14	.	.	PUNCT
dpc-4152	187	1	eur	eur	PROPN
dpc-4152	187	2	j	j	PROPN
dpc-4152	187	3	dermatol	dermatol	NOUN
dpc-4152	187	4	.	.	PUNCT
dpc-4152	188	1	2009;19(4):345	2009;19(4):345	NUM
dpc-4152	188	2	-	-	PUNCT
dpc-4152	188	3	354	354	NUM
dpc-4152	188	4	.	.	NOUN
dpc-4152	188	5	5	5	NUM
dpc-4152	188	6	.	.	X
dpc-4152	188	7	woodhead	woodhead	NOUN
dpc-4152	188	8	ad	ad	NOUN
dpc-4152	188	9	,	,	PUNCT
dpc-4152	188	10	setlow	setlow	NOUN
dpc-4152	188	11	rb	rb	PROPN
dpc-4152	188	12	,	,	PUNCT
dpc-4152	188	13	tanaka	tanaka	PROPN
dpc-4152	188	14	m.	m.	NOUN
dpc-4152	188	15	environmental	environmental	ADJ
dpc-4152	188	16	factors	factor	NOUN
dpc-4152	188	17	in	in	ADP
dpc-4152	188	18	nonmelanoma	nonmelanoma	ADJ
dpc-4152	188	19	and	and	CCONJ
dpc-4152	188	20	melanoma	melanoma	VERB
dpc-4152	188	21	skin	skin	NOUN
dpc-4152	188	22	cancer	cancer	NOUN
dpc-4152	188	23	.	.	PUNCT
dpc-4152	189	1	j	j	PROPN
dpc-4152	189	2	epidemiol	epidemiol	PROPN
dpc-4152	189	3	.	.	PROPN
dpc-4152	189	4	1999;9	1999;9	NUM
dpc-4152	189	5	(	(	PUNCT
dpc-4152	189	6	6	6	NUM
dpc-4152	189	7	suppl	suppl	ADJ
dpc-4152	189	8	):	):	PUNCT
dpc-4152	189	9	s102	s102	PROPN
dpc-4152	189	10	-	-	SYM
dpc-4152	189	11	114	114	NUM
dpc-4152	189	12	.	.	PUNCT
dpc-4152	190	1	6	6	NUM
dpc-4152	190	2	.	.	X
dpc-4152	190	3	frost	frost	NOUN
dpc-4152	190	4	c	c	NOUN
dpc-4152	190	5	,	,	PUNCT
dpc-4152	190	6	williams	williams	PROPN
dpc-4152	190	7	g	g	PROPN
dpc-4152	190	8	,	,	PUNCT
dpc-4152	190	9	green	green	ADJ
dpc-4152	190	10	a.	a.	NOUN
dpc-4152	190	11	high	high	ADJ
dpc-4152	190	12	incidence	incidence	NOUN
dpc-4152	190	13	and	and	CCONJ
dpc-4152	190	14	regression	regression	NOUN
dpc-4152	190	15	rates	rate	NOUN
dpc-4152	190	16	of	of	ADP
dpc-4152	190	17	solar	solar	ADJ
dpc-4152	190	18	keratoses	keratose	NOUN
dpc-4152	190	19	in	in	ADP
dpc-4152	190	20	a	a	DET
dpc-4152	190	21	queensland	queensland	NOUN
dpc-4152	190	22	community	community	NOUN
dpc-4152	190	23	.	.	PUNCT
dpc-4152	190	24	  	  	SPACE
dpc-4152	191	1	j	j	PROPN
dpc-4152	191	2	invest	invest	VERB
dpc-4152	191	3	dermatol	dermatol	NOUN
dpc-4152	191	4	.	.	PUNCT
dpc-4152	192	1	2000;115(2):273	2000;115(2):273	NUM
dpc-4152	192	2	-	-	SYM
dpc-4152	192	3	277	277	NUM
dpc-4152	192	4	.	.	PUNCT
dpc-4152	193	1	7	7	X
dpc-4152	193	2	.	.	X
dpc-4152	193	3	flohil	flohil	PROPN
dpc-4152	193	4	sc	sc	PROPN
dpc-4152	193	5	,	,	PUNCT
dpc-4152	193	6	van	van	PROPN
dpc-4152	193	7	der	der	PROPN
dpc-4152	193	8	leest	leest	PROPN
dpc-4152	193	9	rj	rj	PROPN
dpc-4152	193	10	,	,	PUNCT
dpc-4152	193	11	dowlatshahi	dowlatshahi	PROPN
dpc-4152	193	12	ea	ea	NUM
dpc-4152	193	13	,	,	PUNCT
dpc-4152	193	14	hofman	hofman	PROPN
dpc-4152	193	15	a	a	DET
dpc-4152	193	16	,	,	PUNCT
dpc-4152	193	17	de	de	PROPN
dpc-4152	193	18	vries	vries	PROPN
dpc-4152	193	19	e	e	PROPN
dpc-4152	193	20	,	,	PUNCT
dpc-4152	193	21	nijsten	nijsten	ADJ
dpc-4152	193	22	t.	t.	ADJ
dpc-4152	193	23	prevalence	prevalence	NOUN
dpc-4152	193	24	of	of	ADP
dpc-4152	193	25	actinic	actinic	ADJ
dpc-4152	193	26	keratosis	keratosis	NOUN
dpc-4152	193	27	and	and	CCONJ
dpc-4152	193	28	its	its	PRON
dpc-4152	193	29	risk	risk	NOUN
dpc-4152	193	30	factors	factor	NOUN
dpc-4152	193	31	in	in	ADP
dpc-4152	193	32	the	the	DET
dpc-4152	193	33	general	general	ADJ
dpc-4152	193	34	population	population	NOUN
dpc-4152	193	35	:	:	PUNCT
dpc-4152	193	36	the	the	DET
dpc-4152	193	37	rotterdam	rotterdam	PROPN
dpc-4152	193	38	study	study	NOUN
dpc-4152	193	39	.	.	PUNCT
dpc-4152	193	40	 	 	SPACE
dpc-4152	194	1	j	j	PROPN
dpc-4152	194	2	invest	invest	VERB
dpc-4152	194	3	dermatol	dermatol	NOUN
dpc-4152	194	4	.	.	PUNCT
dpc-4152	195	1	2013;133(8):1971	2013;133(8):1971	NUM
dpc-4152	195	2	-	-	SYM
dpc-4152	195	3	1978	1978	NUM
dpc-4152	195	4	.	.	PUNCT
dpc-4152	196	1	8	8	NUM
dpc-4152	196	2	.	.	X
dpc-4152	196	3	memon	memon	PROPN
dpc-4152	196	4	aa	aa	PROPN
dpc-4152	196	5	,	,	PUNCT
dpc-4152	196	6	tomenson	tomenson	PROPN
dpc-4152	196	7	ja	ja	PROPN
dpc-4152	196	8	,	,	PUNCT
dpc-4152	196	9	bothwell	bothwell	PROPN
dpc-4152	196	10	j	j	PROPN
dpc-4152	196	11	,	,	PUNCT
dpc-4152	196	12	friedmann	friedmann	PROPN
dpc-4152	196	13	ps	ps	PROPN
dpc-4152	196	14	.	.	PROPN
dpc-4152	196	15	prevalence	prevalence	NOUN
dpc-4152	196	16	of	of	ADP
dpc-4152	196	17	solar	solar	ADJ
dpc-4152	196	18	damage	damage	NOUN
dpc-4152	196	19	and	and	CCONJ
dpc-4152	196	20	actinic	actinic	ADJ
dpc-4152	196	21	keratosis	keratosis	NOUN
dpc-4152	196	22	in	in	ADP
dpc-4152	196	23	a	a	DET
dpc-4152	196	24	merseyside	merseyside	ADJ
dpc-4152	196	25	population	population	NOUN
dpc-4152	196	26	.	.	PUNCT
dpc-4152	196	27	 	 	SPACE
dpc-4152	197	1	br	br	PROPN
dpc-4152	197	2	j	j	PROPN
dpc-4152	197	3	dermatol	dermatol	NOUN
dpc-4152	197	4	.	.	PUNCT
dpc-4152	198	1	2000;142(6):1154	2000;142(6):1154	NUM
dpc-4152	198	2	-	-	SYM
dpc-4152	198	3	1159	1159	NUM
dpc-4152	198	4	.	.	PUNCT
dpc-4152	199	1	9	9	NUM
dpc-4152	199	2	.	.	X
dpc-4152	199	3	eder	eder	NOUN
dpc-4152	199	4	j	j	PROPN
dpc-4152	199	5	,	,	PUNCT
dpc-4152	199	6	prillinger	prillinger	NOUN
dpc-4152	199	7	k	k	PROPN
dpc-4152	199	8	,	,	PUNCT
dpc-4152	199	9	korn	korn	PROPN
dpc-4152	199	10	a	a	X
dpc-4152	199	11	,	,	PUNCT
dpc-4152	199	12	geroldinger	geroldinger	NOUN
dpc-4152	199	13	a	a	PRON
dpc-4152	199	14	,	,	PUNCT
dpc-4152	199	15	trautinger	trautinger	PROPN
dpc-4152	199	16	f.	f.	PROPN
dpc-4152	199	17	prevalence	prevalence	PROPN
dpc-4152	199	18	of	of	ADP
dpc-4152	199	19	actinic	actinic	ADJ
dpc-4152	199	20	keratosis	keratosis	NOUN
dpc-4152	199	21	among	among	ADP
dpc-4152	199	22	dermatology	dermatology	NOUN
dpc-4152	199	23	outpatients	outpatient	NOUN
dpc-4152	199	24	in	in	ADP
dpc-4152	199	25	austria	austria	PROPN
dpc-4152	199	26	.	.	PUNCT
dpc-4152	199	27	 	 	SPACE
dpc-4152	200	1	br	br	PROPN
dpc-4152	200	2	j	j	PROPN
dpc-4152	200	3	dermatol	dermatol	NOUN
dpc-4152	200	4	.	.	PUNCT
dpc-4152	201	1	2014;171(6):1415	2014;171(6):1415	NUM
dpc-4152	201	2	-	-	SYM
dpc-4152	201	3	1421	1421	NUM
dpc-4152	201	4	.	.	PUNCT
dpc-4152	202	1	10	10	NUM
dpc-4152	202	2	.	.	PUNCT
dpc-4152	203	1	peris	peris	PROPN
dpc-4152	203	2	k	k	PROPN
dpc-4152	203	3	,	,	PUNCT
dpc-4152	203	4	calzavara	calzavara	NOUN
dpc-4152	203	5	-	-	PUNCT
dpc-4152	203	6	pinton	pinton	NOUN
dpc-4152	203	7	pg	pg	PROPN
dpc-4152	203	8	,	,	PUNCT
dpc-4152	203	9	neri	neri	PROPN
dpc-4152	203	10	l	l	PROPN
dpc-4152	203	11	,	,	PUNCT
dpc-4152	203	12	et	et	PROPN
dpc-4152	203	13	al	al	PROPN
dpc-4152	203	14	.	.	PUNCT
dpc-4152	204	1	italian	italian	ADJ
dpc-4152	204	2	expert	expert	ADJ
dpc-4152	204	3	consensus	consensus	NOUN
dpc-4152	204	4	for	for	ADP
dpc-4152	204	5	the	the	DET
dpc-4152	204	6	management	management	NOUN
dpc-4152	204	7	of	of	ADP
dpc-4152	204	8	actinic	actinic	ADJ
dpc-4152	204	9	keratosis	keratosis	NOUN
dpc-4152	204	10	in	in	ADP
dpc-4152	204	11	immunocompetent	immunocompetent	ADJ
dpc-4152	204	12	patients	patient	NOUN
dpc-4152	204	13	.	.	PUNCT
dpc-4152	204	14	 	 	SPACE
dpc-4152	205	1	j	j	PROPN
dpc-4152	205	2	eur	eur	PROPN
dpc-4152	205	3	acad	acad	PROPN
dpc-4152	205	4	dermatol	dermatol	NOUN
dpc-4152	205	5	venereol	venereol	NOUN
dpc-4152	205	6	.	.	PUNCT
dpc-4152	206	1	2016;30(7):1077	2016;30(7):1077	PROPN
dpc-4152	206	2	-	-	SYM
dpc-4152	206	3	1084	1084	NUM
dpc-4152	206	4	.	.	PUNCT
dpc-4152	207	1	11	11	NUM
dpc-4152	207	2	.	.	PUNCT
dpc-4152	208	1	marks	marks	PROPN
dpc-4152	208	2	r.	r.	PROPN
dpc-4152	208	3	who	who	PRON
dpc-4152	208	4	benefits	benefit	VERB
dpc-4152	208	5	from	from	ADP
dpc-4152	208	6	calling	call	VERB
dpc-4152	208	7	a	a	DET
dpc-4152	208	8	solar	solar	ADJ
dpc-4152	208	9	keratosis	keratosis	NOUN
dpc-4152	208	10	a	a	DET
dpc-4152	208	11	squamous	squamous	ADJ
dpc-4152	208	12	cell	cell	NOUN
dpc-4152	208	13	carcinoma	carcinoma	NOUN
dpc-4152	208	14	?	?	PUNCT
dpc-4152	208	15	.	.	PUNCT
dpc-4152	208	16	 	 	SPACE
dpc-4152	209	1	br	br	PROPN
dpc-4152	209	2	j	j	PROPN
dpc-4152	209	3	dermatol	dermatol	NOUN
dpc-4152	209	4	.	.	PUNCT
dpc-4152	210	1	2006;155(1):23	2006;155(1):23	NUM
dpc-4152	210	2	-	-	SYM
dpc-4152	210	3	26	26	NUM
dpc-4152	210	4	.	.	PUNCT
dpc-4152	211	1	12	12	NUM
dpc-4152	211	2	.	.	PUNCT
dpc-4152	212	1	peris	peris	PROPN
dpc-4152	212	2	k	k	PROPN
dpc-4152	212	3	,	,	PUNCT
dpc-4152	212	4	neri	neri	PROPN
dpc-4152	212	5	l	l	PROPN
dpc-4152	212	6	,	,	PUNCT
dpc-4152	212	7	calzavara	calzavara	PROPN
dpc-4152	212	8	pinton	pinton	PROPN
dpc-4152	212	9	p	p	PROPN
dpc-4152	212	10	,	,	PUNCT
dpc-4152	212	11	et	et	PROPN
dpc-4152	212	12	al	al	PROPN
dpc-4152	212	13	.	.	PUNCT
dpc-4152	212	14	physicians	physician	NOUN
dpc-4152	212	15	’	’	PART
dpc-4152	212	16	opinions	opinion	NOUN
dpc-4152	212	17	and	and	CCONJ
dpc-4152	212	18	clinical	clinical	ADJ
dpc-4152	212	19	practice	practice	NOUN
dpc-4152	212	20	patterns	pattern	NOUN
dpc-4152	212	21	for	for	ADP
dpc-4152	212	22	actinic	actinic	ADJ
dpc-4152	212	23	keratosis	keratosis	NOUN
dpc-4152	212	24	management	management	NOUN
dpc-4152	212	25	in	in	ADP
dpc-4152	212	26	italy	italy	PROPN
dpc-4152	212	27	.	.	PUNCT
dpc-4152	212	28	 	 	SPACE
dpc-4152	213	1	g	g	PROPN
dpc-4152	213	2	ital	ital	ADJ
dpc-4152	213	3	dermatol	dermatol	NOUN
dpc-4152	213	4	venereol	venereol	NOUN
dpc-4152	213	5	.	.	PUNCT
dpc-4152	214	1	2014;149(2):185	2014;149(2):185	NUM
dpc-4152	214	2	-	-	SYM
dpc-4152	214	3	192	192	NUM
dpc-4152	214	4	.	.	NOUN
dpc-4152	215	1	13	13	NUM
dpc-4152	215	2	.	.	PUNCT
dpc-4152	216	1	heaphy	heaphy	PROPN
dpc-4152	216	2	mr	mr	PROPN
dpc-4152	216	3	jr	jr	PROPN
dpc-4152	216	4	,	,	PUNCT
dpc-4152	216	5	ackerman	ackerman	PROPN
dpc-4152	216	6	ab	ab	PROPN
dpc-4152	216	7	.	.	PUNCT
dpc-4152	217	1	the	the	DET
dpc-4152	217	2	nature	nature	NOUN
dpc-4152	217	3	of	of	ADP
dpc-4152	217	4	solar	solar	ADJ
dpc-4152	217	5	keratosis	keratosis	NOUN
dpc-4152	217	6	:	:	PUNCT
dpc-4152	217	7	a	a	DET
dpc-4152	217	8	critical	critical	ADJ
dpc-4152	217	9	review	review	NOUN
dpc-4152	217	10	in	in	ADP
dpc-4152	217	11	historical	historical	ADJ
dpc-4152	217	12	perspective	perspective	NOUN
dpc-4152	217	13	.	.	PUNCT
dpc-4152	217	14	  	  	SPACE
dpc-4152	218	1	j	j	PROPN
dpc-4152	218	2	am	be	AUX
dpc-4152	218	3	acad	acad	ADJ
dpc-4152	218	4	dermatol	dermatol	NOUN
dpc-4152	218	5	.	.	PUNCT
dpc-4152	219	1	2000;43(1	2000;43(1	NUM
dpc-4152	219	2	pt	pt	PROPN
dpc-4152	219	3	1):138	1):138	NUM
dpc-4152	219	4	-	-	PUNCT
dpc-4152	219	5	150	150	NUM
dpc-4152	219	6	.	.	PUNCT
dpc-4152	219	7	14	14	NUM
dpc-4152	219	8	.	.	PUNCT
dpc-4152	220	1	werner	werner	PROPN
dpc-4152	220	2	rn	rn	PROPN
dpc-4152	220	3	,	,	PUNCT
dpc-4152	220	4	stockfleth	stockfleth	PROPN
dpc-4152	220	5	e	e	PROPN
dpc-4152	220	6	,	,	PUNCT
dpc-4152	220	7	connolly	connolly	PROPN
dpc-4152	220	8	sm	sm	PROPN
dpc-4152	220	9	,	,	PUNCT
dpc-4152	220	10	et	et	PROPN
dpc-4152	220	11	al	al	PROPN
dpc-4152	220	12	.	.	PROPN
dpc-4152	221	1	evidenceand	evidenceand	PROPN
dpc-4152	221	2	consensus	consensus	NOUN
dpc-4152	221	3	-	-	PUNCT
dpc-4152	221	4	based	base	VERB
dpc-4152	221	5	(	(	PUNCT
dpc-4152	221	6	s3	s3	PROPN
dpc-4152	221	7	)	)	PUNCT
dpc-4152	221	8	guidelines	guideline	NOUN
dpc-4152	221	9	for	for	ADP
dpc-4152	221	10	the	the	DET
dpc-4152	221	11	treatment	treatment	NOUN
dpc-4152	221	12	of	of	ADP
dpc-4152	221	13	actinic	actinic	ADJ
dpc-4152	221	14	keratosis	keratosis	NOUN
dpc-4152	221	15	international	international	ADJ
dpc-4152	221	16	league	league	NOUN
dpc-4152	221	17	of	of	ADP
dpc-4152	221	18	dermatological	dermatological	ADJ
dpc-4152	221	19	societies	society	NOUN
dpc-4152	221	20	in	in	ADP
dpc-4152	221	21	cooperation	cooperation	NOUN
dpc-4152	221	22	with	with	ADP
dpc-4152	221	23	the	the	DET
dpc-4152	221	24	european	european	PROPN
dpc-4152	221	25	dermatology	dermatology	PROPN
dpc-4152	221	26	forum	forum	PROPN
dpc-4152	221	27	short	short	ADJ
dpc-4152	221	28	version	version	NOUN
dpc-4152	221	29	.	.	PUNCT
dpc-4152	221	30	 	 	SPACE
dpc-4152	222	1	j	j	PROPN
dpc-4152	222	2	eur	eur	PROPN
dpc-4152	222	3	acad	acad	PROPN
dpc-4152	222	4	dermatol	dermatol	NOUN
dpc-4152	222	5	venereol	venereol	NOUN
dpc-4152	222	6	.	.	PUNCT
dpc-4152	223	1	2015;29(11):2069	2015;29(11):2069	NUM
dpc-4152	223	2	-	-	SYM
dpc-4152	223	3	2079	2079	NUM
dpc-4152	223	4	.	.	PUNCT
dpc-4152	224	1	15	15	NUM
dpc-4152	224	2	.	.	PUNCT
dpc-4152	225	1	lai	lai	PROPN
dpc-4152	225	2	v	v	PROPN
dpc-4152	225	3	,	,	PUNCT
dpc-4152	225	4	cranwell	cranwell	VERB
dpc-4152	225	5	w	w	PROPN
dpc-4152	225	6	,	,	PUNCT
dpc-4152	225	7	sinclair	sinclair	PROPN
dpc-4152	225	8	r.	r.	PROPN
dpc-4152	225	9	epidemiology	epidemiology	PROPN
dpc-4152	225	10	of	of	ADP
dpc-4152	225	11	skin	skin	NOUN
dpc-4152	225	12	cancer	cancer	NOUN
dpc-4152	225	13	in	in	ADP
dpc-4152	225	14	the	the	DET
dpc-4152	225	15	mature	mature	ADJ
dpc-4152	225	16	patient	patient	NOUN
dpc-4152	225	17	.	.	PUNCT
dpc-4152	226	1	clin	clin	PROPN
dpc-4152	226	2	dermatol	dermatol	NOUN
dpc-4152	226	3	.	.	PUNCT
dpc-4152	227	1	2018	2018	NUM
dpc-4152	227	2	mar	mar	PROPN
dpc-4152	227	3	-	-	PUNCT
dpc-4152	227	4	apr;36(2):167	apr;36(2):167	PROPN
dpc-4152	227	5	-	-	PUNCT
dpc-4152	227	6	176	176	NUM
dpc-4152	227	7	.	.	PUNCT
dpc-4152	228	1	epub	epub	PROPN
dpc-4152	228	2	2017	2017	NUM
dpc-4152	228	3	oct	oct	NOUN
dpc-4152	228	4	13	13	NUM
dpc-4152	228	5	.	.	PUNCT
dpc-4152	229	1	pmid	pmid	NOUN
dpc-4152	229	2	:	:	PUNCT
dpc-4152	229	3	29566921	29566921	NUM
dpc-4152	229	4	.	.	PUNCT
dpc-4152	230	1	16	16	NUM
dpc-4152	230	2	.	.	PUNCT
dpc-4152	231	1	brash	brash	PROPN
dpc-4152	231	2	de	de	PROPN
dpc-4152	231	3	,	,	PUNCT
dpc-4152	231	4	rudolph	rudolph	PROPN
dpc-4152	231	5	ja	ja	PROPN
dpc-4152	231	6	,	,	PUNCT
dpc-4152	231	7	simon	simon	PROPN
dpc-4152	231	8	ja	ja	PROPN
dpc-4152	231	9	,	,	PUNCT
dpc-4152	231	10	et	et	PROPN
dpc-4152	231	11	al	al	PROPN
dpc-4152	231	12	.	.	PUNCT
dpc-4152	232	1	a	a	DET
dpc-4152	232	2	role	role	NOUN
dpc-4152	232	3	for	for	ADP
dpc-4152	232	4	sunlight	sunlight	NOUN
dpc-4152	232	5	in	in	ADP
dpc-4152	232	6	skin	skin	NOUN
dpc-4152	232	7	cancer	cancer	NOUN
dpc-4152	232	8	:	:	PUNCT
dpc-4152	232	9	uv	uv	NOUN
dpc-4152	232	10	-	-	PUNCT
dpc-4152	232	11	induced	induce	VERB
dpc-4152	232	12	512	512	NUM
dpc-4152	232	13	p53	p53	NOUN
dpc-4152	232	14	mutations	mutation	NOUN
dpc-4152	232	15	in	in	ADP
dpc-4152	232	16	squamous	squamous	ADJ
dpc-4152	232	17	cell	cell	NOUN
dpc-4152	232	18	carcinoma	carcinoma	NOUN
dpc-4152	232	19	.	.	PUNCT
dpc-4152	233	1	proc	proc	PROPN
dpc-4152	233	2	natl	natl	PROPN
dpc-4152	233	3	acad	acad	PROPN
dpc-4152	233	4	sci	sci	PROPN
dpc-4152	233	5	usa	usa	PROPN
dpc-4152	233	6	.	.	PROPN
dpc-4152	233	7	513	513	NUM
dpc-4152	233	8	1991;88(22):10124	1991;88(22):10124	NUM
dpc-4152	233	9	-	-	SYM
dpc-4152	233	10	10128	10128	NUM
dpc-4152	233	11	.	.	PUNCT
dpc-4152	234	1	17	17	NUM
dpc-4152	234	2	.	.	PUNCT
dpc-4152	235	1	anwar	anwar	PROPN
dpc-4152	235	2	j	j	PROPN
dpc-4152	235	3	,	,	PUNCT
dpc-4152	235	4	wrone	wrone	PROPN
dpc-4152	235	5	da	da	PROPN
dpc-4152	235	6	,	,	PUNCT
dpc-4152	235	7	kimyai	kimyai	NOUN
dpc-4152	235	8	-	-	PUNCT
dpc-4152	235	9	asadi	asadi	NOUN
dpc-4152	235	10	a	a	PRON
dpc-4152	235	11	,	,	PUNCT
dpc-4152	235	12	alam	alam	PROPN
dpc-4152	235	13	m.	m.	NOUN
dpc-4152	235	14	the	the	DET
dpc-4152	235	15	development	development	NOUN
dpc-4152	235	16	of	of	ADP
dpc-4152	235	17	actinic	actinic	ADJ
dpc-4152	235	18	keratosis	keratosis	NOUN
dpc-4152	235	19	into	into	ADP
dpc-4152	235	20	invasive	invasive	ADJ
dpc-4152	235	21	squamous	squamous	ADJ
dpc-4152	235	22	cell	cell	NOUN
dpc-4152	235	23	carcinoma	carcinoma	NOUN
dpc-4152	235	24	:	:	PUNCT
dpc-4152	235	25	evidence	evidence	NOUN
dpc-4152	235	26	and	and	CCONJ
dpc-4152	235	27	evolving	evolve	VERB
dpc-4152	235	28	classification	classification	NOUN
dpc-4152	235	29	schemes	scheme	NOUN
dpc-4152	235	30	.	.	PUNCT
dpc-4152	235	31	  	  	SPACE
dpc-4152	235	32	clin	clin	PROPN
dpc-4152	235	33	dermatol	dermatol	NOUN
dpc-4152	235	34	.	.	PUNCT
dpc-4152	236	1	2004;22(3):189	2004;22(3):189	NUM
dpc-4152	236	2	-	-	PUNCT
dpc-4152	236	3	196	196	NUM
dpc-4152	236	4	.	.	PUNCT
dpc-4152	237	1	18	18	NUM
dpc-4152	237	2	.	.	PUNCT
dpc-4152	237	3	ashton	ashton	PROPN
dpc-4152	237	4	kj	kj	PROPN
dpc-4152	237	5	,	,	PUNCT
dpc-4152	237	6	weinstein	weinstein	PROPN
dpc-4152	237	7	sr	sr	PROPN
dpc-4152	237	8	,	,	PUNCT
dpc-4152	237	9	maguire	maguire	PROPN
dpc-4152	237	10	dj	dj	PROPN
dpc-4152	237	11	,	,	PUNCT
dpc-4152	237	12	griffiths	griffiths	PROPN
dpc-4152	237	13	lr	lr	PROPN
dpc-4152	237	14	.	.	PROPN
dpc-4152	237	15	chromosomal	chromosomal	ADJ
dpc-4152	237	16	aberrations	aberration	NOUN
dpc-4152	237	17	in	in	ADP
dpc-4152	237	18	squamous	squamous	ADJ
dpc-4152	237	19	cell	cell	NOUN
dpc-4152	237	20	carcinoma	carcinoma	NOUN
dpc-4152	237	21	and	and	CCONJ
dpc-4152	237	22	solar	solar	ADJ
dpc-4152	237	23	keratoses	keratose	NOUN
dpc-4152	237	24	revealed	reveal	VERB
dpc-4152	237	25	by	by	ADP
dpc-4152	237	26	comparative	comparative	ADJ
dpc-4152	237	27	genomic	genomic	ADJ
dpc-4152	237	28	hybridization	hybridization	NOUN
dpc-4152	237	29	.	.	PUNCT
dpc-4152	237	30	  	  	SPACE
dpc-4152	237	31	arch	arch	ADJ
dpc-4152	237	32	dermatol	dermatol	NOUN
dpc-4152	237	33	.	.	PUNCT
dpc-4152	238	1	2003;139(7):876	2003;139(7):876	NUM
dpc-4152	238	2	-	-	SYM
dpc-4152	238	3	882	882	NUM
dpc-4152	238	4	.	.	NOUN
dpc-4152	239	1	19	19	NUM
dpc-4152	239	2	.	.	PUNCT
dpc-4152	239	3	eisen	eisen	PROPN
dpc-4152	239	4	db	db	PROPN
dpc-4152	239	5	,	,	PUNCT
dpc-4152	239	6	asgari	asgari	PROPN
dpc-4152	239	7	mm	mm	PROPN
dpc-4152	239	8	,	,	PUNCT
dpc-4152	239	9	bennett	bennett	PROPN
dpc-4152	239	10	dd	dd	PROPN
dpc-4152	239	11	,	,	PUNCT
dpc-4152	239	12	et	et	PROPN
dpc-4152	239	13	al	al	PROPN
dpc-4152	239	14	.	.	PUNCT
dpc-4152	240	1	guidelines	guideline	NOUN
dpc-4152	240	2	of	of	ADP
dpc-4152	240	3	care	care	NOUN
dpc-4152	240	4	for	for	ADP
dpc-4152	240	5	the	the	DET
dpc-4152	240	6	management	management	NOUN
dpc-4152	240	7	of	of	ADP
dpc-4152	240	8	actinic	actinic	ADJ
dpc-4152	240	9	keratosis	keratosis	NOUN
dpc-4152	240	10	.	.	PUNCT
dpc-4152	240	11	 	 	SPACE
dpc-4152	241	1	j	j	PROPN
dpc-4152	241	2	am	be	AUX
dpc-4152	241	3	acad	acad	ADJ
dpc-4152	241	4	dermatol	dermatol	NOUN
dpc-4152	241	5	.	.	PUNCT
dpc-4152	242	1	2021;85(4):e209	2021;85(4):e209	NOUN
dpc-4152	242	2	-	-	PUNCT
dpc-4152	242	3	e233	e233	PROPN
dpc-4152	242	4	.	.	PROPN
dpc-4152	242	5	20	20	NUM
dpc-4152	242	6	.	.	PUNCT
dpc-4152	243	1	mittelbronn	mittelbronn	PROPN
dpc-4152	243	2	ma	ma	PROPN
dpc-4152	243	3	,	,	PUNCT
dpc-4152	243	4	mullins	mullins	PROPN
dpc-4152	243	5	dl	dl	PROPN
dpc-4152	243	6	,	,	PUNCT
dpc-4152	243	7	ramos	ramos	PROPN
dpc-4152	243	8	-	-	PUNCT
dpc-4152	243	9	caro	caro	PROPN
dpc-4152	243	10	fa	fa	PROPN
dpc-4152	243	11	,	,	PUNCT
dpc-4152	243	12	flowers	flower	NOUN
dpc-4152	243	13	fp	fp	PROPN
dpc-4152	243	14	.	.	PROPN
dpc-4152	243	15	frequency	frequency	NOUN
dpc-4152	243	16	of	of	ADP
dpc-4152	243	17	pre	pre	ADJ
dpc-4152	243	18	-	-	ADJ
dpc-4152	243	19	existing	exist	VERB
dpc-4152	243	20	actinic	actinic	ADJ
dpc-4152	243	21	keratosis	keratosis	NOUN
dpc-4152	243	22	in	in	ADP
dpc-4152	243	23	cutaneous	cutaneous	ADJ
dpc-4152	243	24	squamous	squamous	ADJ
dpc-4152	243	25	cell	cell	NOUN
dpc-4152	243	26	carcinoma	carcinoma	NOUN
dpc-4152	243	27	.	.	PUNCT
dpc-4152	243	28	 	 	SPACE
dpc-4152	244	1	int	int	PROPN
dpc-4152	244	2	j	j	PROPN
dpc-4152	244	3	dermatol	dermatol	NOUN
dpc-4152	244	4	.	.	PUNCT
dpc-4152	245	1	1998;37(9):677	1998;37(9):677	NUM
dpc-4152	245	2	-	-	PUNCT
dpc-4152	245	3	681	681	NUM
dpc-4152	245	4	.	.	PUNCT
dpc-4152	246	1	21	21	NUM
dpc-4152	246	2	.	.	PUNCT
dpc-4152	246	3	criscione	criscione	NOUN
dpc-4152	246	4	vd	vd	PROPN
dpc-4152	246	5	,	,	PUNCT
dpc-4152	246	6	weinstock	weinstock	PROPN
dpc-4152	246	7	ma	ma	PROPN
dpc-4152	246	8	,	,	PUNCT
dpc-4152	246	9	naylor	naylor	PROPN
dpc-4152	246	10	mf	mf	PROPN
dpc-4152	246	11	,	,	PUNCT
dpc-4152	246	12	et	et	PROPN
dpc-4152	246	13	al	al	PROPN
dpc-4152	246	14	.	.	PROPN
dpc-4152	246	15	actinic	actinic	ADJ
dpc-4152	246	16	keratoses	keratose	NOUN
dpc-4152	246	17	:	:	PUNCT
dpc-4152	246	18	natural	natural	ADJ
dpc-4152	246	19	history	history	NOUN
dpc-4152	246	20	and	and	CCONJ
dpc-4152	246	21	risk	risk	NOUN
dpc-4152	246	22	of	of	ADP
dpc-4152	246	23	malignant	malignant	ADJ
dpc-4152	246	24	transformation	transformation	NOUN
dpc-4152	246	25	in	in	ADP
dpc-4152	246	26	the	the	PRON
dpc-4152	246	27	in	in	ADP
dpc-4152	246	28	the	the	DET
dpc-4152	246	29	reviews	review	NOUN
dpc-4152	246	30	[	[	X
dpc-4152	246	31	44,45,49,50	44,45,49,50	X
dpc-4152	246	32	]	]	PUNCT
dpc-4152	246	33	tirbanibulin	tirbanibulin	PROPN
dpc-4152	246	34	showed	show	VERB
dpc-4152	246	35	the	the	DET
dpc-4152	246	36	lowest	low	ADJ
dpc-4152	246	37	discontinuation	discontinuation	NOUN
dpc-4152	246	38	rate	rate	NOUN
dpc-4152	246	39	with	with	ADP
dpc-4152	246	40	a	a	DET
dpc-4152	246	41	compliance	compliance	NOUN
dpc-4152	246	42	percentage	percentage	NOUN
dpc-4152	246	43	of	of	ADP
dpc-4152	246	44	up	up	ADP
dpc-4152	246	45	to	to	PART
dpc-4152	246	46	100	100	NUM
dpc-4152	246	47	%	%	NOUN
dpc-4152	246	48	.	.	PUNCT
dpc-4152	247	1	this	this	PRON
dpc-4152	247	2	is	be	AUX
dpc-4152	247	3	likely	likely	ADJ
dpc-4152	247	4	due	due	ADP
dpc-4152	247	5	to	to	ADP
dpc-4152	247	6	the	the	DET
dpc-4152	247	7	well	well	ADV
dpc-4152	247	8	-	-	PUNCT
dpc-4152	247	9	tolerated	tolerate	VERB
dpc-4152	247	10	profile	profile	NOUN
dpc-4152	247	11	of	of	ADP
dpc-4152	247	12	the	the	DET
dpc-4152	247	13	drug	drug	NOUN
dpc-4152	247	14	and	and	CCONJ
dpc-4152	247	15	its	its	PRON
dpc-4152	247	16	easy	easy	ADJ
dpc-4152	247	17	administration	administration	NOUN
dpc-4152	247	18	regimen	regiman	NOUN
dpc-4152	247	19	.	.	PUNCT
dpc-4152	248	1	incidentally	incidentally	ADV
dpc-4152	248	2	,	,	PUNCT
dpc-4152	248	3	anecdotal	anecdotal	ADJ
dpc-4152	248	4	experience	experience	NOUN
dpc-4152	248	5	from	from	ADP
dpc-4152	248	6	these	these	DET
dpc-4152	248	7	two	two	NUM
dpc-4152	248	8	studies	study	NOUN
dpc-4152	248	9	proves	prove	VERB
dpc-4152	248	10	that	that	SCONJ
dpc-4152	248	11	the	the	DET
dpc-4152	248	12	antitumoral	antitumoral	ADJ
dpc-4152	248	13	effects	effect	NOUN
dpc-4152	248	14	above	above	ADP
dpc-4152	248	15	make	make	VERB
dpc-4152	248	16	tirbanibulin	tirbanibulin	PRON
dpc-4152	248	17	a	a	DET
dpc-4152	248	18	potential	potential	ADJ
dpc-4152	248	19	candidate	candidate	NOUN
dpc-4152	248	20	for	for	ADP
dpc-4152	248	21	future	future	ADJ
dpc-4152	248	22	treatment	treatment	NOUN
dpc-4152	248	23	of	of	ADP
dpc-4152	248	24	skin	skin	NOUN
dpc-4152	248	25	carcinomas	carcinoma	NOUN
dpc-4152	248	26	,	,	PUNCT
dpc-4152	248	27	especially	especially	ADV
dpc-4152	248	28	basocellular	basocellular	ADJ
dpc-4152	248	29	and	and	CCONJ
dpc-4152	248	30	squamocellular	squamocellular	ADJ
dpc-4152	248	31	carcinomas	carcinoma	NOUN
dpc-4152	248	32	even	even	ADV
dpc-4152	248	33	though	though	SCONJ
dpc-4152	248	34	it	it	PRON
dpc-4152	248	35	is	be	AUX
dpc-4152	248	36	not	not	PART
dpc-4152	248	37	approved	approve	VERB
dpc-4152	248	38	yet	yet	ADV
dpc-4152	248	39	for	for	ADP
dpc-4152	248	40	these	these	DET
dpc-4152	248	41	indications	indication	NOUN
dpc-4152	248	42	[	[	X
dpc-4152	248	43	55,56	55,56	NOUN
dpc-4152	248	44	]	]	PUNCT
dpc-4152	248	45	.	.	PUNCT
dpc-4152	249	1	in	in	ADP
dpc-4152	249	2	patients	patient	NOUN
dpc-4152	249	3	with	with	ADP
dpc-4152	249	4	ak	ak	PROPN
dpc-4152	249	5	,	,	PUNCT
dpc-4152	249	6	a	a	DET
dpc-4152	249	7	new	new	ADJ
dpc-4152	249	8	phase	phase	NOUN
dpc-4152	249	9	1	1	NUM
dpc-4152	249	10	trial	trial	NOUN
dpc-4152	249	11	assessed	assess	VERB
dpc-4152	249	12	the	the	DET
dpc-4152	249	13	safety	safety	NOUN
dpc-4152	249	14	and	and	CCONJ
dpc-4152	249	15	systemic	systemic	ADJ
dpc-4152	249	16	exposure	exposure	NOUN
dpc-4152	249	17	of	of	ADP
dpc-4152	249	18	tirbanibulin	tirbanibulin	PROPN
dpc-4152	249	19	ointment	ointment	NOUN
dpc-4152	249	20	1	1	NUM
dpc-4152	249	21	%	%	NOUN
dpc-4152	249	22	when	when	SCONJ
dpc-4152	249	23	applied	apply	VERB
dpc-4152	249	24	under	under	ADP
dpc-4152	249	25	maximal	maximal	ADJ
dpc-4152	249	26	usage	usage	NOUN
dpc-4152	249	27	settings	setting	NOUN
dpc-4152	249	28	,	,	PUNCT
dpc-4152	249	29	i.e.	i.e.	X
dpc-4152	249	30	,	,	PUNCT
dpc-4152	249	31	350	350	NUM
dpc-4152	249	32	mg	mg	NOUN
dpc-4152	249	33	once	once	SCONJ
dpc-4152	249	34	day	day	NOUN
dpc-4152	249	35	for	for	ADP
dpc-4152	249	36	five	five	NUM
dpc-4152	249	37	days	day	NOUN
dpc-4152	249	38	in	in	ADP
dpc-4152	249	39	a	a	DET
dpc-4152	249	40	row	row	NOUN
dpc-4152	249	41	to	to	ADP
dpc-4152	249	42	100	100	NUM
dpc-4152	249	43	cm2	cm2	NOUN
dpc-4152	249	44	of	of	ADP
dpc-4152	249	45	the	the	DET
dpc-4152	249	46	face	face	NOUN
dpc-4152	249	47	or	or	CCONJ
dpc-4152	249	48	balding	bald	VERB
dpc-4152	249	49	scalp	scalp	NOUN
dpc-4152	249	50	having	have	VERB
dpc-4152	249	51	eight	eight	NUM
dpc-4152	249	52	or	or	CCONJ
dpc-4152	249	53	more	more	ADJ
dpc-4152	249	54	ak	ak	NOUN
dpc-4152	249	55	lesions	lesion	NOUN
dpc-4152	249	56	.	.	PUNCT
dpc-4152	250	1	the	the	DET
dpc-4152	250	2	majority	majority	NOUN
dpc-4152	250	3	of	of	ADP
dpc-4152	250	4	teaes	teaes	NOUN
dpc-4152	250	5	were	be	AUX
dpc-4152	250	6	mild	mild	ADJ
dpc-4152	250	7	,	,	PUNCT
dpc-4152	250	8	with	with	ADP
dpc-4152	250	9	application	application	NOUN
dpc-4152	250	10	site	site	NOUN
dpc-4152	250	11	reactions	reaction	NOUN
dpc-4152	250	12	being	be	AUX
dpc-4152	250	13	the	the	DET
dpc-4152	250	14	most	most	ADV
dpc-4152	250	15	common	common	ADJ
dpc-4152	250	16	treatment	treatment	NOUN
dpc-4152	250	17	-	-	PUNCT
dpc-4152	250	18	related	relate	VERB
dpc-4152	250	19	teaes	teae	NOUN
dpc-4152	250	20	,	,	PUNCT
dpc-4152	250	21	similar	similar	ADJ
dpc-4152	250	22	to	to	ADP
dpc-4152	250	23	other	other	ADJ
dpc-4152	250	24	topical	topical	ADJ
dpc-4152	250	25	ak	ak	PROPN
dpc-4152	250	26	treatments	treatment	NOUN
dpc-4152	250	27	[	[	X
dpc-4152	250	28	57	57	NUM
dpc-4152	250	29	]	]	PUNCT
dpc-4152	250	30	.	.	PUNCT
dpc-4152	251	1	finally	finally	ADV
dpc-4152	251	2	,	,	PUNCT
dpc-4152	251	3	given	give	VERB
dpc-4152	251	4	the	the	DET
dpc-4152	251	5	great	great	ADJ
dpc-4152	251	6	effectiveness	effectiveness	NOUN
dpc-4152	251	7	and	and	CCONJ
dpc-4152	251	8	safety	safety	NOUN
dpc-4152	251	9	of	of	ADP
dpc-4152	251	10	this	this	DET
dpc-4152	251	11	medication	medication	NOUN
dpc-4152	251	12	,	,	PUNCT
dpc-4152	251	13	new	new	ADJ
dpc-4152	251	14	sites	site	NOUN
dpc-4152	251	15	for	for	ADP
dpc-4152	251	16	possible	possible	ADJ
dpc-4152	251	17	application	application	NOUN
dpc-4152	251	18	over	over	ADP
dpc-4152	251	19	the	the	DET
dpc-4152	251	20	approved	approve	VERB
dpc-4152	251	21	face	face	NOUN
dpc-4152	251	22	and	and	CCONJ
dpc-4152	251	23	scalp	scalp	NOUN
dpc-4152	251	24	start	start	VERB
dpc-4152	251	25	to	to	PART
dpc-4152	251	26	be	be	AUX
dpc-4152	251	27	reported	report	VERB
dpc-4152	251	28	.	.	PUNCT
dpc-4152	252	1	as	as	SCONJ
dpc-4152	252	2	shown	show	VERB
dpc-4152	252	3	in	in	ADP
dpc-4152	252	4	this	this	DET
dpc-4152	252	5	case	case	NOUN
dpc-4152	252	6	review	review	NOUN
dpc-4152	252	7	study	study	NOUN
dpc-4152	252	8	[	[	X
dpc-4152	252	9	58	58	NUM
dpc-4152	252	10	]	]	PUNCT
dpc-4152	252	11	tirbanibulin	tirbanibulin	PRON
dpc-4152	252	12	1	1	NUM
dpc-4152	252	13	%	%	NOUN
dpc-4152	252	14	ointment	ointment	NOUN
dpc-4152	252	15	demonstrated	demonstrate	VERB
dpc-4152	252	16	efficacy	efficacy	NOUN
dpc-4152	252	17	for	for	ADP
dpc-4152	252	18	the	the	DET
dpc-4152	252	19	treatment	treatment	NOUN
dpc-4152	252	20	of	of	ADP
dpc-4152	252	21	grade	grade	NOUN
dpc-4152	252	22	i	i	PROPN
dpc-4152	252	23	and	and	CCONJ
dpc-4152	252	24	ii	ii	PROPN
dpc-4152	252	25	aks	ak	NOUN
dpc-4152	252	26	of	of	ADP
dpc-4152	252	27	upper	upper	ADJ
dpc-4152	252	28	arms	arm	NOUN
dpc-4152	252	29	with	with	ADP
dpc-4152	252	30	approximately	approximately	ADV
dpc-4152	252	31	45	45	NUM
dpc-4152	252	32	%	%	NOUN
dpc-4152	252	33	of	of	ADP
dpc-4152	252	34	complete	complete	ADJ
dpc-4152	252	35	clearance	clearance	NOUN
dpc-4152	252	36	after	after	ADP
dpc-4152	252	37	a	a	DET
dpc-4152	252	38	single	single	ADJ
dpc-4152	252	39	cycle	cycle	NOUN
dpc-4152	252	40	of	of	ADP
dpc-4152	252	41	therapy	therapy	NOUN
dpc-4152	252	42	.	.	PUNCT
dpc-4152	253	1	following	follow	VERB
dpc-4152	253	2	the	the	DET
dpc-4152	253	3	profile	profile	NOUN
dpc-4152	253	4	of	of	ADP
dpc-4152	253	5	safeness	safeness	NOUN
dpc-4152	253	6	described	describe	VERB
dpc-4152	253	7	for	for	ADP
dpc-4152	253	8	the	the	DET
dpc-4152	253	9	face	face	NOUN
dpc-4152	253	10	and	and	CCONJ
dpc-4152	253	11	scalp	scalp	NOUN
dpc-4152	253	12	also	also	ADV
dpc-4152	253	13	for	for	ADP
dpc-4152	253	14	the	the	DET
dpc-4152	253	15	upper	upper	ADJ
dpc-4152	253	16	extremities	extremity	NOUN
dpc-4152	253	17	,	,	PUNCT
dpc-4152	253	18	tirbanibulin	tirbanibulin	PROPN
dpc-4152	253	19	showed	show	VERB
dpc-4152	253	20	a	a	DET
dpc-4152	253	21	significative	significative	ADJ
dpc-4152	253	22	level	level	NOUN
dpc-4152	253	23	of	of	ADP
dpc-4152	253	24	tolerability	tolerability	NOUN
dpc-4152	253	25	and	and	CCONJ
dpc-4152	253	26	adherence	adherence	NOUN
dpc-4152	253	27	to	to	ADP
dpc-4152	253	28	treatment	treatment	NOUN
dpc-4152	253	29	thanks	thank	NOUN
dpc-4152	253	30	to	to	ADP
dpc-4152	253	31	its	its	PRON
dpc-4152	253	32	proapoptotic	proapoptotic	ADJ
dpc-4152	253	33	effect	effect	NOUN
dpc-4152	253	34	which	which	PRON
dpc-4152	253	35	reduces	reduce	VERB
dpc-4152	253	36	the	the	DET
dpc-4152	253	37	inflammatory	inflammatory	ADJ
dpc-4152	253	38	necrosis	necrosis	NOUN
dpc-4152	253	39	typical	typical	ADJ
dpc-4152	253	40	of	of	ADP
dpc-4152	253	41	the	the	DET
dpc-4152	253	42	other	other	ADJ
dpc-4152	253	43	medications	medication	NOUN
dpc-4152	253	44	prescribed	prescribe	VERB
dpc-4152	253	45	for	for	ADP
dpc-4152	253	46	aks	ak	NOUN
dpc-4152	253	47	.	.	PUNCT
dpc-4152	254	1	conclusions	conclusion	NOUN
dpc-4152	254	2	considering	consider	VERB
dpc-4152	254	3	the	the	DET
dpc-4152	254	4	short	short	ADJ
dpc-4152	254	5	-	-	PUNCT
dpc-4152	254	6	term	term	NOUN
dpc-4152	254	7	course	course	NOUN
dpc-4152	254	8	of	of	ADP
dpc-4152	254	9	application	application	NOUN
dpc-4152	254	10	,	,	PUNCT
dpc-4152	254	11	the	the	DET
dpc-4152	254	12	low	low	ADJ
dpc-4152	254	13	rate	rate	NOUN
dpc-4152	254	14	of	of	ADP
dpc-4152	254	15	local	local	ADJ
dpc-4152	254	16	cutaneous	cutaneous	ADJ
dpc-4152	254	17	side	side	NOUN
dpc-4152	254	18	effects	effect	NOUN
dpc-4152	254	19	,	,	PUNCT
dpc-4152	254	20	and	and	CCONJ
dpc-4152	254	21	the	the	DET
dpc-4152	254	22	efficacy	efficacy	NOUN
dpc-4152	254	23	profile	profile	NOUN
dpc-4152	254	24	,	,	PUNCT
dpc-4152	254	25	tirbanibulin	tirbanibulin	PROPN
dpc-4152	254	26	represents	represent	VERB
dpc-4152	254	27	a	a	DET
dpc-4152	254	28	safe	safe	ADJ
dpc-4152	254	29	,	,	PUNCT
dpc-4152	254	30	effective	effective	ADJ
dpc-4152	254	31	,	,	PUNCT
dpc-4152	254	32	and	and	CCONJ
dpc-4152	254	33	practical	practical	ADJ
dpc-4152	254	34	option	option	NOUN
dpc-4152	254	35	for	for	ADP
dpc-4152	254	36	managing	manage	VERB
dpc-4152	254	37	grade	grade	NOUN
dpc-4152	254	38	i	i	PRON
dpc-4152	254	39	face	face	VERB
dpc-4152	254	40	and	and	CCONJ
dpc-4152	254	41	scalp	scalp	VERB
dpc-4152	254	42	aks	ak	NOUN
dpc-4152	254	43	.	.	PUNCT
dpc-4152	255	1	in	in	ADP
dpc-4152	255	2	particular	particular	ADJ
dpc-4152	255	3	,	,	PUNCT
dpc-4152	255	4	tirbanibulin	tirbanibulin	PROPN
dpc-4152	255	5	seems	seem	VERB
dpc-4152	255	6	to	to	PART
dpc-4152	255	7	raise	raise	VERB
dpc-4152	255	8	patient	patient	ADJ
dpc-4152	255	9	adherence	adherence	NOUN
dpc-4152	255	10	rates	rate	NOUN
dpc-4152	255	11	to	to	ADP
dpc-4152	255	12	topical	topical	ADJ
dpc-4152	255	13	aks	ak	NOUN
dpc-4152	255	14	therapies	therapy	NOUN
dpc-4152	255	15	.	.	PUNCT
dpc-4152	256	1	furthermore	furthermore	ADV
dpc-4152	256	2	,	,	PUNCT
dpc-4152	256	3	tirbanibulin	tirbanibulin	PROPN
dpc-4152	256	4	shows	show	VERB
dpc-4152	256	5	potential	potential	ADJ
dpc-4152	256	6	benefits	benefit	NOUN
dpc-4152	256	7	also	also	ADV
dpc-4152	256	8	on	on	ADP
dpc-4152	256	9	more	more	ADV
dpc-4152	256	10	advanced	advanced	ADJ
dpc-4152	256	11	aks	ak	NOUN
dpc-4152	256	12	or	or	CCONJ
dpc-4152	256	13	aks	ak	NOUN
dpc-4152	256	14	located	locate	VERB
dpc-4152	256	15	in	in	ADP
dpc-4152	256	16	other	other	ADJ
dpc-4152	256	17	anatomical	anatomical	ADJ
dpc-4152	256	18	areas	area	NOUN
dpc-4152	256	19	.	.	PUNCT
dpc-4152	257	1	head	head	NOUN
dpc-4152	257	2	-	-	PUNCT
dpc-4152	257	3	to	to	ADP
dpc-4152	257	4	-	-	PUNCT
dpc-4152	257	5	head	head	NOUN
dpc-4152	257	6	studies	study	NOUN
dpc-4152	257	7	comparing	compare	VERB
dpc-4152	257	8	the	the	DET
dpc-4152	257	9	efficacy	efficacy	NOUN
dpc-4152	257	10	of	of	ADP
dpc-4152	257	11	different	different	ADJ
dpc-4152	257	12	therapeutical	therapeutical	ADJ
dpc-4152	257	13	options	option	NOUN
dpc-4152	257	14	with	with	ADP
dpc-4152	257	15	tirbanibulin	tirbanibulin	PROPN
dpc-4152	257	16	are	be	AUX
dpc-4152	257	17	required	require	VERB
dpc-4152	257	18	to	to	PART
dpc-4152	257	19	further	far	ADV
dpc-4152	257	20	understand	understand	VERB
dpc-4152	257	21	the	the	DET
dpc-4152	257	22	best	good	ADJ
dpc-4152	257	23	positioning	positioning	NOUN
dpc-4152	257	24	of	of	ADP
dpc-4152	257	25	this	this	DET
dpc-4152	257	26	drug	drug	NOUN
dpc-4152	257	27	in	in	ADP
dpc-4152	257	28	a	a	DET
dpc-4152	257	29	real	real	ADJ
dpc-4152	257	30	-	-	PUNCT
dpc-4152	257	31	life	life	NOUN
dpc-4152	257	32	setting	setting	NOUN
dpc-4152	257	33	.	.	PUNCT
dpc-4152	258	1	references	reference	NOUN
dpc-4152	258	2	1	1	NUM
dpc-4152	258	3	.	.	PUNCT
dpc-4152	258	4	werner	werner	PROPN
dpc-4152	258	5	rn	rn	PROPN
dpc-4152	258	6	,	,	PUNCT
dpc-4152	258	7	sammain	sammain	VERB
dpc-4152	258	8	a	a	PRON
dpc-4152	258	9	,	,	PUNCT
dpc-4152	258	10	erdmann	erdmann	NOUN
dpc-4152	258	11	r	r	NOUN
dpc-4152	258	12	,	,	PUNCT
dpc-4152	258	13	hartmann	hartmann	PROPN
dpc-4152	258	14	v	v	PROPN
dpc-4152	258	15	,	,	PUNCT
dpc-4152	258	16	stockfleth	stockfleth	PROPN
dpc-4152	258	17	e	e	NOUN
dpc-4152	258	18	,	,	PUNCT
dpc-4152	258	19	nast	nast	ADJ
dpc-4152	258	20	a.	a.	NOUN
dpc-4152	258	21	the	the	DET
dpc-4152	258	22	natural	natural	ADJ
dpc-4152	258	23	history	history	NOUN
dpc-4152	258	24	of	of	ADP
dpc-4152	258	25	actinic	actinic	ADJ
dpc-4152	258	26	keratosis	keratosis	NOUN
dpc-4152	258	27	:	:	PUNCT
dpc-4152	258	28	a	a	DET
dpc-4152	258	29	systematic	systematic	ADJ
dpc-4152	258	30	review	review	NOUN
dpc-4152	258	31	.	.	PUNCT
dpc-4152	258	32	 	 	SPACE
dpc-4152	259	1	br	br	PROPN
dpc-4152	259	2	j	j	PROPN
dpc-4152	259	3	dermatol	dermatol	NOUN
dpc-4152	259	4	.	.	PUNCT
dpc-4152	260	1	2013;169(3):502	2013;169(3):502	NUM
dpc-4152	260	2	-	-	SYM
dpc-4152	260	3	518	518	NUM
dpc-4152	260	4	.	.	NOUN
dpc-4152	261	1	2	2	NUM
dpc-4152	261	2	.	.	X
dpc-4152	261	3	de	de	X
dpc-4152	261	4	berker	berker	PROPN
dpc-4152	261	5	d	d	PROPN
dpc-4152	261	6	,	,	PUNCT
dpc-4152	261	7	mcgregor	mcgregor	PROPN
dpc-4152	261	8	jm	jm	PROPN
dpc-4152	261	9	,	,	PUNCT
dpc-4152	261	10	mohd	mohd	PROPN
dpc-4152	261	11	mustapa	mustapa	PROPN
dpc-4152	261	12	mf	mf	PROPN
dpc-4152	261	13	,	,	PUNCT
dpc-4152	261	14	exton	exton	PROPN
dpc-4152	261	15	ls	ls	PROPN
dpc-4152	261	16	,	,	PUNCT
dpc-4152	261	17	hughes	hughes	PROPN
dpc-4152	261	18	br	br	PROPN
dpc-4152	261	19	.	.	PUNCT
dpc-4152	262	1	british	british	PROPN
dpc-4152	262	2	association	association	PROPN
dpc-4152	262	3	of	of	ADP
dpc-4152	262	4	dermatologists	dermatologist	NOUN
dpc-4152	262	5	’	'	PUNCT
dpc-4152	262	6	guidelines	guideline	NOUN
dpc-4152	262	7	for	for	ADP
dpc-4152	262	8	the	the	DET
dpc-4152	262	9	care	care	NOUN
dpc-4152	262	10	of	of	ADP
dpc-4152	262	11	patients	patient	NOUN
dpc-4152	262	12	with	with	ADP
dpc-4152	262	13	actinic	actinic	ADJ
dpc-4152	262	14	keratosis	keratosis	NOUN
dpc-4152	262	15	2017	2017	NUM
dpc-4152	262	16	.	.	PUNCT
dpc-4152	262	17	 	 	SPACE
dpc-4152	263	1	br	br	PROPN
dpc-4152	263	2	j	j	PROPN
dpc-4152	263	3	dermatol	dermatol	NOUN
dpc-4152	263	4	.	.	PUNCT
dpc-4152	264	1	2017;176(1):20	2017;176(1):20	NUM
dpc-4152	264	2	-	-	SYM
dpc-4152	264	3	43	43	NUM
dpc-4152	264	4	.	.	NOUN
dpc-4152	264	5	8	8	NUM
dpc-4152	264	6	review	review	NOUN
dpc-4152	264	7	|	|	ADV
dpc-4152	264	8	dermatol	dermatol	ADJ
dpc-4152	264	9	pract	pract	NOUN
dpc-4152	264	10	concept	concept	NOUN
dpc-4152	264	11	.	.	PUNCT
dpc-4152	265	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	265	2	:	:	PUNCT
dpc-4152	265	3	e2024145s	e2024145s	NOUN
dpc-4152	265	4	38	38	NUM
dpc-4152	265	5	.	.	PUNCT
dpc-4152	266	1	t.	t.	PROPN
dpc-4152	266	2	liu	liu	PROPN
dpc-4152	266	3	,	,	PUNCT
dpc-4152	266	4	w.	w.	PROPN
dpc-4152	266	5	hu	hu	PROPN
dpc-4152	266	6	,	,	PUNCT
dpc-4152	266	7	h.j	h.j	PROPN
dpc-4152	266	8	.	.	PROPN
dpc-4152	266	9	dalton	dalton	PROPN
dpc-4152	266	10	,	,	PUNCT
dpc-4152	266	11	  	  	SPACE
dpc-4152	266	12	et	et	PROPN
dpc-4152	266	13	al	al	PROPN
dpc-4152	266	14	.	.	PUNCT
dpc-4152	266	15	targeting	target	VERB
dpc-4152	266	16	src	src	NOUN
dpc-4152	266	17	and	and	CCONJ
dpc-4152	266	18	tubulin	tubulin	NOUN
dpc-4152	266	19	in	in	ADP
dpc-4152	266	20	mucinous	mucinous	ADJ
dpc-4152	266	21	ovarian	ovarian	ADJ
dpc-4152	266	22	carcinoma	carcinoma	NOUN
dpc-4152	266	23	.	.	PUNCT
dpc-4152	267	1	clin	clin	PROPN
dpc-4152	267	2	cancer	cancer	NOUN
dpc-4152	267	3	res	re	VERB
dpc-4152	267	4	off	off	ADP
dpc-4152	267	5	j	j	PROPN
dpc-4152	267	6	am	be	AUX
dpc-4152	267	7	assoc	assoc	PROPN
dpc-4152	267	8	cancer	cancer	NOUN
dpc-4152	267	9	res	re	NOUN
dpc-4152	267	10	.	.	PROPN
dpc-4152	267	11	,	,	PUNCT
dpc-4152	267	12	19	19	NUM
dpc-4152	267	13	(	(	PUNCT
dpc-4152	267	14	2013	2013	NUM
dpc-4152	267	15	)	)	PUNCT
dpc-4152	267	16	.	.	PUNCT
dpc-4152	268	1	39	39	NUM
dpc-4152	268	2	.	.	PUNCT
dpc-4152	269	1	s.	s.	PROPN
dpc-4152	269	2	kim	kim	PROPN
dpc-4152	269	3	,	,	PUNCT
dpc-4152	269	4	a.	a.	PROPN
dpc-4152	269	5	min	min	PROPN
dpc-4152	269	6	,	,	PUNCT
dpc-4152	269	7	k.-h	k.-h	PROPN
dpc-4152	269	8	.	.	PUNCT
dpc-4152	270	1	lee	lee	PROPN
dpc-4152	270	2	,	,	PUNCT
dpc-4152	270	3	  	  	SPACE
dpc-4152	270	4	et	et	PROPN
dpc-4152	270	5	al	al	PROPN
dpc-4152	270	6	.	.	PUNCT
dpc-4152	271	1	antitumor	antitumor	PROPN
dpc-4152	271	2	effect	effect	NOUN
dpc-4152	271	3	of	of	ADP
dpc-4152	271	4	kx-01	kx-01	NOUN
dpc-4152	271	5	through	through	ADP
dpc-4152	271	6	inhibiting	inhibit	VERB
dpc-4152	271	7	src	src	NOUN
dpc-4152	271	8	family	family	NOUN
dpc-4152	271	9	kinases	kinase	NOUN
dpc-4152	271	10	and	and	CCONJ
dpc-4152	271	11	mitosis	mitosis	NOUN
dpc-4152	271	12	.	.	PUNCT
dpc-4152	272	1	cancer	cancer	NOUN
dpc-4152	272	2	res	re	NOUN
dpc-4152	272	3	treat	treat	VERB
dpc-4152	272	4	off	off	ADP
dpc-4152	272	5	j	j	PROPN
dpc-4152	272	6	korean	korean	PROPN
dpc-4152	272	7	cancer	cancer	PROPN
dpc-4152	272	8	assoc	assoc	PROPN
dpc-4152	272	9	.	.	PROPN
dpc-4152	272	10	,	,	PUNCT
dpc-4152	272	11	49	49	NUM
dpc-4152	272	12	(	(	PUNCT
dpc-4152	272	13	2017	2017	NUM
dpc-4152	272	14	)	)	PUNCT
dpc-4152	272	15	,	,	PUNCT
dpc-4152	272	16	pp	pp	PROPN
dpc-4152	272	17	.	.	PUNCT
dpc-4152	273	1	643	643	NUM
dpc-4152	273	2	-	-	SYM
dpc-4152	273	3	655	655	NUM
dpc-4152	273	4	.	.	PUNCT
dpc-4152	274	1	40	40	NUM
dpc-4152	274	2	.	.	PUNCT
dpc-4152	275	1	m.	m.	NOUN
dpc-4152	275	2	anbalagan	anbalagan	PROPN
dpc-4152	275	3	,	,	PUNCT
dpc-4152	275	4	a.	a.	PROPN
dpc-4152	275	5	ali	ali	PROPN
dpc-4152	275	6	,	,	PUNCT
dpc-4152	275	7	r.k	r.k	PROPN
dpc-4152	275	8	.	.	PROPN
dpc-4152	275	9	jones	jones	PROPN
dpc-4152	275	10	,	,	PUNCT
dpc-4152	275	11	c.g	c.g	PROPN
dpc-4152	275	12	.	.	PROPN
dpc-4152	275	13	marsden	marsden	PROPN
dpc-4152	275	14	,	,	PUNCT
dpc-4152	275	15	 	 	SPACE
dpc-4152	275	16	et	et	PROPN
dpc-4152	275	17	al	al	PROPN
dpc-4152	275	18	.	.	PROPN
dpc-4152	276	1	peptidomimetic	peptidomimetic	PROPN
dpc-4152	276	2	src	src	PROPN
dpc-4152	276	3	/	/	SYM
dpc-4152	276	4	pretubulin	pretubulin	ADJ
dpc-4152	276	5	inhibitor	inhibitor	NOUN
dpc-4152	276	6	kx-01	kx-01	ADV
dpc-4152	276	7	alone	alone	ADV
dpc-4152	276	8	and	and	CCONJ
dpc-4152	276	9	in	in	ADP
dpc-4152	276	10	combination	combination	NOUN
dpc-4152	276	11	with	with	ADP
dpc-4152	276	12	paclitaxel	paclitaxel	PROPN
dpc-4152	276	13	suppresses	suppress	VERB
dpc-4152	276	14	growth	growth	NOUN
dpc-4152	276	15	,	,	PUNCT
dpc-4152	276	16	metastasis	metastasis	NOUN
dpc-4152	276	17	in	in	ADP
dpc-4152	276	18	human	human	ADJ
dpc-4152	276	19	er	er	INTJ
dpc-4152	276	20	/	/	SYM
dpc-4152	276	21	pr	pr	NOUN
dpc-4152	276	22	/	/	SYM
dpc-4152	276	23	her2	her2	NOUN
dpc-4152	276	24	-	-	PUNCT
dpc-4152	276	25	negative	negative	ADJ
dpc-4152	276	26	tumor	tumor	NOUN
dpc-4152	276	27	xenografts	xenograft	NOUN
dpc-4152	276	28	.	.	PUNCT
dpc-4152	277	1	mol	mol	ADP
dpc-4152	277	2	cancer	cancer	NOUN
dpc-4152	277	3	ther	ther	PROPN
dpc-4152	277	4	.	.	PUNCT
dpc-4152	278	1	,	,	PUNCT
dpc-4152	278	2	11	11	NUM
dpc-4152	278	3	(	(	PUNCT
dpc-4152	278	4	2012	2012	NUM
dpc-4152	278	5	)	)	PUNCT
dpc-4152	278	6	,	,	PUNCT
dpc-4152	278	7	pp	pp	ADP
dpc-4152	278	8	.	.	PUNCT
dpc-4152	279	1	1936	1936	NUM
dpc-4152	279	2	-	-	SYM
dpc-4152	279	3	1947	1947	NUM
dpc-4152	279	4	.	.	PUNCT
dpc-4152	280	1	41	41	NUM
dpc-4152	280	2	.	.	PUNCT
dpc-4152	280	3	m.	m.	PROPN
dpc-4152	280	4	anbalagan	anbalagan	PROPN
dpc-4152	280	5	,	,	PUNCT
dpc-4152	280	6	l.	l.	PROPN
dpc-4152	280	7	carrier	carrier	PROPN
dpc-4152	280	8	,	,	PUNCT
dpc-4152	280	9	s.	s.	PROPN
dpc-4152	280	10	glodowski	glodowski	PROPN
dpc-4152	280	11	,	,	PUNCT
dpc-4152	280	12	d.	d.	PROPN
dpc-4152	280	13	hangauer	hangauer	PROPN
dpc-4152	280	14	,	,	PUNCT
dpc-4152	280	15	et	et	PROPN
dpc-4152	280	16	al	al	PROPN
dpc-4152	280	17	.	.	PROPN
dpc-4152	281	1	kx-01	kx-01	PROPN
dpc-4152	281	2	,	,	PUNCT
dpc-4152	281	3	a	a	DET
dpc-4152	281	4	novel	novel	ADJ
dpc-4152	281	5	src	src	NOUN
dpc-4152	281	6	kinase	kinase	PROPN
dpc-4152	281	7	inhibitor	inhibitor	NOUN
dpc-4152	281	8	directed	direct	VERB
dpc-4152	281	9	toward	toward	ADP
dpc-4152	281	10	the	the	DET
dpc-4152	281	11	peptide	peptide	NOUN
dpc-4152	281	12	substrate	substrate	NOUN
dpc-4152	281	13	site	site	NOUN
dpc-4152	281	14	,	,	PUNCT
dpc-4152	281	15	synergizes	synergize	VERB
dpc-4152	281	16	with	with	ADP
dpc-4152	281	17	tamoxifen	tamoxifen	NOUN
dpc-4152	281	18	in	in	ADP
dpc-4152	281	19	estrogen	estrogen	NOUN
dpc-4152	281	20	receptor	receptor	NOUN
dpc-4152	281	21	α	α	DET
dpc-4152	281	22	positive	positive	ADJ
dpc-4152	281	23	breast	breast	NOUN
dpc-4152	281	24	cancer	cancer	NOUN
dpc-4152	281	25	.	.	PUNCT
dpc-4152	282	1	breast	breast	NOUN
dpc-4152	282	2	cancer	cancer	NOUN
dpc-4152	282	3	res	re	NOUN
dpc-4152	282	4	treat	treat	NOUN
dpc-4152	282	5	.	.	PUNCT
dpc-4152	283	1	,	,	PUNCT
dpc-4152	283	2	132	132	NUM
dpc-4152	283	3	(	(	PUNCT
dpc-4152	283	4	2012	2012	NUM
dpc-4152	283	5	)	)	PUNCT
dpc-4152	283	6	,	,	PUNCT
dpc-4152	283	7	pp	pp	PROPN
dpc-4152	283	8	.	.	PUNCT
dpc-4152	284	1	391	391	NUM
dpc-4152	284	2	-	-	SYM
dpc-4152	284	3	409	409	NUM
dpc-4152	284	4	.	.	PUNCT
dpc-4152	285	1	42	42	NUM
dpc-4152	285	2	.	.	PUNCT
dpc-4152	285	3	de	de	PROPN
dpc-4152	285	4	berker	berker	PROPN
dpc-4152	286	1	d	d	PROPN
dpc-4152	286	2	,	,	PUNCT
dpc-4152	286	3	mcgregor	mcgregor	PROPN
dpc-4152	286	4	jm	jm	PROPN
dpc-4152	286	5	,	,	PUNCT
dpc-4152	286	6	mohd	mohd	PROPN
dpc-4152	286	7	mustapa	mustapa	PROPN
dpc-4152	286	8	mf	mf	PROPN
dpc-4152	286	9	,	,	PUNCT
dpc-4152	286	10	exton	exton	PROPN
dpc-4152	286	11	ls	ls	PROPN
dpc-4152	286	12	,	,	PUNCT
dpc-4152	286	13	hughes	hughes	PROPN
dpc-4152	286	14	br	br	PROPN
dpc-4152	286	15	.	.	PUNCT
dpc-4152	287	1	british	british	PROPN
dpc-4152	287	2	association	association	PROPN
dpc-4152	287	3	of	of	ADP
dpc-4152	287	4	dermatologists	dermatologist	NOUN
dpc-4152	287	5	’	'	PUNCT
dpc-4152	287	6	guidelines	guideline	NOUN
dpc-4152	287	7	for	for	ADP
dpc-4152	287	8	the	the	DET
dpc-4152	287	9	care	care	NOUN
dpc-4152	287	10	of	of	ADP
dpc-4152	287	11	patients	patient	NOUN
dpc-4152	287	12	with	with	ADP
dpc-4152	287	13	actinic	actinic	ADJ
dpc-4152	287	14	keratosis	keratosis	NOUN
dpc-4152	287	15	2017	2017	NUM
dpc-4152	287	16	.	.	PUNCT
dpc-4152	288	1	br	br	PROPN
dpc-4152	288	2	j	j	PROPN
dpc-4152	288	3	dermatol	dermatol	NOUN
dpc-4152	288	4	.	.	PUNCT
dpc-4152	289	1	2017	2017	NUM
dpc-4152	289	2	jan;176(1):20	jan;176(1):20	PROPN
dpc-4152	289	3	-	-	PUNCT
dpc-4152	289	4	43	43	PROPN
dpc-4152	289	5	.	.	PUNCT
dpc-4152	289	6	doi	doi	NOUN
dpc-4152	289	7	:	:	PUNCT
dpc-4152	289	8	10.1111	10.1111	NUM
dpc-4152	289	9	/	/	SYM
dpc-4152	289	10	bjd.15107	bjd.15107	PROPN
dpc-4152	289	11	.	.	PUNCT
dpc-4152	290	1	pmid	pmid	NOUN
dpc-4152	290	2	:	:	PUNCT
dpc-4152	290	3	28098380	28098380	NUM
dpc-4152	290	4	.	.	PUNCT
dpc-4152	291	1	43	43	NUM
dpc-4152	291	2	.	.	PUNCT
dpc-4152	292	1	schlesinger	schlesinger	PROPN
dpc-4152	292	2	t	t	PROPN
dpc-4152	292	3	,	,	PUNCT
dpc-4152	292	4	stockfleth	stockfleth	PROPN
dpc-4152	292	5	e	e	PROPN
dpc-4152	292	6	,	,	PUNCT
dpc-4152	292	7	grada	grada	PROPN
dpc-4152	292	8	a	a	PROPN
dpc-4152	292	9	,	,	PUNCT
dpc-4152	292	10	et	et	PROPN
dpc-4152	292	11	al	al	PROPN
dpc-4152	292	12	.	.	PROPN
dpc-4152	292	13	tirbanibulin	tirbanibulin	PROPN
dpc-4152	292	14	for	for	ADP
dpc-4152	292	15	actinic	actinic	ADJ
dpc-4152	292	16	keratosis	keratosis	NOUN
dpc-4152	292	17	:	:	PUNCT
dpc-4152	292	18	insights	insight	NOUN
dpc-4152	292	19	into	into	ADP
dpc-4152	292	20	the	the	DET
dpc-4152	292	21	mechanism	mechanism	NOUN
dpc-4152	292	22	of	of	ADP
dpc-4152	292	23	action	action	NOUN
dpc-4152	292	24	.	.	PUNCT
dpc-4152	293	1	clin	clin	PROPN
dpc-4152	293	2	cosmet	cosmet	PROPN
dpc-4152	293	3	investig	investig	NOUN
dpc-4152	293	4	dermatol	dermatol	NOUN
dpc-4152	293	5	.	.	PUNCT
dpc-4152	294	1	2022	2022	NUM
dpc-4152	294	2	nov	nov	NOUN
dpc-4152	294	3	16;15:2495	16;15:2495	NUM
dpc-4152	294	4	-	-	SYM
dpc-4152	294	5	2506	2506	NUM
dpc-4152	294	6	.	.	PUNCT
dpc-4152	295	1	44	44	NUM
dpc-4152	295	2	.	.	PUNCT
dpc-4152	296	1	s.a	s.a	PROPN
dpc-4152	296	2	.	.	PROPN
dpc-4152	296	3	ainger	ainger	PROPN
dpc-4152	296	4	,	,	PUNCT
dpc-4152	296	5	r.a	r.a	PROPN
dpc-4152	296	6	.	.	PROPN
dpc-4152	296	7	sturm	sturm	PROPN
dpc-4152	296	8	.	.	PUNCT
dpc-4152	297	1	src	src	PROPN
dpc-4152	297	2	and	and	CCONJ
dpc-4152	297	3	scc	scc	NOUN
dpc-4152	297	4	:	:	PUNCT
dpc-4152	297	5	getting	get	VERB
dpc-4152	297	6	to	to	ADP
dpc-4152	297	7	the	the	DET
dpc-4152	297	8	faks	faks	PROPN
dpc-4152	297	9	.	.	PUNCT
dpc-4152	298	1	exp	exp	NOUN
dpc-4152	298	2	dermatol	dermatol	NOUN
dpc-4152	298	3	.	.	PUNCT
dpc-4152	298	4	,	,	PUNCT
dpc-4152	298	5	24	24	NUM
dpc-4152	298	6	(	(	PUNCT
dpc-4152	298	7	2015	2015	NUM
dpc-4152	298	8	)	)	PUNCT
dpc-4152	298	9	,	,	PUNCT
dpc-4152	298	10	pp	pp	ADP
dpc-4152	298	11	.	.	PUNCT
dpc-4152	299	1	487	487	NUM
dpc-4152	299	2	-	-	SYM
dpc-4152	299	3	488	488	NUM
dpc-4152	299	4	.	.	PUNCT
dpc-4152	300	1	45	45	NUM
dpc-4152	300	2	.	.	PUNCT
dpc-4152	301	1	kempers	kempers	PROPN
dpc-4152	301	2	s	s	PROPN
dpc-4152	301	3	,	,	PUNCT
dpc-4152	301	4	dubois	dubois	PROPN
dpc-4152	301	5	j	j	PROPN
dpc-4152	301	6	,	,	PUNCT
dpc-4152	301	7	forman	forman	PROPN
dpc-4152	301	8	s.	s.	PROPN
dpc-4152	301	9	,	,	PUNCT
dpc-4152	301	10	et	et	PROPN
dpc-4152	301	11	al	al	PROPN
dpc-4152	301	12	.	.	PROPN
dpc-4152	302	1	tirbanibulin	tirbanibulin	PROPN
dpc-4152	302	2	ointment	ointment	NOUN
dpc-4152	302	3	1	1	NUM
dpc-4152	302	4	%	%	NOUN
dpc-4152	302	5	as	as	ADP
dpc-4152	302	6	a	a	DET
dpc-4152	302	7	novel	novel	ADJ
dpc-4152	302	8	treatment	treatment	NOUN
dpc-4152	302	9	for	for	ADP
dpc-4152	302	10	actinic	actinic	ADJ
dpc-4152	302	11	keratosis	keratosis	NOUN
dpc-4152	302	12	:	:	PUNCT
dpc-4152	302	13	phase	phase	NOUN
dpc-4152	302	14	1	1	NUM
dpc-4152	302	15	and	and	CCONJ
dpc-4152	302	16	2	2	NUM
dpc-4152	302	17	results	result	NOUN
dpc-4152	302	18	.	.	PUNCT
dpc-4152	303	1	j	j	NOUN
dpc-4152	303	2	drugs	drug	NOUN
dpc-4152	303	3	dermatol	dermatol	NOUN
dpc-4152	303	4	.	.	PUNCT
dpc-4152	304	1	2020	2020	NUM
dpc-4152	304	2	nov	nov	PROPN
dpc-4152	304	3	1;19(11):1093	1;19(11):1093	NUM
dpc-4152	304	4	-	-	SYM
dpc-4152	304	5	1100	1100	NUM
dpc-4152	304	6	.	.	PUNCT
dpc-4152	305	1	46	46	NUM
dpc-4152	305	2	.	.	PUNCT
dpc-4152	305	3	blauvelt	blauvelt	VERB
dpc-4152	305	4	a	a	PRON
dpc-4152	305	5	,	,	PUNCT
dpc-4152	305	6	kempers	kemper	NOUN
dpc-4152	305	7	s	s	PROPN
dpc-4152	305	8	,	,	PUNCT
dpc-4152	305	9	lain	lain	PROPN
dpc-4152	305	10	e	e	NOUN
dpc-4152	305	11	,	,	PUNCT
dpc-4152	305	12	et	et	PROPN
dpc-4152	305	13	al	al	PROPN
dpc-4152	305	14	.	.	PROPN
dpc-4152	305	15	phase	phase	PROPN
dpc-4152	305	16	3	3	NUM
dpc-4152	305	17	tirbanibulin	tirbanibulin	NOUN
dpc-4152	305	18	for	for	ADP
dpc-4152	305	19	actinic	actinic	ADJ
dpc-4152	305	20	keratosis	keratosis	NOUN
dpc-4152	305	21	group	group	NOUN
dpc-4152	305	22	.	.	PUNCT
dpc-4152	306	1	phase	phase	NOUN
dpc-4152	306	2	3	3	NUM
dpc-4152	306	3	trials	trial	NOUN
dpc-4152	306	4	of	of	ADP
dpc-4152	306	5	tirbanibulin	tirbanibulin	PROPN
dpc-4152	306	6	ointment	ointment	NOUN
dpc-4152	306	7	for	for	ADP
dpc-4152	306	8	actinic	actinic	ADJ
dpc-4152	306	9	keratosis	keratosis	NOUN
dpc-4152	306	10	.	.	PUNCT
dpc-4152	307	1	n	n	PROPN
dpc-4152	307	2	engl	engl	PROPN
dpc-4152	307	3	j	j	PROPN
dpc-4152	307	4	med	med	PROPN
dpc-4152	307	5	.	.	PUNCT
dpc-4152	308	1	2021	2021	NUM
dpc-4152	308	2	feb	feb	PROPN
dpc-4152	308	3	11;384(6):512	11;384(6):512	NUM
dpc-4152	308	4	-	-	SYM
dpc-4152	308	5	520	520	NUM
dpc-4152	308	6	.	.	PUNCT
dpc-4152	308	7	47	47	NUM
dpc-4152	308	8	.	.	PUNCT
dpc-4152	309	1	kirchberger	kirchberger	PROPN
dpc-4152	309	2	mc	mc	PROPN
dpc-4152	309	3	,	,	PUNCT
dpc-4152	309	4	gfesser	gfesser	PROPN
dpc-4152	309	5	m	m	PROPN
dpc-4152	309	6	,	,	PUNCT
dpc-4152	309	7	erdmann	erdmann	PROPN
dpc-4152	309	8	m	m	PROPN
dpc-4152	309	9	,	,	PUNCT
dpc-4152	309	10	schliep	schliep	PROPN
dpc-4152	309	11	s	s	NOUN
dpc-4152	309	12	,	,	PUNCT
dpc-4152	309	13	berking	berke	VERB
dpc-4152	309	14	c	c	NOUN
dpc-4152	309	15	,	,	PUNCT
dpc-4152	309	16	heppt	heppt	ADJ
dpc-4152	309	17	mv	mv	PROPN
dpc-4152	309	18	.	.	PROPN
dpc-4152	310	1	tirbanibulin	tirbanibulin	PROPN
dpc-4152	310	2	1	1	NUM
dpc-4152	310	3	%	%	NOUN
dpc-4152	310	4	ointment	ointment	NOUN
dpc-4152	310	5	significantly	significantly	ADV
dpc-4152	310	6	reduces	reduce	VERB
dpc-4152	310	7	the	the	DET
dpc-4152	310	8	actinic	actinic	ADJ
dpc-4152	310	9	keratosis	keratosis	NOUN
dpc-4152	310	10	area	area	NOUN
dpc-4152	310	11	and	and	CCONJ
dpc-4152	310	12	severity	severity	NOUN
dpc-4152	310	13	index	index	NOUN
dpc-4152	310	14	in	in	ADP
dpc-4152	310	15	patients	patient	NOUN
dpc-4152	310	16	with	with	ADP
dpc-4152	310	17	actinic	actinic	ADJ
dpc-4152	310	18	keratosis	keratosis	NOUN
dpc-4152	310	19	:	:	PUNCT
dpc-4152	310	20	results	result	NOUN
dpc-4152	310	21	from	from	ADP
dpc-4152	310	22	a	a	DET
dpc-4152	310	23	real	real	ADJ
dpc-4152	310	24	-	-	PUNCT
dpc-4152	310	25	world	world	NOUN
dpc-4152	310	26	study	study	NOUN
dpc-4152	310	27	.	.	PUNCT
dpc-4152	310	28	  	  	SPACE
dpc-4152	311	1	j	j	PROPN
dpc-4152	311	2	clin	clin	PROPN
dpc-4152	311	3	med	me	VERB
dpc-4152	311	4	.	.	PUNCT
dpc-4152	312	1	2023;12(14):4837	2023;12(14):4837	NUM
dpc-4152	312	2	.	.	PUNCT
dpc-4152	313	1	published	publish	VERB
dpc-4152	313	2	2023	2023	NUM
dpc-4152	313	3	jul	jul	PROPN
dpc-4152	313	4	22	22	NUM
dpc-4152	313	5	.	.	PUNCT
dpc-4152	314	1	48	48	NUM
dpc-4152	314	2	.	.	PUNCT
dpc-4152	315	1	campione	campione	PROPN
dpc-4152	315	2	e	e	PROPN
dpc-4152	315	3	,	,	PUNCT
dpc-4152	315	4	rivieccio	rivieccio	VERB
dpc-4152	315	5	a	a	PRON
dpc-4152	315	6	,	,	PUNCT
dpc-4152	315	7	gaeta	gaeta	PROPN
dpc-4152	315	8	shumak	shumak	PROPN
dpc-4152	315	9	r	r	PROPN
dpc-4152	315	10	,	,	PUNCT
dpc-4152	315	11	et	et	PROPN
dpc-4152	315	12	al	al	PROPN
dpc-4152	315	13	.	.	PROPN
dpc-4152	316	1	preliminary	preliminary	ADJ
dpc-4152	316	2	evidence	evidence	NOUN
dpc-4152	316	3	of	of	ADP
dpc-4152	316	4	efficacy	efficacy	NOUN
dpc-4152	316	5	,	,	PUNCT
dpc-4152	316	6	safety	safety	NOUN
dpc-4152	316	7	,	,	PUNCT
dpc-4152	316	8	and	and	CCONJ
dpc-4152	316	9	treatment	treatment	NOUN
dpc-4152	316	10	satisfaction	satisfaction	NOUN
dpc-4152	316	11	with	with	ADP
dpc-4152	316	12	tirbanibulin	tirbanibulin	PROPN
dpc-4152	316	13	1	1	NUM
dpc-4152	316	14	%	%	NOUN
dpc-4152	316	15	ointment	ointment	NOUN
dpc-4152	316	16	:	:	PUNCT
dpc-4152	316	17	a	a	DET
dpc-4152	316	18	clinical	clinical	ADJ
dpc-4152	316	19	perspective	perspective	NOUN
dpc-4152	316	20	on	on	ADP
dpc-4152	316	21	actinic	actinic	ADJ
dpc-4152	316	22	keratoses	keratose	NOUN
dpc-4152	316	23	.	.	PUNCT
dpc-4152	317	1	pharmaceuticals	pharmaceutical	NOUN
dpc-4152	317	2	(	(	PUNCT
dpc-4152	317	3	basel	basel	PROPN
dpc-4152	317	4	)	)	PUNCT
dpc-4152	317	5	.	.	PUNCT
dpc-4152	318	1	2023;16(12):1686	2023;16(12):1686	NUM
dpc-4152	318	2	.	.	NOUN
dpc-4152	318	3	published	publish	VERB
dpc-4152	318	4	2023	2023	NUM
dpc-4152	318	5	dec	dec	PROPN
dpc-4152	318	6	4	4	NUM
dpc-4152	318	7	.	.	NUM
dpc-4152	318	8	49	49	NUM
dpc-4152	318	9	.	.	PUNCT
dpc-4152	319	1	li	li	PROPN
dpc-4152	319	2	pomi	pomi	PROPN
dpc-4152	319	3	f	f	PROPN
dpc-4152	319	4	,	,	PUNCT
dpc-4152	319	5	vaccaro	vaccaro	PROPN
dpc-4152	319	6	m	m	PROPN
dpc-4152	319	7	,	,	PUNCT
dpc-4152	319	8	pallio	pallio	NOUN
dpc-4152	319	9	g	g	NOUN
dpc-4152	319	10	,	,	PUNCT
dpc-4152	319	11	rottura	rottura	NOUN
dpc-4152	319	12	m	m	PROPN
dpc-4152	319	13	,	,	PUNCT
dpc-4152	319	14	irrera	irrera	NOUN
dpc-4152	319	15	n	n	CCONJ
dpc-4152	319	16	,	,	PUNCT
dpc-4152	320	1	borgia	borgia	PROPN
dpc-4152	320	2	f.	f.	PROPN
dpc-4152	320	3	tirbanibulin	tirbanibulin	PROPN
dpc-4152	320	4	1	1	NUM
dpc-4152	320	5	%	%	NOUN
dpc-4152	320	6	ointment	ointment	NOUN
dpc-4152	320	7	for	for	ADP
dpc-4152	320	8	actinic	actinic	ADJ
dpc-4152	320	9	keratosis	keratosis	NOUN
dpc-4152	320	10	:	:	PUNCT
dpc-4152	320	11	results	result	NOUN
dpc-4152	320	12	from	from	ADP
dpc-4152	320	13	a	a	DET
dpc-4152	320	14	real	real	ADJ
dpc-4152	320	15	-	-	PUNCT
dpc-4152	320	16	life	life	NOUN
dpc-4152	320	17	study	study	NOUN
dpc-4152	320	18	.	.	PUNCT
dpc-4152	321	1	medicina	medicina	PROPN
dpc-4152	321	2	(	(	PUNCT
dpc-4152	321	3	kaunas	kaunas	PROPN
dpc-4152	321	4	)	)	PUNCT
dpc-4152	321	5	.	.	PUNCT
dpc-4152	322	1	2024;60(2):225	2024;60(2):225	NOUN
dpc-4152	322	2	.	.	PUNCT
dpc-4152	323	1	published	publish	VERB
dpc-4152	323	2	2024	2024	NUM
dpc-4152	323	3	jan	jan	PROPN
dpc-4152	323	4	28	28	NUM
dpc-4152	323	5	.	.	PUNCT
dpc-4152	324	1	50	50	NUM
dpc-4152	324	2	.	.	PUNCT
dpc-4152	325	1	markham	markham	PROPN
dpc-4152	325	2	a	a	PROPN
dpc-4152	325	3	,	,	PUNCT
dpc-4152	325	4	duggan	duggan	PROPN
dpc-4152	325	5	s.	s.	PROPN
dpc-4152	325	6	tirbanibulin	tirbanibulin	PROPN
dpc-4152	325	7	:	:	PUNCT
dpc-4152	325	8	first	first	ADJ
dpc-4152	325	9	approval	approval	NOUN
dpc-4152	325	10	.	.	PUNCT
dpc-4152	325	11	 	 	SPACE
dpc-4152	326	1	drugs	drug	NOUN
dpc-4152	326	2	.	.	PUNCT
dpc-4152	326	3	 	 	SPACE
dpc-4152	326	4	2021	2021	NUM
dpc-4152	326	5	mar;81(4	mar;81(4	NOUN
dpc-4152	326	6	):	):	PUNCT
dpc-4152	326	7	509	509	NUM
dpc-4152	326	8	-	-	SYM
dpc-4152	326	9	13	13	NUM
dpc-4152	326	10	.	.	PUNCT
dpc-4152	326	11	51	51	NUM
dpc-4152	326	12	.	.	PUNCT
dpc-4152	327	1	gilaberte	gilaberte	PROPN
dpc-4152	327	2	y	y	PROPN
dpc-4152	327	3	,	,	PUNCT
dpc-4152	327	4	fernández	fernández	PROPN
dpc-4152	327	5	-	-	PUNCT
dpc-4152	327	6	figueras	figueras	PROPN
dpc-4152	327	7	mt	mt	PROPN
dpc-4152	327	8	.	.	PUNCT
dpc-4152	328	1	tirbanibulin	tirbanibulin	PROPN
dpc-4152	328	2	:	:	PUNCT
dpc-4152	328	3	review	review	NOUN
dpc-4152	328	4	of	of	ADP
dpc-4152	328	5	its	its	PRON
dpc-4152	328	6	novel	novel	ADJ
dpc-4152	328	7	mechanism	mechanism	NOUN
dpc-4152	328	8	of	of	ADP
dpc-4152	328	9	action	action	NOUN
dpc-4152	328	10	and	and	CCONJ
dpc-4152	328	11	how	how	SCONJ
dpc-4152	328	12	it	it	PRON
dpc-4152	328	13	fits	fit	VERB
dpc-4152	328	14	into	into	ADP
dpc-4152	328	15	the	the	DET
dpc-4152	328	16	treatment	treatment	NOUN
dpc-4152	328	17	of	of	ADP
dpc-4152	328	18	actinic	actinic	ADJ
dpc-4152	328	19	keratosis	keratosis	NOUN
dpc-4152	328	20	.	.	PUNCT
dpc-4152	329	1	tirbanibulina	tirbanibulina	NOUN
dpc-4152	329	2	:	:	PUNCT
dpc-4152	329	3	revisión	revisión	PROPN
dpc-4152	329	4	de	de	PROPN
dpc-4152	329	5	su	su	PROPN
dpc-4152	329	6	mecanismo	mecanismo	PROPN
dpc-4152	329	7	de	de	PROPN
dpc-4152	329	8	acción	acción	PROPN
dpc-4152	329	9	novedoso	novedoso	PROPN
dpc-4152	329	10	y	y	PROPN
dpc-4152	329	11	de	de	PROPN
dpc-4152	329	12	cómo	cómo	PROPN
dpc-4152	329	13	encaja	encaja	PROPN
dpc-4152	329	14	en	en	PROPN
dpc-4152	329	15	el	el	PROPN
dpc-4152	329	16	tratamiento	tratamiento	PROPN
dpc-4152	329	17	de	de	PROPN
dpc-4152	329	18	la	la	PROPN
dpc-4152	329	19	queratosis	queratosis	NOUN
dpc-4152	329	20	actínica	actínica	NOUN
dpc-4152	329	21	.	.	PUNCT
dpc-4152	330	1	actas	actas	PROPN
dpc-4152	330	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-4152	330	3	.	.	PUNCT
dpc-4152	331	1	2022;113(1):58	2022;113(1):58	X
dpc-4152	331	2	-	-	SYM
dpc-4152	331	3	66	66	NUM
dpc-4152	331	4	.	.	PUNCT
dpc-4152	332	1	52	52	NUM
dpc-4152	332	2	.	.	PUNCT
dpc-4152	333	1	goldenberg	goldenberg	PROPN
dpc-4152	333	2	g.	g.	PROPN
dpc-4152	333	3	treatment	treatment	NOUN
dpc-4152	333	4	considerations	consideration	NOUN
dpc-4152	333	5	in	in	ADP
dpc-4152	333	6	actinic	actinic	ADJ
dpc-4152	333	7	keratosis	keratosis	NOUN
dpc-4152	333	8	.	.	PUNCT
dpc-4152	334	1	j	j	PROPN
dpc-4152	334	2	eur	eur	PROPN
dpc-4152	334	3	acad	acad	PROPN
dpc-4152	334	4	dermatol	dermatol	NOUN
dpc-4152	334	5	venereol	venereol	NOUN
dpc-4152	334	6	.	.	PUNCT
dpc-4152	335	1	2017;31(suppl2):12–16	2017;31(suppl2):12–16	NOUN
dpc-4152	335	2	.	.	PUNCT
dpc-4152	336	1	53	53	NUM
dpc-4152	336	2	.	.	PUNCT
dpc-4152	337	1	grada	grada	PROPN
dpc-4152	337	2	a	a	PROPN
dpc-4152	337	3	,	,	PUNCT
dpc-4152	337	4	feldman	feldman	PROPN
dpc-4152	337	5	sr	sr	PROPN
dpc-4152	337	6	,	,	PUNCT
dpc-4152	337	7	bragazzi	bragazzi	PROPN
dpc-4152	337	8	nl	nl	PROPN
dpc-4152	337	9	,	,	PUNCT
dpc-4152	337	10	et	et	PROPN
dpc-4152	337	11	al	al	PROPN
dpc-4152	337	12	.	.	PUNCT
dpc-4152	337	13	patient	patient	NOUN
dpc-4152	337	14	-	-	PUNCT
dpc-4152	337	15	reported	report	VERB
dpc-4152	337	16	outcomes	outcome	NOUN
dpc-4152	337	17	of	of	ADP
dpc-4152	337	18	topical	topical	ADJ
dpc-4152	337	19	therapies	therapy	NOUN
dpc-4152	337	20	in	in	ADP
dpc-4152	337	21	actinic	actinic	ADJ
dpc-4152	337	22	keratosis	keratosis	NOUN
dpc-4152	337	23	:	:	PUNCT
dpc-4152	337	24	a	a	DET
dpc-4152	337	25	systematic	systematic	ADJ
dpc-4152	337	26	review	review	NOUN
dpc-4152	337	27	.	.	PUNCT
dpc-4152	338	1	dermatol	dermatol	NOUN
dpc-4152	338	2	ther	ther	ADV
dpc-4152	338	3	.	.	PUNCT
dpc-4152	339	1	2021	2021	NUM
dpc-4152	339	2	mar;34(2):e14833	mar;34(2):e14833	NOUN
dpc-4152	339	3	.	.	PUNCT
dpc-4152	340	1	54	54	NUM
dpc-4152	340	2	.	.	PUNCT
dpc-4152	340	3	l.	l.	PROPN
dpc-4152	340	4	niu	niu	PROPN
dpc-4152	340	5	,	,	PUNCT
dpc-4152	340	6	j.	j.	PROPN
dpc-4152	340	7	yang	yang	PROPN
dpc-4152	340	8	,	,	PUNCT
dpc-4152	340	9	w.	w.	PROPN
dpc-4152	340	10	yan	yan	PROPN
dpc-4152	340	11	,	,	PUNCT
dpc-4152	340	12	et	et	PROPN
dpc-4152	340	13	al	al	PROPN
dpc-4152	340	14	.	.	PUNCT
dpc-4152	341	1	reversible	reversible	ADJ
dpc-4152	341	2	binding	binding	NOUN
dpc-4152	341	3	of	of	ADP
dpc-4152	341	4	the	the	DET
dpc-4152	341	5	anticancer	anticancer	NOUN
dpc-4152	341	6	drug	drug	NOUN
dpc-4152	341	7	kxo1	kxo1	PROPN
dpc-4152	341	8	(	(	PUNCT
dpc-4152	341	9	tirbanibulin	tirbanibulin	PROPN
dpc-4152	341	10	)	)	PUNCT
dpc-4152	341	11	to	to	ADP
dpc-4152	341	12	the	the	DET
dpc-4152	341	13	colchicine	colchicine	NOUN
dpc-4152	341	14	-	-	PUNCT
dpc-4152	341	15	binding	bind	VERB
dpc-4152	341	16	site	site	NOUN
dpc-4152	341	17	of	of	ADP
dpc-4152	341	18	veterans	veteran	NOUN
dpc-4152	341	19	affairs	affairs	PROPN
dpc-4152	341	20	topical	topical	ADJ
dpc-4152	341	21	tretinoin	tretinoin	PROPN
dpc-4152	341	22	chemoprevention	chemoprevention	NOUN
dpc-4152	341	23	trial	trial	NOUN
dpc-4152	341	24	.	.	PUNCT
dpc-4152	341	25	 	 	SPACE
dpc-4152	341	26	cancer	cancer	NOUN
dpc-4152	341	27	.	.	PUNCT
dpc-4152	342	1	2009;115(11):2523	2009;115(11):2523	NUM
dpc-4152	342	2	-	-	SYM
dpc-4152	342	3	2530	2530	NUM
dpc-4152	342	4	.	.	PUNCT
dpc-4152	343	1	22	22	NUM
dpc-4152	343	2	.	.	PUNCT
dpc-4152	343	3	marks	mark	VERB
dpc-4152	343	4	r	r	NOUN
dpc-4152	343	5	,	,	PUNCT
dpc-4152	343	6	rennie	rennie	PROPN
dpc-4152	343	7	g	g	PROPN
dpc-4152	343	8	,	,	PUNCT
dpc-4152	343	9	selwood	selwood	NOUN
dpc-4152	343	10	ts	ts	PROPN
dpc-4152	343	11	.	.	PUNCT
dpc-4152	344	1	malignant	malignant	ADJ
dpc-4152	344	2	transformation	transformation	NOUN
dpc-4152	344	3	of	of	ADP
dpc-4152	344	4	solar	solar	ADJ
dpc-4152	344	5	keratoses	keratose	NOUN
dpc-4152	344	6	to	to	ADP
dpc-4152	344	7	squamous	squamous	ADJ
dpc-4152	344	8	cell	cell	NOUN
dpc-4152	344	9	carcinoma	carcinoma	NOUN
dpc-4152	344	10	.	.	PUNCT
dpc-4152	344	11	  	  	SPACE
dpc-4152	345	1	lancet	lancet	NOUN
dpc-4152	345	2	.	.	PUNCT
dpc-4152	346	1	1988;1(8589):795	1988;1(8589):795	NUM
dpc-4152	346	2	-	-	SYM
dpc-4152	346	3	797	797	NUM
dpc-4152	346	4	.	.	PUNCT
dpc-4152	347	1	23	23	NUM
dpc-4152	347	2	.	.	PUNCT
dpc-4152	348	1	dodson	dodson	PROPN
dpc-4152	348	2	jm	jm	PROPN
dpc-4152	348	3	,	,	PUNCT
dpc-4152	348	4	despain	despain	PROPN
dpc-4152	348	5	j	j	PROPN
dpc-4152	348	6	,	,	PUNCT
dpc-4152	348	7	hewett	hewett	PROPN
dpc-4152	348	8	je	je	PROPN
dpc-4152	348	9	,	,	PUNCT
dpc-4152	348	10	clark	clark	PROPN
dpc-4152	348	11	dp	dp	PROPN
dpc-4152	348	12	.	.	PUNCT
dpc-4152	348	13	malignant	malignant	ADJ
dpc-4152	348	14	potential	potential	NOUN
dpc-4152	348	15	of	of	ADP
dpc-4152	348	16	actinic	actinic	ADJ
dpc-4152	348	17	keratoses	keratose	NOUN
dpc-4152	348	18	and	and	CCONJ
dpc-4152	348	19	the	the	DET
dpc-4152	348	20	controversy	controversy	NOUN
dpc-4152	348	21	over	over	ADP
dpc-4152	348	22	treatment	treatment	NOUN
dpc-4152	348	23	.	.	PUNCT
dpc-4152	349	1	a	a	DET
dpc-4152	349	2	patient	patient	NOUN
dpc-4152	349	3	-	-	PUNCT
dpc-4152	349	4	oriented	orient	VERB
dpc-4152	349	5	perspective	perspective	NOUN
dpc-4152	349	6	.	.	PUNCT
dpc-4152	349	7	  	  	SPACE
dpc-4152	349	8	arch	arch	ADJ
dpc-4152	349	9	dermatol	dermatol	NOUN
dpc-4152	349	10	.	.	PUNCT
dpc-4152	350	1	1991;127(7	1991;127(7	NUM
dpc-4152	350	2	):	):	PUNCT
dpc-4152	350	3	1029	1029	NUM
dpc-4152	350	4	-	-	SYM
dpc-4152	350	5	1031	1031	NUM
dpc-4152	350	6	.	.	PUNCT
dpc-4152	351	1	24	24	NUM
dpc-4152	351	2	.	.	PUNCT
dpc-4152	352	1	heppt	heppt	ADJ
dpc-4152	352	2	mv	mv	PROPN
dpc-4152	352	3	,	,	PUNCT
dpc-4152	352	4	dykukha	dykukha	ADJ
dpc-4152	352	5	i	i	PROPN
dpc-4152	352	6	,	,	PUNCT
dpc-4152	352	7	graziadio	graziadio	PROPN
dpc-4152	352	8	s	s	PROPN
dpc-4152	352	9	,	,	PUNCT
dpc-4152	352	10	salido	salido	PROPN
dpc-4152	352	11	-	-	PUNCT
dpc-4152	352	12	vallejo	vallejo	PROPN
dpc-4152	352	13	r	r	PROPN
dpc-4152	352	14	,	,	PUNCT
dpc-4152	352	15	et	et	PROPN
dpc-4152	352	16	al	al	PROPN
dpc-4152	352	17	.	.	PROPN
dpc-4152	352	18	comparative	comparative	ADJ
dpc-4152	352	19	efficacy	efficacy	NOUN
dpc-4152	352	20	and	and	CCONJ
dpc-4152	352	21	safety	safety	NOUN
dpc-4152	352	22	of	of	ADP
dpc-4152	352	23	tirbanibulin	tirbanibulin	PRON
dpc-4152	352	24	for	for	ADP
dpc-4152	352	25	actinic	actinic	ADJ
dpc-4152	352	26	keratosis	keratosis	NOUN
dpc-4152	352	27	of	of	ADP
dpc-4152	352	28	the	the	DET
dpc-4152	352	29	face	face	NOUN
dpc-4152	352	30	and	and	CCONJ
dpc-4152	352	31	scalp	scalp	NOUN
dpc-4152	352	32	in	in	ADP
dpc-4152	352	33	europe	europe	PROPN
dpc-4152	352	34	:	:	PUNCT
dpc-4152	352	35	a	a	DET
dpc-4152	352	36	systematic	systematic	ADJ
dpc-4152	352	37	review	review	NOUN
dpc-4152	352	38	and	and	CCONJ
dpc-4152	352	39	network	network	NOUN
dpc-4152	352	40	meta	meta	ADJ
dpc-4152	352	41	-	-	PUNCT
dpc-4152	352	42	analysis	analysis	NOUN
dpc-4152	352	43	of	of	ADP
dpc-4152	352	44	randomized	randomized	ADJ
dpc-4152	352	45	controlled	control	VERB
dpc-4152	352	46	trials	trial	NOUN
dpc-4152	352	47	.	.	PUNCT
dpc-4152	353	1	j	j	PROPN
dpc-4152	353	2	clin	clin	PROPN
dpc-4152	353	3	med	med	PROPN
dpc-4152	353	4	.	.	PUNCT
dpc-4152	354	1	2022	2022	NUM
dpc-4152	354	2	mar	mar	PROPN
dpc-4152	354	3	16;11(6):1654	16;11(6):1654	NUM
dpc-4152	354	4	.	.	PUNCT
dpc-4152	355	1	25	25	NUM
dpc-4152	355	2	.	.	PUNCT
dpc-4152	355	3	olsen	olsen	PROPN
dpc-4152	355	4	ea	ea	PROPN
dpc-4152	355	5	,	,	PUNCT
dpc-4152	355	6	abernethy	abernethy	ADJ
dpc-4152	355	7	ml	ml	NOUN
dpc-4152	355	8	,	,	PUNCT
dpc-4152	355	9	kulp	kulp	NOUN
dpc-4152	355	10	-	-	PUNCT
dpc-4152	355	11	shorten	shorten	NOUN
dpc-4152	355	12	c	c	NOUN
dpc-4152	355	13	,	,	PUNCT
dpc-4152	355	14	et	et	PROPN
dpc-4152	355	15	al	al	PROPN
dpc-4152	355	16	.	.	PUNCT
dpc-4152	356	1	a	a	DET
dpc-4152	356	2	double	double	ADJ
dpc-4152	356	3	-	-	PUNCT
dpc-4152	356	4	blind	blind	ADJ
dpc-4152	356	5	,	,	PUNCT
dpc-4152	356	6	vehicle	vehicle	NOUN
dpc-4152	356	7	-	-	PUNCT
dpc-4152	356	8	controlled	control	VERB
dpc-4152	356	9	study	study	NOUN
dpc-4152	356	10	evaluating	evaluate	VERB
dpc-4152	356	11	masoprocol	masoprocol	ADJ
dpc-4152	356	12	cream	cream	NOUN
dpc-4152	356	13	in	in	ADP
dpc-4152	356	14	the	the	DET
dpc-4152	356	15	treatment	treatment	NOUN
dpc-4152	356	16	of	of	ADP
dpc-4152	356	17	actinic	actinic	ADJ
dpc-4152	356	18	keratoses	keratose	NOUN
dpc-4152	356	19	on	on	ADP
dpc-4152	356	20	the	the	DET
dpc-4152	356	21	head	head	NOUN
dpc-4152	356	22	and	and	CCONJ
dpc-4152	356	23	neck	neck	NOUN
dpc-4152	356	24	.	.	PUNCT
dpc-4152	357	1	j	j	PROPN
dpc-4152	357	2	am	be	AUX
dpc-4152	357	3	acad	acad	ADJ
dpc-4152	357	4	dermatol	dermatol	NOUN
dpc-4152	357	5	.	.	PUNCT
dpc-4152	358	1	1991	1991	NUM
dpc-4152	358	2	may;24(5	may;24(5	NOUN
dpc-4152	358	3	pt	pt	PROPN
dpc-4152	358	4	1):738	1):738	PROPN
dpc-4152	358	5	-	-	SYM
dpc-4152	358	6	43	43	NUM
dpc-4152	358	7	.	.	PUNCT
dpc-4152	359	1	pmid	pmid	NOUN
dpc-4152	359	2	:	:	PUNCT
dpc-4152	359	3	1869646	1869646	NUM
dpc-4152	359	4	.	.	PUNCT
dpc-4152	360	1	26	26	NUM
dpc-4152	360	2	.	.	PUNCT
dpc-4152	361	1	rowert	rowert	PROPN
dpc-4152	361	2	-	-	PUNCT
dpc-4152	361	3	huber	huber	PROPN
dpc-4152	361	4	j.	j.	PROPN
dpc-4152	361	5	,	,	PUNCT
dpc-4152	361	6	patel	patel	PROPN
dpc-4152	361	7	m.j	m.j	PROPN
dpc-4152	361	8	.	.	PROPN
dpc-4152	361	9	,	,	PUNCT
dpc-4152	361	10	forschner	forschner	PROPN
dpc-4152	361	11	t.	t.	PROPN
dpc-4152	361	12	,	,	PUNCT
dpc-4152	361	13	et	et	PROPN
dpc-4152	361	14	al	al	PROPN
dpc-4152	361	15	.	.	PROPN
dpc-4152	361	16	actinic	actinic	ADJ
dpc-4152	361	17	keratosis	keratosis	NOUN
dpc-4152	361	18	is	be	AUX
dpc-4152	361	19	an	an	DET
dpc-4152	361	20	early	early	ADJ
dpc-4152	361	21	in	in	ADP
dpc-4152	361	22	situ	situ	ADJ
dpc-4152	361	23	squamous	squamous	ADJ
dpc-4152	361	24	cell	cell	NOUN
dpc-4152	361	25	carcinoma	carcinoma	NOUN
dpc-4152	361	26	:	:	PUNCT
dpc-4152	361	27	a	a	DET
dpc-4152	361	28	proposal	proposal	NOUN
dpc-4152	361	29	for	for	ADP
dpc-4152	361	30	reclassification	reclassification	NOUN
dpc-4152	361	31	.	.	PUNCT
dpc-4152	361	32	 	 	SPACE
dpc-4152	362	1	br	br	PROPN
dpc-4152	362	2	.	.	PUNCT
dpc-4152	363	1	j.	j.	PROPN
dpc-4152	363	2	dermatol	dermatol	PROPN
dpc-4152	363	3	.	.	PUNCT
dpc-4152	363	4	 	 	SPACE
dpc-4152	364	1	2007;156(suppl	2007;156(suppl	NUM
dpc-4152	364	2	.	.	PUNCT
dpc-4152	364	3	s3):8–12	s3):8–12	NOUN
dpc-4152	364	4	.	.	PUNCT
dpc-4152	365	1	27	27	NUM
dpc-4152	365	2	.	.	PUNCT
dpc-4152	366	1	casari	casari	PROPN
dpc-4152	366	2	a	a	X
dpc-4152	366	3	,	,	PUNCT
dpc-4152	366	4	chester	chester	PROPN
dpc-4152	366	5	j	j	PROPN
dpc-4152	366	6	,	,	PUNCT
dpc-4152	366	7	pellacani	pellacani	PROPN
dpc-4152	366	8	g.	g.	PROPN
dpc-4152	366	9	actinic	actinic	ADJ
dpc-4152	366	10	keratosis	keratosis	PROPN
dpc-4152	366	11	and	and	CCONJ
dpc-4152	366	12	non	non	ADJ
dpc-4152	366	13	invasive	invasive	ADJ
dpc-4152	366	14	diagnostic	diagnostic	ADJ
dpc-4152	366	15	techniques	technique	NOUN
dpc-4152	366	16	:	:	PUNCT
dpc-4152	366	17	an	an	DET
dpc-4152	366	18	update	update	NOUN
dpc-4152	366	19	.	.	PUNCT
dpc-4152	367	1	biomedicines	biomedicine	NOUN
dpc-4152	367	2	.	.	PUNCT
dpc-4152	368	1	2018	2018	NUM
dpc-4152	368	2	jan	jan	NOUN
dpc-4152	368	3	8;6(1):8	8;6(1):8	NUM
dpc-4152	368	4	.	.	NOUN
dpc-4152	368	5	28	28	NUM
dpc-4152	368	6	.	.	PUNCT
dpc-4152	369	1	slaughter	slaughter	PROPN
dpc-4152	369	2	dp	dp	PROPN
dpc-4152	369	3	,	,	PUNCT
dpc-4152	369	4	southwick	southwick	PROPN
dpc-4152	369	5	hw	hw	PROPN
dpc-4152	369	6	,	,	PUNCT
dpc-4152	369	7	smejkal	smejkal	PROPN
dpc-4152	369	8	w.	w.	PROPN
dpc-4152	369	9	field	field	PROPN
dpc-4152	369	10	cancerization	cancerization	NOUN
dpc-4152	369	11	in	in	ADP
dpc-4152	369	12	oral	oral	ADJ
dpc-4152	369	13	stratified	stratified	ADJ
dpc-4152	369	14	squamous	squamous	ADJ
dpc-4152	369	15	epithelium	epithelium	NOUN
dpc-4152	369	16	;	;	PUNCT
dpc-4152	369	17	clinical	clinical	ADJ
dpc-4152	369	18	implications	implication	NOUN
dpc-4152	369	19	of	of	ADP
dpc-4152	369	20	multicentric	multicentric	ADJ
dpc-4152	369	21	origin	origin	NOUN
dpc-4152	369	22	.	.	PUNCT
dpc-4152	369	23	 	 	SPACE
dpc-4152	370	1	cancer	cancer	NOUN
dpc-4152	370	2	.	.	PUNCT
dpc-4152	371	1	1953;6(5):963	1953;6(5):963	NUM
dpc-4152	371	2	-	-	SYM
dpc-4152	371	3	968	968	NUM
dpc-4152	371	4	.	.	NOUN
dpc-4152	372	1	29	29	NUM
dpc-4152	372	2	.	.	PUNCT
dpc-4152	373	1	willenbrink	willenbrink	PROPN
dpc-4152	373	2	tj	tj	PROPN
dpc-4152	373	3	,	,	PUNCT
dpc-4152	373	4	ruiz	ruiz	NOUN
dpc-4152	373	5	es	es	PROPN
dpc-4152	373	6	,	,	PUNCT
dpc-4152	373	7	cornejo	cornejo	PROPN
dpc-4152	373	8	cm	cm	PROPN
dpc-4152	373	9	,	,	PUNCT
dpc-4152	373	10	et	et	PROPN
dpc-4152	373	11	al	al	PROPN
dpc-4152	373	12	.	.	PROPN
dpc-4152	373	13	field	field	PROPN
dpc-4152	373	14	cancerization	cancerization	NOUN
dpc-4152	373	15	:	:	PUNCT
dpc-4152	373	16	definition	definition	NOUN
dpc-4152	373	17	,	,	PUNCT
dpc-4152	373	18	epidemiology	epidemiology	NOUN
dpc-4152	373	19	,	,	PUNCT
dpc-4152	373	20	risk	risk	NOUN
dpc-4152	373	21	factors	factor	NOUN
dpc-4152	373	22	,	,	PUNCT
dpc-4152	373	23	and	and	CCONJ
dpc-4152	373	24	outcomes	outcome	NOUN
dpc-4152	373	25	.	.	PUNCT
dpc-4152	374	1	j	j	PROPN
dpc-4152	374	2	am	be	AUX
dpc-4152	374	3	acad	acad	ADJ
dpc-4152	374	4	dermatol	dermatol	NOUN
dpc-4152	374	5	.	.	PUNCT
dpc-4152	375	1	2020	2020	NUM
dpc-4152	375	2	sep;83(3):709	sep;83(3):709	NUM
dpc-4152	375	3	-	-	PUNCT
dpc-4152	375	4	717	717	NUM
dpc-4152	375	5	epub	epub	NOUN
dpc-4152	375	6	2020	2020	NUM
dpc-4152	375	7	may	may	AUX
dpc-4152	375	8	7	7	NUM
dpc-4152	375	9	.	.	PUNCT
dpc-4152	376	1	pmid	pmid	NOUN
dpc-4152	376	2	:	:	PUNCT
dpc-4152	376	3	32387665	32387665	NUM
dpc-4152	376	4	.	.	PUNCT
dpc-4152	377	1	30	30	NUM
dpc-4152	377	2	.	.	PUNCT
dpc-4152	378	1	dianzani	dianzani	PROPN
dpc-4152	378	2	c	c	PROPN
dpc-4152	378	3	,	,	PUNCT
dpc-4152	378	4	conforti	conforti	PROPN
dpc-4152	378	5	c	c	PROPN
dpc-4152	378	6	,	,	PUNCT
dpc-4152	378	7	giuffrida	giuffrida	NOUN
dpc-4152	378	8	r	r	NOUN
dpc-4152	378	9	,	,	PUNCT
dpc-4152	378	10	et	et	PROPN
dpc-4152	378	11	al	al	PROPN
dpc-4152	378	12	.	.	PUNCT
dpc-4152	379	1	current	current	ADJ
dpc-4152	379	2	therapies	therapy	NOUN
dpc-4152	379	3	for	for	ADP
dpc-4152	379	4	actinic	actinic	ADJ
dpc-4152	379	5	keratosis	keratosis	NOUN
dpc-4152	379	6	.	.	PUNCT
dpc-4152	380	1	int	int	NOUN
dpc-4152	380	2	j	j	PROPN
dpc-4152	380	3	dermatol	dermatol	NOUN
dpc-4152	380	4	.	.	PUNCT
dpc-4152	381	1	2020	2020	NUM
dpc-4152	381	2	jun;59(6):677	jun;59(6):677	PROPN
dpc-4152	381	3	-	-	PUNCT
dpc-4152	381	4	684	684	NUM
dpc-4152	381	5	31	31	NUM
dpc-4152	381	6	.	.	PUNCT
dpc-4152	382	1	dirschka	dirschka	PROPN
dpc-4152	382	2	t	t	PROPN
dpc-4152	382	3	,	,	PUNCT
dpc-4152	382	4	gupta	gupta	PROPN
dpc-4152	382	5	g	g	PROPN
dpc-4152	382	6	,	,	PUNCT
dpc-4152	382	7	micali	micali	NOUN
dpc-4152	382	8	g	g	PROPN
dpc-4152	382	9	,	,	PUNCT
dpc-4152	382	10	et	et	PROPN
dpc-4152	382	11	al	al	PROPN
dpc-4152	382	12	.	.	PUNCT
dpc-4152	382	13	 	 	SPACE
dpc-4152	382	14	real	real	ADJ
dpc-4152	382	15	-	-	PUNCT
dpc-4152	382	16	world	world	NOUN
dpc-4152	382	17	approach	approach	NOUN
dpc-4152	382	18	to	to	ADP
dpc-4152	382	19	actinic	actinic	ADJ
dpc-4152	382	20	keratosis	keratosis	NOUN
dpc-4152	382	21	management	management	NOUN
dpc-4152	382	22	:	:	PUNCT
dpc-4152	382	23	practical	practical	ADJ
dpc-4152	382	24	treatment	treatment	NOUN
dpc-4152	382	25	algorithm	algorithm	NOUN
dpc-4152	382	26	for	for	ADP
dpc-4152	382	27	office	office	NOUN
dpc-4152	382	28	-	-	PUNCT
dpc-4152	382	29	based	base	VERB
dpc-4152	382	30	dermatology	dermatology	NOUN
dpc-4152	382	31	.	.	PUNCT
dpc-4152	382	32	  	  	SPACE
dpc-4152	383	1	j	j	PROPN
dpc-4152	383	2	dermatolog	dermatolog	NOUN
dpc-4152	383	3	treat	treat	NOUN
dpc-4152	383	4	.	.	PUNCT
dpc-4152	384	1	2017;28(5	2017;28(5	NUM
dpc-4152	384	2	):	):	PUNCT
dpc-4152	385	1	431–442	431–442	NUM
dpc-4152	385	2	.	.	PUNCT
dpc-4152	385	3	doi	doi	NOUN
dpc-4152	385	4	:	:	PUNCT
dpc-4152	385	5	10.1080/09546634.2016.1254328	10.1080/09546634.2016.1254328	NUM
dpc-4152	385	6	32	32	NUM
dpc-4152	385	7	.	.	PUNCT
dpc-4152	386	1	miller	miller	PROPN
dpc-4152	386	2	ac	ac	PROPN
dpc-4152	386	3	,	,	PUNCT
dpc-4152	386	4	adjei	adjei	PROPN
dpc-4152	386	5	s	s	PART
dpc-4152	386	6	,	,	PUNCT
dpc-4152	386	7	temiz	temiz	PROPN
dpc-4152	386	8	la	la	PROPN
dpc-4152	386	9	,	,	PUNCT
dpc-4152	386	10	et	et	PROPN
dpc-4152	386	11	al	al	PROPN
dpc-4152	386	12	.	.	PROPN
dpc-4152	386	13	tirbanibulin	tirbanibulin	PROPN
dpc-4152	386	14	for	for	ADP
dpc-4152	386	15	the	the	DET
dpc-4152	386	16	treatment	treatment	NOUN
dpc-4152	386	17	of	of	ADP
dpc-4152	386	18	actinic	actinic	ADJ
dpc-4152	386	19	keratosis	keratosis	NOUN
dpc-4152	386	20	:	:	PUNCT
dpc-4152	386	21	a	a	DET
dpc-4152	386	22	review	review	NOUN
dpc-4152	386	23	.	.	PUNCT
dpc-4152	387	1	skin	skin	NOUN
dpc-4152	387	2	therapy	therapy	NOUN
dpc-4152	387	3	lett	lett	PROPN
dpc-4152	387	4	.	.	PUNCT
dpc-4152	388	1	2022	2022	NUM
dpc-4152	388	2	jul;27(4):4	jul;27(4):4	PROPN
dpc-4152	388	3	-	-	PUNCT
dpc-4152	388	4	7	7	NUM
dpc-4152	388	5	.	.	NOUN
dpc-4152	388	6	33	33	NUM
dpc-4152	388	7	.	.	PUNCT
dpc-4152	389	1	ranpariya	ranpariya	NOUN
dpc-4152	389	2	vk	vk	PROPN
dpc-4152	389	3	,	,	PUNCT
dpc-4152	389	4	muddasani	muddasani	PROPN
dpc-4152	389	5	s	s	PROPN
dpc-4152	389	6	,	,	PUNCT
dpc-4152	389	7	mahon	mahon	PROPN
dpc-4152	389	8	ab	ab	PROPN
dpc-4152	389	9	,	,	PUNCT
dpc-4152	389	10	et	et	PROPN
dpc-4152	389	11	al	al	PROPN
dpc-4152	389	12	.	.	PROPN
dpc-4152	389	13	frequency	frequency	PROPN
dpc-4152	389	14	of	of	ADP
dpc-4152	389	15	procedural	procedural	ADJ
dpc-4152	389	16	and	and	CCONJ
dpc-4152	389	17	medical	medical	ADJ
dpc-4152	389	18	treatments	treatment	NOUN
dpc-4152	389	19	of	of	ADP
dpc-4152	389	20	actinic	actinic	ADJ
dpc-4152	389	21	keratosis	keratosis	NOUN
dpc-4152	389	22	.	.	PUNCT
dpc-4152	389	23	 	 	SPACE
dpc-4152	390	1	j	j	PROPN
dpc-4152	390	2	am	be	AUX
dpc-4152	390	3	acad	acad	ADJ
dpc-4152	390	4	dermatol	dermatol	NOUN
dpc-4152	390	5	.	.	PUNCT
dpc-4152	390	6	 	 	SPACE
dpc-4152	391	1	2022;86(4):916–918	2022;86(4):916–918	NUM
dpc-4152	391	2	.	.	PROPN
dpc-4152	392	1	34	34	NUM
dpc-4152	392	2	.	.	PUNCT
dpc-4152	392	3	krawtchenko	krawtchenko	PROPN
dpc-4152	392	4	n	n	CCONJ
dpc-4152	392	5	,	,	PUNCT
dpc-4152	392	6	roewert	roewert	PROPN
dpc-4152	392	7	-	-	PUNCT
dpc-4152	392	8	huber	huber	PROPN
dpc-4152	392	9	j	j	PROPN
dpc-4152	392	10	,	,	PUNCT
dpc-4152	392	11	ulrich	ulrich	PROPN
dpc-4152	392	12	m	m	VERB
dpc-4152	392	13	et	et	NOUN
dpc-4152	392	14	al	al	PROPN
dpc-4152	392	15	.	.	PUNCT
dpc-4152	393	1	a	a	DET
dpc-4152	393	2	randomised	randomised	ADJ
dpc-4152	393	3	study	study	NOUN
dpc-4152	393	4	of	of	ADP
dpc-4152	393	5	topical	topical	ADJ
dpc-4152	393	6	5	5	NUM
dpc-4152	393	7	%	%	NOUN
dpc-4152	393	8	imiquimod	imiquimod	ADJ
dpc-4152	393	9	vs.	vs.	ADP
dpc-4152	393	10	topical	topical	ADJ
dpc-4152	393	11	5	5	NUM
dpc-4152	393	12	-	-	PUNCT
dpc-4152	393	13	fluorouracil	fluorouracil	NOUN
dpc-4152	393	14	vs.	vs.	ADP
dpc-4152	393	15	cryosurgery	cryosurgery	NOUN
dpc-4152	393	16	in	in	ADP
dpc-4152	393	17	immunocompetent	immunocompetent	ADJ
dpc-4152	393	18	patients	patient	NOUN
dpc-4152	393	19	with	with	ADP
dpc-4152	393	20	actinic	actinic	ADJ
dpc-4152	393	21	keratoses	keratose	NOUN
dpc-4152	393	22	:	:	PUNCT
dpc-4152	393	23	a	a	DET
dpc-4152	393	24	comparison	comparison	NOUN
dpc-4152	393	25	of	of	ADP
dpc-4152	393	26	clinical	clinical	ADJ
dpc-4152	393	27	and	and	CCONJ
dpc-4152	393	28	histological	histological	ADJ
dpc-4152	393	29	outcomes	outcome	NOUN
dpc-4152	393	30	including	include	VERB
dpc-4152	393	31	1	1	NUM
dpc-4152	393	32	-	-	PUNCT
dpc-4152	393	33	year	year	NOUN
dpc-4152	393	34	follow	follow	NOUN
dpc-4152	393	35	-	-	PUNCT
dpc-4152	393	36	up	up	NOUN
dpc-4152	393	37	.	.	PUNCT
dpc-4152	393	38	 	 	SPACE
dpc-4152	394	1	br	br	PROPN
dpc-4152	394	2	j	j	PROPN
dpc-4152	394	3	dermatol	dermatol	NOUN
dpc-4152	394	4	.	.	PUNCT
dpc-4152	394	5	 	 	SPACE
dpc-4152	395	1	2007;157:34–40	2007;157:34–40	NUM
dpc-4152	395	2	.	.	PROPN
dpc-4152	395	3	35	35	NUM
dpc-4152	395	4	.	.	PUNCT
dpc-4152	396	1	european	european	PROPN
dpc-4152	396	2	medicines	medicine	NOUN
dpc-4152	396	3	agency	agency	NOUN
dpc-4152	396	4	.summary	.summary	PUNCT
dpc-4152	396	5	of	of	ADP
dpc-4152	396	6	product	product	NOUN
dpc-4152	396	7	characteristics	characteristic	NOUN
dpc-4152	396	8	:	:	PUNCT
dpc-4152	396	9	klisyri	klisyri	NOUN
dpc-4152	396	10	10	10	NUM
dpc-4152	396	11	mg	mg	PROPN
dpc-4152	396	12	/	/	SYM
dpc-4152	396	13	g	g	NOUN
dpc-4152	396	14	ointment	ointment	NOUN
dpc-4152	397	1	[	[	X
dpc-4152	397	2	webpage	webpage	NOUN
dpc-4152	397	3	]	]	X
dpc-4152	397	4	 	 	SPACE
dpc-4152	397	5	european	european	PROPN
dpc-4152	397	6	medicines	medicine	NOUN
dpc-4152	397	7	agency	agency	NOUN
dpc-4152	397	8	;	;	PUNCT
dpc-4152	397	9	amsterdam	amsterdam	PROPN
dpc-4152	397	10	,	,	PUNCT
dpc-4152	397	11	the	the	DET
dpc-4152	397	12	netherlands	netherlands	PROPN
dpc-4152	397	13	:	:	PUNCT
dpc-4152	397	14	2021	2021	NUM
dpc-4152	397	15	.	.	PUNCT
dpc-4152	398	1	[	[	X
dpc-4152	398	2	(	(	PUNCT
dpc-4152	398	3	accessed	access	VERB
dpc-4152	398	4	on	on	ADP
dpc-4152	398	5	20	20	NUM
dpc-4152	398	6	january	january	NOUN
dpc-4152	398	7	2022	2022	NUM
dpc-4152	398	8	)	)	PUNCT
dpc-4152	398	9	]	]	PUNCT
dpc-4152	398	10	.	.	PUNCT
dpc-4152	399	1	last	last	ADJ
dpc-4152	399	2	updated	update	VERB
dpc-4152	399	3	august	august	PROPN
dpc-4152	399	4	2021	2021	NUM
dpc-4152	399	5	.	.	PUNCT
dpc-4152	400	1	36	36	NUM
dpc-4152	400	2	.	.	PUNCT
dpc-4152	401	1	s.	s.	PROPN
dpc-4152	401	2	kim	kim	PROPN
dpc-4152	401	3	,	,	PUNCT
dpc-4152	401	4	a.	a.	PROPN
dpc-4152	401	5	min	min	PROPN
dpc-4152	401	6	,	,	PUNCT
dpc-4152	401	7	k.-h	k.-h	PROPN
dpc-4152	401	8	.	.	PUNCT
dpc-4152	402	1	lee	lee	PROPN
dpc-4152	402	2	,	,	PUNCT
dpc-4152	402	3	  	  	SPACE
dpc-4152	402	4	et	et	PROPN
dpc-4152	402	5	al	al	PROPN
dpc-4152	402	6	.	.	PUNCT
dpc-4152	403	1	antitumor	antitumor	PROPN
dpc-4152	403	2	effect	effect	NOUN
dpc-4152	403	3	of	of	ADP
dpc-4152	403	4	kx-01	kx-01	NOUN
dpc-4152	403	5	through	through	ADP
dpc-4152	403	6	inhibiting	inhibit	VERB
dpc-4152	403	7	src	src	NOUN
dpc-4152	403	8	family	family	NOUN
dpc-4152	403	9	kinases	kinase	NOUN
dpc-4152	403	10	and	and	CCONJ
dpc-4152	403	11	mitosis	mitosis	NOUN
dpc-4152	403	12	.	.	PUNCT
dpc-4152	404	1	cancer	cancer	NOUN
dpc-4152	404	2	res	re	NOUN
dpc-4152	404	3	treat	treat	VERB
dpc-4152	404	4	off	off	ADP
dpc-4152	404	5	j	j	PROPN
dpc-4152	404	6	korean	korean	PROPN
dpc-4152	404	7	cancer	cancer	PROPN
dpc-4152	404	8	assoc	assoc	PROPN
dpc-4152	404	9	.	.	PROPN
dpc-4152	404	10	,	,	PUNCT
dpc-4152	404	11	49	49	NUM
dpc-4152	404	12	(	(	PUNCT
dpc-4152	404	13	2017	2017	NUM
dpc-4152	404	14	)	)	PUNCT
dpc-4152	404	15	,	,	PUNCT
dpc-4152	404	16	pp	pp	PROPN
dpc-4152	404	17	.	.	PUNCT
dpc-4152	405	1	643	643	NUM
dpc-4152	405	2	-	-	SYM
dpc-4152	405	3	655	655	NUM
dpc-4152	405	4	.	.	PUNCT
dpc-4152	406	1	37	37	NUM
dpc-4152	406	2	.	.	PUNCT
dpc-4152	407	1	m.p	m.p	PROPN
dpc-4152	407	2	.	.	PROPN
dpc-4152	407	3	smolinski	smolinski	PROPN
dpc-4152	407	4	,	,	PUNCT
dpc-4152	407	5	y.	y.	PROPN
dpc-4152	407	6	bu	bu	PROPN
dpc-4152	407	7	,	,	PUNCT
dpc-4152	407	8	j.	j.	PROPN
dpc-4152	407	9	clements	clements	PROPN
dpc-4152	407	10	,	,	PUNCT
dpc-4152	407	11	i.h	i.h	PROPN
dpc-4152	407	12	.	.	PROPN
dpc-4152	407	13	gelman	gelman	PROPN
dpc-4152	407	14	,	,	PUNCT
dpc-4152	407	15	 	 	SPACE
dpc-4152	407	16	et	et	PROPN
dpc-4152	407	17	al	al	PROPN
dpc-4152	407	18	.	.	PROPN
dpc-4152	407	19	discovery	discovery	PROPN
dpc-4152	407	20	of	of	ADP
dpc-4152	407	21	novel	novel	ADJ
dpc-4152	407	22	dual	dual	ADJ
dpc-4152	407	23	mechanism	mechanism	NOUN
dpc-4152	407	24	of	of	ADP
dpc-4152	407	25	action	action	NOUN
dpc-4152	407	26	src	src	NOUN
dpc-4152	407	27	signaling	signal	VERB
dpc-4152	407	28	and	and	CCONJ
dpc-4152	407	29	tubulin	tubulin	NOUN
dpc-4152	407	30	polymerization	polymerization	NOUN
dpc-4152	407	31	inhibitors	inhibitor	NOUN
dpc-4152	407	32	(	(	PUNCT
dpc-4152	407	33	kx2	kx2	PROPN
dpc-4152	407	34	-	-	X
dpc-4152	407	35	391	391	NUM
dpc-4152	407	36	and	and	CCONJ
dpc-4152	407	37	kx2	kx2	PROPN
dpc-4152	407	38	-	-	PUNCT
dpc-4152	407	39	361	361	NUM
dpc-4152	407	40	)	)	PUNCT
dpc-4152	407	41	.	.	PUNCT
dpc-4152	408	1	j	j	PROPN
dpc-4152	408	2	med	med	PROPN
dpc-4152	408	3	chem	chem	NOUN
dpc-4152	408	4	.	.	PUNCT
dpc-4152	408	5	,	,	PUNCT
dpc-4152	408	6	61	61	NUM
dpc-4152	408	7	(	(	PUNCT
dpc-4152	408	8	2018	2018	NUM
dpc-4152	408	9	)	)	PUNCT
dpc-4152	408	10	,	,	PUNCT
dpc-4152	408	11	pp	pp	PROPN
dpc-4152	408	12	.	.	PUNCT
dpc-4152	408	13	4704	4704	NUM
dpc-4152	408	14	-	-	SYM
dpc-4152	408	15	47190	47190	NUM
dpc-4152	408	16	.	.	PUNCT
dpc-4152	409	1	review	review	NOUN
dpc-4152	409	2	|	|	ADV
dpc-4152	409	3	dermatol	dermatol	ADJ
dpc-4152	409	4	pract	pract	NOUN
dpc-4152	409	5	concept	concept	NOUN
dpc-4152	409	6	.	.	PUNCT
dpc-4152	410	1	2024;14(3)s1	2024;14(3)s1	NOUN
dpc-4152	410	2	:	:	PUNCT
dpc-4152	410	3	e2024145s	e2024145s	NOUN
dpc-4152	410	4	9	9	NUM
dpc-4152	410	5	58	58	NUM
dpc-4152	410	6	.	.	PUNCT
dpc-4152	411	1	dubois	dubois	PROPN
dpc-4152	411	2	j	j	PROPN
dpc-4152	411	3	,	,	PUNCT
dpc-4152	411	4	jones	jones	PROPN
dpc-4152	411	5	tm	tm	PROPN
dpc-4152	411	6	,	,	PUNCT
dpc-4152	411	7	lee	lee	PROPN
dpc-4152	411	8	ms	ms	PROPN
dpc-4152	411	9	,	,	PUNCT
dpc-4152	411	10	et	et	PROPN
dpc-4152	411	11	al	al	PROPN
dpc-4152	411	12	.	.	PUNCT
dpc-4152	411	13	pharmacokinetics	pharmacokinetic	NOUN
dpc-4152	411	14	,	,	PUNCT
dpc-4152	411	15	safety	safety	NOUN
dpc-4152	411	16	,	,	PUNCT
dpc-4152	411	17	and	and	CCONJ
dpc-4152	411	18	tolerability	tolerability	NOUN
dpc-4152	411	19	of	of	ADP
dpc-4152	411	20	a	a	DET
dpc-4152	411	21	single	single	ADJ
dpc-4152	411	22	5	5	NUM
dpc-4152	411	23	-	-	PUNCT
dpc-4152	411	24	day	day	NOUN
dpc-4152	411	25	treatment	treatment	NOUN
dpc-4152	411	26	of	of	ADP
dpc-4152	411	27	tirbanibulin	tirbanibulin	PROPN
dpc-4152	411	28	ointment	ointment	NOUN
dpc-4152	411	29	1	1	NUM
dpc-4152	411	30	%	%	NOUN
dpc-4152	411	31	in	in	ADP
dpc-4152	411	32	100	100	NUM
dpc-4152	411	33	cm2	cm2	NOUN
dpc-4152	411	34	:	:	PUNCT
dpc-4152	411	35	a	a	DET
dpc-4152	411	36	phase	phase	NOUN
dpc-4152	411	37	1	1	NUM
dpc-4152	411	38	maximal	maximal	ADJ
dpc-4152	411	39	-	-	PUNCT
dpc-4152	411	40	use	use	NOUN
dpc-4152	411	41	trial	trial	NOUN
dpc-4152	411	42	in	in	ADP
dpc-4152	411	43	patients	patient	NOUN
dpc-4152	411	44	with	with	ADP
dpc-4152	411	45	actinic	actinic	ADJ
dpc-4152	411	46	keratosis	keratosis	NOUN
dpc-4152	411	47	.	.	PUNCT
dpc-4152	412	1	clin	clin	PROPN
dpc-4152	412	2	pharmacol	pharmacol	PROPN
dpc-4152	412	3	drug	drug	PROPN
dpc-4152	412	4	dev	dev	PROPN
dpc-4152	412	5	.	.	PUNCT
dpc-4152	413	1	2024;13(2):208	2024;13(2):208	NUM
dpc-4152	413	2	-	-	PUNCT
dpc-4152	413	3	218	218	NUM
dpc-4152	413	4	.	.	PUNCT
dpc-4152	414	1	59	59	NUM
dpc-4152	414	2	.	.	PUNCT
dpc-4152	415	1	iglesias	iglesias	PROPN
dpc-4152	415	2	-	-	PUNCT
dpc-4152	415	3	puzas	puza	NOUN
dpc-4152	415	4	á	á	PROPN
dpc-4152	415	5	,	,	PUNCT
dpc-4152	415	6	conde	conde	PROPN
dpc-4152	415	7	-	-	PUNCT
dpc-4152	415	8	taboada	taboada	PROPN
dpc-4152	415	9	a	a	PROPN
dpc-4152	415	10	,	,	PUNCT
dpc-4152	415	11	campos	campos	PROPN
dpc-4152	415	12	-	-	PUNCT
dpc-4152	415	13	muñoz	muñoz	PROPN
dpc-4152	415	14	l	l	PROPN
dpc-4152	415	15	,	,	PUNCT
dpc-4152	415	16	sirgado	sirgado	PROPN
dpc-4152	415	17	martínez	martínez	PROPN
dpc-4152	415	18	a	a	PROPN
dpc-4152	415	19	,	,	PUNCT
dpc-4152	415	20	lópez	lópez	NOUN
dpc-4152	415	21	-	-	PUNCT
dpc-4152	415	22	bran	bran	NOUN
dpc-4152	415	23	e.	e.	PROPN
dpc-4152	415	24	1	1	NUM
dpc-4152	415	25	%	%	NOUN
dpc-4152	415	26	tirbanibulin	tirbanibulin	PROPN
dpc-4152	415	27	ointment	ointment	NOUN
dpc-4152	415	28	for	for	ADP
dpc-4152	415	29	actinic	actinic	ADJ
dpc-4152	415	30	keratoses	keratose	NOUN
dpc-4152	415	31	on	on	ADP
dpc-4152	415	32	upper	upper	ADJ
dpc-4152	415	33	extremities	extremity	NOUN
dpc-4152	415	34	:	:	PUNCT
dpc-4152	415	35	a	a	DET
dpc-4152	415	36	retrospective	retrospective	ADJ
dpc-4152	415	37	case	case	NOUN
dpc-4152	415	38	review	review	NOUN
dpc-4152	415	39	study	study	NOUN
dpc-4152	415	40	.	.	PUNCT
dpc-4152	415	41	 	 	SPACE
dpc-4152	416	1	acta	acta	PROPN
dpc-4152	416	2	derm	derm	PROPN
dpc-4152	416	3	venereol	venereol	NOUN
dpc-4152	416	4	.	.	PUNCT
dpc-4152	417	1	2023;103	2023;103	NUM
dpc-4152	417	2	:	:	PUNCT
dpc-4152	417	3	adv15296	adv15296	NOUN
dpc-4152	417	4	.	.	PUNCT
dpc-4152	418	1	60	60	NUM
dpc-4152	418	2	.	.	PUNCT
dpc-4152	419	1	nazzaro	nazzaro	NOUN
dpc-4152	419	2	g	g	NOUN
dpc-4152	419	3	,	,	PUNCT
dpc-4152	419	4	carugno	carugno	VERB
dpc-4152	419	5	a	a	DET
dpc-4152	419	6	,	,	PUNCT
dpc-4152	419	7	bortoluzzi	bortoluzzi	NOUN
dpc-4152	419	8	p	p	NOUN
dpc-4152	419	9	,	,	PUNCT
dpc-4152	419	10	et	et	PROPN
dpc-4152	419	11	al	al	PROPN
dpc-4152	419	12	.	.	PROPN
dpc-4152	419	13	efficacy	efficacy	NOUN
dpc-4152	419	14	and	and	CCONJ
dpc-4152	419	15	tolerability	tolerability	NOUN
dpc-4152	419	16	of	of	ADP
dpc-4152	419	17	tirbanibulin	tirbanibulin	DET
dpc-4152	419	18	1	1	NUM
dpc-4152	419	19	%	%	NOUN
dpc-4152	419	20	ointment	ointment	NOUN
dpc-4152	419	21	in	in	ADP
dpc-4152	419	22	the	the	DET
dpc-4152	419	23	treatment	treatment	NOUN
dpc-4152	419	24	of	of	ADP
dpc-4152	419	25	cancerization	cancerization	NOUN
dpc-4152	419	26	field	field	NOUN
dpc-4152	419	27	:	:	PUNCT
dpc-4152	419	28	a	a	DET
dpc-4152	419	29	real	real	ADJ
dpc-4152	419	30	-	-	PUNCT
dpc-4152	419	31	life	life	NOUN
dpc-4152	419	32	italian	italian	ADJ
dpc-4152	419	33	multicenter	multicenter	NOUN
dpc-4152	419	34	observational	observational	ADJ
dpc-4152	419	35	study	study	NOUN
dpc-4152	419	36	of	of	ADP
dpc-4152	419	37	250	250	NUM
dpc-4152	419	38	patients	patient	NOUN
dpc-4152	419	39	.	.	PUNCT
dpc-4152	420	1	int	int	NOUN
dpc-4152	420	2	j	j	PROPN
dpc-4152	420	3	dermatol	dermatol	NOUN
dpc-4152	420	4	.	.	PUNCT
dpc-4152	421	1	published	publish	VERB
dpc-4152	421	2	online	online	ADJ
dpc-4152	421	3	april	april	PROPN
dpc-4152	421	4	11	11	NUM
dpc-4152	421	5	,	,	PUNCT
dpc-4152	421	6	2024	2024	NUM
dpc-4152	421	7	.	.	PUNCT
dpc-4152	422	1	β	β	X
dpc-4152	422	2	-	-	PUNCT
dpc-4152	422	3	tubulin	tubulin	NOUN
dpc-4152	422	4	explains	explain	VERB
dpc-4152	422	5	kxo1	kxo1	PROPN
dpc-4152	422	6	’s	’s	PART
dpc-4152	422	7	low	low	ADJ
dpc-4152	422	8	clinical	clinical	ADJ
dpc-4152	422	9	toxicity	toxicity	NOUN
dpc-4152	422	10	.	.	PUNCT
dpc-4152	423	1	j	j	PROPN
dpc-4152	423	2	biol	biol	PROPN
dpc-4152	423	3	chem	chem	PROPN
dpc-4152	423	4	.	.	PUNCT
dpc-4152	423	5	,	,	PUNCT
dpc-4152	423	6	294	294	NUM
dpc-4152	423	7	(	(	PUNCT
dpc-4152	423	8	2019	2019	NUM
dpc-4152	423	9	)	)	PUNCT
dpc-4152	423	10	,	,	PUNCT
dpc-4152	423	11	pp	pp	PROPN
dpc-4152	423	12	.	.	PUNCT
dpc-4152	424	1	18099	18099	NUM
dpc-4152	424	2	-	-	SYM
dpc-4152	424	3	18108	18108	NUM
dpc-4152	424	4	.	.	PUNCT
dpc-4152	425	1	55	55	NUM
dpc-4152	425	2	.	.	X
dpc-4152	426	1	dosik	dosik	PROPN
dpc-4152	426	2	j	j	PROPN
dpc-4152	426	3	,	,	PUNCT
dpc-4152	426	4	cutler	cutler	PROPN
dpc-4152	426	5	dl	dl	PROPN
dpc-4152	426	6	,	,	PUNCT
dpc-4152	426	7	fang	fang	PROPN
dpc-4152	426	8	j	j	PROPN
dpc-4152	426	9	,	,	PUNCT
dpc-4152	426	10	padullés	padullés	PROPN
dpc-4152	426	11	l.	l.	PROPN
dpc-4152	426	12	contact	contact	PROPN
dpc-4152	426	13	sensitization	sensitization	NOUN
dpc-4152	426	14	and	and	CCONJ
dpc-4152	426	15	phototoxic	phototoxic	ADJ
dpc-4152	426	16	and	and	CCONJ
dpc-4152	426	17	photoallergic	photoallergic	ADJ
dpc-4152	426	18	potential	potential	NOUN
dpc-4152	426	19	of	of	ADP
dpc-4152	426	20	tirbanibulin	tirbanibulin	DET
dpc-4152	426	21	1	1	NUM
dpc-4152	426	22	%	%	NOUN
dpc-4152	426	23	ointment	ointment	NOUN
dpc-4152	426	24	in	in	ADP
dpc-4152	426	25	healthy	healthy	ADJ
dpc-4152	426	26	volunteers	volunteer	NOUN
dpc-4152	426	27	.	.	PUNCT
dpc-4152	426	28	 	 	SPACE
dpc-4152	427	1	jid	jid	PROPN
dpc-4152	427	2	innov	innov	PROPN
dpc-4152	427	3	.	.	PUNCT
dpc-4152	428	1	2022;3(2):100170	2022;3(2):100170	X
dpc-4152	428	2	.	.	PUNCT
dpc-4152	428	3	doi:10.1016	doi:10.1016	PROPN
dpc-4152	428	4	/	/	SYM
dpc-4152	428	5	j.xjidi.2022.100170	j.xjidi.2022.100170	PROPN
dpc-4152	428	6	56	56	NUM
dpc-4152	428	7	.	.	PUNCT
dpc-4152	429	1	moore	moore	PROPN
dpc-4152	429	2	ay	ay	PROPN
dpc-4152	429	3	,	,	PUNCT
dpc-4152	429	4	moore	moore	PROPN
dpc-4152	429	5	s.	s.	PROPN
dpc-4152	429	6	topical	topical	PROPN
dpc-4152	429	7	tirbanibulin	tirbanibulin	PROPN
dpc-4152	429	8	eradication	eradication	NOUN
dpc-4152	429	9	of	of	ADP
dpc-4152	429	10	periungual	periungual	ADJ
dpc-4152	429	11	squamous	squamous	ADJ
dpc-4152	429	12	cell	cell	NOUN
dpc-4152	429	13	carcinoma	carcinoma	NOUN
dpc-4152	429	14	.	.	PUNCT
dpc-4152	430	1	jaad	jaad	NOUN
dpc-4152	430	2	case	case	NOUN
dpc-4152	430	3	rep	rep	PROPN
dpc-4152	430	4	.	.	PROPN
dpc-4152	430	5	2021	2021	NUM
dpc-4152	430	6	jun	jun	PROPN
dpc-4152	430	7	26;14:101	26;14:101	NUM
dpc-4152	430	8	-	-	SYM
dpc-4152	430	9	103	103	NUM
dpc-4152	430	10	.	.	PUNCT
dpc-4152	430	11	57	57	NUM
dpc-4152	430	12	.	.	PUNCT
dpc-4152	431	1	moore	moore	PROPN
dpc-4152	431	2	a	a	PROPN
dpc-4152	431	3	,	,	PUNCT
dpc-4152	431	4	hurley	hurley	PROPN
dpc-4152	431	5	k	k	PROPN
dpc-4152	431	6	,	,	PUNCT
dpc-4152	431	7	moore	moore	PROPN
dpc-4152	431	8	sa	sa	PROPN
dpc-4152	431	9	.	.	PUNCT
dpc-4152	431	10	rapid	rapid	ADJ
dpc-4152	431	11	resolution	resolution	NOUN
dpc-4152	431	12	of	of	ADP
dpc-4152	431	13	recalcitrant	recalcitrant	ADJ
dpc-4152	431	14	basal	basal	NOUN
dpc-4152	431	15	cell	cell	NOUN
dpc-4152	431	16	carcinoma	carcinoma	NOUN
dpc-4152	431	17	of	of	ADP
dpc-4152	431	18	the	the	DET
dpc-4152	431	19	ear	ear	NOUN
dpc-4152	431	20	with	with	ADP
dpc-4152	431	21	topical	topical	ADJ
dpc-4152	431	22	tirbanibulin	tirbanibulin	PROPN
dpc-4152	431	23	.	.	PUNCT
dpc-4152	432	1	jaad	jaad	NOUN
dpc-4152	432	2	case	case	NOUN
dpc-4152	432	3	rep	rep	PROPN
dpc-4152	432	4	.	.	PROPN
dpc-4152	432	5	2022	2022	NUM
dpc-4152	432	6	aug	aug	PROPN
dpc-4152	432	7	10;28:11	10;28:11	NUM
dpc-4152	432	8	-	-	SYM
dpc-4152	432	9	13	13	NUM
dpc-4152	432	10	.	.	PUNCT